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 The purpose of the project was to investigate the impact of IV and PO routes difference for 
MDZ, a prototypical CYP3A substrate, and two CYP3A inhibitors (CYP3AI) -FLZ and ERY-, 
on the magnitude and time course of their inhibitory metabolic DDI.  
 Individual semi-PBPK models for MDZ, FLZ and ERY were developed and validated 
separately, using pharmacokinetic (PK) parameters from clinical/in-vitro studies and published 
physiological parameters. Subsequently, DDI sub-models between MDZ and CYP3AIs 
incorporated non-competitive and mechanism-based inhibition (MBI) for FLZ and ERY, 
xxviii 
	
respectively, on hepatic and gut wall (GW) CYP3A metabolism of MDZ, using available in-
vitro/in-vivo information.  Model-simulated MDZ PK profiles were compared with observed data 
from available clinical PK and DDI studies, by visual predictive check and exposure metrics 
comparison. DDI magnitude and time course for CYP3AI (IV vs. PO) followed by MDZ (IV vs. 
PO) at various time points were predicted by the validated semi-PBPK-DDI models. Two 
hypothetical CYP3A substrates and four CYP3AI (derived from MDZ, FLZ and ERY, with GW 
metabolism removed, hepatic metabolism reduced, or oral bioavailability (Foral) and/or 
elimination half-life (t1/2) modified) were also simulated to generalize conclusions. 
 The final semi-PBPK-DDI models predict well the PK profiles for IV/PO MDZ in 
absence/presence of IV/PO CYP3AI, with deviations between model-predicted and observed 
exposure metrics within 30%.  Prospective simulations demonstrate that: 
1) CYP3A substrates, e.g., MDZ, are consistently more sensitive to metabolic inhibition after 
PO than after IV administration, due to pre-systemic hepatic and/or GW metabolism. For 
substrates without GW metabolism and limited hepatic metabolism, only a marginal route 
difference for substrate administration is observed. 
2) For high-Foral CYP3AIs, e.g., FLZ, no inhibitor IV-PO route DDI differences are expected, 
unless they are given simultaneously with PO MDZ. 
3) For low-Foral CYP3AIs, e.g., ERY, greater inhibition is expected after IV than after PO 
administration for IV MDZ, but is difficult to predict for PO MDZ. 
4) In addition to Foral and plasma t1/2 of CYP3AIs, the DDI onset, peak and duration are 
determined by their oral absorption rate and by the resulting hepatic and/or GW 
concentration profiles relative to Ki for noncompetitive CYP3AIs, but by CYP3A kinetics 
(synthesis, degradation rate) for MBI CYP3AIs.
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CHAPTER 1 
 
 
1 INTRODUCTION 
 
 
 
 
1.1 Clinical significance of drug-drug interaction (DDI) 
 
By definition, drug-drug interaction (DDI) occurs when a drug (“victim” drug)’s clinical 
efficacy or toxicity is affected by the co-administration of another drug (“perpetrator” drug). This 
could result from the pharmacokinetics (when plasma concentration is affected, through 
absorption, distribution, metabolism and excretion (ADME) processes) of the victim drug or its 
metabolites; and/or from the impact on pharmacodynamics, when changes in drug action occur 
in the area of target receptors (Pleuvry, 2005).   
DDI remains an important issue in clinical practice and is most commonly observed in the 
elderly population due to polypharmacy. The incidence and extent of DDI may increase as the 
number of drugs prescribed increases, as is illustrated by Figure 1.1 (Delafuente, 2003).  
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Figure 1.1  Probability of potential drug interactions. 
The open bars are model calculated probabilities of having a drug-drug interaction. The solid 
bars are observed interactions identified in patients. 
 
 
If not being taken care of appropriately, DDI can result in severe adverse drug events (ADEs), 
due to toxicity or lack of efficacy. ADEs are reported to be the 4th leading cause of death in the 
US, with more than 2,216,000 serious ADEs reported in hospitalized patients which caused more 
than 100,000 deaths yearly (FAERS Reporting by Patient Outcomes by Year, 2015). Moura et al. 
(2009) estimated the cost of drug-related morbidity and mortality annually is $136 billion, which 
is more than the total cost of cardiovascular or diabetic care in the US. A 2-fold greater mean 
length of stay, cost and mortality have been reported for hospitalized patients suffered from 
ADEs compared to patients without ADEs (Sultana et al., 2013). According to the study by 
Agrawal et al. (2009), DDI represent 3-5% of all in-hospital medication errors, and DDI is also 
an important cause of patient visits to emergency departments (Ray et al., 2010). Despite the 
modest overall incidence of ADEs caused by DDI, the consequences of DDI is usually severe, 
which in most cases lead to hospitalization (Mirošević Skvrce et al., 2011). Some DDIs have led 
to life-threatening ADEs during treatment, resulting in restrictions in the prescription of drugs or 
even withdrawal of drugs from the market. This brought huge economic consequences for the 
J.C. Delafuente / Critical Reviews in Oncology/Hematology 48 (2003) 133–143 135
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Fig. 1. Probability of potential drug interactions. The opened bars are theoretical probabilities of having a drug–drug interaction. The solid bars are
potential interactions identified in patients. Data extracted from [11].
2.3. Polypharmacy and drug interactions
Fig. 1 shows the increasing risk of potential drug–drug
interactions with increasing use of prescribed medication.
Using combinatorial analysis there is a theoretical probabil-
ity of over 50% for having a drug interaction occur when
a patient is re eiving five medications, and the probability
increases to 100% when seven drugs are used. When risk
probabilities were determined in actual patients, these theo-
retical probabilities were very close to actual data [11]. The
authors of this study did not evaluate the clinical outcomes
of these potential interactions, but did state that 20% could
be very clinically significant.
2.4. Acquiring accurate information
In addition to using multiple medications, having multiple
prescribers probably increases the risk of drug–drug interac-
tions. Duplication of therapies or prescribing counter-acting
drugs can occur when two or more prescribers do not know
what the others are doing. It is common for prescribers to
have inaccurate information about the drugs their patients
are taking. Seventy-six percent of patient charts reviewed
in cardiologists’ and internists’ office practices contained
discrepant information regarding medication use [12]. In
this study, 51% of the patients were taking medication not
recorded in the physician’s record; 29% of the patients were
not using a medication that was recorded; and 20% of the pa-
tients were using a different dosage than what was recorded.
The most significant correlates of discrepancies in medica-
tion use were older age and polypharmacy. To avoid drug
interactions it is imperative that a thorough medication his-
tory be taken at each visit and the history must include non-
prescription drugs and herbal supplements as well. Patients
should be instructed to bring all their medications, includ-
ing nonprescription and herbal products, to their physicians
for review.
3. Frequency of drug–drug interactions
3.1. Emergency department visits
Recent data on the incidence of potential drug–drug in-
teractions in community-dwelling elderly is difficult to find.
Data are available from several stu i s conduct d in emer-
gency departments. Goldberg et al. [16] retrospectively re-
viewed medical records of patients seen in two emergency
departments. During the data collection period, all patients
using three or more medications and all patients over 50
years using at least two medications were included in the
study. Drug regimens were reviewed for potential drug in-
teractions using a computer program and only those in-
teractions deemed to be moderate or high in clinical sig-
nificance were included in their data. Forty-seven percent
of the patients studied had potential drug interactions. The
incidence of potential drug interactions increased as the
number of total medications increased, ranging from 13%
for two drugs to 82% for seven or more medications. In
more than 50% of the patients, the drug interaction was re-
sponsible for the emergency department visit. Eleven drugs
were responsible for almost all of the potential interac-
tions and included: furosemide, digoxin, prednisone, theo-
phylline, enalapril, nifedipine, prochlorperazine, ranitidine,
glyburide, phenytoin, and aspirin.
In a prospective study, Herr et al. [17] examined medica-
tions being used by all patients at admission to the emer-
gency department and medications added by emergency
department physicians. Medications were entered into a
drug interaction program to screen for potential interactions.
Upon admission to the emergency department 30.3% of the
patients were at risk of a potential drug interaction. This
increased to 47.4% after being treated in the emergency de-
partment. However, only 9.7% of the interactions identified
upon admission to the emergency department and 3.1% of
the interactions caused by emergency department personnel
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pharmaceutical industry and the loss from the marketplace of effective drugs. For example, 
concurrent administration of terfenadine and cytochrome P450 3A (CYP3A) inhibitors, such as 
ketoconazole, itraconazole, erythromycin, has resulted in fatal arrhythmia (torsades de pointes), 
and led to the withdrawal of terfenadine (Seldane®) from US market in 1998 (Seldane (Rxlist)). 
Cisapride (Propulside®) had been discontinued in the US in 2000, due to ventricular arrhythmias 
caused by co-administration of CYP3A inhibitors (Michalets & Williams, 2000). Cerivastatin 
(Lipobay®) was withdrawn from the US market in 2001, due to rhabdomyolysis that leads to 
kidney failure in patients. This risk was caused by inhibition of cerivastatin’s uptake into liver 
and hepatic metabolic clearance by gemfibrozil and its metabolite gemfibrozil glucuronide 
(Furberg & Pitt, 2001). 
The topic of DDI has received a great deal of recent attention from regulatory, scientific and 
health care communities worldwide, and due to a large number of drugs introduced annually (45 
novel drug approval for 2015 in the US (Novel drug approval for 2015), pharmaceutical 
companies should investigate the interactions between a presumably new drug and other drugs 
during drug development process, as part of an adequate assessment of drug’s safety and 
effectiveness (FDA, 2012). The US Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) have both published guidelines on the investigation of drug 
interactions, and the main focus of these guidance is pharmacokinetic drug interactions 
(European Medicines Agency, 2012; FDA, 2012) 
 
1.2 Strategies to assess metabolic DDI 
Metabolic DDI, caused by the inhibition and/or induction of cytochrome P450s (CYPs), are 
the major components of DDIs. The general strategy to assess metabolic DDI is to begin with in-
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vitro studies to determine whether a drug is a substrate, inhibitor, or inducer of metabolic 
enzymes. The results of in-vitro studies, along with clinical pharmacokinetic (PK) data, may help 
with ruling out the need for additional in-vivo studies, or providing a proper design of clinical 
trials using a modeling and simulation (M&S) approach (FDA, 2012). If potential DDI is 
possible between investigational agent and other drugs, in-vivo clinical studies should be 
conducted to determine clinical recommendations for the DDI. In-vivo animal DDI studies may 
also be conducted during exploratory drug development process. However, final DDI 
recommendations should be based on results from in-vitro human enzymes, or in-vivo studies 
performed in humans (European Medicines Agency, 2012). A decision tree from FDA for 
metabolism-based DDI studies was demonstrated in Figure 1.2 (FDA, 2012).
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Figure 1.2  Metabolism-Based Drug-Drug Interaction Studies – Decision Tree (FDA, 2012).  
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In the in-vitro studies, if the investigational drug is a possible victim for any metabolic 
inhibition or induction, the need for in-vivo DDI studies are determined by quantitative 
measurement of the contribution of one specific enzyme or multiple metabolic enzymes to the 
overall systemic clearance of the drug. If the investigational drug is a possible perpetrator, the 
decision to conduct in-vivo study or not should be based on quantitative analysis of both in-vitro 
and clinical PK data, by using a variety of models (i.e. basic models, mechanistic static models, 
PBPK models, etc.).  
In the in-vivo studies, if the investigational drug is a possible victim for any metabolic DDI, 
in-vivo studies should start with a strong inhibitor/inducer of the targeted enzyme. If the results 
from the study with strong inhibitors/inducers indicate positive interactions, the impact of a less 
strong inhibitor/inducer should be evaluated. Generally, crossover designs in which same 
subjects receive victim drug in the absence and presence of perpetrator are more efficient. Dose 
of the substrate and interacting drug should maximize the possibility of DDI, thus the maximum 
planned or approved dose and shortened dosing interval of the interacting drug should be used. 
Sequence of administration and the time interval between dosing of substrate and 
inhibitor/inducer should also be chosen to maximize the DDI effect, depending on mechanism of 
DDIs. Other factors, such as safety, objectives of the studies, genetic polymorphism of targeted 
enzymes, clinical relevant usage, PK and pharmacodyanmic (PD) characteristics, etc., can also 
affect the selection of study design. Simulations (e.g., by PBPK models) can provide valuable 
insight into optimizing the study design. In most scenarios, in- vivo DDI studies can be 
performed in healthy volunteers, however, patient population may be used for the sake of safety 
considerations in healthy volunteers, or the intention to evaluate PD endpoints. 
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In terms of route of administration, generally, the route of administration should be the one 
planned for clinical use. However, DDI studies may need to be conducted on multiple routes of 
administration, if more than one route is being developed. The changes in PK parameters are 
generally used to assess clinical significance of DDI, such as change in area-under-the-curve 
(AUC), peak plasma concentration (Cmax) and time to peak concentration (tmax). DDI study 
results should be reported as 90% confidence intervals (CIs) of the geometric mean ratio of the 
observed PK measures of substrate with and without inhibitor/inducer. When the 90% CIs of the 
ratios fall entirely within the equivalence range of 80%-125%, no DDI effect can be claimed; 
otherwise, dosing recommendations should be provided based on clinical significance of the DDI. 
 
1.3 Use of Physiologically-based pharmacokinetic (PBPK) modeling in quantitative 
assessment of DDI 
To better inform clinical design and optimize dosing regimen for individual patients, 
physiologically-based pharmacokinetic (PBPK) models have increasingly been employed during 
drug discovery and development process (Huang & Rowland, 2012). A public workshop entitled 
“Application of Physiologically-based Pharmacokinetic (PBPK) Modeling to Support Dose 
Selection” was held by FDA on Mar 10, 2014, to discuss the role of PBPK in drug development 
and regulation (Wagner et al., 2015). Between 2008 and 2013, the US FDA received 84 
IND/NDA (Investigational New Drug/ New Drug Application) submissions containing PBPK 
modeling approaches (Zhao et al., 2011). Of these, 60% are related to the predictions of DDI 
(Zhao et al., 2011).. 
According to FDA drug interactions guidance, ‘PBPK is a useful tool that can help sponsors 
(1) better design drug-drug interaction studies, dedicated trials and population pharmacokinetic 
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studies, and (2) quantitatively predict the magnitude of drug-drug interactions in various clinical 
situations’ (FDA, 2012). Compared with conventional compartmental models, it integrates 
system-dependent parameters (based on physiological knowledge) and drug-dependent 
parameters (factors that influence ADME processes of the drug) into the description of PK, 
which offers clear advantages in certain situations. First, PBPK model can be used to simulate 
the dynamics of drug interactions after various doses, routes of administration or dosing intervals 
between victim and perpetrator drugs, and to evaluate the necessity for additional in-vivo studies. 
Second, it assumes a particular mechanism of drug interactions based on in vitro-in vivo 
extrapolation (IVIVE), which can be used to investigate the magnitude and time course of drug 
exposure in the tissues of interest. In addition, it can incorporate multiple patient intrinsic (e.g., 
age, gender, genetics, etc.) and/or extrinsic (e.g., organ dysfunction, etc.) factors into the 
prediction of patient-specific drug exposures, and allow the dosing recommendation or study 
design for specific population. The overall workflow and input information for a PBPK model to 
simulate a DDI study is demonstrated in Figure 1.3 (modified from Zhao et al. (2011)). Instead 
of traditional whole-body PBPK models, semiphysiologically-based pharmacokinetic (semi-
PBPK) models, which lump together body tissues that are not of interest, are more often utilized, 
to reduce the dimensionality and complexity of whole-body PBPK model (Cao & Jusko, 2012), 
but still allows the investigation of DDI at drug interaction sites (tissues). 
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Figure 1.3  Using a PBPK model to explore drug-drug interaction potential between a 
substrate drug and an interacting drug (FDA, 2012).  
 
 
1.4 Mechanism of metabolic inhibition  
Metabolic inhibition is a major component of DDI. During PBPK modeling process, 
different types of metabolic inhibition models should be applied at interaction sites (hepatocytes, 
enterocytes, etc.), according to mechanism of metabolic inhibition, in-vitro enzyme inhibitory 
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information, and unbound target tissue concentrations of perpetrator drug. Mechanisms and 
corresponding models used in different types of metabolic inhibition are discussed below, with 
focus on competitive, noncompetitive and mechanism-based inhibition (MBI). 
As to competitive inhibition, inhibitor and the substrate compete for the same enzyme active 
site, which prevents binding of substrate to it metabolic enzyme. It is usually a reversible 
inhibition, and the inhibitory effect can be overcome by increasing substrate concentration. 
Apparent binding affinity of substrate (Km’) depends on unbound concentration of inhibitor ([I]u) 
and binding affinity of inhibitor to the target enzyme (KI), and can be expressed as equation 
(1.1). Therefore, competitive inhibitor will decrease binding affinity of substrate (Km), but has no 
effect on maximum metabolizing velocity (vmax). K"# = K" ∙ (1 + ) *+, )                                                       (1.1) 
A scheme of competitive inhibition is shown in Figure 1.4 (Inhibition of Enzyme Activity, 
class handout). 
  
Figure 1.4  Scheme of competitive inhibition. 
E = enzyme, S = substrate, ES = enzyme-substrate complex, EI = enzyme-inhibitor complex, P = 
product, I = competitive inhibitor.  
 
 
As to non-competitive inhibition, inhibitor can bind to both substrate and enzyme-substrate 
complex with equal affinity (if not equal, it is call mixed inhibition) and to a different site with 
1
Inhibition of Enzyme Activity
Types of Inhibition:
Competitive
Noncompetitive
Uncompetitiv
Product Inhibiti
Suicide Inhibition
Competitive Inhibition
Fig 8-15
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substrate. However, when both the substrate and inhibitor are bound to the enzyme, this enzyme-
substrate-inhibitor complex cannot form product and can only be converted back to ES or EI. 
The inhibitor is not necessarily structurally similar to substrate, so it does not affect Km of 
substrate. However, since ES has a different fate (binding to inhibitor) other than forming 
product, the maximum velocity to produce the product (vmax) is decreased, and the extent of 
decrease is determined by [I]u and noncompetitive binding affinity to the enzyme or ES (KI, 
assuming same binding affinity to enzyme as to ES), shown in equation (1.2). This inhibition is 
also reversible inhibition. v"/0# = v"/0/(1 + ) *+, )                                                       (1.2) 
vmax’ is the apparent vmax in presence of noncompetitive inhibitor. 
 A scheme of non-competitive inhibition is shown in Figure 1.5. (Inhibition of Enzyme 
Activity, class handout) 
 
Figure 1.5  Scheme of noncompetitive inhibition. 
I = non-competitive inhibitor, ESI = enzyme-substrate-inhibitor complex, KI = affinity of 
noncompetitive inhibitor to enzyme, KI’ = affinity of noncompetitive inhibitor to enzyme-
substrate complex (might be equal to KI or not, if not, which is called mixed inhibition). 
 
 
 2
Competitive Inhibition
COMPETITIVE Equilibria Scheme
E  +  S           ES                  P    +    E
+
I
EI c
c
Kc
Km
slope = Km  . (1+ [I c] / K c) /  Vmax
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MBI is a form of irreversible enzyme inhibition. The inhibitor chemically resembles the 
substrate and binds to the active site in the same way as substrate binds. EI is then catalyzed to a 
reactive intermediate that could either be metabolized to product of inhibitor, or (more 
importantly) covalently bind to a moiety in the enzyme active site, resulting in chemically 
modification and inactivation of the enzyme protein (Yang et al., 2005). Since MBI is associated 
with irreversible loss of enzyme function and it takes time to synthesis new enzyme before 
activity is restored, it can typically cause hepatotoxicity and should be avoided in drug 
development. Due to the loss of enzyme activity, vmax is decreased by MBI, and Km does not 
change. A scheme of MBI is shown in Figure 1.6 (Rowland & Tozer, 2011; Yang et al., 2005).  
 
Figure 1.6  Scheme of MBI 
EI’ is the reactive enzyme-inhibitor intermediate, Ei is the inactivated enzyme, P is metabolite of 
MBI inhibitor. k1 and k-1 represents association and disassociation constants between inhibitor 
and enzyme, k2 is catalytic activity of EI to form EI’, k3 is the catalytic activity to form 
metabolite of MBI inhibitor, k4 is catalytic activity of enzyme inactivation. 
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To incorporate MBI in a PBPK model, a published PBPK model (Quinney et al., 2010) of 
DDI between MDZ and clarithromycin, which is a CYP3A MBI, is introduced here. At steady 
state, the amount of active CYP3A enzyme (E0) available in the liver or intestinal wall is 
determined by a zero-order synthesis rate (R0) and first-order degradation rate (kdeg) of enzyme. 
The rate of change of active enzyme (dEt/dt) in the absence of a CYP3A MBI is given by 
equation (1.3) 
23425 = R7 − k2:;×E7                                                (1.3) 
At steady state (equation 1.4), R7 = k2:;×E7                                                     (1.4) 
E0 is the baseline (at time 0) amount of active CYP3A. 
In the presence of a MBI, the degradation rate of enzyme is increased by an inactivation rate 
constant, kobs (equation 1.5), Rate	of	inactivation = kGHI×E(5) = JKLMN4×)4+,O)4 ×E(5)                        (1.5) 
 kinact is the maximum rate of enzyme inactivation, KI is the dissociation rate constant of the 
inhibitor, and It is the unbound concentration of inhibitor at the enzyme site at time t. kinact and KI 
can be described by k2, k3 and k4, shown in equation (1.6-1.7), which were mathematically 
derived in Tatsunami et al. (1981): kPQ/R5 = JSJTJSOJUOJT                                                     (1.6) K) = JVWOJSJW JSJTJSOJUOJT                                                 (1.7) 
 The rate of change of CYP3A in response to inactivation can be described by equation (1.8), 
23(4)25 = R7 − k2:;×E 5 − JKLMN4×)4+,O)4 ×E(5)                                 (1.8) 
 E(t) is the amount of active CYP3A enzyme present at time t.  
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 At time = t, GW and hepatic clearance of MDZ should be corrected by a factor of 
E(t),GW/E0,GW and E(t),hep/E0,hep, where subscript GW and hep represent GW and hepatic CYP3A 
enzyme, respectively. Among these parameters, R0 and kdeg can be estimated from in-vivo 
experiments measuring CYP3A recovery following enzyme MBI or inducer administration. KI 
and kinact can be obtained from in-vitro inhibitory studies. 
 
1.5 Known/suspected differences in DDI between IV and PO routes of administration 
and clinical significance of exploring routes of administration impact on DDI 
Different routes of administration of victim/perpetrator could have a different magnitude 
and/or time course for DDI. As is mentioned in FDA drug interactions guidance, the route of 
administration chosen for a metabolic DDI study is very important, and the possibility of 
formulation differences in the DDI potential should be considered when extrapolating interaction 
study results across formulations. Generally, the route of administration should be the one 
planned for clinical use, and ‘if multiple routes are being developed, the need for metabolic 
interaction studies by each route depends on the expected mechanisms of interaction and the 
similarity of corresponding concentration-time profiles for parent drug and metabolites’ (FDA, 
2012). 
The two commonly used routes, intravenous (IV) and oral (PO) routes of administration, are 
chosen as routes of interest in this project, because in contrast to IV administration, drugs can 
undergo absorption and/or pre-systemic clearance after PO administration. Figure 1.7 illustrates 
the physiological processes a drug has experienced after IV and PO administration. After IV 
administration, drug is injected into systemic blood, distributes into tissues through artery blood 
flows and eliminates by systemic hepatic clearance (CLhep) and/or other clearances (CLother), 
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such as renal clearance (CLren). After PO administration, drug gets into gut lumen first, and only 
the soluble and permeable drug (Fabs) can be absorbed into GW enterocytes. Within enterocytes, 
if possible, a fraction of drug could be metabolized by GW enzymes, and the rest of drug which 
survives from this pre-systemic GW metabolism (Fabs•FGI) permeates into portal vein. Drug in 
portal vein is then brought into liver through portal vein blood flow, and liver can pre-
systemically metabolize and/or excrete a portion of drug, and the rest reaches systemic 
circulation (Fabs•FGI•Fhep). The final fraction of drug gets absorbed into systemic circulation is 
oral bioavailability (Foral), which is a product of Fabs, FGI and Fhep. After it reaches systemic 
circulation, the drug behaves the same as after IV administration.  
 
Figure 1.7  Scheme of disposition processes a drug has experienced after IV and PO 
administration. 
Fabs is the fraction of PO dose absorbed from gut lumen, FGI is the fraction of absorbed drug that 
reaches portal vein, escaping first-pass GW metabolism. Fhep is the fraction of drug absorbed into 
portal vein that escaping hepatic pre-systemic clearance. ERhep is hepatic extraction ratio. CLGW 
is GW clearance 
 
 
 
Several clinical DDI studies (Gorski et al., 1998; Kharasch et al. 2005; Kupferschmidt et al. 
1995; Olkkola et al., 1993; Olkkola et al., 1996; Tsunoda et al., 1999) have investigated the 
impact of route of administration of MDZ, a typically used CYP3A substrate, on its inhibitory 
DDI by other CYP3A inhibitors (e.g. ketoconazole, itraconazole, fluconazole, erythromycin, 
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clarithromycin, etc.), and concluded that PO MDZ exposure is increased more by CYP3A 
inhibitors (CYP3AI) than IV MDZ exposure, mainly due to pre-systemic hepatic and GW 
inhibition. However, all the CYP3AI used in these studies were administered as PO 
administration. In terms of route of administration impact of perpetrator drugs, Ahonen et al. 
conducted a three-phase crossover study, to investigate 400mg IV 1 hour-infusion and PO FLZ’s 
inhibitory effect on PO MDZ. Their conclusions are the AUC0-3 and peak concentration (cmax) of 
MDZ were significantly higher after PO than after IV 1 hour-infusion FLZ, however, AUC0-∞ of 
MDZ were not statistically significant between different FLZ routes (Ahonen et al., 1997). 
Another study performed by Palkama et al. (1998) demonstrated that both IV 1 hour-infusion 
and PO 400mg FLZ result in the same inhibitory extent to IV alfentanil exposure, which is 
another CYP3A substrate. Nevertheless, no others were found to investigate route difference of 
perpetrator drugs on DDI outcome, and even for FLZ, route of administration impact of FLZ was 
not tested when IV MDZ or PO alfentanil was administered.  
The impact of routes of administration difference on the magnitude and time course of DDI 
outcome depends on the dynamic PK profiles of both victim and perpetrator drugs at the sites of 
drug-drug interaction, as well as the expected mechanism and potency of interaction. Dynamic 
PK profiles of either victim or perpetrator are determined by three factors: patient-specific (e.g., 
age, gender, genetics, ethnicity, etc.), drug-specific (e.g., Foral, elimination half-life, mechanism 
and potency of interaction, etc.) and dosing regimen-specific (e.g., dose, administration 
sequence/interval between perpetrator and victim, formulation, etc.) characteristics. In this 
research, the aim is to investigate the impact of routes of administration of both victim and 
perpetrator drugs on the magnitude and time course of metabolic DDI using semi-PBPK M&S. 
This may be beneficial to comprehensively assessing key factors that determine DDI differences, 
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and at which scenario the interaction study results can be extrapolated between different routes 
of administration without additional in-vivo DDI studies. 
 
1.6 Selection of prototypical drug metabolism enzyme (DME): CYP3A 
 CYP3A is the most important enzyme of the cytochrome P450 superfamily because of its 
abundance in the liver and intestine and its ability to metabolize more than half of therapeutic 
compounds that undergo oxidation.(Tsunoda et al., 1999) The CYP3A subfamily primarily 
consists of three known isoforms in humans – CYP3A4, CYP3A5 and CYP3A7 and CYP3A43 
(Isoherranen et al., 2008). Among adults, CYP3A4 is the dominant CYP3A enzyme in liver and 
small intestine. CYP3A5 is also found in adult liver and small intestine (Daly, 2006), and other 
organs, like kidney, colon and peripheral blood (Janardan et al., 1996), but its expression is 
clearly polymorphic. CYP3A7 is the major fetal liver CYP3A enzyme, although in rare cases, 
CYP3A7 mRNA has also been detected in adults (Williams et al., 2002). CYP3A43 has revealed 
a much lower catalytic activity, which is unlikely to contribute much to the metabolic clearance 
of CYP3A substrate (Daly, 2006). 
A number of different polymorphisms, which lead to complete absence of CYP3A5 
expression, are now known, with the CYP3A5*3 allele being by far the most common, and 
additional rare polymorphisms including CYP3A5*6 and CYP3A5*7 (Daly, 2006). In different 
populations, CYP3A5*3 has different distribution, with a frequency of 85-95% in Caucasians, 
60-73% in Asians and 27-50% in African Americans (Miao et al., 2009). CYP3A5*1 allele is the 
wild type of CYP3A5, and subjects who possess at least one copy of CYP3A5*1 allele do 
express CYP3A5 (Daly, 2006). Ethnicity also affect the expression of CYP3A5*1 allele, with 
African-Americans more commonly expressed CYP3A5 enzymes (more than 50%) than 
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Caucasians (10-20%) (Jonge et al., 2013). According to Lown et al. (1994), CYP3A4 and 
CYP3A5 are independently regulated in liver and small intestine. Some CYP3A inhibitors 
(ketoconazole (Shirasaka et al., 2013), itraconazole (Yu et al., 2004), fluconazole (Yang et al., 
2012), etc.) are more potent inhibitors to CYP3A4 than CYP3A5. 
 The activity of CYP3A can be influenced by many factors, like age, gender, hormones, and 
DDI, and all these factors can cause difficulty in the therapeutic use of CYP3A substrates. In 
addition, expression of CYP3A is independently regulated in intestine and liver (Tsunoda et al., 
1999), so it is likely that these factors may differently modulate intestinal and hepatic CYP3A 
activity. Therefore a practical in-vivo probe method that characterizes and quantitates both 
intestinal and hepatic CYP3A activity would be useful. 
 
1.7 Selection of prototypical CYP3A substrate: MDZ 
 MDZ is a commonly used CYP3A in-vivo probe substrate, which is a short acting 
benzodiazepine used for conscious sedation. MDZ can be administered both intravenously and 
orally, which allows both hepatic and intestinal metabolism investigation. Several PK properties 
make MDZ an attractive in-vivo probe for CYP3A. It is has a short half-life (t1/2), 1.8-6.4 h, and 
can be rapidly eliminated exclusively by CYP3A to one predominant metabolite (1ʹ-
hydroxymidazolam, 1’-OH-MDZ) with negligible renal elimination and limited P-glycoprotein 
(P-gp) modulation (Baxter Healthcare Corporation.; Tolle-Sander et al., 2003). More importantly, 
a large number of clinical DDI studies were conducted using IV or PO MDZ as a victim drug, 
and CYP3AI as perpetrators (see Chapter 3), providing diverse choices of CYP3AI (different 
mechanism of interaction, different PK properties, etc.) to make comparisons among them. In 
addition, several studies have compared inhibitory effect of PO CYP3AI (e.g., ketoconazole 
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(Chien et al., 2006), diltiazem (Zhang et al., 2009), clarithromycin (Quinney et al., 2010), 
voriconzole (Frechen et al., 2013), etc.) on MDZ after IV/PO administration by using semi-
PBPK models. Although research objectives were different in these publications, their model 
skeletons can be used as the basis of our MDZ PBPK model. 
 MDZ has a molecular weight (MW) of 325.77 g/mol, and the structure is shown in Figure 
1.8. Due to its low solubility when pH > 4 (Midazolam SciFinder Rerport), MDZ hydrochloride 
is formulated in sterile water for IV injection and syrup or tablet for PO administration. Each mL 
contrains MDZ hydrochloride equivalent to 1-5 mg MDZ in sterile water for injection (Baxter 
Healthcare Corporation.), and contains 2 mg MDZ in syrup (Ranbaxy Pharmaceuticals Inc., 
2013). Under the acidic conditions required to solubilize MDZ in the product, MDZ is present as 
an equilibrium mixture (shown in Figure 1.9) of the closed-ring form and an open-ring structure. 
The amount of open-ring form is dependent upon the pH of the solution. At the specified pH of 
sterile water for injection (pH = 2.5 – 3.7) and syrup (pH = 3.1 – 3.3), the solution may contain 
up to about 25% and 40 %, respectively, of the open-ring compound. At the physiological 
conditions under which the product is absorbed (pH of 5 to 8) into the systemic circulation, any 
open-ring form present reverts to the physiologically active, lipophilic, closed-ring form (MDZ), 
as shown in Figure 1.10. 
 
Figure 1.8  Structure of MDZ. 
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Figure 1.9  Equilibrium between closed-ring and open-ring form of MDZ (Ranbaxy 
Pharmaceuticals Inc., 2013). 
	
	
Figure 1.10  pH-dependence of open-ring form MDZ in water (Ranbaxy Pharmaceuticals 
Inc., 2013). 
	
 
MDZ is lipophilic (LogP = 3.78 (Midazolam SciFinder Rerport)) and highly plasma protein 
bound (97%), and the steady-state volume of distribution (Vdss) ranges from 1.0-3.1 L/kg 
(Midazolam Hydrochloride – Injection FDA Label). After IV administration, the urinary 
recovery of its metabolite (1’-OH-MDZ), as its glucuronide, accounts for at least 70% of an 
administered dose (Thummel et al., 1996). Formation of two minor metabolites, 4-
hydroxymidazoam (4-OH-MDZ) and 1’, 4-dihydroxymidazolam, are also catalyzed by CYP3A 
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and together, as glucuronide conjugates, comprise another 4%-6% of an administered dose 
(Thummel et al., 1996). Recent in-vitro (Hyland et al., 2009; Klieber et al., 2008) and in-vivo 
(Hyland et al., 2009) studies demonstrate that MDZ can also be metabolized directly by 
glucuronosyltransferase (UGT) and the glucuronide MDZ accounts for 1%-2% of total dose. 
After IV administration, MDZ can be only metabolized by hepatic CYP3A through systemic 
clearance; while after PO administration, it is rapidly and completely dissolved and permeates 
into intestinal epithelium (Heizmann et al., 1983) (BCS Class 1 drug (Wu & Benet, 2005)), and 
then subject to substantial intestinal and hepatic first-pass metabolism, before reaching systemic 
circulation (Ranbaxy Pharmaceuticals Inc., 2013). CYP3AI can inhibit all the three pathways 
(pre-systemic intestinal/hepatic metabolism, systemic hepatic metabolism), but the inhibitory 
extent on intestinal and hepatic CYP3A activity might be different.  
 
 
1.7.1 Metabolites of MDZ 
 
 1’-OH-MDZ and 4-OH-MDZ are the primary metabolites of MDZ, which are converted 
subsequently to N- and O-glucuronides by UGT (Yang et al., 2012). Their molecular weight is 
341.77 g/mol, with the structures shown in Figure 1.11 a-b. 1’-OH-MDZ has a larger total 
clearance than MDZ (680 ± 19 ml/min vs. 523 ± 31 ml/min) (Mandema et al., 1992); the plasma 
protein binding of 1’-OH-MDZ is 90%, and Vdss is 54 ± 4 L (Mandema et al., 1992). In-vivo 
studies in humans suggest that 1’-OH-MDZ is at least as potent as the parent compound and may 
contribute to the net pharmacologic activity of MDZ (Mandema et al., 1992). In-vitro studies 
have demonstrated that the affinities of 1’- and 4-OH-MDZ for the benzodiazepine receptor are 
approximately 20% and 7%, respectively, relative to MDZ (Mandema et al., 1992). It is reported 
that relatively high concentration of 1’-OH-MDZ was observed after PO administration of MDZ, 
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and can shift the concentration-effect relationship of MDZ based on reaction time measurements 
more to the left than IV route (Mandema et al., 1992). The formation of 1’-OH-MDZ had the 
characteristics of substrate-inhibition kinetics when tested with recombinantly expressed 
CYP3A4, and its formation can be inhibited by CYP3AI, like fluconazole, to a greater extent 
than 4-OH-MDZ, resulting in a metabolic switch to 4-OH-MDZ pathway (Yang et al., 2012). 
                               a)                                                             b) 
                  
Figure 1.11  Structure of metabolites of MDZ. 
Structure of metabolites of MDZ. a) 1’-OH-MDZ. b) 4-OH-MDZ. 
 
1.8 Selection of prototypical CYP3AI: Fluconazole (FLZ) and Erythromycin (ERY) 
1.8.1 FLZ 
 
 FLZ is an azole antifungal drug, which can be administered by both IV and PO 
administration clinically. This is the only CYP3AI that clinical DDI studies of both IV and PO 
FLZ are available (Ahonen et al., 1997), using MDZ as victim drug, which allows us to validate 
DDI semi-PBPK model between IV perpetrator and victim drug. “Validate” or “Validation” 
throughout the dissertation indicates that the semi-PBPK models were verified and sometimes 
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optimized, if necessary, by observed clinical studies, and in other literatures, “qualification” or 
“calibration” might be used to indicate the same meaning. 
 FLZ has a MW of 306.27 g/mol, and the structure is shown in Figure 1.12. FLZ is sparingly 
soluble at pH range of 3-8 (solubility = 0.98 g/L at pH of 3; solubility ≈ 0.30 g/L at pH = 4-8). 
FLZ is formulated as sterile solution for IV injection, and as power (for suspension) or tablet for 
PO administration. IV FLZ injection solution is usually formulated in a sodium chloride or 
dextrose diluent, and each mL contains 2 mg of FLZ and 9 mg of sodium chloride or 56 mg of 
dextrose, hydrous. PO FLZ tablets and suspension are formulated with several inactive 
ingredients, as details listed in DIFLUCAN label (Pfizer, 2011). The PK properties of FLZ are 
similar following IV and PO administration, with Foral above 90% (Humphrey et al., 1985; 
Pfizer, 2011; Washton, 1989), which is defined as BCS Class 1 drug (Lindenberg et al., 2004). It 
is less lipophilic (logP = 0.4 (DrugBank Fluconazole)), and low plasma protein bound (11%-
12%) (Humphrey et al., 1985), and Vdss is about 0.7 L/kg in humans (Humphrey et al., 1985; 
Carrasco-Portugal & Flores-Murrieta, 2007); the ratio of distribution to different tissues is near 
to 1 (Carrasco-Portugal & Flores-Murrieta, 2007). FLZ is cleared primarily by renal excretion, 
and approximately 70% (Humphrey et al., 1985; Ripa et al., 1993; Sobue et al., 2004; Washton, 
1989) of the administered dose appear in the urine as unchanged drug. About 11% of the dose is 
excreted in the urine as metabolites and only two metabolites are present in detectable quantities, 
a glucuronide conjugate of unchanged FLZ and a FLZ N-oxide, which account for 6.5 and 2.0% 
of an administered dose (Brammer et al., 1991; Pfizer, 2011). Renal clearance is reported to be 
0.2ml/min/kg on average (Ripa et al., 1993; Sobue et al., 2004), and all non-renal pathways are 
assumed to be hepatic metabolism. The mean terminal plasma elimination t1/2 ranges from 22 to 
37 hours, indicating its prolonged inhibitory effect on hepatic and intestinal CYP3A. It is a less 
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profound (moderate) CYP3AI (Kharasch et al., 2005; Drug Interactions & Labeling Drug 
Development and Drug Interactions Table of Substrates, Inhibitors and Inducers), which can 
non-competitively inhibit hepatic and intestinal CYP3A (Gibbs et al., 1999; Isoherranen et al., 
2008), with comparable KiFLZ to human intestinal and hepatic microsomes (10.7 ± 4.2 µM and 
10.4 ± 2.9 µM, respectively) (Isoherranen et al., 2008).  
 
Figure 1.12  Structure of FLZ. 
	
	
1.8.2 ERY 
 
 ERY is a macrolide antibiotic which is active against gram-positive bacteria and some gram-
negative bacteria (Hospira, 2013). It can be administered both intravenously and orally, and 
different oral dosage forms are available, such as enteric coated tablet, ERY stearate, ERY 
ethylsuccinate, to avoid its degradation by gastric acid. It is a commonly used mechanism-based 
CYP3AI, and metabolites of ERY has no clinical significant CYP3AI (Zhang, 2007), if any, 
could largely increase the complexity of DDI semi-PBPK model between ERY and MDZ. 
 ERY has a MW of 733.94 g/mol, and the structure is shown in Figure 1.13. It is a basic and 
less lipophilic drug (pKa = 8.8, logP = 0.8 (DrugBank Erythromycin; Erythromycin Scifinder 
Report)), with very high solubilityi across physiologically relevant pH (solubility > 73 g/L at pH 
1-8). ERY is known to exhibit a predominant binding to α1-acid glycoprotein (AAG) at 
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therapeutic relevant concentrations, and to albumin at higher than therapeutic concentrations 
(Dette & Knothe, 1986) (fu = 0.31 after 500mg IV ERY in-vivo (Suarez et al.)), resulting in 
increasing Vdss with dose (Austin et al., 1980). Vdss at 125mg IV ERY is 0.47L/kg (Austin et al., 
1980), still larger than blood volume, indicating that ERY is well distributed in the body. Tissue 
levels (e.g. liver, spleen, kidneys, and lungs) are generally higher than serum levels and persist 
longer (Suarez et al.). After IV administration, ERY unbound hepatic clearance is similar to 
hepatic blood flow (Qhep) (Barre et al., 1987), indicating its high hepatic extraction ratio (ERhep). 
It is partially metabolized by CYP3A to its major metabolite N-demethyl-erythromycin (nd-
ERY). Integration of CO2 flux to time infinity, measured in Erythromycin breath test (EBT), 
demonstrated that only up to 1/3 of ERY is metabolized by CYP3A at low dose (Rivory et al., 
2001). As a substrate for P-gp and MRP2 (Kurnik et al., 2006) (Km unknown), mean bile levels 
of ERY were approximately 10 times higher than corresponding serum concentration 1 h after 
I.V. ERY (Chelvan et al., 1997) in human, indirectly indicating that biliary excretion might be a 
major route of elimination of ERY. Only 2-15% of unchanged ERY is observed in urine, 
depending on dose. t1/2 of ERY is about 1.5-2 hours (Austin et al., 1980). After PO 
administration, Foral of ERY is quite variable (18%-45%) (Somogyi et al., 1995), and due to 
extensively hydrolysis by gastric acid, enteric-coated tablets or pellets, less soluble salts and pro-
drugs are adopted as dosage forms. It is a BCS Class 3 drug (Heizmann et al., 1983), and pre-
systemic intestinal/hepatic CYP3A metabolism and biliary excretion may also prevent the 
absorption of ERY into systemic circulation. ERY can inhibit CYP3A by irreversibly binding, 
resulting in MBI of CYP3A. KIERY and kinactERY measured in in-vitro experiments (Ito et al., 
2003; McConn et al., 2004; Rowland et al., 2011; Xu et al., 2009; Yamano et al., 2001; Yates et 
al., 2012; Zhang et al., 2009; Zhang et al., 2010; Ping et al., 2005) using human liver microsomes 
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(HLM) were highly variable, with KIERY ranged from 1.48 – 109 µM and kinactERY ranged from 
0.017 – 0.066 min-1.  
 
Figure 1.13  Structure of ERY. 
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CHAPTER 2 
 
 
2 HYPOTHESIS, SPECIFIC AIMS AND OVERALL STRATEGIES 
 
 
 
 
2.1 Hypothesis 
 
The route of administration (IV vs PO) for MDZ, a prototypical CYP3A substrate, and 
prototypical CYP3AI will affect the magnitude and time course of their metabolic DDI, due to 
different sites of metabolic interaction (i.e., liver, GW). The DDI depends on the PK 
characteristics of the CYP3AI (Foral, dose/time-dependent PK, etc.), mechanism and potency of 
inhibition, dosing regimen (dose, single vs. repeat- dosing, different formulations, etc.) and 
administration time interval between MDZ and CYP3AI.  
2.2 Specific Aims 
The overall objective of this research is to explore the impact of differences between IV and 
PO route of administration for both victim drugs (MDZ and hypothetical substrates) and 
perpetrator drugs (CYP3AI) on the magnitude and time course of CYP3A-mediated metabolic 
DDI (i.e., plasma concentration-time profile and exposure metrics (cmax, tmax, AUC)). To 
accomplish this objective, the specific aims are as follows:  
1) Assess the contribution of intestinal and hepatic CYP3A metabolism to the PK of MDZ after 
IV and PO administration in humans. In addition, compare the inhibitory effect of various 
CYP3AI on the hepatic and intestinal metabolism of MDZ by conducting an exhaustive 
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literature search and a quantitative meta-analysis. Select CYP3AI of interest for further 
PBPK modeling. 
2) Build and validate a semi-PBPK model for MDZ, to predict its plasma, hepatic and GW 
concentrations after IV or PO administration. 
3) Build and validate a semi-PBPK model for FLZ (a highly oral bioavailable, noncompetitive 
CYP3AI), to predict its plasma, hepatic and GW concentrations after IV or PO 
administration. 
4) Build and validate a semi-PBPK metabolic inhibition model between MDZ and FLZ. Assess 
route-dependent DDI profiles by simulations (IV MDZ and IV FLZ, IV MDZ and PO.FLZ, 
PO MDZ and IV FLZ, PO MDZ and PO FLZ) 
5) Build and validate a semi-PBPK model for ERY (a relatively poorly orally bioavailable, 
mechanism-based CYP3AI), to predict its dose-/time-dependent PK, and predict its plasma, 
hepatic and GW concentrations after IV or PO administration 
6) Build and validate a semi-PBPK metabolic inhibition model between MDZ and ERY. Assess 
route-dependent DDI by simulations (IV MDZ and IV ERY, IV MDZ and PO ERY, PO 
MDZ and IV ERY, PO MDZ and PO ERY) 
7) Generate hypothetical MDZ-like substrates and FLZ- (ERY-) like CYP3AI by changing key 
PK properties and compare their route-dependent DDI profiles 
2.3 Overall strategy 
 In order to accomplish the specific aims and test the research hypothesis, the following steps 
were followed: 
a. Extensive literature search and quantitative meta-analysis were carried out to collect 
human PK information for both MDZ and the selected CYP3AI (i.e., FLZ and ERY) after 
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IV and PO administration.  
b. The semi-PBPK models for MDZ and CYP3AI were developed separately based on 
compiled clinical PK information and physiological parameters from the literature. 
Models were validated by clinical PK profiles after IV and PO administration for each 
drug, and sensitivity analyses were performed to optimize model parameters and identify 
key parameters. 
c. The drug interaction models between MDZ and CYP3AI for GW and liver CYP3A were 
established from in-vitro studies and were subsequently validated by clinical DDI studies. 
Sensitivity analyses were performed to identify key model parameters. 
d. Final DDI semi-PBPK models were used to investigate impact of route of administration 
for MDZ and CYP3AI at different clinical scenarios (i.e., various doses, different 
administration time interval, formulation, etc.). A series of hypothetical drugs were also 
simulated to come up with general (proposed) rules regarding route-dependent DDI. 
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CHAPTER 3 
 
 
3 QUANTITATIVE META-ANALYSIS OF MDZ PK AFTER IV/PO 
ADMINISTRATION WITHOUT AND WITH IV/PO CYP3AI 
 
 
 
 
3.1 Background and Objective 
 
 MDZ is a prototypical CYP3A substrate, with negligible renal clearance and P-gp 
modulation (Baxter Healthcare Corporation; Tolle-Sander et al., 2003). Due to the abundance of 
CYP3A in small intestine and liver, MDZ could be metabolized by both intestinal and hepatic 
CYP3A enzyme. Intestinal CYP3A metabolism of MDZ is generally assumed to occur during 
first-pass metabolism only, thus, IV MDZ is only cleared by systemic hepatic CYP3A 
metabolism, whereas PO MDZ is exposed to both intestinal and hepatic pre-systemic metabolism, 
as well as systemic hepatic clearance. It will be of interest to assess the contribution of intestinal 
and hepatic CYP3A to the overall metabolic clearance of MDZ.  
 In presence of CYP3AI, pre-systemic intestinal/hepatic metabolism and systemic hepatic 
metabolism may be inhibited to different extent, due to the mechanism, potency, and PK profiles 
of CYP3AI. More specifically, a study by Kharasch et al. (2005) investigated the dose-dependent 
CYP3A inhibition by FLZ, in which 12 subjects received IV or PO MDZ in absence or presence 
of single dose of 100, 200, or 400 mg PO FLZ. Dose/concentration-dependent inhibition of FLZ 
on IV/PO MDZ could be determined through this study. Furthermore, Ahonen et al (1997) 
performed a double-dummy, randomized, 3-way cross-over study in 9 healthy volunteers, in 
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which subjects were dosed with PO MDZ in absence or presence of either IV or PO FLZ. This 
study can be used to compare the route-dependent inhibitory effect on intestinal and hepatic 
metabolism of MDZ. 
 In addition, MDZ is mainly metabolized to 1’-OH-MDZ, with urinary recovery of 1’-OH-
MDZ, as its glucuronide, accounts for at least 70% of an IV MDZ dose. (Thummel et al., 1996) 
Therefore, the formation of 1’-OH-MDZ by pre-systemic intestinal and pre-systemic/systemic 
hepatic CYP3A can also implicate their contribution to MDZ clearance, as well as the inhibitory 
effect on GW and hepatic CYP3A. 
The major objectives of this chapter were to: 
a. Assess the contribution of intestinal and hepatic CYP3A to the overall metabolic 
clearance of MDZ and systemic/pre-systemic formation of 1’-OH-MDZ 
b. Compare the effects of various CYP3AI on PK of MDZ and formation of 1’-OH-MDZ 
c. Determine the dose/concentration-dependent inhibition of PO FLZ 
d. Investigate the route-dependent inhibitory effect on intestinal and hepatic metabolism of 
IV/PO FLZ. 
 
3.2 Methods 
3.2.1 Data collection 
 
 An extensive literature search was carried out in PubMed, to search for any MDZ PK studies 
with CYP3AI in humans. MDZ was to have been administered both intravenously and orally, 
and plasma exposures (their means and standard deviations (SD)) after IV and PO administration 
should be well estimated and provided for both control and inhibitor treatment groups. Due to the 
age-related decline in the metabolism of MDZ (Dundee et al., 1985), studies in the elderly (age > 
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60 years) were excluded from the final database. There is also evidence showing that Japanese 
have significantly lower systemic clearance of MDZ than Caucasians (Ozawa et al., 2004); thus 
one study in the Asian population was also excluded. All studies were to have been conducted in 
healthy volunteers without any co-medications, except women who may have used oral 
contraceptives. All the exposure metrics (AUC, cmax, etc.), demographics, study design (dose, 
sample size, sampling time, etc.) and bio-analytical (LLOQ, assay method, etc.) information for 
both MDZ and 1’-OH-MDZ were extracted from the studies.  
3.2.2 PK dose-proportionality assessment 
 
 Most secondary PK parameters are derived and interpreted based on the assumption of linear 
PK. Therefore, it is necessary to determine dose-proportionality of both MDZ and 1’-OH-MDZ. 
Mean plasma exposures of MDZ and 1’-OH-MDZ were plotted against their corresponding 
MDZ dose after IV and PO administration on log scales. A power model (y = axb) was then fit 
the data; an exponent value of 1 indicates dose-proportional PK. 95% CI of the exponent, b, was 
generated by JMP Pro 9.0 (SAS, Cary, NC) to assess if there was significant deviation from 1 (p 
< 0.05).  
 According to several clinical studies (Yang et al., 2012; Mandema et al., 1992), 1’-OH-MDZ 
is an active metabolite of MDZ, presumably equally potent as MDZ. Estimation of metabolic 
ratio (MR) is a method to evaluate the exposure of metabolite relative to the parent compound 
(MDZ). The equation to calculate MR is as follows, MR = YZ[\]4YZ[^_` ∙ (ab^_`ab\]4 )                                              (3.1) 
 MWMDZ is the molecular weight of MDZ, 325.78 g/mol; MWmet is the molecular weight of 
1’-OH-MDZ, 341.77 g/mol; AUCmet is AUC of 1’-OH-MDZ. In some studies, AUC ratio 
between MDZ and 1’-OH-MDZ was provided instead of AUCmet, thus AUCmet was calculated 
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accordingly. Furthermore, one-way analysis of variance (ANOVA) was used to compare MR 
across various doses. Finally, AUCmet was plotted against AUCMDZ, after both IV and PO routes, 
to detect nonlinear formation or elimination of 1’-OH-MDZ. Superscripts ‘MDZ’ and ‘met’ refer 
to MDZ and 1’-OH-MDZ, respectively; subscripts ‘IV’ and ‘PO’ refer to different route of 
administration of MDZ. If not mentioned otherwise, AUC refers to AUC from time 0 to 
infinitive. 
3.2.3 Estimation of secondary PK parameters in the absence of CYP3AI 
 
 In all of the following equations, it is assumed that MDZ and 1’-OH-MDZ follow dose-
proportional PK within corresponding IV and PO MDZ dose ranges. 
3.2.3.1 MDZ (parent compound) 
 
 The algorithms of estimating secondary PK parameters for IV and PO MDZ in absence of 
CYP3AI are presented in Figure 3.1 and Figure 3.2, respectively. 
 After IV administration of MDZ, total plasma clearance (CLtot,pMDZ) was calculated by 
administered dose (DoseIVMDZ) and AUC after IV MDZ (AUCIVMDZ) as follows: 
    CL5G5,fagh = gGI:,i^_`YZ[,i^_`                                                        (3.2) 
 A value of 0.86 (Chien et al., 2006) was used as blood to plasma partitioning ratio (B:PMDZ), 
in order to convert CLtot,pMDZ to total blood clearance (CLtot,bMDZ). Since MDZ is exclusively 
metabolized by CYP3A and has negligible renal clearance, hepatic extraction ratio (ERhepMDZ) 
was then calculated as follows: 
 ERj:fagh = [k4l4,m^_`no]p                                                         (3.3) 
where Qhep is hepatic blood flow, fixed at 21.4 mL/min/kg (Tsunoda et al., 1999). The 
fraction of MDZ dose absorbed into portal vein that escapes liver pre-systemic metabolism (Fhep) 
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was then estimated by equation (3.4): 
      Fj:fagh = 1 − ERj:fagh                                                     (3.4) 
Hepatic intrinsic clearance (CLint,hepMDZ), after fuMDZ correction, was estimated by equation 
(3.5), assuming that MDZ is in equilibrium between hepatocytes and venous outflow (well-
stirred model): 
    fragh ∙ CLPQ5,j:fagh = no]p∙[k4l4,m^_`no]ps[k4l4,m^_`                                                  (3.5) 
After PO administration of MDZ, the oral bioavailability of MDZ (ForalMDZ) was estimated as 
follows, assuming dose-proportional PK: 
FGt/uagh = YZ[,i^_` gGI:,i^_`YZ[vw^_` gGI:vw^_`                                                  (3.6) 
The overall pre-systemic extraction ratio (ERpresysMDZ) was determined by equation (3.7): ERft:IxIagh = 1 − FGt/uagh                                                 (3.7) 
Under the assumption that CLint,hepMDZ and Qhep remain the same for systemic and pre-
systemic metabolism, the fraction of MDZ dose that reaches portal vein (FabsMDZ·FGIMDZ) was 
calculated as follows: 
F/HIagh ∙ Fy)agh = zl{M|^_`zo]p^_` = zl{M|^_`}s3~o]p^_`                                               (3.8) 
FabsMDZ is the fraction of MDZ dose absorbed from gut lumen, and FGIMDZ is the fraction of 
absorbed MDZ dose that reaches portal vein, escaping first-pass GI wall metabolism.  
Based on the BCS class (Wu & Benet, 2005) and physicochemical properties(Andersin, 1991) 
of MDZ, MDZ is a BCS class 1 drug, (FabsMDZ > 90%), with high solubility (soluble in 250 ml or 
less of aqueous media over a pH range of 1–7.5 at 37°C (Wu & Benet, 2005)) and high 
permeability (the extent of the absorption (parent drug plus metabolites) in humans is determined 
to be ≥ 90% of an administered dose based on a mass balance determination or in comparison to 
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an intravenous reference dose (Wu & Benet, 2005)). Therefore, FabsMDZ is assumed to be 100%. 
The pre-systemic gastrointestinal extraction ratio (ERGIMDZ) was then calculated by equation 
(3.9): ERy)agh = 1 − Fy)agh                                                           (3.9) 
 ERpresysMDZ versus ERhepMDZ, ERGIMDZ versus ERhepMDZ and ERpresysMDZ versus ERGIMDZ were 
plotted to compare the pre-systemic hepatic and intestinal CYP3A metabolism of MDZ. JMP Pro 
9.0 (SAS, Cary, NC) was used to estimate the correlation coefficient between the two variables 
in each comparison pair, and if the correlation coefficient (r) was larger than 0.9, linear 
regression was conducted for the two variables. 
 
Figure 3.1  Equations and assumptions used in estimating secondary PK parameters for 
MDZ after IV administration. 
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Figure 3.2  Equations and assumptions used in estimating secondary PK parameters for 
MDZ after PO administration. 
 
3.2.3.2 1-hydroxy-midazolam (1’-OH-MDZ, metabolite) 
 
Using the corresponding AUCmet information, Foralmet’ (apparent oral bioavailability of 1’-
OH-MDZ after PO MDZ) was estimated as follows: 
  FGt/u":5# = YZ[vw\]4 gGI:vw^_`YZ[,i\]4 gGI:,i^_`                                              (3.10) 
Combining equation (3.1), (3.6) and (3.10), we can obtain: 
  zl{M|\]4zl{M|^_` = a~vwa~,i                                                       (3.11) 
MRIV and MRPO are the metabolic ratio after IV and PO MDZ, respectively. If Foralmet’ is 
greater than ForalMDZ (MRPO/MRIV > 1), it indicates that formation of 1’-OH-MDZ also occurs 
pre-systemically.  
AUC of 1’-OH-MDZ after IV MDZ (AUCIVmet) can be estimated as follows: 
AUC)Ç":5 = gGI:,i^_`∙(^É\]4^É^_`)∙Ñ\]4[k4l4,p\]4                                                  (3.12) 
fmet is the fraction of IV MDZ dose that converted to 1’-OH-MDZ, CLtot,pmet is the total 
plasma clearance of 1’-OH-MDZ after IV 1’-OH-MDZ. 
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Likewise, AUCmet after PO administration of MDZ that formed by systemic metabolism 
(AUCsysmet) can be estimated as follows, under the major assumption that both fmet and CLtot,pmet 
remain the same after IV and PO routes of MDZ. 
 AUCIxI":5 = gGI:vw^_`∙zl{M|^_`∙(^É\]4^ÉpN )∙Ñ\]4[k4l4,p\]4                                       (3.13) 
Thus, AUCsysmet can then be derived as 
   AUCIxI":5 = AUC)Ç":5 ∙ (gGI:vw^_`gGI:,i^_`) ∙ FGt/uagh                                    (3.14) 
 AUCmet formed pre-systemically (AUCpresysmet) can be estimated from AUCPOmet as follows:  AUCft:IxI":5 = AUCÖÜ":5 − AUCIxI":5                                             (3.15) 
To separate AUCmet formed pre-systemically by liver and GW, Figure 3.3 and Table 3.1 
illustrates the estimation methods.  
 
 
Figure 3.3  Scheme of MDZ pre-systemic metabolism. 
fpresys-GImet, fpresys-hepmet and fsysmet are corresponding fmet of pre-systemic GI metabolism, pre-
systemic hepatic metabolism and systemic clearance.  
 
 
Table 3.1  Composition of AUCPOmet formed by pre-systemic GI/hepatic and systemic 
hepatic metabolism. 
 
Composition Fraction of PO MDZ dose left in the compartment 
Fraction 
converted to 1’-
OH-MDZ 
AUCPOmet of 1’-OH-MDZ formed 
Gut lumen 1-FabsMDZ 0 0 
     Pre-systemic GW 1-FGIMDZ fpresys-GImet Dose·FabsMDZ·(1-FGIMDZ)· fpresys-GImet /CLtot,pmet 
Pre-systemic Liver FabsMDZ·FGIMDZ·(1-FhepMDZ) fpresys-hepmet 
Dose·FabsMDZ·FGIMDZ·(1-FhepMDZ)·fpresys-hepmet 
/CLtot,pmet 
Systemic Liver FabsMDZ·FGIMDZ·FhepMDZ fsysmet Dose·FabsMDZ·FGIMDZ·FhepMDZ·fsysmet /CLtot,pmet 
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 fpresys-GImet, fpresys-hepmet and fsysmet are assumed to be the same, referred as fmet. CLtot,pmet is also 
presumed to be the same for pre-systemic GW metabolism, pre-systemic hepatic metabolism and 
systemic metabolism. However, it is likely that due to the different enzyme expression/activity 
(CYP3A or UGT) and/or different drug permeability into the liver and GW, fmet and/or CLtot,pmet 
for GW metabolism and pre-/systemic hepatic metabolism may be quite different.  
 Based on equations (3.12), (3.14) and Table 3.1, AUCmet after PO administration of MDZ 
that is formed by pre-systemic hepatic metabolism (AUCpresys-hepmet) was estimated as follows: 
AUCft:IxIsj:f":5 = AUCIxI":5 ∙ zMmá^_`∙zà,^_`∙(}szo]p^_`)zl{M|^_`                                       (3.15) 
AUCmet after PO administration of MDZ that formed by pre-systemic GW metabolism 
(AUCpresys-GImet) was estimated as equation (3.16): AUCft:IxIsy)":5 = AUCft:IxI":5 − AUCft:IxIsj:f":5                                      (3.16) 
Furthermore, AUCmet after PO administration of MDZ that formed by hepatic (pre-systemic 
+ systemic) metabolism (AUChepmet) can be estimated as follows: AUCj:f":5 = AUCIxI":5 ∙ zMmá^_`∙zà,^_`zl{M|^_`                                                (3.17) 
Meanwhile, based on equation (3.1) and (3.12), MRIV can be calculated as follows, MR)Ç = Ñ\]4∙[k4l4,p^_`[k4l4,p\]4                                                      (3.18) 
AUCpresysmet versus AUCpresys-hepmet, AUCpresys-GImet versus AUCpresys-hepmet and AUCpresysmet 
versus AUCpresys-hepmet were plotted to compare the pre-systemic hepatic and intestinal formation 
of 1’-OH-MDZ. The correlation coefficient between the two variables in each comparison pair 
was estimated by JMP Pro 9.0 (SAS, Cary, NC), and if the correlation coefficient (r) was larger 
than 0.9, linear regression was conducted for the two variables.  
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3.2.4 Estimation of inhibitory effect on hepatic and intestinal metabolism by CYP3AI 
 
Secondary parameters in presence of inhibitors: ERhep(i)MDZ, ERGI(i)MDZ, ERpresys(i)MDZ, 
CLint,hep(i)MDZ, Foral(i)MDZ, FGI(i)MDZ and Fhep(i)MDZ were estimated by using the method in Section 
3.2.3.1, assuming that Qhep, fuMDZ and FabsMDZ remain the same after co-administration of 
CYP3AI. MR(i), Foral(i) met’, AUCsys(i) met, AUCpresys(i) met, AUCpresys-hep(i) met, AUCpresys-GI(i) met and 
AUChep(i) met were calculated by the method in Section 3.2.3.2, assuming fraction unbound of 1’-
OH-MDZ (fumet) remains the same in the presence of CYP3AI. The subscript (i) refers to the 
corresponding parameter in the presence of CYP3AI. The ratios of ERhep(i)MDZ, CLint,hep(i)MDZ, 
Foral(i)MDZ, FGI(i)MDZ, AUC (i)met and MR(i) over baseline values, in absence of inhibitor, (indicated 
as “inhibition ratio” for ERhepMDZ, CLint,hepMDZ, AUCmet and MR(i), and “relative change” for 
Foral(i)MDZ and FGI(i)MDZ were plotted against the baseline values. The correlation coefficient 
between the two variables was estimated by JMP Pro 9.0 (SAS, Cary, NC), and p < 0.05 was 
considered as significantly correlated. 
3.2.5 Dose/concentration-dependent inhibition of FLZ 
 
Dose/concentration-dependent inhibition on intestinal and hepatic MDZ metabolism was 
determined by the data from Kharasch et al (2005) (study 21) and Ahonen et al (1997) (study 
103), both using FLZ as CYP3AI.  
 In study 21, twelve volunteers were enrolled in a randomized 4-way crossover study, 
separated by at least 2 weeks between each session. They received single dose of 0, 100, 200, or 
400 mg PO FLZ, followed 2 hour later by 1mg IV MDZ; the next day, they received the same 
dose of FLZ, followed by 3 mg PO MDZ. Plasma concentrations of MDZ after IV and PO 
administration were both determined up to 8 h. CLint,hepMDZ, ERhepMDZ and ERGIMDZ were then 
calculated using the method in Section 3.2.3.1 for control and FLZ treatment groups, and the 
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inhibition ratios of CLint,hepMDZ, ERhepMDZ and  ERGIMDZ were plotted against FLZ exposure 
metrics (FLZ dose, cmax-lumenFLZ, cmax-GIFLZ and cmax,u-hepFLZ).   
 cmax-lumanFLZ is the maximal concentration of FLZ in the gut lumen (apical side of GW). It was 
calculated as follows, assuming FLZ was dissolved in 250 ml aqueous media. c"/0sur":Qzkh = gGI:vwâä`ãå7                                                       (3.19) 
 cmax-GIFLZ is the maximal concentration of FLZ in the enterocytes. It was calculated by 
equation (3.20) (FDA, 2012): c"/0sy)zkh = zMmáâä`∙JMâä`∙gGI:vwâä`n]L                                             (3.20)  
 Qen is the enterocyte blood flow, which is 4.3 mL/min/kg (FDA, 2012). FabsFLZ was assumed 
to be 100%, due to its BCS class 1 (Lindenberg et al., 2004; World Health Organization, 2005) 
property. A value of 1.28 h-1 was used for FLZ absorption rate constant (kaFLZ) (Olkkola et al., 
1996). 
 cmax,u-hepFLZ is the maximal FLZ concentration in the hepatocyte, which was calculated as 
follows (FDA, 2012), 
c"/0,rsj:fzkh = frzkh ∙ (c"/0,rzkh + k/zkh ∙ F/HIzkh ∙ Fy)zkh ∙ gGI:vwâä`no]p )                                (3.21)  
 Qhep was fixed at 21.4 mL/min/kg (Tsunoda et al., 1999), FabsFLZ and FGIFLZ were both 
assumed to be 100%. fuFLZ is 0.88, based on the experiment from Ripa et al. (1993) (K T Olkkola 
et al., 1996). cmax,uFLZ is the maximal unbound blood/plasma concentration of FLZ, which was 
calculated by equations (3.22) - (3.24) (Dhillon & Gill, (2006)), assuming FLZ follows 1-
compartmental body model with first-order elimination (Humphrey et al., 1985): 
c"/0,rzkh = Ñ*âä`∙zl{M|âä` ∙gGI:vwâä`∙:Vç]âä`∙4\Méâä`Ç2âä`                                             (3.22) 
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t"/0zkh = kQ(JMâä`)skQ(J]âä`)JMâä`sJ]âä`                                                 (3.23) k:zkh = 7.êëí5W/Sâä`                                                          (3.24) 
 ForalFLZ is assumed to be 100%, due to its high oral bioavailability ( > 90%) (Ripa et al., 
1993); t1/2FLZ was set at 30 h; VdFLZ is 0.7 L/kg (Olkkola et al., 1996), and 70 kg was used for 
body weight. FLZ plasma concentration was assumed to be the same as blood concentration 
(B:PFLZ = 1.0) (Ervine & Houston, 1994). 
 Nonlinear regression using a hyperbolic model (y = }îîïñâä`O}) was performed for each relationship 
using Scientist v2.0 (Micromath®, MO) to estimate D50FLZ, cmax-lumen,50FLZ, cmax-GI,50FLZ  and cmax,u-
hep,50
FLZ (X represents dose, cmax-lumenFLZ, cmax-GIFLZ, cmax-hepFLZ, respectively), assuming the mechanism 
of inhibition of FLZ on MDZ is non-competitive inhibition (Gibbs et al., 1999) (reduce vmax and has 
no effect on Km of CYP3A), and the maximum inhibition on both hepatic and GW metabolism is 
100%. 
 In study 103, a double-dummy, randomized, 3-way cross-over study was performed in 9 
healthy volunteers. The subjects were given PO FLZ 400 mg and IV saline within 60 min; PO 
placebo and IV FLZ 400 mg; or PO placebo and IV saline. An oral dose of 7.5 mg midazolam 
was ingested 60 min after oral intake of FLZ or placebo (at the end of the corresponding 
infusion). Plasma concentrations of MDZ, 1’-OH-MDZ and FLZ were determined for up to 17 h. 
This study can be used to compare the inhibitory effect on intestinal and hepatic metabolism of 
IV and PO FLZ. However, MDZ was not administered intravenously in the study. In order to 
calculate CLint,hepMDZ, ERhepMDZ and ERGIMDZ for this study, the value for ERhepMDZ from Palkama 
et al.(Palkama et al., 1999) was used, because these two studies ingested similar MDZ doses and 
achieved similar AUCPOMDZ after PO MDZ in the control group. Therefore, subjects in these two 
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studies were likely to have similar CYP3A activity in the absence of CYP3AI. To estimate 
secondary parameters in presence of FLZ in study 103, inhibition ratio of ERhepMDZ was assumed 
to be the same after PO FLZ as in study 21, due to the same PO FLZ dose administered in the 
two studies. Inhibition ratio of ERhepMDZ after IV FLZ was predicted by the hyperbolic model 
between ERhep(i)MDZ/ERhepMDZ and cmax,u-hepFLZ, supposing that cmax,u-hepFLZ after IV FLZ was 
comparable with plasma cmax,uFLZ, which was reported in study 103. ERGI(i)MDZ as well as its 
inhibition ratio was calculated by method in section 3.2.3.1, and cmax-GIFLZ was predicted by the 
developed hyperbolic model (ERGI(i)MDZ/ERGIMDZ vs. cmax-GIFLZ) based on calculated 
ERGI(i)MDZ/ERGIMDZ. 
 
3.3 Results and Discussion 
3.3.1 Data collection 
 
 A total of 20 studies with 242 healthy volunteers were included in the final database, with 
127 males and 91 females. Each study was assigned a study ID number. Gender information was 
not available for study 23 (Garg et al., 2012). Study 1 (Vieira et al., 2012) , study 8 (Zhang et al., 
2009), study 11 (Krishna et al., 2009), study 16 (Palkama et al., 1999), 17 (Tsunoda et al., 1999), 
study 18 (Gorski et al., 1998), study 20 (Kirby et al., 2011), study 21(Kharasch et al., 2005), 
study 22 (Kharasch et al., 2004), study 23 (Garg et al., 2012), study 25 (Saari et al., 2006), study 
26 (Olkkola et al., 1996), study 28 (Olkkola et al., 1993) and study 30 (Kupferschmidt et al., 
1995) provided AUCMDZ in the absence and presence of CYP3AI after IV and PO administration 
of MDZ. Studies 16 (Palkama et al., 1999), 25 (Saari et al., 2006) and 30 (Kupferschmidt et al., 
1995) also provided AUCmet. Study 23 (Garg et al., 2012) provided only AUCmet after PO MDZ 
for the control and inhibitor treatment groups. Studies 201 (Mandema et al., 1992), 202 
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(Thummel et al., 1996), 203 (Fetzner et al., 2011) and 204 (Link et al., 2008) provided AUCMDZ 
and AUCmet without CYP3AI after IV and PO MDZ. Study 103(Ahonen et al., 1997) was 
included to compare the inhibitory effect on intestinal and hepatic metabolism of IV and PO 
CYP3AI, but only AUCMDZ and AUCmet after PO MDZ for control and inhibitor (FLZ) treatment 
groups were given. Study 158 (Yang et al., 2012) was another study using PO FLZ as the 
CYP3AI, and provided AUCmet after MDZ IV route both in the absence and presence of FLZ.  
 IV doses of MDZ ranged from 0.005 mg/kg to 0.1 mg/kg, and PO doses ranged from 0.025 
mg/kg to 0.244 mg/kg. Age ranged from 20 to 46 years, and body weight ranged from 56 to 100 
kg, with four studies not providing that information. Studies 18 (Gorski et al., 1998) and 20 
(Kirby et al., 2011) were both conducted in 16 volunteers: 1 Asian, 1 African Americans, and 14 
Caucasians. We assume that the only Asian in both studies had no large influence on the mean 
AUCMDZ and AUCmet of the whole study population, and kept these two studies in the final 
database. Study 158 performed in African Americans due to their higher rate of CYP3A5*1/*1 
expression, but no major / clinically important differences in CYP3A activity is known to be 
present between African Americans and Caucasians (Wandel et al., 2000). All other studies were 
conducted in Caucasians, with 15 studies not providing ethnicity information. The CYP3AI used 
in these studies can be divided into five categories: antifungal azoles (ketoconazole, fluconazole, 
itraconazole, voriconazole, and posaconazole), macrolide antibiotic (telithromycin, 
clarithromycin, troleandomycin and erythromycin), HIV protease inhibitor (saquinavir, telaprevir, 
ritonavir, nelfinavir) and others (diltiazem and grapefruit juice). FLZ was administered by both 
IV and PO routes, while all other CYP3AI were only given by PO route. Other relevant PK, 
demographic, study design and sample analysis information for both MDZ and 1’-OH-MDZ was 
summarized in Appendices A. 
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3.3.2 PK dose-proportionality assessment 
 
 Figures 3.4 (a-c) illustrates the dose-proportionality of MDZ and 1’-OH-MDZ. The 
parameter estimates for the power model and their 95% CIs were summarized in Table 3.2. 
Power model fit MDZ and 1’-OH-MDZ exposure metrics well, with r2 > 0.8; however, cmax of 
metabolite is poorly characterized by the model, with a lower r2 value and wider 95% CIs of the 
estimated exponent. Possible explanations could be small sample sizes, narrow dose range, and 
large variability with regard to the formation and elimination of 1’-OH-MDZ in the studies that 
reported cmaxmet. PO exposure metrics exhibits inferior fit than IV exposures, either because PO is 
a more complex process physiologically (i.e. involved with absorption and first-pass metabolism) 
than IV, or because PO studies have narrower dose range than IV studies. MDZ follows dose-
proportional PK within the respective IV and PO dose ranges, however, 1’-OH-MDZ follows 
apparent infra-proportional PK after IV route of MDZ. The possible explanations might be 
presumably saturable plasma protein binding (increased CLtot,pmet), or presumably saturable 1’-
OH-MDZ formation, resulting in a metabolic switch to non-1’-OH-MDZ pathways (decrease in 
fmet). However, none of these explanations are consistent with the dose-proportional PK of 1’-
OH-MDZ after PO route of MDZ. The mean MRIV is 0.13 (range: 0.08-0.18), and mean of MRPO 
is 0.39 (range: 0.29-0.52), suggesting that there is first-pass formation of metabolite during 
absorption process. MR is not significantly different among doses, and the AUCmet vs. AUCMDZ 
relationship is well fit by a linear model (Figure 3.4c), both of which indicate dose-proportional 
PK of 1’-OH-MDZ pathway. Therefore, the infra-proportional PK for AUCIVmet vs. DoseIVMDZ is 
likely to be an artifact, due to large inter-study variability (e.g. subjects in study 201 had higher 
CLtot,pMDZ than other studies). Overall, both MDZ and 1’-OH-MDZ follow dose-proportional PK 
across the IV MDZ doses ranging from 0.005 mg/kg - 0.1 mg/kg, and PO doses ranging from 
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0.025 mg/kg to 0.244 mg/kg. This allows the use and interpretation of the secondary PK 
parameters. 
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a)       b) 
 
                                                              c)       
 
Figure 3.4  Dose proportionality assessment. 
The colored lines represent fits by power (a-b) or linear model (c), and symbols represent the observed values. Values are expressed as 
mean ± SD. The number inside each point is the study ID. 
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Table 3.2  Summary of power model fit of exposure metrics vs dose plots. 
 
No. of 
studies (n) 
Dependent 
Variable 
Independent 
variable 
Dose range 
(mg/kg) 
Power 
coefficient 
95% CI of 
power 
Intercept r2 
19 AUCIVMDZ DoseIVMDZ 0.005-0.100 0.95 0.80, 1.10 3.35 0.904 
19 AUCPOMDZ DosePOMDZ 0.025-0.244 0.91 0.70, 1.13 2.80 0.806 
8 AUCIVmet DoseIVMDZ 0.013-0.100 0.76 0.59, 0.95 2.24 0.913 
9 AUCPOmet DosePOMDZ 0.027-0.214 0.92 0.58, 1.26 2.42 0.805 
17 Cmax-POMDZ DosePOMDZ 0.025-0.244 1.08 0.84, 1.32 2.54 0.847 
5 Cmax-IVmet DoseIVMDZ 0.029-0.071 0.75 0.22, 1.28 1.62 0.726 
8 Cmax-POmet DosePOMDZ 0.027-0.214 1.02 0.37, 1.67 2.16 0.623 
  
 After dose-proportional PK was ascertained, linear regression was then performed for 
AUCIVMDZ vs DoseIVMDZ, AUCPOMDZ vs DosePOMDZ, AUCIVmet vs DoseIVmet, AUCPOmet vs 
DosePOmet, AUCIVmet vs AUCIVMDZ and AUCPOmet vs AUCPOMDZ plots, and the respective slopes 
(summarized in Table 3.3) can translate into important secondary PK parameters, namely 
CLtot,pMDZ, ForalMDZ, etc. Across studies, CLtot,pMDZ is estimated as 7.04 ml/min/kg, which is far 
less than liver blood flow (21.4 ml/min/kg), suggesting liver blood flow doesn’t limit the 
metabolism of MDZ in the liver. ForalMDZ is estimated as 31.6% from CLtot,pMDZ and 
CLtot,pMDZ/ForalMDZ. However as for 1’-OH-MDZ, CLtot,pmet/fmet is larger than 
CLtot,pmet/(fmet·ForalMDZ), implicating ForalMDZ larger than 1, which is not possible. The reason 
might be poor goodness of fit of AUCIVmet vs DoseIVMDZ and AUCPOmet vs DosePOMDZ plots, 
reflected by large 95% CIs of estimated slopes. 
 Another way to estimate CLtot,pMDZ, CLtot,pMDZ/ForalMDZ, CLtot,pmet/fmet and 
CLtot,pmet/(fmet·ForalMDZ) is to calculate weighted mean and SD across studies, with sample size 
used as weighting factor for each study (presented in Table 3.3). Weighted mean values for 
CLtot,pMDZ, CLtot,pMDZ/ForalMDZ, MRIV, MRPO estimations are close to the slopes, whereas mean 
CLtot,pmet/fmet and CLtot,pmet/(fmet·ForalMDZ) are less than their slope estimates, suggesting that some 
studies with higher CLtot,pmet/fmet and CLtot,pmet/(fmet·ForalMDZ) might have small sample size, and 
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bias the slope estimates. Conjugated 1’-OH-MDZ in urine accounts for ~70% 20,25 of PO MDZ, 
and 69.3% 20 after IV MDZ. If we assume a constant fmet of 70% in all the studies, CLtot,pmet 
should be 24.6 mL/min/kg, which is very close to Qhep (21.4mL/min/kg (Tsunoda et al., 1999)), 
indicating that Qhep may be the rate-limiting step for the elimination of metabolite, and 1’-OH-
MDZ is a very high ERhep drug by itself. Foral of MDZ is estimated as 68.9% from CLtot,pmet/fmet 
and CLtot,pmet/(fmet·ForalMDZ), which is much higher than that estimated from CLtot,pMDZ and 
CLtot,pMDZ/ForalMDZ. This is more likely due to the large inter-study variability of CLtot,pmet, fmet 
and/or ForalMDZ, although different CLtot,pmet and/or fmet after IV or PO MDZ may also explain this. 
MRPO is significantly larger than MRIV (p < 0.0001), implying that more 1’-OH-MDZ is formed 
pre-systemically than systemically.  
Table 3.3  Summary of linear regression of exposure metric vs dose plots. 
 
No. of 
studies 
(n) 
Dependent 
Variable 
Independent 
variable 
Slope 
(units) 
Unit 
corrected  
slope 
95% CI of 
slope Intercept r
2 Weighted Mean (SD) 
19 AUCIVMDZ DoseIVMDZ CLtot,pMDZ (mL/min/kg) 7.04 5.71, 9.20 11.4 0.811 6.1 (1.5) 
19 AUCPOMDZ DosePOMDZ 
CLtot,pMDZ/ForalMDZ 
(mL/min/kg) 22.3 18.7, 27.7 5.37 0.862 21.0 (7.2) 
8 AUCIVmet DoseIVMDZ 
CLtot,pmet/fmet 
(mL/min/kg) 64.1 49.3, 91.8 4.45 0.880 35.2 (10.3) 
9 AUCPOmet DosePOMDZ 
CLtot,pmet/(fmet·ForalMDZ) 
(mL/min/kg) 60.8 39.3, 134.8 5.49 0.654 51.1 (18.0) 
8 AUCIVmet AUCIVMDZ MRIV 0.12 0.09, 0.15 1.23 0.872 0.10 (0.02) 
9 AUCmetPO AUCPOMDZ MRPO 0.41 0.28, 0.54 -0.42 0.860 0.38 (0.06) 
 
3.3.3 Estimation of PK exposure metrics and parameters in absence of CYP3AI  
3.3.3.1 MDZ (parent compound) 
 
 Figure 3.5a shows that in absence of CYP3AI, MDZ is a low to intermediate ERhepMDZ drug 
(21%-47%). ERpresysMDZ has wider range (41%-78%) than ERhepMDZ, and consistently exceeds 
ERhepMDZ (except one arm in study 11(Krishna et al., 2009)), suggesting the presence of intestinal 
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metabolism of MDZ. There is no correlation between these variables, indicating high inter-study 
variability of the intestinal metabolism, which is independent of the variability in hepatic 
metabolism. Study 11 was performed in 12 healthy volunteers, with 6 subjects in each arm. No 
extraordinary study design or demographic information could be found; and therefore, the 
absence of GW metabolism in arm 1 might be caused by some factors that were not mention in 
the study, such as dietary habits, or genetic polymorphism of CYP3A. 
 ERGIMDZ has a much wider range (0%-73%) than ERhep, and there is no correlation between 
these two variables (Figure 3.5b), confirming the fact that intestinal and hepatic CYP3A 
metabolism are independently regulated (Tsunoda et al., 1999). The reasons for the higher inter-
study variability of intestinal than hepatic metabolism may be due to different dietary habits 
across study (Won et al. 2013). The mean ERGIMDZ estimate (51%) is much greater than the 
mean ERhepMDZ value (32%), indicating larger intestinal first-pass than hepatic first pass 
metabolism of MDZ on average. 
 In Figure 3.5c, the relationship between ERpresysMDZ and ERGIMDZ is fit well by a linear 
model (r2 = 0.91). Therefore, 91% of the variability in ERpresysMDZ can be explained by the 
variability of ERGIMDZ, in other words, the higher range of ERpresysMDZ is primarily due to the 
high variability of intestinal metabolism of MDZ, rather than hepatic metabolism. 
 Descriptive statistics of important PK parameters (ERhepMDZ, CLint,hepMDZ, ForalMDZ, ERGIMDZ) 
are summarized in Table 3.4
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                                                     a)                                                                  b) 
 
                                                                                          c) 
 
Figure 3.5  Comparison of pre-systemic hepatic and GI metabolism of MDZ in absence of CYP3AI. 
a) Relationship between ERpresysMDZ and ERhepMDZ. b) Relationship between ERGIMDZ and ERhepMDZ. c) Relationship between 
ERpresysMDZ and ERGIMDZ. The red dashed line in Figure 3.5a is the line of identity. The yellow solid line in Figure 3.5c is the linear 
model fit for the data (y = 0.49x+0.43, r2 = 0.91). The number inside each point is study ID. 
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Table 3.4  Descriptive statistics of important PK endpoints in absence of CYP3AI across 
studies. 
 
Endpoints No. of Studies Mean SD Minimum Median Maximum 
ERhepMDZ 19 33% 9% 21% 33% 47% 
CLint,hepMDZ (ml/min) 19 10.8 4.3 4.6 9.9 19.2 
ForalMDZ 18 32% 10% 22% 29% 59% 
ERGIMDZ 18 51% 19% 0% 57% 73% 
 
3.3.3.2 1’-OH-MDZ (metabolite) 
 
 All the secondary parameter estimates using AUCmet are presented in Table 3.5. Foralmet’ in 
all the studies are 2-3 fold higher than ForalMDZ, indicating that 1’-OH-MDZ formed pre-
systemically exceeds that formed systemically. Figure 3.6a demonstrates that AUCpresys-hepmet in 
all studies are less than the corresponding AUCpresysmet, confirming that 1’-OH-MDZ is also 
formed by intestinal metabolism. These two terms are not correlated with each other. Figure 
3.6b also illustrates the independently regulated formation of 1’-OH-MDZ by hepatic and 
intestinal CYP3A metabolisms, and 1’-OH-MDZ formed by GW metabolism exceeds that 
formed by pre-systemic hepatic metabolism. In Figure 3.6c, all the points are close to the line of 
identity, suggesting that most 1’-OH-MDZ is formed by GW instead of the liver pre-systemically. 
Linear regression characterizes the relationship well (r2 = 0.96); thus, 96% of the change in 
AUCpresysmet is due to the change in AUCpresys-GImet.  
 All the conclusions obtained from the metabolite estimations agree well with the conclusions 
from MDZ estimations. However, all of them are based on an important assumption that fpresys-
GI
met, fpresys-hepmet and fsys-hepmet are the same, indicated as fmet. 
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Table 3.5  Exposure metrics and PK parameter estimates of 1’-OH-MDZ in absence of 
CYP3AI. 
 
Study ID Foralmet' ForalMDZ 
AUCPOmet 
[µg/L*hrs] MRPO 
AUCsysmet 
[µg/L*hrs] 
AUCpresysmet 
[µg/L*hrs] 
AUCpresys-hepmet AUCpresys-GImet AUChepmet 
[µg/L*hrs] [µg/L*hrs] [µg/L*hrs] 
16 92% 42% 45.4 0.40 20.5 24.8 9.7 15.2 30.2 
25 81% 32% 24.4 0.29 9.7 14.7 3.3 11.4 13.0 
30 78% 24% 57.2 0.40 17.6 39.6 6.6 33.0 24.2 
201 65% 24% 19.7 0.41 7.3 12.4 3.9 8.6 11.1 
202 77% 26% 8.9 0.36 3.0 5.9 0.9 5.0 3.9 
203 100% 27% 18.8 0.41 5.2 13.7 2.0 11.6 7.2 
204 103% 22% 56.6 0.52 12.0 44.6 2.5 42.1 14.5 
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a)                                                  b) 
 
                                                                                     c) 
 
Figure 3.6  Comparison of pre-systemic hepatic and intestinal formation of 1’-OH-MDZ. 
a) Relationship between AUCpresysmet and AUCpresys-hepmet. b) Relationship between AUCpresys-GImet and AUCpresys-hepmet. c) Relationship 
between AUCpresysmet and AUCpresys-GImet. The red dash lines in Figure 3.6a and 3.6c are the line of identity. The yellow solid line in 
Figure 3.6c is the linear model fit for the data (y = 1.04x+3.39, r2 = 0.96). The number inside each point is the study ID. 
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3.3.4 Estimation of inhibitory effect on hepatic and intestinal metabolism of CYP3AI  
 
3.3.4.1 MDZ (parent compound) 
 
 To investigate the inhibitory effect on systemic MDZ metabolism, ERhepMDZ and CLint,hepMDZ 
in presence of CYP3AI are plotted against baseline ERhepMDZ and CLint,hepMDZ respectively in 
Figure 3.7a-b. Inhibitors consistently reduce hepatic metabolism of MDZ in all the studies, 
resulting in reduction in ERhepMDZ and CLint,hepMDZ by between 4% and 96%. Study 30 
(Kupferschmidt et al., 1995) only has 4% reduction in ERhepMDZ, because the inhibitor used was 
PO grapefruit juice (GFJ), which is a selective intestinal CYP3AI (Kupferschmidt et al., 1995). 
PO GFJ is also a known P-pg substrate, making it difficult to reach the liver and affect hepatic 
metabolism. ERhepMDZ and CLint,hepMDZ in presence of inhibitors are not correlated with their 
corresponding values without inhibitor, probably because the inhibitors used in the various 
studies have different potency, mechanism of inhibition and dosing regimen, leading to large 
inter-study variability.   
 
 
 
 
  
55 
	
      a)                                b) 
 
Figure 3.7  Evaluation of hepatic inhibitory effect of CYP3AI. 
a) Relationship between ERhep(i)MDZ and baseline ERhepMDZ. b) Relationship between CLint,hep(i)MDZ and baseline CLint,hepMDZ. The red 
dashed lines are the lines of identity. The number inside each point is the study ID. 
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 Relative change in FGIMDZ and ForalMDZ were then plotted against baseline FGIMDZ and 
ForalMDZ, to assess the inhibitory effect on intestinal metabolism as well as overall pre-systemic 
extraction. Inhibitors consistently decreased intestinal metabolism in most studies (except study 
11), leading to an increase of FGIMDZ by 38% to 132%, as well as an increase in ForalMDZ by 46% 
to 248%. The degree of increase in FGIMDZ or ForalMDZ is negatively correlated with FGIMDZ (r = - 
0.83, n = 21, p < 0.0001, Figure 3.8a) or ForalMDZ (r = -0.64, n = 21, p = 0.0011, Figure 3.8b) 
without CYP3AI, respectively; thus, subjects with lower baseline FGIMDZ (and lower ForalMDZ) are 
more sensitive to CYP3A inhibition, and CYP3AI can decrease the inter-study variability of 
intestinal bioavailability and overall oral bioavailability. 
 Study 11 is an outlier, suggesting a slight induction in GW metabolism. This might be owing 
to two reasons: subjects in study 11 had higher ForalMDZ (59%) in the control group, thus CYP3AI 
may have fewer enzymes to act on. Furthermore, the CYP3AI (400 mg QD ketoconazole and 
200 mg/400 mg BID posaconazole) were administered for 7 days, which may have started to 
induce CYP3A enzyme. Other outliers such as study 21 (100 mg PO FLZ), 22 (single dose PO 
GFJ) and 30 (double dose PO GFJ) had low ForalMDZ values in their control groups, but were also 
less sensitive to their corresponding inhibitors. This is likely because - besides CYP3A activity 
in the control group - the inhibitory effect is also determined by potency, mechanism of action 
and dosing regimen of the inhibitors. Studies 22 and 30 used less potent CYP3A inhibitor (GFJ), 
and study 21 used a moderate CYP3A inhibitor (FLZ) with a low single dose, which may make 
them appear as outliers.  
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             a)                                                                                     b) 
 
 
Figure 3.8  Evaluation of intestinal/overall pre-systemic inhibitory effect of CYP3AI. 
a) Relationship between FGI(i)MDZ and baseline FGIMDZ. b) Relationship between Foral(i)MDZ and baseline ForalMDZ. The red dashed lines 
are horizontal lines with intercept of 1. The number inside each point is the study ID. 
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 Relative change in ForalMDZ is plotted against relative change in FGIMDZ in Figure 3.9a, to 
assess the contribution of GW metabolism inhibition to the overall pre-systemic inhibition. The 
reason to use ForalMDZ and FGIMDZ, instead of ERpresysMDZ and ERGIMDZ is that the estimation 
process of ForalMDZ and FGIMDZ includes fewer assumptions than ERpresysMDZ and ERGIMDZ 
(section 3.2.3.1), thus it is more accurate to use the two bioavailability terms, instead of 
extraction ratios. The relationship between increase in ForalMDZ and increase in FGIMDZ can be fit 
well by a linear model (y = 1.21x+0.17, r2 = 0.87), suggesting that the variability of increase in 
ForalMDZ can mainly be explained by the increase in FGIMDZ, and the average increase in FhepMDZ is 
21%, as is indicated by the slope. 
After excluding study 11, the change in ERGIMDZ is positively correlated with the change in 
ERhepMDZ (r = 0.78, n = 18, p < 0.0001, Figure 3.9b), illustrating that inhibitory effect on hepatic 
and intestinal metabolism of a specific CYP3AI are highly associated, regardless of its potency, 
mechanism of inhibition and dosing regimen. 
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                     a)                                              b) 
 
Figure 3.9  Evaluation of inhibitory effect of CYP3AI. 
a) Relationship between relative change in Foral(i)MDZ and FGI(i)MDZ. b) Relationship between inhibitory ratio of ERGI(i)MDZ and 
ERhep(i)MDZ. The yellow solid line in Figure 3.9a is the linear model fit the the data. The number inside each point is the study ID. 
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3.3.4.2 1’-OH-MDZ (metabolite) 
 
 All the estimates by using AUC(i)met are exhibited in Table 3.6. Foral(i)met’ in study 16 
(Palkama et al., 1999) (voriconazole was used as the CYP3AI) is the same as Foral(i)MDZ, 
indicating no 1’-OH-MDZ formed by pre-systemic metabolism in this study. However, 
ERpresysMDZ in presence of voriconazole is 13%, suggesting that other pre-systemic pathways, like 
4-OH-MDZ or 1,4-dihydroxymidazolam, might contribute to the first-pass metabolism in study 
16. In study 25 and 30, Foral(i)met’ are greater than Foral(i)MDZ, suggesting that 1’-OH-MDZ can be 
formed pre-systemically in this two studies.  
Table 3.6  Exposure metrics and PK parameter estimates of 1’-OH-MDZ in presence of 
CYP3AI. 
 
Study ID Foral(i)met' Foral(i)MDZ 
AUCPO(i)met 
[µg/L*hrs] MRPO(i) 
AUCsys(i)met 
[µg/L*hrs] 
AUCpresys(i)met 
[µg/L*hrs] 
AUCpresys-hep(i) met 
[µg/L*hrs] 
AUCpresys-GI(i) met 
[µg/L*hrs] 
AUChep(i)met 
[µg/L*hrs] 
16 0.87 87% 44.7 0.08 44.7 0.00   44.7 
25 1.20 85% 60.8 0.07 43.2 17.6 3.33 14.2 46.6 
30 0.95 35% 74.6 0.32 27.4 47.2 9.78 37.5 37.1 
  
 Inhibition ratio of AUCmet is plotted against AUCmet without inhibitor after IV and PO routes 
of MDZ in Figure 3.10a. In the presence of CYP3AI, AUCIVmet in all the studies were higher 
than the control group; while AUCPOmet change differently across studies. When MDZ is 
administered intravenously, AUCIVmet can be estimated by equation 3.12:   
AUC$%&'( = *+,'-./01∙(/4567/4/01)∙9567:;7<7,>567   
 In the presence of CYP3AI, assuming inhibitor has no inhibitory effect on CLtot,pmet,  
AUC$%(?)&'( = *+,'-./01∙(/4567/4/01)∙9(@)567:;7<7,>567                                         (3.25) 
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 In all the studies, AUCIV(i)met were greater than AUCIVmet, translating into an increase f(i)met 
after IV MDZ, which could not be explained with current assumptions. Hence CLtot,pmet might 
also be affected by CYP3AI. Nevertheless 1’-OH-MDZ is primarily cleared by glucuronidation, 
which is unlikely to be inhibited by the inhibitors used in these studies. More investigation is 
required to explore the underlying reasons of this finding. 
 The change in AUCPOmet is the combined effect on ForalMDZ, fPOmet and CLtot,pmet by CYP3AI. 
Only two studies (study 25 and 30) provided both AUCmet information after IV and PO 
administration of MDZ; thus, it is hard to draw valid conclusions regarding inhibitors’ effect on 
ForalDMZ, fPOmet and CLtot,pmet. 
 
 According to Figure 3.10b, the fold change in AUCMDZ is consistently larger than fold 
change in AUCmet after both IV and PO MDZ, which implies that MR declines after co-
administration with inhibitors. By the same token, the change in MR is an integrated outcome of 
the changes in fmet, CLtot,pMDZ and CLtot,pmet, and more evidence is required to evaluate inhibitors’ 
effect on the three terms. Only three studies (study 16, 25, 30) are available to calculate all the 
derived AUCmet, including study 30 which used GFJ, a less potent inhibitor. Hence it is difficult 
to explore any correlation between AUCmet in presence of CYP3AI and AUCmet in the control 
groups. 
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         a)                        b) 
 
 
Figure 3.10  Evaluation of inhibitory effect of CYP3AI on MDZ and 1’-OH-MDZ exposures. 
The red dash line in Figure 3.10a is a horizontal line with the intercept of 1. The dash line in Figure 3.10b is the line of identity. The 
number inside each point is the study ID. 
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3.3.5 Dose/concentration dependent inhibition by FLZ 
 
 X50 (estimates and 95% CIs) for different models are summarized in Table 3.7, and the 
predicted and observed profiles are shown in Figure 3.11a-f. Figures 3.11a-c demonstrates the 
change of inhibition ratio of CLint,hepMDZ, ERhepMDZ and ERGIMDZ versus PO FLZ dose, estimated 
from study 21. With single increasing dose, FLZ shows stronger inhibition on both hepatic and 
GW metabolism, while the inhibitory effect on intestinal metabolism is saturated more easily 
than hepatic metabolism (D50FLZ for ERhepMDZ inhibition = 426mg; D50FLZ for ERGIMDZ inhibition 
= 209mg). r2 for ERhep(i)MDZ/ERhepMDZ vs DoseFLZ regression is larger than ERGI(i)MDZ/ERGIMDZ vs 
DoseFLZ, indicating that a hyperbolic model might not be enough to describe relationship 
between ERGI(i)MDZ/ERGIMDZ vs DoseFLZ. It is possible that inhibition ratio on ERGIMDZ is more 
sensitive to FLZ dose, and may be better characterized by a sigmoidal model.  
 Figures 3.11d-f demonstrates the fold change of ERhepMDZ and ERGIMDZ with PO FLZ versus 
maximal FLZ unbound hepatic concentration (cmax,u-hepFLZ), maximal FLZ gut lumen 
concentration (cmax-lumenFLZ) or maximal FLZ GW concentration (cmax-GIFLZ).  These models are 
more physiologically based. If complete inhibition is assumed in both hepatic and intestinal 
metabolism, IC50 (concentration of inhibitor to produce half of maximum inhibition) can be 
estimated by non-linear regression with hyperbolic models. cmax,u-hep,50FLZ and cmax-GI,50FLZ are 
estimated to be 10.22 mg/L and 14.94 mg/L, which are in the same magnitude with Ki obtained 
in some in-vitro studies using FLZ to inhibition MDZ metabolism in liver and intestine 
microsomes: Ki,hepFLZ = 0.4 – 8.2 mg/L (1.27-25µM (Galetin et al., 2005; Gibbs et al., 1999; 
Isoherranen et al., 2008; von Moltke et al., 1996; Yang et al., 2012)); Ki,GWFLZ = 3.3 mg/L 
(10.4µM (Gibbs et al., 1999)). However cmax-lumen,50FLZ is estimated to be 836 mg/L, much higher 
than Ki,GWFLZ, confirming that CYP3A is located intra-cellularly in the enterocytes. Hepatic 
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CYP3A is almost equally sensitive to the inhibitory effect of FLZ as GW CYP3A, suggested by 
tissue IC50 estimations, whereas GW CYP3A is more sensitive to metabolic inhibition than 
hepatic CYP3A supported by FLZ dose models. 
Table 3.7  Summary of dose/concentration-dependent inhibition model of FLZ estimated 
from study 21. 
 
Independent variable Dependent variable X501 95% CI r2 
DoseFLZ 
[mg] 
CLint,hep(i)MDZ/CLint,hepMDZ 285 253-317 0.996 
ERhep(i)MDZ/ERhepMDZ 426 378-474 0.997 
ERGI(i)MDZ/ERGIMDZ 209 129-291 0.968 
cmax,uFLZ 
cmax,u-hepFLZ 
[mg/L] ERhep(i)
MDZ/ERhepMDZ 10.22 9.05-10.51 0.997 
cmax-lumenFLZ 
[mg/L] ERGI(i)
MDZ/ERGIMDZ 836 516-1164 0.968 
cmax-GIFLZ 
[mg/L] ERGI(i)
MDZ/ERGIMDZ 14.91 9.14-20.68 0.968 
 
1 Represents D50FLZ (mg), cmax,u-hep,50FLZ (mg/L) cmax-lumen,50FLZ (mg/L) cmax-GI,50FLZ (mg/L) in different models 
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a)                                                                   b) c) 
         
 
d)                                                                  e)                                                                      f) 
          
 
Figure 3.11  Dose/concentration-dependent inhibition of FLZ. 
a) Relationship between CLint,hepMDZ inhibition ratio and single PO FLZ dose. b) Relationship between ERhepMDZ inhibition ratio and 
single PO FLZ dose. c) Relationship between ERGIMDZ inhibition ratio and single PO FLZ dose. d) Relationship between ERhepMDZ 
inhibition ratio and cmax,u-hepFLZ. e) Relationship between ERGIMDZ inhibition ratio and cmax-lumen FLZ. f) Relationship between ERGIMDZ 
inhibition ratio and cmax-GI FLZ. The symbols are the observed values in study 21, the solid lines are the predicted profiles in study 21. 
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 ERhepMDZ and ERGIMDZ in absence/presence of FLZ in study 21 and 103, along with the 
predicted maximum inhibitory concentration in liver and gut are demonstrated in Table 3.8. The 
calculated cmax,uFLZ (6.67 µg/mL) after oral dose of 400 mg in study 21 is comparable to the 
observed cmax, uFLZ (7.22 µg/mL) in study 103, confirming the validity of parameters used in 
calculating cmax,uFLZ. Observed cmax,uFLZ after IV (7.39 µg/mL) and PO FLZ (7.22 µg/mL) are 
quite similar, due to the rapid absorption rate and high Foral of FLZ. 
 Inhibitory effect on GW metabolism after 400 mg PO FLZ in study 103 is lower than study 
21, probably because study 103 had higher baseline FGI (48%) than study 21 (36%), resulting in 
less intestinal CYP3A available to be inhibited (less sensitive to inhibitors). Both IV and PO FLZ 
can inhibit hepatic and GW metabolism, while IV FLZ demonstrates less inhibition on hepatic 
and intestinal metabolism than PO FLZ at the same dose, mainly because it gets into the 
enterocytes and hepatocytes through systemic circulation rather than absorption through gut 
lumen or portal vein blood flow, hence concentration in the GW and liver should be lower after 
IV administration. 
 To compare cmax,u-hepFLZ and cmax-GIFLZ after IV and PO FLZ, IV FLZ has slightly lower cmax,u-
hep
FLZ than PO FLZ (7.22 vs. 9.59 µg/mL), and a larger difference is found in cmax-GIFLZ (16.14 
µg/mL vs. 28.44 µg/mL) between IV and PO FLZ. cmax-GIFLZ is much higher than cmax,u-hepFLZ and 
calculated cmax,uFLZ (6.77 µg/mL) after PO FLZ in study 21, whereas cmax,u-hepFLZ and cmax,uFLZ are 
comparable, because liver is highly a perfused organ, compared with gut, leading to more rapid 
concentration equilibrium between liver and blood. After IV FLZ, we assumed that cmax,u-hepFLZ 
and cmax,uFLZ are the same in our previous calculation, because more than 90% FLZ gets absorbed 
into systemic circulation, indicating a very limited hepatic first pass metabolism. Estimated cmax-
GI
FLZ after IV FLZ is higher than cmax,uFLZ, may be due to a high partitioning ratio of FLZ into 
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GW.  
Table 3.8  Summary of extraction ratios and FLZ concentrations in various compartments. 
 
Parameters Study 21 Study 103 Study 103 (400 mg PO FLZ) (400 mg IV FLZ) (400 mg PO FLZ) 
ERhep(i)/ERhep 0.52 0.62 0.52 1 
ERGI(i)/ERGI 0.34 0.53 0.42 
cmax,uFLZ 6.77 7.39 2 7.22 2 
cmax,u-hepFLZ 9.59 7.39 3 9.59 4 
cmax-GIFLZ 28.44 16.14 28.44 4 
 
1 Assumed to be the same as study 21 
2 Observed cmaxFLZ in study 103, corrected by fuFLZ (fuFLZ = 0.88 (Olkkola et al., 1996)) 
3 Assumed to be the same as cmax,uFLZ after IV FLZ in study 103 
4 Assumed to be the same as study 21 
 
 
 
3.4 Conclusions 
 In conclusion, both MDZ and 1’-OH-MDZ follow dose-proportional PK within the 
respective IV and PO MDZ dose range in our database. MDZ is a low to intermediate ERhepMDZ 
drug. Intestinal metabolism exists for MDZ during first pass metabolism, and 1’-OH-MDZ gets 
formed more in the GW than in the liver pre-systemically. High variability of intestinal 
metabolism is the main source of the high variability in ForalMDZ of MDZ in the absence and 
presence of CYP3AI. CYP3AI can inhibit hepatic and intestinal metabolism, hence decrease 
CLint,hepMDZ, ERhepMDZ and ERGIMDZ. Subjects with lower FGIMDZ (and lower ForalMDZ) are more 
sensitive to the inhibitors, thus inhibitors can decrease the variability of FGIMDZ and ForalMDZ. On 
average, FhepMDZ shows a 21% increase due to pre-systemic, metabolic DDI. CYP3AI can 
increase AUCIVmet, but the effect on AUCPOmet varies among studies. MRs after both IV and PO 
routes of MDZ go down in all the studies. Owing to limited studies and unexplained MR 
decrease for 1’-OH-MDZ, only DDI on parent compound (MDZ) is considered for further PBPK 
modeling. 
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With single increasing dose, FLZ demonstrates stronger inhibition on both hepatic and 
intestinal metabolism, however hepatic CYP3A is less sensitive to the inhibitory effect of FLZ 
than GW CYP3A when using the dose model, and equally sensitive when using the inhibitory 
concentration models. Both IV and PO FLZ inhibit hepatic and GW metabolism of MDZ, and 
concentration of FLZ is lower after IV route than PO both in the liver and small intestine, leading 
to less inhibition on ERhepMDZ and ERGIMDZ after IV FLZ. Representative CYP3AI will be 
selected based on the analysis above, and PBPK models will be developed to characterize the 
magnitude and time course of DDI between MDZ and CYP3AI.   
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CHAPTER 4 
 
 
4 SEMI-PBPK MODELING OF IV/PO FLZ 
 
 
 
 
4.1 Background and Objectives 
4.1.1 Selection of CYP3AI 
	
 Based on the quantitative meta-analysis discussed in Chapter 3, study 103 (Ahonen et al., 
1997) is the only in-vivo DDI study that administered CYP3AI – FLZ both IV and PO 
concomitant with MDZ. The CYP3AI in other studies within the final database were all dosed 
orally. As a consequence, study 103 is the only choice to validate MDZ PK profiles after both IV 
and PO inhibitors, and FLZ is the selected CYP3AI. Besides study 103, study 21(Kharasch et al., 
2005) and study 26 (Olkkola et al., 1996) were another two in-vivo DDI studies between MDZ 
and FLZ, however, only study 103 provided FLZ plasma concentration-time profile along with 
MDZ profiles, while the other two studies only reported MDZ profiles. Therefore, study 103 is a 
key reference to validate semi-PBPK model of FLZ.  
4.1.2 FLZ PK information and simulation strategies 
	
 Clinically, FLZ is a triazole antifungal agent, available as tablets or suspension for oral 
administration, or as a sterile solution for IV administration (Pfizer, 2011). The general dosing 
regimen of FLZ is 200 - 800 mg loading dose and 200 – 800 mg maintenance dosing once daily, 
with duration and dosage depending on location and severity of infection (Fluconazole . 
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Lexi.com). IV and PO formulations have the same recommended dose, indicating its high ForalFLZ 
(> 90%) (Humphrey et al., 1985; Pfizer, 2011; Washton, 1989). Dose proportional PK is 
established between 50 and 400mg single oral dose range (Pfizer, 2011). After IV administration, 
FLZ is well-characterized by a 1-compartmental body model (Humphrey et al., 1985), with 
reported Vdss about 0.7 L/kg in humans (Humphrey et al., 1985; Carrasco-Portugal & Flores-
Murrieta, 2007). It is cleared primarily by renal excretion, with approximately 70% (Humphrey 
et al., 1985; Ripa et al., 1993; Sobue et al., 2004; Washton, 1989) of the administered dose 
appear in the urine as unchanged drug, and all non-renal pathways are assumed to be hepatic 
metabolism (Humphrey et al., 1985). The mean terminal plasma elimination half-life (t1/2FLZ) 
ranges from 22 to 37 hours, indicating its prolonged inhibitory effect on hepatic and intestinal 
metabolism of MDZ. It is a less profound (moderate) CYP3AI (Kharasch et al., 2005; Drug 
Interactions & Labeling Drug Development and Drug Interactions Table of Substrates, Inhibitors 
and Inducers), which can non-competitively inhibit hepatic and intestinal CYP3A (Gibbs et al., 
1999; Isoherranen et al., 2008). After PO administration, it is well absorbed into GW (BCS class 
1 drug (World Health Organization, 2005)), and first-pass metabolism is very limited.   
 Besides study 103, FLZ plasma concentration-time profiles were available in several other 
clinical studies, making it easy to validate its concentration in plasma (blood) compartment of 
the semi-PBPK model. However, inhibition on CYP3A occurs in the enterocytes and hepatocytes, 
so it is more important to characterize FLZ PK profiles in liver and GW, which cannot be 
validated through any study in human. In this case, sensitivity analysis was used to detect key 
PK/physiological parameters in the semi-PBPK model, that could influence FLZ exposure in 
liver and GW considerably, to facilitate future DDI model optimization.   
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4.1.3 Objectives 
	
 The major objectives of the chapter were to: 
a. Develop a semi-PBPK model of FLZ to describe its PK profiles in human after IV and 
PO administration 
b. Validate the model using plasma concentration-time profiles in clinical FLZ PK studies, 
and identify pivotal PK/physiological parameters that determine FLZ exposure in liver 
and GW by sensitivity analysis 
c. Predict hepatic and intestinal concentration – time profiles of FLZ using the validated 
semi-PBPK model 
 
4.2 Methods 
4.2.1 Development of FLZ semi-PBPK model 
 
4.2.1.1 FLZ semi-PBPK model after IV administration 
 
 A semi-PBPK model for IV FLZ was developed, based on the reported PK and physiological 
parameters (Table 4.1). A conventional one-compartmental body model with additional 
compartments for GW, portal vein, and liver was built, and showed in Figure 4.1. Since no 
saturable protein binding was observed for FLZ, the semi-PBPK model was developed based on 
total (unbound + bound) FLZ mass transfer. After IV administration, FLZ is injected directly 
into the systemic circulation and distributes into GW and liver through the superior mesenteric 
artery and hepatic artery, with the blood flow of villous blood flow (Qvilli) (Yang et al., 2007) and 
hepatic artery blood flow (QHA). Qvilli was chosen instead of total mesenteric artery blood flow or 
intestinal mucosa blood flow, because the metabolic CYP enzymes are located at the villous tips 
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(Watkins, 1997; Yang et al., 2007). Portal vein flow (QPV) is formed by the confluence of the 
superior mesenteric and splenic veins, and also receives blood from the inferior mesenteric 
gastric, and cystic veins (Abboud et al., 2009). Drug distributed to portal vein from other veins 
can be regarded as directly distributed from central compartment, with the blood flow of QPV-
Qvilli. An additional scaling factor (fPV) is added, to adjust for the components of portal vein that 
contain drug. fPV was set at 1 for initial model simulation, and sensitivity analysis was conducted 
for fPV on FLZ concentrations (see section 4.2.3). The hepatic vein supplies blood flow from 
liver to systemic blood with blood flow of Qhep. FLZ can be eliminated from the body through 
renal elimination and hepatic metabolism, with the respective clearance of CLrenFLZ and 
fuFLZ•CLint,hepFLZ.  
 
 
 
Figure 4.1  Semi-PBPK model scheme for the disposition of FLZ after IV administration. 
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1) Differential equations: 
 Based on the model above, differential equations for total (unbound + bound) FLZ mass 
transfer between compartments were expressed as equations (4.1) to (4.4): dA#$%& tdt = k*$%& + C-./$%&K/,-./$%& ∙ Q-./ − c#$%& ∙ CL7.8$%& − c#$%& ∙ f:; ∙ Q:; − Q<=>>= − c#$%& ∙ Q?@− c#$%& ∙ Q<=>>= 
when t = 0, ABFLZ (0) = 0; when t = tinf, ABFLZ (tinf) = DoseIVFLZ    (4.1) dAAB$%& tdt = c#$%& ∙ Q<=>>= − ( cAB$%&K/,AB$%& ) ∙ Q<=>>= 
when t = 0, AGWFLZ (0) = 0             (4.2)
  
dA:;$%& tdt = c#$%& ∙ f:; ∙ Q:; − Q<=>>= + cAB$%&K/,AB$%& ∙ Q<=>>= − c:;$%& ∙ Q:; 
when t = 0, APVFLZ (0) = 0             (4.3) dA-./$%& tdt = c#$%& ∙ Q?@ + c:;$%& ∙ Q:; − C-./$%&K/,-./$%& ∙ Q-./ − c-./$%& ∙ fE$%& ∙ CL=8F,-./$%&  
 when t = 0, AhepFLZ (0) =0              (4.4)
              
 ABFLZ, AGWFLZ, APVFLZ and AhepFLZ are the amounts of drug in central, GW, portal vein and 
liver compartments, respectively; cBFLZ, cGWFLZ, cPVFLZ, chepFLZ are drug concentrations in central, 
GW, portal vein and liver compartments, calculated by dividing amount (A) by the respective 
compartment volume: VBFLZ, VGW, VPV and Vhep, which are FLZ volume of blood compartment, 
volume of GW, portal vein and liver. In most FLZ IV studies, FLZ was administered as IV 
infusion, hence an infusion rate k0FLZ was introduced in equation (4.1) as a dose input rate, and 
initial amounts for all the four compartments are 0. 
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2) Volume of distributions 
 The volume of blood compartment of FLZ (VBFLZ) should be: V#$%& = VdHH$%& − K/,-./$%& ∙ V-./ − V:; − K/,AB$%& ∙ VAB                                           (4.5) 
 VdssFLZ is the observed steady-state volume of distribution of FLZ from literature (0.7 L/kg) 
(Humphrey et al., 1985). 
 VGW is the volume of GW epithelium, which can be estimated as equation (4.6), assuming 
small intestine is a cylinder and VGW is the volume of the surface for this cylinder with a certain 
thickness: 
   VAB = π(R + t)KL − πRKL                                                  (4.6) 
 R (= 1.75cm) (Fenneteau et al. 2010) is the mean radius of gut lumen, t (= 3mm) (Fleischer et 
al., 1981) is the mean thickness of GW, and L (= 680cm) (Fenneteau et al., 2010) is the total 
small intestine length. Therefore, the calculated VGW is 2.43 L.  
 Vhep was estimated by equation (4.7 - 4.8) (Heinemann et al., 1999; Kan & Hopkins, 1979) 
(Heinemann et al., 1999): V-./	 ml = 1072.8 ∙ BSA mK − 345.7                                          (4.7)  BSA mK = BW(kg)*.\K]×BL cm *._K]×0.007184                              (4.8)  
 BSA is body surface area, BW is mean body weight and BL is mean body length (height). 
Mean body weight is set as 72kg, and average height is assumed to be 170cm. 
 VPV is the portal vein volume extracted from literature (Ito et al., 2003).  
3) Partition coefficient between blood and tissue (Kp) 
 Kp,GWFLZ and Kp,hepFLZ are the GW-to-blood partition coefficient and liver-to-blood partition 
coefficient, which were set to 1 (Carrasco-Portugal & Flores-Murrieta, 2007).  
4) Blood flows (Q) 
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 Qhep was set as 21.4ml/min/kg (Tsunoda et al., 1999). QPV and QHA are the portal vein blood 
flow and hepatic artery blood flow, which represent 75% and 25% of Qhep, respectively. Qvilli is 
4.3ml/min/kg, according to literature (Yang et al., 2007). 
5) Clearance 
 fuFLZ•CLint,hepFLZ can be calculated by equation (4.9) 
fE$%& ∙ CL=8F,-./$%& = `%abcdef∙gabcgabch`%abcdef                                                (4.9) 
 Assuming all non-renal clearance is hepatic clearance, CLhepFLZ should be (CLtot,pFLZ - 
CLrenFLZ). CLtot,pFLZ and CLrenFLZ were extracted from literatures (Ripa et al., 1993; Sobue et al., 
2004).  
6) Fraction unbound and blood-to-plasma partitioning ratio 
 Due to limited information, fraction unbound of FLZ (fuFLZ) was assumed to be 
time/concentration independent, and fuFLZ in plasma, hepatocyte and enterocyte were assumed to 
be the same, which is 0.88 (Humphrey et al., 1985). Blood-to-plasma partitioning ratio of FLZ 
(B:PFLZ) was assumed to be 1.0 (Ervine & Houston, 1994) 
4.2.1.2 FLZ semi-PBPK model after PO administration 
 
 A semi-PBPK model for PO FLZ (Figure 4.2) was developed based on the reported PK and 
physiological parameters (Table 4.1). A conventional one-compartmental body model with 
additional compartments for gut lumen, GW, portal vein, and liver was developed, by adding an 
absorption compartment (gut lumen) to the IV model.  
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Figure 4.2  Semi-PBPK model scheme for the disposition of FLZ after PO administration. 
 
 After PO administration, FLZ is dissolved in the gut lumen first, and a fraction of drug 
(FabsFLZ) permeates through the GW, with a first order absorption rate kGLFLZ. Since FLZ is a 
BCS class 1 drug (World Health Organization, 2005), with high solubility and high permeability, 
it is reasonable to assume FabsFLZ = 100%, and drug transporters have little effect on its 
absorption. Due to the high observed ForalFLZ and low GW and hepatic first-pass effect of FLZ, 
drug permeating into the GW is assumed to be the rate-limiting step of its oral absorption; hence, 
kGLFLZ is equal to kaFLZ, which was reported in literature (Ripa et al., 1993). VGL is the same as 
the volume of water a patient would take to administer the drug, which was set to be 250 ml 
(FDA, 2012). Assuming no drug gets metabolized in the GW, FLZ is carried into portal vein 
with blood flow of Qvilli, and reaches the liver via QPV. Before getting into the systemic blood 
compartment, FLZ can be metabolized by liver pre-systemically with the clearance of 
fuFLZ•CLint,hepFLZ. Once it gets into the systemic blood, the disposition is the same as IV 
administration.  
 Based on the model scheme, differential equations for mass transfer between compartments 
are expressed as equations (4.10) to (4.14): 
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dAA%$%& tdt = −cA%$%& ∙ VA% ∙ FjkH$%& ∙ kA%$%& − cA%$%& ∙ VA% ∙ (1 − FjkH$%&) ∙ kA%$%& 
when t = 0, AGLFLZ (0) = DosePOFLZ     (4.10) dAAB$%& tdt = cA%$%& ∙ VA% ∙ FjkH$%& ∙ kA%$%& + c#$%& ∙ Q<=>>= − ( cAB$%&K/,AB$%& ) ∙ Q<=>>= 
when t = 0, AGWFLZ (0) = 0             (4.11)
    
dA:;$%& tdt = c#$%& ∙ f:; ∙ Q:; − Q<=>>= + cAB$%&K/,AB$%& ∙ Q<=>>= − c:;$%& ∙ Q:; 
when t = 0, APVFLZ (0) = 0             (4.12) dA-./$%& tdt = c#$%& ∙ Q?@ + c:;$%& ∙ Q:; − C-./$%&K/,-./$%& ∙ Q-./ − c-./$%& ∙ fE$%& ∙ CL=8F,-./$%&  
 when t = 0, AhepFLZ (0) =0              (4.13)
  
dA#$%& tdt = k*$%& + C-./$%&K/,-./$%& ∙ Q-./ − c#$%& ∙ CL7.8$%& − c#$%& ∙ f:; ∙ Q:; − Q<=>>= − c#$%& ∙ Q?@− c#$%& ∙ Q<=>>= 
when t = 0, ABFLZ (0) = 0             (4.14) 
 AGLFLZ and CGLFLZ are the amount and concentration of drug in gut lumen compartment, and 
CGLFLZ is calculated by dividing AGLFLZ by VGL.  
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4.2.1.3 Model parameters and assumptions 
 
	 Model parameters used in semi-PBPK models of IV/PO FLZ were summarized in Table 4.1. 
	
Table 4.1  Semi-PBPK FLZ model parameters. 
 
Parameter Definition Value Source 
Physiological parameters 
VGL (ml/kg) Volume of gut lumen 3.57 
Assumed to be 250ml (USA Food and 
Drug Administration, 2012) 
VGW (ml/kg) Volume of GW 33.6 
Calculated by equation (4.6), assumed to 
be the surface of gut lumen cylinder 
VPV (ml/kg) Volume of portal vein 0.97 Unknown methods (Ito et al., 2003) 
Vhep (ml/kg) Volume of liver 22.5 Calculated by equation (4.7) and (4.8) 
Qvilli (ml/min/kg) Villous blood flow 4.30 In-vivo experiment (Yang et al., 2007) 
Qhep (ml/min/kg) Hepatic blood flow 21.4 In-vivo experiment (Tsunoda et al., 1999) 
fHA 
Fraction of hepatic artery to total hepatic 
blood flow 0.25 
(Eipel et al., 2010) (QHA was calculated 
as fHA•Qhep; QPV was calculated as (1-
fHA•Qhep) 
fPV 
Fraction of the components of portal vein 
that contain drug 1.00 
A correction factor that can be adjusted 
according to simulation results. 
FLZ PK Parameters 
VBFLZ (ml/kg) Volume of systemic blood compartment 641 
Calculated by equation (4.5) (Carrasco-
Portugal & Flores-Murrieta, 2007; 
Humphrey et al., 1985) 
fuFLZ 
Fraction unbound of FLZ in hepatocytes 
and enterocytes 0.88 
Assumed to be the same as fraction 
unbound in plasma (Humphrey et al., 
1985) 
Kp,GWFLZ GW-to-blood partition coefficient 1 
Assumed to be 1 (Carrasco-Portugal & 
Flores-Murrieta, 2007) 
Kp,hepFLZ Liver-to-blood partition coefficient 1 
Assumed to be 1 (Carrasco-Portugal & 
Flores-Murrieta, 2007) 
CLint,hepFLZ 
(ml/min/kg) Hepatic intrinsic clearance 0.11 Calculated by equation (4.9) 
CLrenFLZ (ml/min/kg) Renal clearance 0.2 
In-vivo experiment (Ripa et al., 1993; 
Sobue et al., 2004) 
B:PFLZ Blood to plasma partitioning ratio 1 (Ervine & Houston, 1994) 
kGLFLZ (min-1) 
Absorption rate constant from gut lumen to 
GW 0.0213 
Assumed to be kaFLZ from in-vivo 
experiment (Ripa et al., 1993) 
FabsFLZ Fraction of FLZ absorbed from gut lumen 100% 
BCS Class 1 drug (Lindenberg et al., 
2004) 
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The assumptions made in FLZ semi-PBPK modeling included: 
1) FLZ is virtually instantaneously and homogenously distributed across the body after IV 
administration. (i.e. follows a 1-compartmental body model) (Humphrey et al., 1985) 
2) Perfusion (blood flow) is the rate-limiting step for FLZ distribution, rather than tissue uptake. 
3) All non-renal clearance of FLZ is due to hepatic clearance (i.e., other elimination pathways, 
such as GW metabolism, are negligible). 
4) Negligible, if any, drug transporter effect involved in GI absorption of FLZ. 
5) FLZ follows dose-proportional PK at relevant dose range after IV/PO administration. 
6) Partition coefficient (Kp) for GW and liver are 1 (Carrasco-Portugal & Flores-Murrieta, 
2007), and are constant at simulated concentrations. 
7) FLZ plasma concentration is assumed to be the same as blood concentration (Ervine & 
Houston, 1994). 
8) Fraction unbound of FLZ in the blood, liver and GW are assumed to be the same. 
9) FLZ is rapidly dissolved in gut lumen, and completely absorbed from gut lumen (FabsFLZ = 
100%). 
10) FLZ follows 1st-order diffusion across GW, and this process is the rate-limiting step of its 
absorption. 
11)  MDZ has no effect on FLZ PK. 
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4.2.2 Model qualification and predictions 
 
 IV and PO FLZ semi-PBPK model were validated using the observed mean PK profiles from 
study 103 (Ahonen et al., 1997), and other FLZ clinical PK studies, based on a comprehensive 
literature search of FLZ clinical PK studies after IV and PO administration. In study 103, FLZ 
was administered as 400 mg 1 hour IV infusion and 400 mg PO; concentrations in all the other 
studies were normalized to 400 mg dose. Concentrations in all compartments were simulated 
using Simbiology (MATLAB, 2015a), and the predicted exposure metrics were summarized and 
compared to reported values. The most commonly used criteria of prediction acceptance: 
predicted exposure metrics are within 0.5 to 2-fold of observed, were used to assess performance 
of FLZ semi-PBPK model. FLZ concentrations in all compartments were then simulated using 
the validated semi-PBPK model, in order to compare tissue concentration-time profiles after 
different route of administration. 
4.2.3 Sensitivity Analysis  
 
 Sensitivity analyses were performed to provide information of specific parameters that the 
model predictions are most sensitive to. Parameters (i.e. fpv, Kp,GWFLZ, Kp,hepFLZ, CLint,hepFLZ, 
CLrenFLZ, and kGLFLZ ) that are uncertain/highly variable and/or expected to affect FLZ 
blood/hepatic/GW exposures the most were selected to perform sensitivity analysis. All 
parameters (except fpv, which was simulated at 0.0, 0.5 and 1.0) were increased and decreased by 
2-fold relative to their original values (overall-fold change in values = 4 - fold), as showed in 
Table 4.2, and the respective unbound blood/hepatic/GW concentration - time profiles were 
predicted under 400 mg 1 hour IV infusion or PO FLZ, as a representative of the dosing regimen 
in study 103, as well as the most commonly used daily dosing regimen of FLZ. Exposure metrics 
(AUC, cmax, tmax) of FLZ in blood, liver and GW were identified and the sensitivity to each 
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parameter was assessed by dividing respective exposure metrics simulated at the upper limit by 
that simulated at the lower limit. 
 
 
Table 4.2  Values of parameters used in sensitivity analysis. 
 
Parameter Name Initial Value Lower/Upper Sensitivity Limits 
fpv 1.0 0; 1.0 
Kp,hepFLZ  1.0 0.5; 2 
Kp,GWFLZ 1.0 0.5; 2 
CLint,hepFLZ (ml/min/kg) 0.1 0.05; 0.2 
CLrenFLZ (ml/min/kg) 0.2 0.1; 0.4 
kGLFLZ (min-1) 0.0213 0.0106; 0.0426 
 
 
4.3 Results and Discussion 
4.3.1 Model evaluation 
 
4.3.1.1 Predictive performance check 
 
 Semi-PBPK model after IV FLZ was validated using the observed mean PK profile from 
study 103 (Ahonen et al., 1997), and mean plasma concentrations digitized from studies 103 
(Ahonen et al., 1997), 301 (Humphrey et al., 1985), 308 (Jovanovid et al., 2005), 309 (Porta et 
al., 2005), 310 (Zimmermann et al., 1994) and 311 (Yeates et al., 1995) were utilized to validate 
PO FLZ model. Based on the assumption of dose-proportional PK, each concentration-time 
profile digitized from the literatures was corrected by the dose of study 103, which is 400 mg.  
Since IV FLZ was administered with different infusion times in different studies, observed 
profiles in other IV FLZ PK studies cannot be conveniently normalized to 400 mg dose, and as 
AUC after IV FLZ has small inter-study variability (<10%), (because FLZ is primarily renal-
cleared, and is not a potent substrate to any transporters in the kidney), only study 103, which is 
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a DDI study between MDZ and FLZ, was used to validate semi-PBPK model of FLZ after IV 
administration. Figure 4.3a demonstrates that the final PBPK model of FLZ can adequately 
predict FLZ plasma concentration after 1 hour IV infusion, with all simulated values within ± SD 
of the observed mean data. For PO FLZ (50 - 800 mg), the model can predict all observed 
exposure metrics within roughly 50% deviations (Table 4.3), with observed PK profiles evenly 
spread throughout the entire simulated PK profile. Differences in analytical methods, sampling 
strategies, subjects’ demographics may account for the variation among studies.  
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Figure 4.3  Observed and PBPK model-predicted FLZ PK profiles. 
 a) PK profile of 400 mg FLZ administered after 1 hour IV infusion. b) PK profiles of 400 mg 
PO FLZ. The solid lines reflect the predicted PK profiles. The circles and bars are observed 
means and SD values from study 103. Other symbols are observed mean values from different 
studies (indicated by study ID). 
Table 4.3  Comparison of reported and PBPK model-predicted FLZ plasma (blood) 
exposure metrics. 
Deviations of AUC and cmax are marked as bold. 
 
Validation 
study Route 
Reported 
Mean AUC 
Predicted 
Mean AUC  Deviation (%) 
Reported 
Mean cmax 
Predicted 
Mean cmax 
Deviation 
(%) 
Reported 
Mean tmax 
Predicted 
Mean tmax 
(µg/ml•hr) (µg/ml•hr) (µg/ml) (µg/ml) (hr) (hr) 
103 IV  (0-18h) 118 ± 7.5 114 3% 8.4 ± 0.6 8.1 -3% 1 1 
301 PO (0-∞) 239 370 55%    ~1 3.4 
308 PO (0-∞) 293 370 26% 7.1 8.1 14% 2.37 3.4 
309 PO (0-∞) 345 370 7% 8.2 8.1 -2% 3 3.4 
310 PO (0-∞) 452 370 -18% 9.4 8.1 -14% 3.08 3.4 
311 PO (0-∞) 456 370 -19% 9.4 8.1 -14 3.08 3.4 
103 PO (0-18h) 121 ± 9.5 113 -7% 8.2 ± 0.6 7.5 -9% 4 3.4 
 
4.3.1.2 Sensitivity analysis 
 
 The -fold change in unbound blood/hepatic/GW AUC0-∞, cmax and tmax were calculated by 
dividing respective exposure metrics simulated at the upper limit by that simulated at the lower 
limit (Table 4.4 and Table 4.5). A greater than 2-fold or less than 0.5-fold change was 
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highlighted as bold, indicating the corresponding exposure was sensitive to that parameter. After 
IV FLZ, CLrenFLZ substantially affects the AUC in all the three compartments, because FLZ is 
primarily (67%) eliminated through kidney in the model, and hepatic and GW concentrations 
mimics the decline of blood concentration at pseudo steady-state. Kp,hepFLZ and Kp,GWFLZ are 
pivotal parameters determining hepatic and GW concentrations, respectively, albert no big effect 
on blood concentration. Increasing fpv can significantly increase drug exposure in the liver, 
mainly because more drugs got into the liver through portal vein, resulting in slightly reduction 
in blood AUC (19%) as well. After PO FLZ, most parameters affect corresponding exposure 
metrics with the same trend as IV FLZ, but a larger fpv drastically prolongs tmax of hepatic 
concentration. This is within expectation because a greater fpv triggers a faster input of drug into 
liver compartment systemically, and even if the drug has been mostly absorbed, the rapid 
systemic input can still sustain drug levels in the liver for a while, which delays its tmax in the 
liver. kGLFLZ has no influence on AUC, but can alter tmax in all the compartments and cmax in GW 
considerably. The more impact of hepatic tmax (~10-fold difference with lower and upper limit of 
kGLFLZ) than GW tmax (~2-fold difference with lower and upper limit of kGLFLZ) is presumably 
because systemic input of FLZ into liver (through both hepatic artery and portal vein) is pretty 
fast, which can maintain drug levels and prolong tmax quite a bit (similar as fpv’s effect), if kGLFLZ 
is not fast enough. On the other hand, systemic input of FLZ into GW through Qvilli can barely 
impact tmax of cGWFLZ, due to the slow input rate (i.e. Qvilli) and the rapid output rate (i.e. QPV). 
However, in MDZ and FLZ DDI studies (Ahonen et al., 1997; Kharasch et al., 2005; Olkkola et 
al., 1996), MDZ was administered 1-2 hours after the administration of FLZ, thus the change in 
tmax might not be clinical significant. FLZ PK profiles in all sensitivity analyses are presented in 
Appendices B. 
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Table 4.4  Sensitivity analysis heat-map results for semi-PBPK IV FLZ model. 
(More solid green indicates smaller value; more solid red indicates larger value) 
 Parameter -Fold Change 
-Fold change in blood 
exposure metrics 
-Fold change in hepatic 
exposure metrics 
-Fold change in GW 
exposure metrics 
AUC0-∞ cmax tmax AUC0-∞ cmax tmax AUC0-∞ cmax tmax 
fPV 0-1 0.81 0.98 1.00 1.79 2.17 0.90 0.81 0.98 0.95 
Kp,hepFLZ 4 0.61 0.95 1.00 2.42 3.73 0.97 0.61 0.94 0.95 
Kp,GWFLZ 4 1.00 0.95 1.00 1.00 0.92 1.17 3.99 3.66 1.50 
CLint,hepFLZ 4 0.61 0.99 1.00 0.61 0.98 0.96 0.61 0.99 1.00 
CLrenFLZ 4 0.43 0.99 1.00 0.43 0.98 0.92 0.43 0.98 0.96 
 
4.5  Sensitivity analysis heat-map results for semi-PBPK PO FLZ model . 
(More solid green indicates smaller value; more solid red indicates larger value) 
 
Parameter -Fold Change 
-Fold change in blood 
exposure metrics 
-Fold change in hepatic 
exposure metrics 
-Fold change in GW 
exposure metrics 
AUC0-∞ cmax tmax AUC0-∞ cmax tmax AUC0-∞ cmax tmax 
fPV 0-1 0.81 0.97 0.96 1.77 1.64 5.69 0.82 1.00 1.01 
Kp,hepFLZ 4 0.61 0.91 0.97 2.42 3.67 0.89 0.63 0.99 0.95 
Kp,GWFLZ 4 1.00 0.93 1.13 1.00 0.93 1.05 3.99 2.97 1.50 
CLint,hepFLZ 4 0.61 0.96 0.88 0.61 0.96 0.84 0.63 1.00 1.00 
CLrenFLZ 4 0.43 0.99 1.00 0.43 0.98 0.92 0.43 0.98 0.96 
kGLFLZ 4 1.00 1.09 0.37 1.00 1.23 0.09 1.00 2.79 0.51 
 
4.3.2 Model Predictions 
Model predicted FLZ concentrations for all the compartments after 400 mg 1 hour IV 
infusion or PO FLZ are showed in Figure 4.4a-b. After IV administration, GW, portal vein and 
liver concentration almost mimic the blood concentrations, due to rapid equilibrium among all 
the compartments. As a consequence, FLZ is instantaneously and homogenously distributed 
throughout the whole body tissue, which follows one-compartment body model. This is in 
agreement with the conclusion from other FLZ clinical PK study (Humphrey et al., 1985).  
 After PO administration, drug in gut lumen is fully absorbed after 7.5 hours. cmax of GW, 
portal vein, liver and systemic blood are sequentially achieved, at 0.3 hour, 2.23 hours, 2.63 
hours and 3.23 hours, respectively, which is in consistent with the oral absorption order of FLZ. 
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After around 4 hours, the distribution of FLZ has reached pseudo steady-state, and 
concentrations of all the compartments decline at the same rate. 
 To compare GW and liver concentration after IV and PO administration (Figure 4.4c), FLZ 
unbound hepatic concentrations are almost superimposable, although marginal difference is 
observed during the first 2 hours. GW concentration after PO FLZ is much higher than IV FLZ 
during the first 4 hours, but no difference is found after 4 hours. As a result, it is expected that 
PO FLZ would have greater inhibition on MDZ GW metabolism than IV FLZ, while no 
significant difference could be found as to hepatic metabolism inhibition. However, the 
inhibitory effect is also determined by the dynamic concentration of MDZ after IV and PO 
administration, as well as the inhibitory potency of FLZ on hepatic and GW CYP3A. 
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a)          b) 
 
c) 
 
 
Figure 4.4  Model predicted FLZ concentrations in different compartments. 
a) FLZ unbound concentration – time profiles after 400 mg 1 hour IV infusion FLZ. b) FLZ unbound concentration – time profiles 
after 400 mg PO FLZ. c) FLZ unbound hepatic and GW concentration – time profiles.  
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4.4 Conclusions 
 A FLZ semi-PBPK model was developed to describe its clinical PK after IV and PO 
administration. The model was validated by several clinical PK studies of FLZ, and plasma 
concentration – time profiles can be characterized well by the model, after dose correction. 
Formal parameter sensitivity analyses were conducted for six key/uncertain model parameters, 
and CLrenFLZ is the only influential parameter on FLZ plasma concentration after both IV and PO 
administration, while kGLFLZ can only affect tmax after PO FLZ. In addition to CLrenFLZ and kGLFLZ, 
hepatic and GW FLZ concentrations are also sensitive to fpv, Kp,hepFLZ and Kp,GWFLZ. Since 
CLrenFLZ and kGLFLZ are supported by FLZ clinical PK literatures, fpv and Kp,hepFLZ and Kp,GWFLZ 
are the pivotal parameters affecting chepFLZ and cGWFLZ, which may require further optimization 
once MDZ and FLZ DDI model is built. GW concentration after PO FLZ is much higher than 
that after IV infusion FLZ, indicating that FLZ may be expected to have greater inhibition on 
GW metabolism of MDZ after PO than IV infusion administration. Hepatic FLZ concentration 
doesn’t have much difference between IV and PO administration, suggesting no route difference 
of FLZ on hepatic metabolism of MDZ. 
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CHAPTER 5 
 
 
5 SEMI-PBPK MODELING OF IV/PO MDZ 
 
 
 
 
5.1 Background and Objectives  
5.1.1 MDZ PK information 
	
 Clinically, MDZ is a short-acting benzodiazepine, indicated for preoperative 
sedation/amnesia/anxiolysis for adults after IV or intramuscular injection, or oral syrup for 
pediatric patients (Baxter Healthcare Corporation; Ranbaxy Pharmaceuticals Inc., 2013). From 
Chapter 3, dose proportional PK was established between 0.005 mg/kg - 0.1 mg/kg after IV 
MDZ and between 0.025 mg/kg - 0.244 mg/kg after PO MDZ. After IV administration, MDZ 
was well-characterized by a 3-compartmental body model in study 21 (Kharasch et al., 2005b), 
and rapidly eliminated by hepatic CYP3A metabolism exclusively, with negligible renal 
elimination (Baxter Healthcare Corporation; Tolle-Sander et al., 2003). It has a short half-life 
(t1/2MDZ) of 1.8-6.4 hours, and a high plasma protein binding (fuMDZ = 0.03 (Baxter Healthcare 
Corporation)). After PO administration, it is well absorbed into GW (BCS class 1 drug (Wu & 
Benet, 2005)), and sequentially subject to extensive pre-systemic GW and hepatic CYP3A 
metabolism before reaching systemic circulation.   
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5.1.2 Available validation studies and simulation strategies 
	
 Based on the quantitative meta-analysis discussed in Chapter 3, study 21(Kharasch et al., 
2005), study 26 (Olkkola et al., 1996) and study 103 (Ahonen et al., 1997) are the three clinical 
studies to assess DDI between MDZ and FLZ in our final database. Therefore, MDZ semi-PBPK 
model should be validated by the observed MDZ plasma concentration – time profiles in absence 
of FLZ in the three studies. 
 In study 21, twelve volunteers were enrolled in a randomized 4-way crossover study, 
separated by at least 2 weeks between each session. They received single dose of 0, 100, 200, or 
400 mg PO FLZ, followed 2 hours later by 1mg IV MDZ; the next day, they received the same 
dose of placebo or FLZ, followed by 3 mg PO MDZ. Plasma concentrations of MDZ after IV 
and PO administration were both determined up to 8 h by LC-MS (LLOQ = 0.1ng/ml). 
 In study 103, a double-dummy, randomized, 3-way cross-over study was performed in 9 
healthy volunteers. The subjects were given 7.5 mg PO MDZ 1 hour after placebo, IV 400mg 
FLZ over 1-hour infusion or PO 400 mg FLZ. Plasma concentrations of MDZ and FLZ were 
determined for up to 17 h by HPLC (LLOQ = 1ng/ml). 
 In study 26, a double-blind, randomized, 3-phase cross-over study was conducted in 12 
healthy volunteers (7 males and 5 females). The subjects were given orally, once daily either 
placebo or FLZ 400 mg on the first day and then 200 mg daily for 5 days. On the first day of 
pretreatment, 7.5 mg of PO MDZ was ingested 2 hours after the first dose of placebo or FLZ. IV 
MDZ 0.05 mg/kg, was administered over 2 min injection on the 4th day of pretreatment. The 
third dose, 7.5 mg of PO MDZ was ingested on the 6th day. MDZ was always administered 2 
hours after placebo or FLZ doses. Plasma concentrations of MDZ were determined for up to 17 h 
by gas chromatography (LLOQ = 0.1ng/ml).  
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 After model qualification by the three studies, sensitivity analyses were performed to detect 
key PK/physiological parameters in MDZ semi-PBPK model that could influence MDZ plasma 
exposures the most, to facilitate future DDI model optimization. 
5.1.3 Objectives 
	
 The major objectives of the chapter were to: 
a. Develop a semi-PBPK model of MDZ to describe its PK profiles in human after IV and 
PO administration 
b. Validate the model using plasma concentration-time profiles in clinical DDI studies 
(without FLZ group), and identify pivotal PK/physiological parameters that determine 
MDZ plasma exposure metrics by sensitivity analysis 
c. Predict tissue (e.g. hepatic, GW) concentration – time profiles of MDZ using the 
validated semi-PBPK model 
 
5.2 Methods 
5.2.1 Development of MDZ semi-PBPK model 
 
5.2.1.1 MDZ semi-PBPK model after IV administration 
 
 A semi-PBPK model for IV MDZ was built based on the reported in-vitro metabolic 
information, PK and physiological parameters (Table 5.1). A conventional three-compartmental 
body model with additional compartments for GW serosa, portal vein, and liver was developed, 
and showed in Figure 5.1. This model is similar to the FLZ semi-PBPK model (see Chapter 4, 
Section 4.2.1), with the following differences: (1) After IV administration, MDZ is injected 
directly into the systemic circulation, and assumed to distribute to a rapidly equilibrating 
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“shallow” peripheral compartment (Peripheral Cpt-1) and a slowly equilibrating “deep” 
peripheral compartment (Peripheral Cpt-2), with the inter-compartmental clearance of Q2MDZ to 
Peripheral Cpt-1 and Q3MDZ to Peripheral Cpt-2, except GW, portal vein and liver, as tissues of 
interest. (2) MDZ has negligible renal elimination, and hepatic intrinsic clearance is expressed as 
vmax,hepMDZ/Km,hepMDZ. (3) In terms of GW metabolism, after scaling from in-vitro metabolic study 
to in-vivo intrinsic clearance of unbound MDZ (Paine et al., 1997), intrinsic GW clearance 
(CLint,GWMDZ)  is only 1.3% of CLint,hepMDZ, confirming the assumption of negligible GW 
metabolism of MDZ after IV administration. Hence, hepatic clearance is assumed to be the only 
elimination pathway after IV MDZ. 
 
Figure 5.1  Semi-PBPK model scheme for the disposition of MDZ after IV administration. 
 
1) Differential equations: 
 Based on the model above, differential equations for total (unbound + bound) MDZ mass 
transfer between compartments were expressed as equations (5.1) to (5.6): dA#$%& tdt = k*$%& + c-.$%& ∙ Q1$%& + c-1$%& ∙ Q2$%& + C456$%&K6,456$%& ∙ Q456 − c#$%& ∙ f-;∙ Q-; − Q<=>>= − c#$%& ∙ Q?@ − c#$%& ∙ Q<=>>= − c#$%& ∙ Q1$%& − c#$%& ∙ Q2$%& 
when t = 0, ABMDZ (0) = 0; when t = 2 min, ABMDZ (2) = DoseIVMDZ    (5.1) dA-.$%& tdt = c#$%& ∙ Q1$%& − c-1$%& ∙ Q1$%& 
93	
	
 
when t = 0, AP1MDZ (0) = 0             (5.2)
  
dA-1$%& tdt = c#$%& ∙ Q2$%& − c-1$%& ∙ Q2$%& 
when t = 0, AP2MDZ (0) = 0             (5.3)
  
dAABCD$%& tdt = c#$%& ∙ Q<=>>= − (cABCD$%&K6,AB$%& ) ∙ Q<=>>= 
when t = 0, AGW-SMDZ (0) = 0             (5.4)
  
dA-;$%& tdt = c#$%& ∙ f-; ∙ Q-; − Q<=>>= + cABCD$%&K6,AB$%& ∙ Q<=>>= − c-;$%& ∙ Q-; 
when t = 0, APVMDZ (0) = 0             (5.5) dA456$%& tdt = c#$%& ∙ Q?@ + c-;$%& ∙ Q-; − C456$%&K6,456$%& ∙ Q456 − c456$%& ∙ fG$%& ∙ vIJK,456$%& /KI,456$%&  
 when t = 0, AhepMDZ (0) =0              (5.6)
              
 ABMDZ, AP1MDZ, AP2MDZ, AGW-SMDZ, APVMDZ and AhepMDZ are the amounts of drug in central, 
shallow peripheral, deep peripheral, GW serosa, portal vein and liver compartments, 
respectively; cBMDZ, cP1MDZ, cP2MDZ, cGW-SMDZ, cPVMDZ, chepMDZ are drug concentrations in central, 
shallow peripheral, deep peripheral, GW serosa, portal vein and liver compartments, calculated 
by dividing amount (A) by the respective compartment volume: VBMDZ, VP1MDZ, VP2MDZ, VGW, 
VPV and Vhep, which are MDZ volume of central, shallow peripheral, deep peripheral 
compartments, volume of GW, portal vein and liver. IV bolus is assumed to be a 2-min IV 
infusion, thus an infusion rate k0MDZ was introduced in equation (5.1) as a dose input rate, and 
initial amounts for all the six compartments are 0. 
2) Volume of distributions and inter-departmental clearance 
Systemic blood compartment volume of distribution (VBMDZ), shallow peripheral 
compartment volume of distribution (VP1MDZ), deep peripheral compartment volume of 
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distribution (VP2MDZ), Q2MDZ and Q3MDZ were estimated from the digitized plasma concentration 
– time data of MDZ in absence of FLZ in study 21 (Kharasch et al., 2005b), with a traditional 
three-compartmental body model (See Appendix C).  
VGW, Vhep and VPV were used the same values as FLZ semi-PBPK model (see Chapter 4, 
section 4.2.1.3). 
3) Partition coefficient between blood and tissue (Kp) 
 Kp,GWMDZ and Kp,hepMDZ are the GW-to-blood partition coefficient and liver-to-blood partition 
coefficient, which are 1.12 and 1.09 (Björkman et al., 2001), respectively.  
4) Blood flows (Q) 
 Qhep, QPV, QHA and Qvilli were used the same values as FLZ semi-PBPK model (see Chapter 
4, section 4.2.1.3) 
5) Clearance 
 Since MDZ follows dose-proportional PK under 0.1 mg/kg after IV MDZ, and under 0.224 
mg/kg after PO MDZ (according to Chapter 3), CLint,hepMDZ can be represented as 
vmax,hepMDZ/Km,hepMDZ. Km,hepMDZ was set as in-vitro Km of human liver microsomes from 4 donors 
by measuring the formation rate of 1’-OH-MDZ (Thummel et al., 1996). vmax,hepMDZ was quite 
variable across in-vitro metabolic studies, hence CLint,hepMDZ was calculated by equation (5.7) 
using study 21.  
CL=NO,456$%& = ( PQRSTUVW∙XRSTXRSTCPQRSTUVW)/fG$%&                                            (5.7) 
 CLhepMDZ is the systemic hepatic clearance (corrected by blood-to-plasma partitioning ratio of 
MDZ) estimated from study 21 using non-compartmental analysis, assuming system hepatic 
clearance is the only elimination pathway after IV MDZ. fuMDZ is the fraction unbound of MDZ 
in hepatocytes. vmax,hepMDZ was then calculated by equation (5.8), 
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      vIJK,456$%& = CL=NO,456$%& ∙ KI,456$%&                                         (5.8) 
6) Fraction unbound and blood-to-plasma partitioning ratio 
 Due to limited information, fraction unbound of MDZ (fuMDZ) was assumed to be 
time/concentration independent, and fuMDZ in plasma and hepatocytes were assumed to be the 
same, which is 0.03 (Gandhi et al., 2012). Blood-to-plasma partitioning ratio of MDZ (B:PMDZ) 
was set as 0.86 (Ervine & Houston, 1994).  
 Body weight was set as the mean body weight (70kg) of subjects in study 21. 
5.2.1.2 MDZ semi-PBPK model after PO administration 
 
 A semi-PBPK model for PO MDZ (Figure 5.2) was built based on the reported in-vitro 
metabolic information, PK and physiological parameters (Table 5.1). A conventional three-
compartmental body model with additional compartments for gut lumen, GW mucosa, GW 
serosa, portal vein, and liver was developed, by adding two absorptive compartments (gut lumen 
and GW mucosa) to the IV model. After PO administration, MDZ is dissolved in the gut lumen 
first, and a fraction of drug (FabsMDZ) permeates through GW, with a first order absorption rate 
kGLMDZ. Since MDZ is a BCS class 1 drug (Wu & Benet, 2005), with high solubility across the 
whole gastrointestinal tract pH range and high permeability, it is reasonable to assume that 
FabsMDZ = 100%, and drug transporters have little effect on its absorption (Tolle-Sander et al., 
2003). Due to the rapid diffusion of MDZ into GW, portal vein and liver, permeating into the 
GW was assumed to be the rate-limiting step of its oral absorption, and kGLMDZ ≈ kaMDZ (kaMDZ 
was the observed oral absorption rate constant of MDZ reported in literatures (Johnson et al., 
2002; Kato et al., 2008). Once it is permeated into GW through mucosa side, MDZ can be 
metabolized by GW CYP3A enzymes located at the villous tips (Yang et al., 2007; Watkins, 
1997). Pre-systemic GW extraction is much higher than systemic GW extraction, due to the 
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negligible protein binding (fu,GW-MMDZ = 1.0) and potential higher concentrations at the mucosal 
side of intestinal epithelium. To calculate pre-systemic GW intrinsic clearance (CLint,GWMDZ), 
vmax,GWMDZ and Km,GWMDZ values were extrapolated from in-vitro metabolic study(Thummel et 
al., 1996). fvilli was added as an in vitro – in vivo scaling factor, as well as an adjustment of the 
real functional GW CYP3A (drugs may not diffuse to certain regions of GW, or oxygen may not 
be sufficient, inter-individual variability, etc.). Sensitivity analysis was conducted to fvilli on 
MDZ plasma concentrations (See section 5.2.3).  In addition, the potential high concentration of 
MDZ at GW mucosa may lead to saturable GW metabolism, therefore, CLint,GWMDZ was 
expressed as a Michaelis-Menten equation format (5.9) 
           CL=NO,AB$%& = YZ[\\[∙<]^_,`aUVWb],`aUVW cYd,`aeUUVW ∙f`aeUUVW                                           (5.9) 
 Furthermore, a transit rate constant (kT) from mucosa to serosa was added to connect the two 
sides of GW, and set as Qvilli/VGW, to keep the outflow from mucosa to serosa of intestinal 
epithelium constant to be Qvilli. MDZ is then carried into portal vein with blood flow of Qvilli, and 
reaches liver via portal vein. Before getting into the systemic blood compartment, it can be 
metabolized by liver pre-systemically. Once it gets into the systemic blood, the disposition is the 
same as IV administration.  
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Figure 5.2  Semi-PBPK model scheme for the disposition of MDZ after PO administration.
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 Based on the model scheme, differential equations for mass transfer between compartments 
were expressed as equations (5.10) to (5.17): 
!"#$%&' (!( = −c,-./0 ∙ V,- ∙ F456./0 ∙ k,-./0 − c,-./0 ∙ V,- ∙ (1 − F456./0) ∙ k,-./0  
when t = 0, AGLMDZ (0) = DosePOMDZ     (5.10) dA,=>../0 tdt = c,-./0 ∙ V,- ∙ F456./0 ∙ k,-./0 − 	c,=>../0 ∙ V,= ∙ kA − fC, =>../0 ∙ c,=>../0 ∙ fEFGGF∙ vI4J, =./0 /(KI, =./0 + fC, =>../0 ∙ c,=>../0 ) 
when t = 0, AGW-MMDZ (0) = 0             (5.11)
    
dA,=>N./0 tdt = c,=>../0 ∙ V,= ∙ kA + cO./0 ∙ QEFGGF − (c,=>N./0KQ, =./0 ) ∙ QEFGGF 
when t = 0, AGW-SMDZ (0) = 0             (5.12)
  
dARS./0 tdt = cO./0 ∙ fRS ∙ QRS − QEFGGF + c,=>N./0KQ, =./0 ∙ QEFGGF − cRS./0 ∙ QRS 
when t = 0, APVMDZ (0) = 0             (5.13) dATUQ./0 tdt = cO./0 ∙ QV" + cRS./0 ∙ QRS − CTUQ./0KQ,TUQ./0 ∙ QTUQ − cTUQ./0 ∙ fC./0 ∙ vI4J,TUQ./0 /KI,TUQ./0  
 when t = 0, AhepMDZ (0) =0              (5.14)
              
dAO./0 tdt = cRX./0 ∙ QY./0 + cRY./0 ∙ QZ./0 + CTUQ./0KQ,TUQ./0 ∙ QTUQ − cO./0 ∙ fRS ∙ QRS − QEFGGF− cO./0 ∙ QV" − cO./0 ∙ QEFGGF − cO./0 ∙ QY./0 − cO./0 ∙ QZ./0 
when t = 0, AB (0) = 0              (5.15) dARX./0 tdt = cO./0 ∙ QY./0 − cRY./0 ∙ QY./0 
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when t = 0, AP1MDZ (0) = 0             (5.16)
  
dARY./0 tdt = cO./0 ∙ QZ./0 − cRY./0 ∙ QZ./0 
when t = 0, AP2MDZ (0) = 0             (5.17)
  
 AGLMDZ and AGW-MMDZ are the amounts of drug in gut lumen and GW mucosa, respectively; 
CGLMDZ and CGW-MMDZ are drug concentrations in gut lumen and GW mucosa, calculated by 
dividing amount (A) by the respective compartment volume: VGL and VGW. Volume of both GW 
mucosa and serosa were assumed to be the same as VGW. 
5.2.1.3 Model parameters and assumptions 
 
 Initial model parameters used in semi-PBPK models of IV/PO MDZ are summarized in 
Table 5.1. Physiological parameters were the same as FLZ semi-PBPK model, except for adding 
fvilli. vmax,hepMDZ and fvilli, representing hepatic CYP3A capacity and scaling factor for GW 
CYP3A capacity, were adjusted during model qualification processes, which were discussed in 
section 5.3.1.1. 
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Table 5.1  Initial semi-PBPK MDZ model parameters. 
Parameter Definition Value Source 
Physiological parameters 
VGL (ml/kg) Volume of gut lumen 3.57 Assumed to be 250ml (FDA, 2012) 
VGW (ml/kg) Volume of GW 33.6 
Calculated by equation (4.6), assumed to be the 
surface of gut lumen cylinder 
VPV (ml/kg) Volume of portal vein 0.97 Unknown methods (Ito et al., 2003) 
Vhep (ml/kg) Volume of liver 22.5 Calculated by equation (4.7) and (4.8) 
Qvilli 
(ml/min/kg) Villous blood flow 4.30 In-vivo experiment (Yang et al., 2007) 
Qhep 
(ml/min/kg) Hepatic blood flow 21.4 In-vivo experiment (Tsunoda et al., 1999) 
fHA 
Fraction of hepatic artery to total 
hepatic blood flow 0.25 
(Eipel et al., 2010) (QHA was calculated as fHA•Qhep; 
QPV was calculated as (1-fHA•Qhep) 
fPV 
Fraction of the components of portal 
vein that contain drug 1.00 
A correction factor that can be adjusted according to 
simulation results. 
1fvilli 
IVIVE scaling factor and IIV adjusting 
factor 2.2 Optimized with data from study 21 
MDZ PK Parameters 
VBMDZ (ml/kg) 
Volume of systemic blood 
compartment 140.4 See Appendices C 
VP1MDZ (ml/kg) 
Volume of shallow peripheral 
compartment 313.7 See Appendices C 
VP2MDZ (ml/kg) 
Volume of deep  
peripheral compartment 531.4 See Appendices C 
Q2MDZ(min-1) 
Inter-compartmental clearance 
between central and peripheral cpt-1 55.27 See Appendices C 
Q3MDZ(min-1) 
Inter-compartmental clearance 
between central and peripheral cpt-2 7.25 See Appendices C 
fuMDZ Fraction unbound of MDZ 0.03 
Assume to be the same in plasma and hepatocytes 
(Gandhi et al., 2012) 
fu,GW-MMDZ 
Fraction unbound at mucosal side of 
intestinal epithelium 1.0 Assumed to be negligible bound 
vmax,GWMDZ 
(ng/min/kg) 
GW CYP3A capacity to metabolize 
MDZ 3357.6 In-vitro experiment (Thummel et al., 1996) 
Km,GWMDZ 
(ng/ml) 
GW CYP3A affinity of metabolizing 
MDZ 1173 In-vitro experiment (Thummel et al., 1996) (3.6µM) 
1vmax,hepMDZ 
(ng/min/kg) 
Hepatic CYP3A capacity to 
metabolize MDZ 305067 
In-vivo experiment, calculated from equation (5.7-
5.8), using data from study 21 
Km,hep (ng/ml) 
Hepatic CYP3A affinity of 
metabolizing MDZ 880 In-vitro experiment (Thummel et al., 1996) (2.7µM) 
Kp,GWMDZ  GW-to-blood partition coefficient 1.12 Scaled from rats Kp (Björkman et al., 2001) 
Kp,hepMDZ  Liver-to-blood partition coefficient 1.09 Scaled from rats Kp (Björkman et al., 2001) 
B:PMDZ Blood-to-plasma partitioning ratio 0.86 (Ervine & Houston, 1994) 
kGLMDZ (min-1) 
Absorption rate constant from gut 
lumen to GW 0.05 
In-vivo experiment (Johnson et al., 2002; Kato et al., 
2008), assumed to be kaMDZ 
kT (min-1) 
Transit rate from mucosal to serosal 
side of intestinal epithelium 0.13 Assumed, calculated from Qvilli/VGW 
FabsMDZ 
Fraction of MDZ absorbed from gut 
lumen 100% BCS Class 1 drug (Wu & Benet, 2005) 
 
1Parameter values were adjusted in study 103 and 26. 
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The assumptions made in MDZ semi-PBPK modeling included: 
1) MDZ followes a three-compartmental body disposition model (except GW, portal vein, liver) 
after IV administration (based on observed PK profile in study 21). 
2) Perfusion (blood flow) is the rate-limiting step for MDZ tissue distribution, rather than tissue 
uptake. 
3) Renal clearance of MDZ is negligible. 
4) Negligible drug transporter effect, if any, on MDZ PK. 
5) CYP3A is the only elimination pathway in GW and liver (metabolic fraction by CYP3A is 
0.93 (Quinney et al., 2010; Zhang et al., 2009)), and the formation of other metabolites 
(besides 1’-OH-MDZ) is negligible. 
6) MDZ is at equilibrium between hepatocytes and hepatic venous outflow (well-stirred model). 
7) Partition coefficient (Kp) for GW and liver are constant. 
8) No/negligible GW metabolism occurs after IV MDZ. 
9) MDZ’s binding to hepatic proteins is assumed to be the same as plasma protein binding; 
protein binding at mucosal side of intestinal epithelium is negligible. 
10) MDZ is rapidly dissolved in gut lumen, and completely absorbed from gut lumen. 
(FabsMDZ=100%) 
11) MDZ follows 1st-order diffusion across GW, and this process is the rate-limiting step of its 
oral absorption. (kGLMDZ ≈ kaMDZ) 
12) GW compartment is divided into mucosal side and serosal side; volumes of the two 
compartments are both VGW, and the transit rate (kT) from mucosa to serosa is Qvilli/VGW. 
13) MDZ follows dose-proportional PK at relevant dose range. (CLint,hepMDZ can be represented 
by vmax,hep/Km,hep) 
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5.2.2 Model qualification and predictions 
 
 Model simulated MDZ plasma concentration-time profiles were compared with observed 
profiles in absence of FLZ from study 21 (Kharasch et al., 2005), study 103 (Ahonen et al., 
1997) and study 26 (Olkkola et al., 1996), to assess model validity by predictive visual check and 
exposure metrics comparison. Since some parameters (i.e. vmax,hepMDZ and fvilli, discussed later) 
were optimized in different MDZ PK studies - due to the large inter-study variability of hepatic 
and GW CYP3A-, a more stringent acceptance criterion: predicted exposure metrics are ± 30% 
of observed, were used to assess performance of MDZ semi-PBPK model. Plasma concentrations 
were simulated using Simbiology (MATLAB, 2015a), and the predicted exposure metrics were 
summarized and compared to reported values. MDZ concentrations in all compartments were 
simulated using the semi-PBPK model, in order to compare tissue concentration-time profiles 
after different route of administration. 
5.2.3 Sensitivity Analysis 
 
 Formal sensitivity analyses were conducted by altering the values for 8 key seim-PBPK 
model parameters (fPV, vmax,hepMDZ, Kp,hepMDZ, Kp,GWMDZ, Q2MDZ, Q3MDZ, fvilli and kGLMDZ), to 
assess their significance on MDZ systemic plasma exposures in absence of FLZ. All parameters 
(except fpv, which was simulated at 0.0, 0.5 and 1.0) were increased and decreased by 2-fold 
relative to their original values (overall-fold change in values = 4 - fold), as showed in Table 5.2, 
and the respective plasma concentration - time profiles were predicted under 1 mg IV bolus 
MDZ over 2 min or 3 mg PO MDZ, as a representative of the dosing regimen in study 21. 
Plasma exposure metrics (AUC, cmax, tmax) were identified, and the sensitivity to each parameter 
was assessed by dividing respective exposure metrics simulated at the upper limit by that 
simulated at the lower limit. 
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Table 5.2   Values of parameters used in sensitivity analysis. 
 
Parameter Name Initial Value Lower/Upper Sensitivity Limits 
fpv 1.0 0; 1.0 
vmax,hepMDZ (ng/min/kg) 305067 152534; 610134 
Kp,hepMDZ  1.09 0.55; 2.18 
Kp,GWMDZ 1.12 0.56; 2.24 
Q2MDZ (ml/min/kg) 55.3 27.7; 110.6 
Q3MDZ (ml/min/kg) 7.25 3.63; 14.5 
fvilli 2.2 1.1; 4.4 
kGLMDZ (min-1) 0.05 0.025; 0.1 
 
 
5.3 Results and Disucssion 
5.3.1 Model evaluation 
 
5.3.1.1 Predictive performance check 
 
 The observed and model-predicted MDZ PK profiles for study 21 are showed in Figure 
5.3a-b and the comparison of observed and model simulated exposure metrics are summarized in 
Table 5.3. Figure 5.3a-b demonstrate that the model can predict MDZ PK profiles well after 
both IV and PO administration in study 21, with all predicted values superimposable with 
observed data. Deviations (%) of AUC0-∞ and cmax are all less than 30%, which is a pre-defined 
cut-off of precise prediction, and tmax difference was quite minimal. 
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a)   b) 
 
  
 
c)     d) 
  
 
Figure 5.3  Observed and PBPK-model simulated MDZ PK profiles in study 21. 
a-b) IV MDZ 1 mg (0.014mg/kg) in the absence of FLZ (Cartesian and semi-log plots). c-d) PO 
MDZ 3mg (0.043mg/kg) in the absence of FLZ (Cartesian and semi-log plots). The solid lines 
reflect the predicted PK profiles. The symbols are reported mean concentrations in study 21. 
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 For study 103, all the parameters were originally assumed to be the same with study 21. 
However, the predicted terminal slope was apparently steeper than the observed slope (Figure 
5.4, dashed lines), resulting in under-estimation of MDZ AUC0-∞ by 51%. Since MDZ was only 
administered orally in study 103, CLint,hepMDZ cannot be estimated through observed data. As a 
result, vmax,hepMDZ was optimized based on visual inspection of the terminal slope, and a value of  
170,000ng/min/kg was finally chosen to simulate PK profiles in study 103. This adjustment is 
within the 4.2-fold inter-study variability of CLint,hepMDZ, as characterized in Chapter 3, section 
3.3.3.1. After changing vmax,hepMDZ, the adjusted PBPK model predicts MDZ PK profile 
reasonably well (shown in Figure 5.4), with deviations (%) of AUC0-∞ and cmax less than 30%, 
and marginal tmax difference (see Table 5.3). 
a)     b) 
 
  
 
Figure 5.4  Observed and PBPK-model simulated MDZ PK profiles in study 103. 
a) PO MDZ 7.5 mg (0.104mg/kg) in the absence of FLZ (Cartesian plot) b) PO MDZ 7.5 mg 
(0.104mg/kg) in the absence of FLZ (Semi-log plot). The dashed lines reflect the predicted PK 
profiles without vmax,hepFLZ adjustment. The solid lines reflect the predicted PK profiles after 
vmax,hepMDZ adjustment. The symbols and bars are reported mean concentrations and SD in study 
103 if available. 
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 For study 26, all the parameters were originally assumed to be the same with study 21. IV 
MDZ PK profile (Figure 5.5a-b) can be well characterized by the original model parameters, 
however, after PO MDZ, the predicted concentrations (including cmax) were consistently lower 
than observed values (Figure 5.5c-f, dashed lines), resulting in underestimation of PO MDZ 
AUC0-∞ by 32% and 41% compared with MDZ exposure on day 1 and day 6, respectively. 
Therefore, fvilli (adjusting intestinal CYP3A capacity) for study 26 was changed to 1.45 from 
original value of 2.2, based on ERGI calculation for study 21 (ERGI = 56%) and 26 (ERGI = 37%) 
in Chapter 3. After changing fvilli, the adjusted PBPK model predicts PO MDZ PK profiles 
much better than before (shown in Figure 5.5), and AUC0-∞ and cmax deviations are all less than 
30% after adjustment (see Table 5.3). 
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a) b) 
  
c)   d) 
  
e) f) 
  
Figure 5.5  Observed and PBPK-model simulated MDZ PK profiles in study 26. 
a-b) IV bolus (over 2 min) MDZ 0.05 mg/kg in absence of FLZ administered on day 4 (Cartesian 
and semi-log plots). c-d) PO MDZ 7.5 mg (0.107 mg/kg) in absence of FLZ administered on day 
1 (Cartesian and semi-log plots). e-f) PO MDZ 7.5 mg (0.107 mg/kg) in absence of FLZ 
administered on day 6 (Cartesian and semi-log plots). The dashed lines reflect predicted PK 
profiles without fvilli adjustment. The solid lines reflect predicted PK profiles after fvilli 
adjustment. The symbols and bars are reported mean concentrations and SD in study 26. 
0
50
100
150
200
250
72 77 82 87 92
IV
 M
D
Z
 P
la
sm
a 
C
on
c 
(d
ay
 
4)
 (n
g/
m
l)
Time After 1st FLZ Dosing (hr)
0.1
1
10
100
1000
72 77 82 87 92I
V
 M
D
Z
 P
la
sm
a 
C
on
ce
  (
da
y 
4)
 (n
g/
m
l)
Time After 1st FLZ Dosing (hr)
0
5
10
15
20
25
30
35
0 5 10 15 20
PO
 M
D
Z
 P
la
sm
a 
C
on
c 
(d
ay
 
1)
 (n
g/
m
l)
Time After FLZ Dosing (hr)
0.1
1
10
100
0 5 10 15 20
PO
 M
D
Z
 P
la
sm
a 
C
on
c 
(d
ay
 
1)
 (n
g/
m
l)
Time After FLZ Dosing (hr)
0
5
10
15
20
25
30
35
40
120 125 130 135 140
PO
 M
D
Z
 P
la
sm
a 
C
on
c 
(d
ay
 
6)
 (n
g/
m
l)
Time After FLZ Dosing (hr)
0.1
1
10
100
120 125 130 135 140
PO
 M
D
Z
 P
la
sm
a 
C
on
c 
(d
ay
 
6)
 (n
g/
m
l)
Time After FLZ Dosing (hr)
108	
	
 
 Predictive performance checks for all the three studies after adjustments suggest that the 
semi-PBPK model for IV or PO MDZ in the absence FLZ predicts the reported data from three 
clinical studies well, confirming the validity of this model and model parameters. Adjusted 
parameter values were presented in Table 5.4. 
109	
	
 
Table 5.3  Comparison of reported and semi-PBPK model-predicted MDZ plasma exposure metrics in the absence FLZ using 
initial model (study 21) and adjusted model (study 103 and 26) parameters. 
Deviations greater than 30% were marked as bold. 
 
Study 
ID Route & Dose (MDZ) 
Reported Mean 
AUC0-∞(ng/ml*hr) 
Predicted 
AUC0-∞  
(ng/ml*hr) 
Deviation 
(%) 
Reported 
Mean 
cmax (ng/ml) 
Predicted 
cmax (ng/ml) 
Deviation 
(%) 
Start from MDZ was 
administered 
Reported 
Mean tmax (hr) 
Predicted 
tmax (hr) 
21 IV (0.014mg/kg) 29.8 27.6 -7% 53.5 55.1 3%   21 PO (0.043mg/kg) 24.0 23.0 -4% 8.1 9.1 12% 0.77 0.67 
103 PO (0.104mg/kg) vmax,hepMDZ not adjusted 
113 55.8 -51% 24.9 22.4 -10% 0.55 0.67 
103 PO (0.104mg/kg) vmax,hepMDZ adjusted 
113 106.3 -6% 24.9 30.6 23% 0.55 0.73 
26 IV (0.05mg/kg) 117.0 96.7 -17%      
26 PO (0.107mg/kg) day 1; day 6 fvilli not adjusted 
87.0; 101.3 59.3 -32%; -41% 25.7; 33.3 23.1 -10%; -30% 1; 1 0.67 
26 PO (0.107mg/kg) day 1; day 6 fvilli adjusted 
87.0; 101.3 76.2 -12%; -25% 25.7; 33.3 30.4 19%; -9% 1; 1 0.7 
 
 
Table 5.4  Adjusted semi-PBPK MDZ model parameters. 
 
Parameter Definition Value Source 
fvilli IVIVE scaling factor and IIV adjusting factor 1.45 
Value used for study 26 based on difference in ERGIMDZ 
between study 21 and 26 
vmax,hepMDZ 
(ng/min/kg) Hepatic CYP3A capacity to metabolize MDZ 170000 
Value used for study 103 based on terminal slope 
optimization 
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5.3.1.2 Sensitivity analysis 
 
 The -fold change in plasma AUC0-∞, cmax and tmax were calculated by dividing plasma 
exposure metrics simulated at the upper limit of a certain parameter by that simulated at the 
lower limit (Table 5.5). A greater than 2-fold or less than 0.5-fold change was marked as bold, 
indicating the corresponding exposure is sensitive to that parameter. After IV MDZ, fpv, 
vmax,hepMDZ and Kp,hepMDZ substantially affect MDZ AUC, because IV MDZ is exclusively 
metabolized in the liver, and all the three parameters influence MDZ hepatic concentration 
and/or hepatic clearance considerably. Increasing fpv and Kp,hepMDZ increases drug exposure in the 
liver, resulting in more drug got metabolized, while increasing vmax,hepMDZ accelerates hepatic 
metabolism, also leading to more drug gets cleared. After PO MDZ, increasing fpv, vmax,hepMDZ 
and Kp,hepMDZ also significantly decreases MDZ exposures, as a consequence, both AUC and cmax 
are reduced. AUC is altered to the same extent by fpv after PO MDZ as that after IV MDZ, 
because fpv can only affect drug input into the liver systemically. However, PO MDZ AUC and 
cmax are more sensitive to Kp,hepMDZ and vmax,hepMDZ than IV MDZ, because both parameters play 
a role in pre-systemic hepatic metabolism as well. fvilli potentially affects GW CYP3A capacity, 
and a higher fvilli exerts greater intestinal CYP3A metabolism of MDZ, and produces a lower 
AUC and cmax. MDZ plasma PK profiles for all sensitivity analyses are presented in Appendices 
D. 
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Table 5.5  Sensitivity analysis heat-map results for semi-PBPK IV/PO MDZ model. 
(More solid green indicates smaller value; more solid red indicates larger value) 
 
MDZ Sensitivity Analysis 1 mg IV MDZ 3 mg PO MDZ -Fold change in plasma exposure metrics -Fold change in plasma exposure metrics 
Parameter -Fold Change AUC0-∞ cmax tmax AUC0-∞ cmax tmax 
fPV 0-1 0.45 0.96 1.00 0.45 0.84 0.85 
vmax,hepMDZ 4 0.41 0.99 1.00 0.25 0.49 0.79 
Kp,hepMDZ 4 0.41 0.97 1.00 0.25 0.49 0.92 
Kp,GWMDZ 4 1.00 1.00 1.00 1.00 0.83 1.44 
Q2MDZ 4 1.00 0.72 1.00 1.00 1.01 1.20 
Q3MDZ 4 1.00 0.94 1.00 1.00 0.79 0.91 
fvilli 4 - - - 0.44 0.44 0.91 
kGLMDZ 4 - - - 1.05 1.65 0.52 
 
5.3.2 Model Predictions 
 
 Model predicted MDZ concentrations after 1 mg IV bolus (over 2 min) and 3 mg PO 
administration for all the compartments are demonstrated in Figure 5.5a-d. After IV 
administration, pseudo steady-state is reached 2 hours after administration, with concentrations 
in all compartments declined at the same rate. Portal vein and shallow peripheral compartment 
concentrations are overlapped with blood concentrations, due to rapid equilibrium among the 
three compartments. Hepatic concentration profile mimics blood concentration profile, with 
lower concentrations at the terminal phase, making MDZ continuously transfer from blood to the 
liver, and get cleared by the liver. There is an obvious rising phase of the deep peripheral 
compartment concentration profile, due to the slow distribution to this compartment, and the 
concentration difference between deep peripheral compartment and blood is the driving force of 
its redistribution. A clear three-phase profile is exhibited in Figure 5.5b for all compartments, 
except deep peripheral compartment. Since MDZ GW compartment is separated to mucosa and 
serosa, and GW metabolism is only assumed to occur after PO MDZ in mucosa compartment, 
CGW-MMDZ profile is only plotted after PO MDZ. 
112	
	
 
 After PO administration, drug concentration in gut lumen peaks at time 0 (not shown due to 
extremely high level), and MDZ is quickly absorbed into GW mucosa with a rate constant of 
kGLMDZ. cGW-MMDZ has much higher peak (~150 ng/ml) than other tissue concentrations, except 
cGLMDZ, primarily because extensive GW metabolism removes MDZ pre-systemically quite a bit. 
Afterwards, MDZ is transited into GW serosa, carried into liver through portal vein and reached 
systemic circulation via hepatic vein. cmax of GW mucosa, portal vein, liver and systemic blood 
are sequentially achieved, at 0.12 hour, 0.35 hour, 0.35 hour and 0.65 hour, respectively, which 
is in consistent with the oral absorption order of MDZ. Once the drug reaches systemic 
circulation, the disposition profiles mimics PK profiles after IV administration. Pseudo steady-
state is achieved at around 3 hours after PO administration, when concentrations in blood, 
hepatic, portal vein and two peripheral compartments decline at the same rate. Nevertheless, drug 
in gut lumen and GW mucosa compartments drop faster than other compartments, because MDZ 
PBPK model assumes no equilibrium between GW mucosa and systemic circulation, and kGLMDZ, 
which determines the decline of cGW-MMDZ concentration, is faster than elimination rate constant 
(ke) of MDZ (~0.004 min-1) 
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c) 
 
d) 
 
 
Figure 5.6  Model predicted MDZ concentrations in different compartments. 
a) MDZ total concentration – time profiles after 1 mg IV bolus (over 2min) MDZ on linear scale. 
b) MDZ total concentration – time profiles after 1 mg IV bolus (over 2min) MDZ on semi-log 
scale. c) MDZ total concentration – time profiles after 3 mg PO MDZ on linear scale. d) MDZ 
total concentration – time profiles after 3 mg PO MDZ on semi-log scale. 
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5.4 Conclusions 
 A semi-PBPK model was developed to describe MDZ clinical PK profiles after IV and PO 
administration. The model was validated by MDZ plasma concentration – time profiles in 
absence of FLZ in three clinical DDI studies between MDZ and FLZ.  After reasonable 
adjustments on vmax,hepMDZ and fvilli (representing hepatic CYP3A capacity and the scaling factor 
of intestinal CYP3A capacity), plasma concentration – time profiles of MDZ in all the three 
studies can be characterized well by the model, with all predicted AUC0-∞ and cmax within 30% of 
observed, and minimal difference in tmax. Formal parameter sensitivity analyses were conducted 
for eight key/uncertain model parameters, and fpv, Kp,hepMDZ and vmax,hepMDZ, which considerably 
affect hepatic drug levels/clearance, are the pivotal parameters determining both IV and PO 
MDZ exposure metrics, indicating the important contribution of hepatic metabolism to the 
disposition of MDZ after both IV and PO administration. Exposure metrics after PO MDZ is also 
sensitive to fvilli, suggesting that PO MDZ is also subject to extensive pre-systemic GW 
metabolism. As a result, fpv, Kp,hepMDZ, Kp,GWMDZ, vmax,hepMDZ and fvilli are the most sensitive 
parameters affecting plasma concentrations of MDZ, which may require further optimization 
once MDZ and FLZ DDI model is built. Concentrations in all tissues reach pseudo steady-state 
around 2 hours after IV administration, and around 3 hours after PO administration. Due to the 
unidirectional transfer from GW mucosa to serosa, as assumed in model structure, no distribution 
equilibrium is obtained at pseudo steady-state between GW mucosa and systemic circulation, 
thus GW mucosa concentrations decline much faster than other compartments at the terminal 
phase, governed by absorption rate constant (kGLMDZ). 
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CHAPTER 6 
 
 
6 SEMI-PBPK MODELING OF METABOLIC INHIBITION BETWEEN IV/PO FLZ 
AND IV/PO MDZ 
 
 
 
6.1 Background and Objectives 
6.1.1 Available DDI studies 
	
 As mentioned in Chapter 3, study 103 (Ahonen et al., 1997) is the only in-vivo DDI study in 
our final database that administered CYP3AI – FLZ both IV and PO concomitantly with MDZ, 
assessing the impact of route of administration of CYP3AI. As a result, the CYP3AI used in 
study 103, FLZ, was selected as one of the inhibitors of interest, and other MDZ and FLZ DDI 
studies (study 21(Kharasch et al., 2005) and study 26 (Olkkola et al., 1996)), together with study 
103 were used to validate MDZ - FLZ PBPK DDI model, by comparing the observed IV/PO 
MDZ plasma concentration – time profiles in presence of IV/PO single- and repeat- doses FLZ 
to corresponding model predicted profiles. 
6.1.2 FLZ inhibitory information and simulation strategies 
	
 FLZ is a less profound (moderate) CYP3AI (Kharasch et al., 2005; Drug Interactions & 
Labeling Drug Development and Drug Interactions Table of Substrates, Inhibitors and Inducers) 
which can non-competitively inhibit hepatic and intestinal CYP3A (Gibbs et al., 1999; 
Isoherranen et al., 2008), with comparable Ki to human intestinal and hepatic microsomes (10.7 
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± 4.2 µM and 10.4 ± 2.9 µM, respectively) (Isoherranen et al., 2008). After IV MDZ, hepatic 
CYP3A metabolism is assumed to be the only elimination pathway of MDZ, thus magnitude and 
time course of DDI are determined by FLZ unbound hepatic concentration over time, relative to 
Ki of FLZ on hepatic CYP3A (Ki,hepFLZ). After PO administration, MDZ is subject to both GW 
and hepatic metabolism pre-systemically, as well as systemic hepatic clearance. Hence, unbound 
FLZ concentration – time profiles in both GW and liver, relative to Ki,GWFLZ and Ki,hepFLZ, 
respectively, govern the magnitude and time course of FLZ inhibition. Due to the high ForalFLZ (> 
90%) of FLZ (Humphrey et al., 1985; Pfizer, 2011; Washton, 1989), IV and PO FLZ have 
similar hepatic concentration profiles, suggesting similar inhibitory effects on hepatic 
metabolism. Nevertheless, GW concentrations after PO FLZ are higher than that after IV FLZ, 
during the first 4 hours (discussed in Chapter 4), potentially leading to greater GW inhibition 
after PO FLZ. Furthermore, FLZ has a long terminal plasma elimination half-life (t1/2FLZ), 
ranging from 22 to 37 hours, indicating its prolonged inhibitory effect on hepatic and intestinal 
CYP3A. 
 Meanwhile, the impact of route of administration for either MDZ or FLZ is also affected by 
dose, administration time interval between FLZ and MDZ, as well as inhibitory potency of FLZ 
to intestinal/hepatic CYP3A. To explore these factors, simulations were performed to assess dose 
and time-dependency of route difference in DDI, by varying IV/PO FLZ single dose and 
administration time interval between FLZ and MDZ, to better understand route-dependent DDI 
in multiple clinical scenarios. Sensitivity analyses were also performed on key PK/physiological 
parameters in the MDZ - FLZ DDI semi-PBPK model, to identify pivotal parameters that 
determine MDZ exposure metrics in presence FLZ. 
 Finally, several hypothetical CYP3AIs and CYP3A substrates were created based on FLZ 
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and MDZ individual semi-PBPK models, to assess the impact of Foral and t1/2 for a 
noncompetitive CYP3AI and hepatic/GW metabolism for a CYP3A substrate on the magnitude 
and time course of route-dependent DDI.  
6.1.3 Objectives 
	
The major objectives of the chapter were to: 
a. Develop a semi-PBPK DDI model between MDZ and FLZ, to describe IV/PO MDZ PK 
profiles in presence of IV/PO FLZ. 
b. Validate the model using MDZ plasma concentration-time profiles (with co-
administration of FLZ) in clinical DDI studies, and identify pivotal PK/physiological 
parameters that determine MDZ plasma exposure metrics in presence of FLZ by 
sensitivity analyses 
c. Assess impact of route of administration for MDZ and FLZ on the magnitude and time 
course of their metabolic DDI after various administration time intervals between the two 
drugs 
d. Predict profiles of FLZ concentrations and relative CYP3A activity levels in GW and 
liver 
e. Assess impact of route of administration for MDZ and FLZ on the magnitude and time 
course of their metabolic DDI after various single dose of FLZ    
f. Explore route-dependent DDI between MDZ and several hypothetical CYP3AIs that have 
low Foral and/or short t1/2 and between two hypothetical CYP3A substrates with 
hepatic/GW metabolism reduced/removed and FLZ 
 
119	
	
 
6.2 Methods 
6.2.1 Development of MDZ-FLZ DDI PBPK model 
 
 A semi-PBPK model for MDZ in presence of FLZ was built based on the reported in-vitro 
metabolic inhibitory information and the previously presented FLZ semi-PBPK and MDZ semi-
PBPK models (Figure 6.1). Metabolic inhibition parameters, along with previously discussed 
MDZ (initial and adjusted) and FLZ model parameters were summarized in Table 6.1 and Table 
6.2. In presence of IV/PO FLZ, unbound FLZ in liver and GW non-competitively (Isoherranen et 
al., 2008; Gibbs et al., 1999) inhibit hepatic and intestinal intrinsic clearance of MDZ, decreasing 
vmax,hepMDZ and vmax,GWMDZ by 1/(1+fuFLZ•chepFLZ/Ki,hepFLZ)  and 1/(1+ fuFLZ•cGWFLZ/Ki,GWFLZ), 
respectively, and the corresponding differential equations for MDZ hepatic and GW mucosa 
mass transfer were expressed as equations (6.1) and (6.2): dA#$%&'( tdt = c,&'( ∙ Q/0 + c23&'( ∙ Q23 − C#$%&'(K%,#$%&'( ∙ Q#$% − c#$%&'(
∙ f9&'( ∙ v;<=,#$%&'( /(1 + f9AB( ∙ c#$%AB(KC,#$%AB( )/K;,#$%&'(  
 when t = 0, AhepMDZ (0) =0              (6.1)
              
dAEFG&&'( tdt = cEB&'( ∙ VEB ∙ F<JK&'( ∙ kEB&'( − 	cEFG&&'( ∙ VEF ∙ kN − f9,EFG&&'( ∙ cEFG&&'( ∙ fOCPPC
∙ v;<=,EF&'( /(1 + f9AB( ∙ cEFAB(KC,EFAB( )/(K;,EF&'( + f9,EFG&&'( ∙ cEFG&&'( ) 
when t = 0, AGW-MMDZ (0) =0             (6.2)
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Figure 6.1  Semi-PBPK model scheme of MDZ in presence of FLZ.
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Table 6.1  Initial Semi-PBPK MDZ - FLZ DDI model parameters. 
 
Parameter Definition Value Source 
Physiological parameters 
VGL (ml/kg) Volume of gut lumen 3.57 Assumed to be 250ml (FDA, 2012) 
VGW (ml/kg) Volume of GW 33.6 
Calculated by equation (4.6), assumed to be the 
surface of gut lumen cylinder 
VPV (ml/kg) Volume of portal vein 0.97 Unknown methods (Ito et al., 2003) 
Vhep (ml/kg) Volume of liver 22.5 Calculated by equation (4.7) and (4.8) 
Qvilli 
(ml/min/kg) Villous blood flow 4.30 In-vivo experiment (Yang et al., 2007) 
Qhep 
(ml/min/kg) Hepatic blood flow 21.4 In-vivo experiment (Tsunoda et al., 1999) 
fHA 
Fraction of hepatic artery to total 
hepatic blood flow 0.25 
(Eipel et al., 2010) (QHA was calculated as fHA•Qhep; 
QPV was calculated as (1-fHA•Qhep) 
fPV 
Fraction of the components of portal 
vein that contain drug 1.00 
A correction factor that can be adjusted according to 
simulation results. 
*fvilli 
IVIVE scaling factor and IIV adjusting 
factor 2.2 Optimized with data from study 21 
FLZ PK Parameters 
VBFLZ (ml/kg) 
Volume of systemic blood 
compartment 641 
Calculated by equation (4.5) (Carrasco-Portugal & 
Flores-Murrieta, 2007; Humphrey et al., 1985) 
fuFLZ 
Fraction unbound of FLZ in 
hepatocytes and enterocytes 0.88 
Assumed to be the same as fraction unbound in 
plasma (Humphrey et al., 1985) 
Kp,GWFLZ GW-to-blood partition coefficient 1 
Assumed to be 1 (Carrasco-Portugal & Flores-
Murrieta, 2007) 
Kp,hepFLZ Liver-to-blood partition coefficient 1 
Assumed to be 1 (Carrasco-Portugal & Flores-
Murrieta, 2007) 
CLint,hepFLZ 
(ml/min/kg) Hepatic intrinsic clearance 0.11 Calculated by equation (4.9) 
CLrenFLZ 
(ml/min/kg) Renal clearance 0.2 
In-vivo experiment (Ripa et al., 1993; Sobue et al., 
2004)  
B:PFLZ Blood to plasma partitioning ratio 1 (Ervine & Houston, 1994) 
kGLFLZ (min-1) 
Absorption rate constant from gut 
lumen to GW 0.0213 
Assumed to be kaFLZ from in-vivo experiment (Ripa 
et al., 1993) 
FabsFLZ 
Fraction of FLZ absorbed from gut 
lumen 100% BCS class 1 drug (Lindenberg et al., 2004) 
MDZ PK Parameters 
VBMDZ (ml/kg) 
Volume of systemic blood 
compartment 140.4 See Appendices C 
VP1MDZ (ml/kg) 
Volume of shallow peripheral 
compartment 313.7 See Appendices C 
VP2MDZ (ml/kg) 
Volume of deep  
peripheral compartment 531.4 See Appendices C 
Q2MDZ(min-1) 
Inter-compartmental clearance 
between central and peripheral cpt-1 55.27 See Appendices C 
Q3MDZ(min-1) 
Inter-compartmental clearance 
between central and peripheral cpt-2 7.25 See Appendices C 
fuMDZ Fraction unbound of MDZ 0.03 
Assume to be the same in plasma and hepatocytes 
(Gandhi et al., 2012) 
fu,GW-MMDZ 
Fraction unbound at mucosal side of 
intestinal epithelium 1.0 Assumed to be negligible bound 
vmax,GWMDZ GW CYP3A capacity to metabolize 3357.6 In-vitro experiment (Thummel et al., 1996) 
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(ng/min/kg) MDZ 
Km,GWMDZ 
(ng/ml) 
GW CYP3A affinity of metabolizing 
MDZ 1173 In-vitro experiment (Thummel et al., 1996) (3.6µM) 
*vmax,hepMDZ 
(ng/min/kg) 
Hepatic CYP3A capacity to 
metabolize MDZ 305067 
In-vivo experiment, calculated from equation (5.7)-
(5.8), using data from study 21 
Km,hep (ng/ml) 
Hepatic CYP3A affinity of 
metabolizing MDZ 880 In-vitro experiment (Thummel et al., 1996) (2.7µM) 
Kp,GWMDZ  GW-to-blood partition coefficient 1.12 Scaled from rat Kp (Björkman et al., 2001) 
Kp,hepMDZ  Liver-to-blood partition coefficient 1.09 Scaled from rat Kp (Björkman et al., 2001) 
B:PMDZ Blood-to-plasma partitioning ratio 0.86 (Ervine & Houston, 1994) 
kGLMDZ (min-1) 
Absorption rate constant from gut 
lumen to GW 0.05 
In-vivo experiment (Johnson et al., 2002; Kato et al., 
2008), assumed to be kaMDZ 
kT (min-1) 
Transit rate from mucosal to serosal 
side of intestinal epithelium 0.13 Assumed, calculated from Qvilli/VGW 
FabsMDZ 
Fraction of MDZ absorbed from gut 
lumen 100% BCS class 1 drug (Wu & Benet, 2005) 
DDI Parameters (Noncompetitive inhibition) 
Ki,GWFLZ (ng/ml) 
FLZ inhibitory potency on GW 
CYP3A 3182 In-vitro experiment (Gibbs et al., 1999) (10µM) 
Ki,hepFLZ (ng/ml) 
FLZ inhibitory potency on hepatic 
CYP3A 3829 
In-vitro experiment (Isoherranen et al., 2008; Gibbs 
et al., 1999) (12.5µM) 
 
*Parameter values were adjusted in study 103 and study 26. 
 
Table 6.2  Adjusted semi-PBPK MDZ model parameters. 
 
Parameter Definition Value Source 
fvilli 
IVIVE scaling factor and IIV adjusting 
factor 1.45 
Value used for study 26 based on 
difference in ERGIMDZ between study 21 
and 26 
vmax,hepMDZ 
(ng/min/kg) 
Hepatic CYP3A capacity to metabolize 
MDZ 170000 
Value used for study 103 based on terminal 
slope optimization 
 
 Besides the assumptions mentioned in Chapter 4 and Chapter 5, two additional 
assumptions were made during the DDI modeling processes, which were: 
1) Noncompetitive inhibition by FLZ is assumed for both GW and liver CYP3A.  
2) Negliglible CYP3A5 is expressed in both hepatic and intestinal CYP3A. (Ki,hepMDZ and 
Ki,GWMDZ are in respective to CYP3A4 inhibition only).  
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6.2.2 Model qualification and predictions 
 
 Model simulated MDZ plasma concentration-time profiles in presence of FLZ were 
compared with observed profiles from study 21(Kharasch et al., 2005), study 103 (Ahonen et al., 
1997) and study 26 (Olkkola et al., 1996), to assess model validity by predictive visual check and 
exposure metrics comparison. Since some parameters (i.e. vmax,hepMDZ and fvilli) were optimized in 
different MDZ and FLZ DDI studies - due to the large inter-study variability of hepatic and GW 
CYP3A-, a more stringent acceptance criterion: predicted exposure metrics are ± 30% of 
observed, were used to assess performance of MDZ and FLZ DDI semi-PBPK model. Plasma 
concentrations were simulated using Simbiology (MATLAB, 2015a), and the predicted exposure 
metrics were summarized and compared to reported values. FLZ GW and liver concentrations, as 
well as relative intestinal and hepatic CYP3A activity levels were also simulated, to better 
interpret the impact of route difference for FLZ. 
6.2.3 Sensitivity Analysis 
 
 Formal sensitivity analyses were conducted by altering the values for 10 key PBPK model 
parameters (fPV, vmax,hepMDZ, Kp,hepMDZ, Kp,GWMDZ, Kp,hepFLZ, Kp,GWFLZ, Ki,hepFLZ, Ki,GWFLZ, fvilli and 
kGLMDZ), to assess their significance on MDZ systemic plasma exposures in presence of FLZ. All 
parameters (except fpv, which was simulated at 0.0, 0.5 and 1.0) were increased and decreased by 
2-fold relative to their original values (overall-fold change in values = 4 - fold), as shown in 
Table 6.3, and the respective plasma concentration - time profiles were predicted under 1 mg IV 
bolus MDZ over 2 min or 3 mg PO MDZ, administered 2 hours after 400 mg 1 hour IV infusion 
or PO FLZ. Plasma exposure metrics (AUC0-∞, cmax, tmax) were estimated, and the sensitivity to 
each parameter was assessed by dividing respective exposure metrics simulated at the upper limit 
by that simulated at the lower limit. 
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Table 6.3  Values of parameters used in sensitivity analysis. 
 
Parameter Name Initial Value Lower/Upper Sensitivity Limits 
fpv 1.0 0; 1.0 
vmax,hepMDZ (ng/min/kg) 305067 152534; 610134 
Kp,hepMDZ 1.09 0.55; 2.18 
Kp,GWMDZ 1.12 0.56; 2.24 
Kp,hepFLZ 1.0 0.5; 2 
Kp,GWFLZ 1.0 0.5; 2 
Ki,hepFLZ (ng/ml) 3829 (10µM) 1915; 7658 
Ki,GWFLZ (ng/ml) 3182 (12.5µM) 1591; 6364 
fvilli 2.2 1.1; 4.4 
kGLMDZ (min-1) 0.05 0.025; 0.1 
 
6.2.4 Simulations of route-dependent DDI with various administration time intervals  
 
 To investigate impact of route difference of MDZ and FLZ at different administration time 
intervals between the two drugs, as well as explore the duration of FLZ inhibition, semi-PBPK 
model of MDZ in presence of FLZ (using initial model parameters in Table 6.1) was employed 
to simulate MDZ PK profiles after 400mg FLZ as IV-1hr-infusion, and PO administered at 0, 0.5, 
1, 2, 5, 10, 20, 50, 100 hours before 1 mg IV MDZ or 3 mg PO MDZ was given. Simulated DDI 
dosing scheme is illustrated in Figure 6.2. AUC0-∞ increase ratio (AUCR) of MDZ for each 
scenario was calculated to assess the extent of inhibition. 
 
Figure 6.2  Simulated DDI dosing scheme between FLZ and MDZ. 
 
6.2.5 Simulations of route-dependent DDI with various FLZ doses  
 
 To investigate impact of FLZ dose on the route-dependent DDI between the two drugs, MDZ 
AUC0-∞ after 1 mg IV or 3 mg PO administration concurrent with (administration time interval = 
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0) a series of SAD of FLZ (40 mg, 80 mg, 200 mg, 400 mg, 800 mg, 2,000 mg, 4,000 mg) 
administered either as 1-hour IV infusion or orally were simulated. AUCR of MDZ for each 
scenario was calculated, and FLZ route difference was assessed to be the ratio of MDZ AUCR 
by PO FLZ and that by IV FLZ.  
 
6.2.6 Simulation of route-dependent DDI between CYP3A substrates and CYP3AIs 
 FLZ is a high ForalFLZ (> 90%) and long t1/2FLZ (~30%) noncompetitive CYP3AI, which are 
two important PK characteristics that would determine its route of administration impact on 
MDZ metabolic inhibition. Semi-PBPK models for three hypothetical drugs (3AIX1, 3AIX2, 
3AIX3) were developed based on the semi-PBPK model for FLZ, with modification of FabsFLZ 
and/or CLrenFLZ, to generate low Foral and/or short t1/2 CYP3AI. FabsFLZ was decreased from 1.0 to 
0.1, to generate a low Foral drug (3AIX1), clinically could due to its low solubility, low 
permeability and/or degradation in gut lumen. As to 3AIX2, CLrenFLZ was increased from 0.2 
ml/min/kg to 3 ml/min/kg, which shortened elimination t1/2 to almost 1/10 of FLZ (CLintFLZ was 
not adjusted to avoid change in first-pass metabolism or Foral). Furthermore, a drug with low Foral 
and short t1/2 was created by changing both ForalFLZ and CLrenFLZ.  
With respect to MDZ, route different of IV/PO MDZ is primarily due to existence of pre-
systemic hepatic/GW metabolism after PO (but not IV) MDZ, and as discussed in Chapter 4, 
PO FLZ has higher GW concentration than the same dose of IV infusion FLZ, whereas hepatic 
FLZ concentration doesn’t have much route difference. Hence it is of interest to investigate route 
difference for both substrate and inhibitor when the substrate doesn’t have GW metabolism. A 
CYP3A substrate without GW metabolism (3ASX1) was derived from MDZ PBPK model, by 
setting fvilli, the parameter to adjust GW CYP3A activity, to 0. Actually based on quantitative 
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meta-analysis in Chapter 3, ERGIMDZ has very large inter-study variability, and the derived 
ERGIMDZ in study 11 (Krishna et al., 2009) was 0, proving the clinical relevance of making this 
hypothetical CYP3A substrate.  
Furthermore, a second CYP3A substrate (3ASX2) was generated by setting fvilli to 0 (no GW 
metabolism), along with decreasing vmax,hepMDZ by 5-fold, to create a high Foral (Foral = 89%) 
CYP3A substrate with limited first pass effect.  
All other PBPK parameters, including metabolic inhibitory potency and IV/PO doses, for the 
five hypothetical drugs (3AIX1/2/3, 3ASX1/2) remained unchanged from their original drugs, 
and changes were summarized in Table 6.4. 
Table 6.4  Parameter modifications for hypothetical drugs, based on FLZ and MDZ 
individual semi-PBPK models. 
(MDZ initial model parameters were used.) 
 
CYP3AI Foral t1/2 Mechanism of DDI Change 
FLZ > 90% ~30 hrs Noncompetitive - 
3AIX1 ~10 % ~30 hrs Noncompetitive Change FabsFLZ from 1.0 to 0.1 
3AIX2 > 90% ~3 hrs Noncompetitive Change CLrenFLZ from 0.2ml/min/kg to 3ml/min/kg 
3AIX3 ~10% ~3 hrs Noncompetitive Change Fabs
FLZ from 1.0 to 0.1 and change CLrenFLZ 
from 0.2ml/min/kg to 3ml/min/kg 
CYP3A 
Substrate Foral ERhep ERGI Change 
MDZ 0.28 0.40 (t1/2: ~2.5 hrs) 0.52 - 
3ASX1 0.60 0.40 (t1/2: ~2.5 hrs) 0 Change fvilli from 2.2 to 0.0. 
3ASX2 0.89 0.11 (t1/2: ~9 hrs) 0 
Change vmax,hepMDZ from 305067 µg/min/kg to 
61013.4 µg/min/kg and change fvilli from 2.2 to 0.0. 
 
 The route impact on metabolic DDI between MDZ (IV: 1 mg, PO: 3 mg) and 3AIX1/2/3 
(400 mg IV-1 hours-infusion and PO) and between 3ASX1/2 (same dose as MDZ) and FLZ (400 
mg IV-1 hour-infusion and PO) were investigated by simulating the -fold AUC0-∞substrate increase 
by CYP3AI at varying time intervals between single-dose substrate and CYP3AI administration 
(same strategy as Figure 6.2). Since 3ASX2 has a longer plasma t1/2 than MDZ and 3ASX1, 
different magnitude of DDI may be expected between short and long t1/2 CYP3AI. Therefore, the 
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same simulation strategy (as Figure 6.2) was used to predict magnitude and time course of DDI 
between 3ASX2 and 3AIX2. Unbound GW and hepatic concentrations of 3AIX1/3AIX2/3AIX3, 
as well as relative hepatic and intestinal CYP3A levels in presence of three hypothetical 
CYP3AIs were also simulated, to better interpret the route-dependent DDI between MDZ and the 
three drugs. 
 
6.3 Results and Discussion 
6.3.1 Model evaluation 
 
6.3.1.1 Predictive performance check 
	
6.3.1.1.1 Study 21 
 
 The observed and model-predicted MDZ PK profiles in absence/presence of FLZ in study 21 
were showed in Figure 6.3a-d and comparison of observed and model simulated exposure 
metrics was summarized in Table 6.5. Figure 6.3a-d demonstrate that the model captures MDZ 
observed profiles in presence of FLZ well after both IV and PO MDZ, with all predicted values 
superimposable with observed data. From Table 6.5, deviations (%) of AUC0-∞ and cmax are all 
less than 30%, which is a pre-defined cut-off of precise prediction. In addition, Foral in 
absence/presence of FLZ and AUCR in presence of FLZ can also be well characterized in all 
scenarios, indicating that no apparent bias is observed in model predictions.  
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a)       b) 
  
 
c)        d) 
  
 
Figure 6.3  Observed and PBPK model-simulated MDZ PK profiles in study 21. 
a-b) IV MDZ 1 mg administered 2 hours after placebo, 100, 200, 400 mg PO FLZ (Cartesian 
plots and semi-log plots). c-d) PO MDZ 3 mg administered 2 hours after placebo, 100, 200, 400 
mg PO FLZ (Cartesian plots and semi-log plots). The solid lines reflect the predicted PK profiles. 
The symbols and bars are reported means and SD values (if available). 
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 In study 21, FLZ was administered 100 mg, 200 mg or 400 mg orally for two consecutive 
days, and the predicted unbound hepatic and GW concentrations relative to Ki,hepFLZ and Ki,GWFLZ 
are plotted in Figure 6.4a-b. FLZ concentrations in liver and GW increase proportionally with 
dose, and concentrations at the highest dose (400 mg PO FLZ) exceed respective Ki values for 
more than 50 hours. Accumulation of hepatic and GW concentrations at the end of the first dose 
are 1.53 – fold for all dose levels, which are estimated as the ratio of cminFLZ after 2nd dose and 
cminFLZ after 1st dose.  
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a)  
  
   
b) 
 
 
Figure 6.4  Semi-PBPK model-predicted FLZ unbound hepatic and GW concentration – 
time profiles in study 21. 
a) FLZ unbound hepatic concentration – time profiles after 100 mg, 200 mg, and 400 mg PO 
FLZ once daily for 2 days. b) FLZ unbound GW concentration – time profiles after 100 mg, 200 
mg, and 400 mg PO FLZ once daily for 2 days. 
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6.3.1.1.2  Study 103 
	
For study 103, after changing vmax,hepMDZ, the adjusted PBPK model predictes MDZ PK 
profiles in absence/presence of FLZ reasonably well (shown in Figure 6.5), with deviations (%) 
of AUC0-∞ and cmax less than 30% (see Table 6.5). However, even after adjustment, cmaxMDZ in 
presence of IV FLZ is beyond mean ± SD of the observed data, which may be due to inter-study 
variability related to GW metabolism, DDI parameters (Ki,hepFLZ, Ki,GWFLZ), and/or differences in 
subject demographics, analytical method or sampling strategy. The PBPK model over-estimates 
MDZ AUCR in presence of IV or PO FLZ by 22% and 29%, respectively, possibly owing to 
slight misspecification of distribution parameters (i.e. VP1MDZ, VP2MDZ, Q2MDZ, Q3MDZ) for study 
103. Hepatic and GW FLZ concentration and CYP3A levels were predicted and discussed in 
section 6.3.2.1.  
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a)  
  
 
b) 
 
 
Figure 6.5  Observed and PBPK model (vmax,hepMDZ adjusted) - simulated MDZ PK profiles 
for study 103. 
a-b) PO MDZ 7.5 mg administered 1 hour after placebo, 400 mg IV 1-hour infusion, 400 mg PO 
FLZ on Cartesian and semi-log plots. The solid lines reflect predicted PK profiles. The symbols 
and bars are reported means and SD values (if available). 
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6.3.1.1.3 Study 26 
	 	
Similarly, for study 26, after changing fvilli, the adjusted PBPK model adequately describes 
MDZ PK profiles in control and single-/repeat-doses FLZ groups (shown in Figure 6.6). 
Deviations (%) of all exposure metrics, as well as Foral and AUCR are within 30%, except cmax 
and AUCR when PO MDZ was administered on the 6th day of FLZ dose (Table 6.5). The reason 
for the poor predictions could be that all the AUC0-∞ of MDZ in absence of FLZ is still under-
estimated, even with fvilli adjustment. Also, observed PO MDZ AUC0-∞ administered on 6th day is 
16% higher than that administered on 1st day, ultimately resulting in over-prediction of AUCR 
after repeat- FLZ doses to a greater extent. The model predictions may be improved by tweaking 
fvilli even more, or changing vmax,hepMDZ, however, further adjustment is not considered necessary, 
given the adequate prediction accuracy in most scenarios.  
  
134	
	
 
a)        b) 
  
 
c)       d) 
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e)       f) 
  
 
Figure 6.6  Observed and PBPK model (fvilli adjusted) - simulated MDZ PK profiles for 
study 26. 
Placebo or PO FLZ was administered 400 mg on the 1st day and then 200 mg daily for 5 days. 
a-b) PO MDZ 7.5 mg administered 2 hours after the 1st dose of placebo or FLZ (Cartesian plots 
and semi-log plots). c-d) IV MDZ 0.05mg/kg administered 2 hours after the 4th dose of placebo 
or FLZ. e-f) PO MDZ 7.5 mg administered 2 hours after the 6th dose of placebo or FLZ. The 
solid lines reflect predicted PK profiles. The symbols and bars are reported means and SD values 
(if available). 
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Table 6.5  Comparison of reported and semi-PBPK model-predicted MDZ plasma 
exposure metrics in the absence/presence of IV/PO FLZ using initial model (study 21) and 
adjusted model (study 103 and 26) parameters. 
(Deviation greater than 30% were marked as bold.) 
 
Study 
ID MDZ FLZ 
Deviation (%) 
AUC0-∞ 
(ng/ml•hr) 
Cmax 
(ng/ml) Foral AUCR 
21 IV: 1mg - -7% 3%   21 IV: 1mg PO Single Dose: 100mg -9% -3%  -2% 21 IV: 1mg PO Single Dose: 200mg -10% -3%  -3% 21 IV: 1mg PO Single Dose: 400mg -4% -11%  4% 
21 PO: 3mg - -4% 12% 3%  21 PO: 3mg PO Multiple Doses: 100mg (2 days) -9% 16% 0% -5% 
21 PO: 3mg PO Multiple Doses: 200mg (2 days) -10% 16% 0% -6% 
21 PO: 3mg PO Multiple Doses: 400mg (2 days) 2% 11% 7% 7% 
103 PO: 7.5mg (Adjust vmax,hepMDZ) - -6% 23%   103 PO: 7.5mg (Adjust vmax,hepMDZ) IV 1-hr infusion: 400mg 14% 26%  22% 103 PO: 7.5mg (Adjust vmax,hepMDZ) PO Single Dose: 400mg 21% -2%  29% 26 IV: 0.05mg/kg - -17%    
26 IV: 0.05mg/kg PO Multiple Doses (day 1: PO 400mg; day 2-4: PO 200mg -3%   18% 
26 PO: 7.5mg (Adjust fvilli) - -12% 19%   26 PO: 7.5mg (Adjust fvilli) PO Single Dose: 400mg 3% 16%  18% 26 PO: 7.5mg (Adjust fvilli) - -25% -9%   
26 PO: 7.5mg (Adjust fvilli) 
PO Multiple Doses (day 1: PO 
400mg; day 2-6: PO 200mg 6% 33%  41% 
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In study 26, FLZ was administered 400 mg on the first day and then 200 mg daily for 5 days, 
and the predicted unbound hepatic and GW concentrations relative to Ki,hepFLZ and Ki,GWFLZ are 
plotted in Figure 6.7a-b. Since loading dose (400 mg) doubles from maintenance dose (200 mg 
daily), chepFLZ and cGWFLZ reach steady-state almost after the first dose, with all concentrations 
exceeding respective Ki values for more than 140 hours. Although cmax,GWFLZ 
after the first dose is ~50% higher than cmax,GWFLZ of the following doses, it quickly drops to a 
similar level, and as MDZ is administered 2 hours after FLZ, the 50% higher cmax,GWFLZ after 
loading dose would not translate into any difference in inhibitory effect after single- or repeat- 
doses FLZ.  
a)     b) 
  
 
Figure 6.7  Semi-PBPK model predicted FLZ unbound hepatic and GW concentration – 
time profiles for study 26. 
PO FLZ was administered 400 mg on the first day and then 200 mg daily for 5 days. a) FLZ 
unbound hepatic concentration – time profile. b) FLZ unbound GW concentration – time profile. 
  
Predictive performance checks for all the three studies after adjustments suggest that the 
semi-PBPK model for IV or PO MDZ in the absence/presence of IV or PO FLZ predicts the 
reported data from three clinical studies well, confirming the validity of this model and model 
parameters. 
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6.3.1.2 Sensitivity analysis 
 
 The -fold change in plasma AUC0-∞, cmax and tmax were calculated by dividing plasma 
exposure metrics simulated at the upper limit of a certain parameter by that simulated at the 
lower limit (Table 6.6). A greater than 2-fold or less than 0.5-fold change was highlighted in 
bold, indicating the corresponding exposure is sensitive to that parameter. With the co-
administration of IV or PO FLZ, exposure metrics of IV MDZ are substantially affected by fpv, 
vmax,hepMDZ and Kp,hepMDZ, the same parameters as IV MDZ without FLZ, because hepatic 
metabolism is the only source of MDZ elimination after IV administration, no matter FLZ is 
given or not, and all the three parameters influence MDZ hepatic concentration and/or hepatic 
clearance considerably. Increasing fpv amplifies both MDZ and FLZ exposures in the liver, 
resulting in more MDZ metabolism and more enzymes inhibition by FLZ. Kp,hepMDZ and 
vmax,hepMDZ only affect MDZ; larger values of both parameters would lead to higher MDZ 
metabolism in the liver and less systemic exposure. After PO MDZ, besides fpv, vmax,hepMDZ and 
Kp,hepMDZ, which play essential roles in both pre-systemic and systemic hepatic metabolism, 
Kp,hepFLZ and Ki,hepFLZ are also pivotal parameters, regardless of FLZ routes. A larger Kp,hepFLZ 
value reflectes higher FLZ hepatic concentrations and greater inhibition on MDZ hepatic 
metabolism, eventually resulting in higher MDZ systemic exposure. Increased Ki,hepFLZ reduces 
FLZ inhibitory potency to hepatic CYP3A, so that MDZ hepatic metabolism is less inhibited. 
Kp,GWFLZ and Ki,GWFLZ also affect MDZ systemic exposure to the same direction as Kp,hepFLZ and 
Ki,hepFLZ, but to a less extent, due to the fact that Kp,hepFLZ and Ki,hepFLZ influence both pre-
systemic and systemic MDZ clearance, while Kp,GWFLZ and Ki,GWFLZ only alter MDZ first pass 
GW metabolism. Under non-competitive inhibition, MDZ systemic exposure is actually affected 
by the ratios between Ki,hepFLZ and Kp,hepFLZ (Ki,hepFLZ/Kp,hepFLZ) and between Ki,GWFLZ and 
139	
	
 
Kp,GWFLZ (Ki,GWFLZ/Kp,GWFLZ), instead of a single parameter. Hence, even if some parameters used 
in the model (i.e., Kp,hepFLZ and Kp,GWFLZ) may not be qualified clinically, the two ratios 
Ki,hepFLZ/Kp,hepFLZ and Ki,GWFLZ/Kp,GWFLZ were indirectly validated by MDZ and FLZ DDI studies. 
No FLZ route difference in the metabolic DDI sensitivity analysis is observed, probably 
because there is a dosing lag-time between the two drugs (MDZ was administered 2 hours after 
FLZ). MDZ plasma PK profiles in presence of IV/PO FLZ for all sensitivity analyses are 
presented in Appendices E. 
Table 6.6  Sensitivity analysis heat-map results for semi-PBPK MDZ and FLZ DDI model. 
(More solid green indicates smaller value; more solid red indicates larger value) 
FLZ+MDZ Sensitivity 
Analysis (IV MDZ) 
400mg 1hr IV infusion FLZ + 1 mg IV 
MDZ (2hr later) 
400mg PO FLZ + 1 mg IV MDZ (2hr 
later) 
-Fold change in plasma exposure metrics -Fold change in plasma exposure metrics 
Parameter -Fold Change AUC0-∞ cmax tmax AUC0-∞ cmax tmax 
fPV 0-1 0.48 0.96 1.00 0.48 0.96 1.00 
vmax,hepMDZ 4 0.34 1.00 1.00 0.34 1.00 1.00 
Kp,hepMDZ 4 0.34 0.97 1.00 0.34 0.97 1.00 
Kp,GWMDZ 4 1.00 1.00 1.00 1.00 1.00 1.00 
Kp,hepFLZ 4 1.82 1.00 1.00 1.82 1.00 1.00 
Ki,hepFLZ 4 0.51 1.00 1.00 0.51 1.00 1.00 
FLZ+MDZ Sensitivity 
Analysis (PO MDZ) 
400mg 1hr IV infusion FLZ + 3 mg PO 
MDZ (2hr later) 
400mg PO FLZ + 3 mg PO MDZ (2hr 
later) 
-Fold change in plasma exposure metrics -Fold change in plasma exposure metrics 
Parameter Fold Change AUC0-∞ cmax tmax AUC0-∞ cmax tmax 
fPV 0-1 0.48 0.90 0.97 0.48 0.90 0.98 
vmax,hepMDZ 4 0.27 0.67 0.94 0.27 0.67 0.94 
Kp,hepMDZ 4 0.27 0.65 0.98 0.27 0.65 0.95 
Kp,GWMDZ 4 0.99 0.86 1.12 0.99 0.86 1.11 
Kp,hepFLZ 4 2.03 1.24 1.02 2.04 1.24 1.02 
Kp,GWFLZ 4 1.25 1.27 1.03 1.26 1.27 1.03 
Ki,hepFLZ 4 0.45 0.79 0.99 0.45 0.79 0.98 
Ki,GWFLZ 4 0.76 0.77 0.97 0.77 0.77 0.97 
fvilli 4 0.65 0.66 0.99 0.67 0.68 0.96 
kGLMDZ 4 1.04 1.48 0.83 1.05 1.48 0.82 
 
6.3.2 Model Predictions  
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6.3.2.1 Simulation of route-dependent DDI between MDZ and FLZ after various 
administration time intervals 
 
 AUCR for each scenario was calculated to assess the extent of inhibition, and was plotted 
against administration interval time shown in Figure 6.8. After IV MDZ, no apparent difference 
is found among IV 1-hour infusion and PO FLZ at all time intervals. Within 5 hours, both routes 
of FLZ increase AUCMDZ by 2-fold, and the inhibition lasts for more than 100 hours. However, 
after PO MDZ, PO FLZ has 62% more increase in AUCMDZ than the same dose of IV infusion 
FLZ, when simultaneously administered with MDZ. With increasing delay in MDZ 
administration, the route difference is gradually reduced, and no route difference is demonstrated 
after 5 hours. The short duration of route difference is because FLZ has very high Foral (> 90%) 
and can be absorbed into systemic circulation quite fast, leading to similar drug levels after IV 
and PO administration. Regardless of route, FLZ increases AUCMDZ more for PO MDZ than for 
IV MDZ, because pre-systemic hepatic and GW metabolism is inhibited after PO MDZ but not 
IV MDZ. Inhibition of CYP3A metabolism by FLZ fades after >100 hours, due to the long 
terminal t1/2 of FLZ in plasma.  
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Figure 6.8  MDZ AUCR by 400 mg IV 1-hour infusion or PO FLZ administered at various 
time intervals before 1 mg IV/3 mg PO MDZ. 
Red dash line indicates no inhibition on MDZ exposure.  
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 To better interpret impact of route of administration of FLZ, plots of FLZ concentration and 
relative CYP3A activity levels in GW and liver were simulated (Figure 6.9), based on the dosing 
regimen of 400 mg IV 1-hour infusion or PO FLZ. Unbound hepatic and GW concentrations 
exceed relative Ki values for 25 and 30 hours, respectively, resulting in ~65% maximal 
inhibition on hepatic CYP3A at cmax,u,hepFLZ, and 70% after IV FLZ and 85% inhibition after PO 
FLZ on GW CYP3A at cmax,u,GWFLZ. No apparent route difference is observed with respect to 
hepatic CYP3A inhibition, reflecting marginal FLZ route difference when MDZ is dosed 
intravenously. GW concentration after PO FLZ is much higher than IV FLZ during the first 1-2 
hours, but no difference is found after 5 hours, indicating stronger inhibition on GW CYP3A 
after PO than IV FLZ when PO MDZ is dosed simultaneously with FLZ, but no route difference 
when they are dosed 5 hours apart. Inhibitory effect lasts for more than 100 hours, as both 
hepatic and GW CYP3A are inhibited by more than 10% at 100 hours administration interval. 
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a) b) 
  
 
c) d) 
   
 
Figure 6.9  Plots of FLZ unbound concentrations and relative CYP3A activity under 400 
mg IV 1-hour-infusion or PO FLZ. 
a) FLZ unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of FLZ. c) FLZ unbound GW concentration – time profiles. d) Relative GW CYP3A 
activity in presence of FLZ. Dash lines in a) and c) represent Ki,hepFLZ and Ki,GWFLZ values. Dash 
lines in b) and d) represent no change in hepatic and GW CYP3A activity. 
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6.3.2.2 Simulation of route-dependent DDI between MDZ and FLZ after various single 
dose of FLZ 
 To compare impact of FLZ route of administration on DDI after various FLZ dose, ratio of 
MDZ AUCR after PO FLZ and after IV FLZ were plotted against FLZ single dose (Figure 6.10). 
After IV MDZ, no apparent route difference (< 10%) of FLZ is observed, due to similar FLZ 
hepatic concentration profiles after IV or PO administration across doses. After PO MDZ, route 
difference – FLZ dose profile appeares to be a “bell” shape curve: at both low end (40 mg) and 
high end (4000 mg) FLZ doses, slight route differences are demonstrated (~20%), while 
maximal route difference occurs at middle dose (400 mg). This is because at very low dose, both 
IV and PO FLZ have likely trivial inhibition on hepatic and GW CYP3A, while at very high dose, 
both routes completely inhibite hepatic and GW CYP3A. It is at the middle dose, when FLZ GW 
concentration is close to Ki,GWFLZ, that the GW concentration difference of FLZ translates into 
the largest GW CYP3A inhibition difference. 
 
Figure 6.10  Ratio of MDZ AUCR by PO FLZ and by IV 1-hour infusion FLZ after various 
FLZ single doses.  
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6.3.2.3 Simulation of route-dependent DDI between MDZ and hypothetical CYP3AI and 
between hypothetical CYP3A substrates and ERY 
6.3.2.3.1 Route-dependent DDI between MDZ and 3AIX1/2/3 
 
 To change FLZ to a low Foral CYP3AI (3AIX1), FabsFLZ was decreased from 1.0 to 0.1. MDZ 
AUC in presence of IV/PO 3AIX1 with different administration time interval were simulated, 
and AUCR of MDZ for each scenario is plotted against administration interval time shown in 
Figure 6.11. Plots of 3AIX1 concentration and relative CYP3A levels in GW and liver were 
simulated (Figure 6.12), based on the dosing regimen of 400 mg IV 1-hour infusion or PO 
3AIX1. From Figure 6.12, due to the low Foral of 3AIX1, IV 3AIX1 haS much higher hepatic 
and GW concentrations than PO 3AIX1, producing more inhibition of CYP3A in liver and GW, 
regardless of MDZ route. Consequently, IV 3AIX1 consistently yieldes higher AUCR than PO 
3AIX1, as is demonstrated in Figure 6.11. The DDI (peak 4.5-fold) lasts for up to one week, due 
to the long t1/2 of 3AIX1 at pseudo steady-state (same as FLZ). In terms of MDZ route difference, 
PO MDZ is consistently more sensitive to the metabolism inhibition than IV MDZ, in line with 
the conclusions from MDZ and FLZ DDI simulations.  
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Figure 6.11  MDZ AUCR by 400 mg IV 1-hour infusion or PO 3AIX1 administered at 
various time intervals before 1 mg IV/3 mg PO MDZ. 
Red dash line indicates no inhibition on MDZ exposure. 
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a)                                                                           b) 
  
 
c)     d) 
  
 
Figure 6.12  Plots of 3AIX1 unbound concentrations and relative CYP3A activity under 
400 mg IV 1-hour infusion or PO 3AIX1. 
a) 3AIX1 unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of 3AIX1. c) 3AIX1 unbound GW concentration – time profiles. d) Relative GW 
CYP3A activity in presence of 3AIX1. Dash lines in a) and c) represent Ki,hep3AIX1 and Ki,GW3AIX1 
values. Dash lines in b) and d) represent no change in hepatic and GW CYP3A activity. 
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To change FLZ to a short t1/2 CYP3AI (3AIX2), CLrenFLZ was increased from 0.2 ml/min/kg 
to 3 ml/min/kg, which shortens elimination t1/2 of this drug to ~1/10 of FLZ (CLintFLZ was not 
adjusted to avoid change in first-pass metabolism and Foral). MDZ AUC in presence of IV/PO 
3AIX2 with different administration time interval were simulated, and AUCR of MDZ for each 
scenario is plotted against administration interval time shown in Figure 6.13. Plots of 3AIX2 
concentration and relative CYP3A levels in GW and liver were simulated (Figure 6.14), based 
on the dosing regimen of 400 mg IV 1-hour infusion or PO 3AIX2.  
Only a small (<10%) route difference of 3AIX2 is observed after IV MDZ, given similar 
3AIX2 hepatic concentration after both routes (Figure 6.14 a-b). However, after PO MDZ, PO 
administration of 3AIX2 results in a 68% higher (3.8- vs. 2.3-fold) DDI than IV, only when both 
drugs are administered simultaneously - primarily caused by higher GW concentrations after PO 
than IV administration during the first 1-2 hours. With increasing delay in MDZ administration, 
the route difference gradually reduces, but consistently exists. This is confirmed by the slightly 
higher hepatic and GW 3AIX2 concentration after PO administration than after IV infusion. To 
explain the sustained concentration difference, plasma concentrations of 3AIX2 after both routes 
were compared with FLZ plasma concentrations (Figure 6.15), because concentrations in both 
tissues (liver and GW) are driven by plasma concentrations after absorption. From Figure 6.15b, 
both FLZ and 3AIX2 are completely absorbed within 4 hours, as IV and PO concentrations 
decline at the same rate after 4 hours, indicating the only process going on after 4 hours is 
elimination (1 – compartmental body model drug). As to FLZ, IV and PO FLZ profiles intercross 
exactly at 4 hours, so that no concentration difference is observed afterwards. However, with 
respect to 3AIX2, due its faster elimination, intersection of IV and PO profiles occurs earlier 
than 4 hours (~2.3 hours), and after 2.3 hours, absorption process has not completed yet, leading 
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to shallower declining rate after PO 3AIX2 than IV 3AIX2 from 2.3 to 4 hours. Eventually at 4 
hours, 3AIX2 has higher concentration after PO administration than after IV administration, and 
the concentration difference between routes consistently exists throughout the entire terminal 
phase (after 4 hours). Due to the short t1/2 of 3AIX2, inhibition on hepatic and GW CYP3A only 
last for 20 hours, which is much shorter than inhibitory duration of FLZ.  Regardless of route, 
3AIX2 increases AUCMDZ more for PO MDZ than for IV MDZ, because pre-systemic hepatic 
and GW metabolism are inhibited after PO MDZ but not IV MDZ.  
 
Figure 6.13  MDZ AUCR by 400 mg IV 1-hour infusion or PO 3AIX2 administered at 
various time intervals before 1 mg IV/3 mg PO MDZ. 
Red dash line indicates no inhibition on MDZ exposure. 
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a) b) 
  
 
c)    d) 
  
 
Figure 6.14  Plots of 3AIX2 unbound concentrations and relative CYP3A activity in 
presence of 400 mg IV 1-hour infusion or PO 3AIX2. 
a) 3AIX2 unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of 3AIX2. c) 3AIX2 unbound GW concentration – time profiles. d) Relative GW 
CYP3A activity in presence of 3AIX2. Dash lines in a) and c) represent Ki,hep3AIX2 and Ki,GW3AIX2 
values. Dash lines in b) and d) represent no change in hepatic and GW CYP3A activity. 
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a)       b) 
   
Figure 6.15  Unbound plasma concentration of 400 mg IV 1-hour infusion and PO 
administration of 3AIX2 and FLZ on Cartesian and semi-log plots. 
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To change FLZ to a low Foral and short t1/2 CYP3AI (3AIX3), both FabsFLZ and CLrenFLZ were 
adjusted, with FabsFLZ decreasing from 1.0 to 0.1 and CLrenFLZ increasing from 0.2 ml/min/kg to 
3.0 ml/min/kg. MDZ AUC in presence of IV/PO 3AIX3 with different administration time 
interval were simulated, and AUCR of MDZ for each scenario is plotted against administration 
interval time shown in Figure 6.16. Plots of 3AIX3 concentration and relative CYP3A levels in 
GW and liver were simulated (Figure 6.17), based on the dosing regimen of 400 mg IV 1-hour 
infusion or PO 3AIX3. From Figure 6.17, due to the low Foral of 3AIX3, IV 3AIX3 has much 
higher hepatic and GW concentrations than PO 3AIX3, leading to more inhibition of CYP3A in 
liver and GW, regardless of MDZ route. Consequently, IV 3AIX3 consistently yields higher 
AUCR than PO 3AIX3, as is demonstrated in Figure 6.16. Due to the short t1/2 of 3AIX3, 
inhibition on hepatic and GW CYP3A only last for 20 hours, which is much shorter than 
inhibitory duration of FLZ.  Regardless of route, 3AIX3 increases AUCMDZ more for PO MDZ 
than for IV MDZ, because of the inhibition on pre-systemic hepatic and GW metabolism. 
 
Figure 6.16  MDZ AUCR by 400 mg IV 1-hour infusion or PO 3AIX3 administered at 
various time intervals before 1 mg IV/3 mg PO MDZ. 
Red dash line indicates no inhibition on MDZ exposure. 
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a)          b) 
  
 
c)           d) 
  
 
Figure 6.17  Plots of 3AIX3 unbound concentrations and relative CYP3A activity in 
presence of 400 mg IV 1-hour infusion or PO 3AIX3. 
a) 3AIX3 unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of 3AIX3. c) 3AIX3 unbound GW concentration – time profiles. d) Relative GW 
CYP3A activity in presence of 3AIX3. Dash lines in a) and c) represent Ki,hep3AIX3 and Ki,GW3AIX3 
values. Dash lines in b) and d) represent no change in hepatic and GW CYP3A activity. 
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6.3.2.3.2 Route-dependent DDI between 3ASX1/2 and FLZ 
	
Subsequently, two CYP3A substrate (3ASX1: no GW metabolism; 3ASX2: no GW 
metabolism and decreased hepatic metabolism) were derived from MDZ PBPK model. 3ASX1/2 
AUC in presence of 400 mg IV 1-hour infusion or PO FLZ with different administration time 
interval were simulated, and AUCR of 3ASX1/2 for each scenario is plotted against 
administration interval time shown in Figure 6.18 and Figure 6.19. 
From Figure 6.18, PO 3ASX1 is consistently more sensitive to metabolic inhibition than IV 
3ASX1, due to the existence of pre-systemic hepatic metabolism after PO administration. 
However, the impact of the FLZ administration route is the same regardless of 3ASX1 route, as 
metabolic DDI is limited to hepatic metabolism of 3ASX1 (no GW metabolism). 
 
Figure 6.18  3ASX1 AUCR by 400 mg (IV: 1-hour infusion or PO) FLZ administered at 
various time intervals before 1 mg IV/3 mg PO 3ASX1. 
Red dash line indicates no inhibition on 3ASX1 exposure. 
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From Figure 6.19, no clinical significant IV-PO route difference (<10%) of 3ASX2 is 
observed, due to limited pre-systemic hepatic extraction (ERhep3AIX2 = 0.11) and no GW 
metabolism. The impact of the FLZ administration route is the same regardless of 3ASX2 route, 
as metabolic DDI is limited to hepatic metabolism of 3ASX2 (no GW metabolism). To compare 
Figure 6.18 and Figure 6.19, maximal DDI between PO 3ASX2 and FLZ is smaller than 
maximal DDI between PO 3ASX1 and FLZ, because 3ASX1 has lower Foral than 3ASX2, and 
more potential to increase Foral in presence of FLZ. IV 3ASX2 can be inhibited slightly more 
than IV 3ASX1, because as a very low ERhep drug (ERhep = 0.11), the decrease in its CLhep is 
almost the same as the decrease in its CLint,hep (by FLZ), given the limited influence of Qhep on its 
CLhep. However, 3ASX1 has higher ERhep (ERhep = 0.40) than 3ASX2, and Qhep will have larger 
impact on its CLhep, resulting in less decrease in CLhep than decrease in its CLint,hep. Hence, the 
smaller the ERhep, the greater extent of inhibition should be observed in CLhep of the substrate, 
and the closer the decrease in CLhep to the decrease in CLint,hep. If a high ERhep (> 0.7) substrate is 
used, given the same FLZ dose, marginal increase in AUC should be observed, because for a 
high ERhep drug, CLhep is not dependent on CLint,hep, but on Qhep. 
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Figure 6.19  3ASX2 AUCR by 400 mg (IV: 1-hour infusion or PO) FLZ administered at 
various time intervals before 1 mg IV/3 mg PO 3ASX2. 
Red dash line indicates no inhibition on 3ASX1 exposure. 
6.3.2.3.3 Route-dependent DDI between 3ASX2 and 3AIX2 
	
AUCR of 3ASX2 in presence of 400 mg IV 1-hour infusion or PO FLZ with different 
administration time intervals was demonstrated in Figure 6.20. No clinical significant IV-PO 
route difference (<10%) of 3ASX2 is observed, due to its limited re-systemic hepatic extraction 
ratio and no GW metabolism. Duration of DDI is less than 10 hours, due to the short plasma t1/2 
of 3AIX2. To compare Figure 6.19 and Figure 6.20, AUCR of 3ASX2 is much lower in 
presence of 3AIX2 (AUCR range: 1.34 – 1.42) than FLZ (AUCR range: 2.10 – 2.25), because 
3AIX2 produces shorter duration of DDI, and the terminal phase of 3ASX2’s plasma 
concentration – time profiles is less inhibited. Therefore, DDI magnitude is also affected by t1/2 
of CYP3AI, relative to t1/2 of CYP3A substrate. 
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Figure 6.20  3ASX2 AUCR by 400 mg (IV: 1-hour infusion or PO) 3AIX2 administered at 
various time intervals before 1 mg IV/3 mg PO 3ASX2. 
Red dash line indicates no inhibition on 3ASX2 exposure. 
6.4 Conclusions 
 A semi-PBPK DDI model was developed to describe IV/PO MDZ clinical PK profiles in 
presence of IV/PO FLZ. The model was validated by MDZ plasma concentration – time profiles 
and exposure metrics in presence of FLZ in three clinical DDI studies. All the observed profiles 
are captured well by the model (with adjustment on vmax,hepMDZ and fvilli in study 103 and study 26, 
respectively), with deviations (%) of exposure metrics less than ± 30% in most scenarios. Formal 
parameter sensitivity analyses were conducted for ten key/uncertain model parameters, and fpv, 
Kp,hepMDZ and vmax,hepMDZ, which considerably affect hepatic drug levels/clearance, are the pivotal 
parameters determining both IV and PO MDZ exposure metrics in presence of FLZ. Exposure 
metrics of PO MDZ in presence of FLZ is also sensitive to Kp,hepFLZ and Ki,hepFLZ, regardless of 
FLZ routes. No FLZ route difference in the metabolic DDI sensitivity analysis is observed, 
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probably because there is a dosing lag-time between the two drugs (MDZ was administered 2 
hours after FLZ). As a result, fpv, Kp,hepMDZ, vmax,hepMDZ, Kp,hepFLZ and Ki,hepFLZ are the most 
sensitive parameters affecting plasma concentrations of MDZ in presence of FLZ, and may be 
tweaked when the predicted profile cannot adequately describe observed data. Given the accurate 
predictions with the current parameter sets, no additional adjustments are considered at this point.  
Using the semi-PBPK DDI model, simulations were performed to assess impact of route of 
administration for both MDZ and FLZ on their metabolic DDI, after different administration 
time intervals between the two drugs. After IV MDZ, no apparent FLZ route difference is found, 
while after PO MDZ, PO FLZ has more inhibition on GW metabolism than IV infusion FLZ, 
when the two drugs are dosed simultaneously. With increasing delay in MDZ administration, 
route difference of FLZ gradually reduces, and no route difference is found after 5 hours. 
Maximal inhibition on hepatic and GW CYP3A occur when FLZ concentration in liver and GW 
peak, and metabolic inhibition lasts for more than 100 hours, due to the long terminal t1/2 of FLZ 
in plasma. Regardless of route, PO MDZ is more sensitive to metabolic inhibition of FLZ than 
IV MDZ.  
Furthermore, a series of FLZ doses were simulated simultaneously administered with IV/PO 
MDZ, to compare FLZ route difference across doses. After IV MDZ, no apparent route 
difference (< 10%) of FLZ is detected across doses. After PO MDZ, only a slight FLZ route 
difference is observed at the lowest and the highest simulated FLZ dose, while the middle dose 
(400 mg) has the largest route difference, which is caused by the relationship between hepatic 
and GW FLZ concentrations relative to the corresponding Ki values.  
Three hypothetical CYP3AIs (3AIX1/2/3) with Foral and/or t1/2 modified from FLZ semi-
PBPK model, and two hypothetical CYP3A substrates with hepatic or GW metabolism reduced 
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or removed from MDZ semi-PBPK model (3ASX1/2) were also simulated to generalize 
conclusions. For DDI between MDZ and 3AIX1/2/3, when decreasing FabsFLZ by 10 fold 
(3AIX1/3), IV FLZ consistently has greater inhibition than PO FLZ, regardless of administration 
time intervals, although clinically, PO dose is usually adjusted to match systemic exposure after 
IV dose. When shortening t1/2FLZ by ~10 fold (3AIX2/3), FLZ inhibition only lasts less than 20 
hours, indicating that duration of inhibition is determined by pseudo steady-state plasma t1/2 of 
CYP3AI for non-competitive inhibition. For DDI between 3ASX1 and FLZ, PO 3ASX1 was still 
be inhibited more than IV 3ASX1, but the route effects of FLZ are the same no matter how 
3ASX1 is given. For DDI between 3ASX2 and FLZ, marginal route difference of 3ASX2 is 
observed, due to its limited hepatic first-pass metabolism (low ERhep3ASX2). DDI magnitude 
between 3ASX2 and 3AIX2 is much less than that between 3ASX2 and FLZ, suggesting that 
extent of DDI is also affected by t1/2 of CYP3AI, relative to t1/2 of CYP3A substrate. 
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CHAPTER 7 
 
 
7 SEMI-PBPK MODELING OF IV/PO ERY 
 
 
 
 
7.1 Background and Objectives 
7.1.1 Selection of CYP3AI 
	
 From Chapter 6, the route difference for MDZ and FLZ metabolic DDI is only evident when 
the two drugs are administered simultaneously, due to the high Foral of FLZ. However, if another 
CYP3AI has a low Foral, a marked difference of CYP3AI exposure after IV/PO administration is 
expected, leading to larger route differences, even when MDZ is dosed with longer delay time 
after CYP3AI. In contrast to FLZ, a second CYP3AI should meet three criteria: 1) CYP3AI can 
be clinically administered as both IV and PO administration, and its PK profiles in clinical 
studies after both routes should be accessible; 2) Foral is relatively low; 3) no inhibitory 
metabolites are formed, otherwise the interpretation of DDI results would be more complicated 
and model modification and additional model parameters would be required. After a preliminary 
screening of all the CYP3AI in the final meta-analysis database (Chapter 3), erythromycin 
(ERY) was chosen as a desirable inhibitor.  
7.1.2 ERY PK information and simulation strategies 
	
 ERY is a macrolide antibiotic, and has widespread clinical use in various infections. 
According to Erythromycin (Systemic) Lexi.com, IV ERY is usually administered as the form of 
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lactobionate salt, with 15-20 mg/kg/day equivalent base divided every 6 hours (q6h) and a 
maximum dose of 4 g daily. PO ERY can be administered either as enteric-coated base or salt or 
ester form, with 250 mg q6h, or 500 mg every 12 hours (q12h), and dosage may be increased up 
to 4 g per day according to the severity of the infection (Arbor Pharmaceuticals, 2013). Oral 
bioavailability of ERY is relatively low and quite variable (18% - 45%) (Somogyi et al., 1995), 
because of several reasons. Firstly, it is extensively hydrolyzed by gastric acid, thus, various 
approaches, such as ERY base enteric-coated tablets, ERY stearate salts or ERY ethylsuccinate, 
have been adopted to improve its ForalERY (Somogyi et al., 1995). Secondly, it is classified as 
BCS class 3 (Heizmann et al., 1983) drug, which is identified as a potent P-gp substrate in Caco-
2 cells (Lin et al., 2011; Nožini et al., 2010; Schuetz et al., 1998). However, since ERY 
concentration (50 µM) used in these in-vitro studies was much lower than clinical relevant gut 
lumen concentration of ERY, assuming it is dissolved in 250 ml aqueous liquid in gut lumen, P-
gp may be saturated at clinical dose. Last but not least, it is metabolized by CYP3A in both small 
intestine and liver, and can be excreted unchanged into bile. CLhep,uERY was reported to be 98.6 
L/hr (Barre et al., 1987), indicating its high hepatic extraction ratio as unbound drug. Once 
absorbed into systemic circulation, ERY can be characterized by a 2 –compartmental body 
model (Hall et al., 1982; Parsons & David, 1980), and exhibits a predominant binding to AAG at 
therapeutic relevant concentrations, and to albumin at higher than therapeutic concentrations 
(Dette & Knothe, 1986), resulting in increasing Vdss with dose (Austin et al., 1980). It is partly 
cleared by CYP3A to its major metabolite N-demethyl-erythromycin (nd-ERY) and also 
excreted primarily unchanged in bile (Frassetto et al. 2007). Nd-ERY is considerably less 
microbiologically active than the parent compound (Austin et al., 1980), and its exposure is 4% 
and 12%, respectively, of parent drug exposure after IV and PO administration of ERY (Sun et 
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al., 2010), indicating its negligible role in pharmacological effect. Only 2-15% of unchanged 
ERY is observed in urine, depending on dose (Austin et al. 1981), and elimination t1/2 of ERY is 
about 1.5-2 hours (Austin et al., 1980). In-vitro metabolic study (Xu et al., 2009) showed that 
ERY can inhibit CYP3A by irreversible binding, resulting in MBI of CYP3A. 
 ERY clinical PK studies after IV and PO administration were searched, to look for 
appropriate studies to validate semi-PBPK model after IV and PO ERY. Once the model was 
qualified by clinical PK profiles, ERY hepatic and GW concentrations was simulated via the 
semi-PBPK model after different dosing regimen, to forecast impact of ERY administration 
route on its metabolic inhibition on MDZ.  
7.1.3 Objectives 
	
The major objectives of the chapter were to:   
a. Search for ERY clinical PK studies and look for appropriate studies to validate semi-
PBPK model of ERY 
b. Develop a semi-PBPK model of ERY to describe its PK profiles in human after IV and 
PO administration 
c. Validate the model using ERY plasma concentration-time profiles in clinical PK studies 
d. Predict concentration – time profiles of ERY and relative CYP3A activity levels change 
in liver and GW using the validated semi-PBPK model 
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7.2 Methods 
7.2.1 ERY PK meta-analysis 
	
 An extensive literature search was carried out in PubMed, to search for any ERY PK studies 
in absence or presence of MDZ. ERY was to have been administered either intravenously or 
orally, and plasma exposures (their means and SD) after IV or PO administration should be well 
estimated and provided, or could be calculated based on the provided information. All studies 
were to have been conducted in healthy volunteers without any co-medications, except women 
who may have used oral contraceptives. All the exposure metrics (AUCERY, cmaxERY, etc.), PK 
information (fuERY, CLtotERY, CLrenERY etc.), PK parameters estimated by compartmental analysis 
(ka, k12, k21, V1, V2, etc.), demographics, dosing regimen design (dose, formulation, sample size, 
sampling time, etc.) and bio-analytical (LLOQ, assay method, etc.) information for both ERY 
and MDZ were extracted from the studies. 
7.2.2 Saturable plasma protein binding model of ERY 
	
 Austin et al.(Austin et al., 1980) conducted a SAD study of IV infusion ERY lactobionate 
(equivalent to 125 mg, 250 mg, 500 mg and 900 mg ERY base), and plasma and urinary 
concentrations were measured by bioassay using Sarcina lutea. Based on parameters estimated 
by two-compartment models, central compartment volume of distribution (Vdcc) and Vdss 
increased with dose, implying potential satuarable plasma protein binding. In addition, Dette et 
al. (Dette et al., 1982) characterized in-vitro binding profiles of ERY to human serum as a 
function of unbound ERY concentration. Total protein binding and non-specific binding 
(albumin, etc.) of ERY were measured by in-vitro equilibrium dialysis, and specific binding 
(presumably AAG binding) was obtained by subtraction of non-specific binding from total 
binding. Results (Figure 7.1) demonstrated that with increasing free ERY concentration, bound 
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ERY concentration increased less than proportionally: specific (AAG) binding profile exhibited 
a hyperbolic curve and non-specific binding profile showed a straight line, and the highest 
concentration in Austin et al. study (~12 µM) fell into the plateau part of specific binding curve. 
As a result, a mathematical model could be generated to predict fraction unbound of ERY (fuERY) 
in plasma at various concentrations, and assess dose-proportionality of ERY PK after correcting 
by plasma protein binding. Two models were tried to characterize specific (AAG) binding profile: 
a hyperbolic model and a sigmoidal model. A straight line started from origin (y = mx) was used 
to describe non-specific binding profile. Total bound concentration (Cbo-total) was then expressed 
as a hyperbolic/linear model (equation (7.1)) and a sigmoidal/linear model (equation (7.2)):  C"#$%#%&' = )*+,∙./01,345./ + m ∙ C8                             (7.1) - Model 1 C"#$%#%&' = )*+,∙./901,349 5./9 + m ∙ C8                            (7.2) – Model 2 
 Bmax is the binding capacity of specific (AAG) binding, Kb,50 is the binding affinity of ERY 
to AAG, m is the slope of non-specific binding linear regression, n is the hill coefficient in 
sigmoidal model, and cu is unbound ERY concentration. Only observed total binding and non-
specific binding profiles were digitized from Dette et al. (Dette et al., 1982), because specific 
binding profile was the subtraction of the two, which was not measured data. A linear regression 
was performed to fit non-specific binding profile, and m was estimated and fixed in future 
modeling process, due to parameter identification issues when estimating all parameters together. 
Afterwards, the two models were separately employed to fit digitized total binding profile, and a 
better model (based on visual predictive check and statistical report) was selected to depict 
saturable plasma protein binding in ERY semi-PBPK model. All modeling was implemented by 
ADAPT 5 (Argenio et al., 2009) (BMSR Biomedical Simulations Resource, available at 
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https://bmsr.usc.edu/software/adapt/), with control profiles and observed data summarized in 
Appendices F. 
 
 
Figure 7.1  Binding of [14C]-ERY to human serum as a function of unbound ERY 
concentration. 
Open circles represent total bound profile (specific + non-specific), open triangles represent non-
specific bound profile, solid circles represent specific bound profile, which were calculated by 
subtraction of nonspecific from total bound profile.   
 
 
7.2.3 Development of ERY semi-PBPK model 
	
7.2.3.1 ERY semi-PBPK model after single IV administration 
	
	
Semi-PBPK model for IV ERY was developed based on the reported in- vitro metabolic 
information, PK and physiological parameters (Table 7.1). Since model development was based 
on results from section 7.3.1 - 7.3.3, it is suggested to read these three sections first, before start 
reading this part. A conventional two-compartmental body model with additional compartments 
for GW serosa, portal vein, and liver was developed, and showed in Figure 7.2. Since saturable 
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plasma protein binding of ERY was demonstrated after single ascending IV dose of ERY, the 
semi-PBPK model was developed using unbound ERY mass transfer. The predicted unbound 
concentration in blood was converted to total concentration in plasma, by dividing fuERY at 
corresponding unbound concentration, and a constant B:PERY, in model validation. This model is 
similar to the FLZ semi-PBPK model (see Chapter 4, Section 4.2.1), with the following 
differences: (1) After IV administration, ERY is injected directly into systemic circulation, and 
assumed to be distributed to a peripheral compartment (Peripheral Cpt) with the inter-
compartmental clearance (Q2,uERY), except GW serosa, portal vein and liver, as tissues of interest. 
(2) Unbound renal clearance of ERY (CLren,uERY) increases with dose, so that an empirical 
hyperbolic equation was applied to describe dose-dependent CLren,uERY (3) Hepatic intrinsic 
clearance was expressed as addition of two Michaelis – Menten equations, to characterize 
hepatic CYP3A metabolism and biliary excretion, respectively. As to CYP3A metabolism 
pathway, specifically, a CYP3A MBI model was introduced to delineate auto-inhibition of ERY 
on its own metabolism. (4) With respect to GW metabolism, after scaling from in-vitro metabolic 
study to in-vivo intrinsic clearance of unbound ERY (Paine et al., 1997), intrinsic GW clearance 
(CLint,GWERY) was only 1.3% of CLint,hep-3AERY, thus GW metabolism of ERY after IV 
administration is assumed to be negligible. 
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Figure 7.2  Semi-PBPK model scheme for the disposition of ERY after IV administration.
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1) Differential equations: 
 Based on the model above, differential equations for unbound ERY mass transfer between 
compartments were expressed as equations (7.1) to (7.6): dA#,%&'( tdt = k,&'( + c/01,%&'( ∙ Q/01K1,%,/01&'( + c5,%&'( ∙ Q6,%&'( − c#,%&'(
∙ CL:0;,%,<=;&'( + DoseBC&'(EDE,&'( + DoseBC&'( ∙ (CL:0;,%,<GH&'( − CL:0;,%,<=;&'( ) − c#,%&'( ∙ QJ=KK=− c#,%&'( ∙ f5C ∙ Q5C − QJ=KK= − c#,%&'( ∙ QMN − c#,%&'( ∙ Q6,%&'( 
when t = 0, ABERY (0) = 0; when t = tinf, AB,uERY (tinf) = DoseIVERY    (7.1)
  
dA1,%&'( tdt = c#,%&'( ∙ Q6,%&'( − c5,%&'( ∙ Q6,%&'( 
when t = 0, AP,uERY (0) = 0           (7.2)
  
dAOPQR,%&'( tdt = c#,%&'( ∙ QJ=KK= − cOPQR,%&'( ∙ QJ=KK=K1,%,OP&'(  
when t = 0, AGW-S,uERY (0) = 0           (7.3)
  
dA5C,%&'( tdt = cOPQR,%&'( ∙ QJ=KK=K1,%,OP&'( + c#,%&'( ∙ f5C ∙ Q5C − QJ=KK= − c5C,%&'( ∙ Q5C 
when t = 0, APV,uERY (0) = 0           (7.4)
  
dA/01,%&'( tdt = c#,%&'( ∙ QMN + c5C,%&'( ∙ Q5C − c/01,%&'( ∙ Q/01K1,%,/01&'( − c/01,%&'(
∙ v<GH,/01QTN&'( ∙ E/01E,K<,/01QTN&'( + c/01,%&'( + v<GH,U=K0&'(K<,U=K0&'( + c/01,%&'(  
                                                                         
when t = 0, Ahep,uERY (0) = 0           (7.5) 
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dE/01(t)dt = k=; − E/01 ∙ kV0W − E/01 ∙ ( k=;GXY&'( ∙ c/01,%&'(KB&'( + c/01,%&'( ) 
when t = 0, Ehep (0) = 1           (7.6)
  
AB,uERY, AP,uERY, AGW-S,uERY, APV,uERY and Ahep,uERY are the amounts of unbound ERY in 
central, peripheral, GW serosa, portal vein and liver compartments, respectively; cB,uERY, cP,uERY, 
cGW-SERY, cPVERY, chepERY are unbound drug concentrations in central, peripheral, GW serosa, 
portal vein and liver compartments, calculated by dividing amount (A) by the respective 
compartment volume: VB,uERY, VP,uERY, VGW, VPV and Vhep, which are unbound ERY volume of 
central and peripheral compartments, volume of GW, portal vein and liver. In most ERY IV 
studies, ERY was administered as IV infusion, so an infusion rate k0ERY was introduced in 
equation (7.1) as a dose input rate, and initial amount for all the five tissue compartments 
(equation 7.1-7.5) were 0. In terms of CYP3A activity, E0 (assumed to be 1) is baseline CYP3A 
activity without ERY, which is determined by a zero-order synthesis rate (kin) and a first-order 
degradation rate (kdeg) of CYP3A enzyme. Ehep is relative hepatic CYP3A level changed with 
time. kinactERY is the maximum rate of enzyme inactivation by ERY and KIERY is the ERY 
inhibitory potency on CYP3A. 
2) Volume of distributions and inter-compartmental clearance 
Unbound central compartment volume of distribution (VB,uERY), unbound peripheral 
compartment volume of distribution (VP,uERY) and inter-compartmental clearance (Q2,uERY) were 
estimated from digitized plasma concentration – time profiles of ERY in study 611(Austin et al., 
1980), with a traditional two-compartmental body model (See Appendices G).  
VGW, Vhep and VPV were used the same values as FLZ semi-PBPK model (see Chapter 4, 
section 4.2.1.3). 
3) Partition coefficient between blood and tissue (Kp) 
170	
	
 
Kp,hep,uERY is the liver-to-blood partition coefficient of unbound ERY, reported as 2.71 
(Ahmad, 2007).  Kp,GW,uERY is GW-to-blood partition coefficient of unbound ERY, assumed to be 
the same as Kp,hep,uERY. 
4) Blood flows (Q) 
 Qhep, QPV, QHA and Qvilli were used the same values as FLZ semi-PBPK model (see Chapter 
4, section 4.2.1.3) 
5) Clearance 
Hepatic clearance of ERY includes two parts: CYP3A metabolism and biliary excretion. 
According to an in-vitro metabolic kinetics study (Riley & Howbrook, 1998) using human liver 
microsomes (HML) to characterize Michaelis-Menten parameters of ERY N-demethylation, 
vmax,hep-3AERY and Km,hep-3AERY were reported as 345 ± 13 pmol/min/mg and 88 ± 10 µM. After 
IVIVE of vmax,hep-3AERY by equation (7.7), vmax,hep-3AERY in-vivo was estimated to be 285 
µg/min/kg, which was used as initial parameter value, and optimized in future modeling 
processes. v<GH,/01QTN&'( 	[\	][]^ = v<GH,/01QTN&'( 	[\	][_`^ ∙ E6.E<W	1:bY0=;W	K=J0: ∙ 	 cE,,W	K=J0:d,	eW	UbVf	g0=W/Y     (7.7) 
As for biliary excretion, no vmax,bileERY or Km,bileERY values were reported in any literature. As 
a result, values for vmax,hep-3AERY, vmax,bileERY and Km,bileERY were optimized together, to finalize a 
parameter set that could characterize observed PK profiles across doses (125 – 900 mg single 
dose) in study 611. Since ERY has a very short plasma elimination t1/2 (1.5 – 2 hrs), 
enterohepatic circulation (EHC) of ERY would not contribute significantly to its total systemic 
exposure (no clinical data was found), and as a potent P-gp substrate, ERY could be effectively 
pumped out of GW during EHC phase. Therefore, EHC of ERY was assumed to be negligible in 
this model. 
171	
	
 
As mentioned in section 7.3.3, unbound ERY renal clearance after IV administration (CLren,u-
IV
ERY) increased with dose in study 611, indicating potential saturable reabsorption. An empirical 
hyperbolic equation was applied to describe the relationship between ERY dose and CLren,u-IVERY, 
shown in equation (7.8) CL:0;,%QBC&'( = CL:0;,%,<=;&'( + hbi0jkl&hmnjklohbi0jkl ∙ (CL:0;,%,<GH&'( − CL:0;,%,<=;&'( )              (7.8) 
 Since it was impossible to estimate all the parameters (i.e. CLren,u,minERY, CLren,u,maxERY and 
ED50ERY) based on CLren,uERY at only four dose levels, parameter optimizations were performed 
based on visual inspection, and residual at each dose level was calculated to assess predictability 
of equation (7.8). Ultimately, CLren,u,minERY and CLren,u,maxERY were optimized to be 0.5 ml/min/kg 
and 3.5 ml/min/kg, and ED50ERY was set at 475 mg. 
Assumptions and predictability of empirical hyperbolic model were discussed in Appendices 
J. 
6) Fraction unbound and blood-to-plasma partitioning ratio 
 Relationship between fuERY and cb,uERY was expressed as equation (7.24) (see section 7.3.2). 
Each cb,uERY was converted to total plasma concentration by dividing corresponding fuERY and 
B:PERY (set at 0.85 (Ahmad, 2007)). 
7) Auto-inhibition on hepatic CYP3A metabolism 
 Since all IV ERY PK studies were single dose studies, auto-inhibition of CYP3A by ERY 
was not evident in these studies. However, in ERY and MDZ DDI studies, ERY was given orally 
after repeat- doses, which may exhibit substantial auto-inhibition characteristics. To keep 
systemic disposition model structure after IV and PO ERY the same, auto-inhibition on hepatic 
CYP3A metabolism was also incorporated in IV ERY semi-PBPK model, and detailed enzyme 
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turnover model was discussed in section 7.2.3.2.  
 Body weight throughout the model was set as the median body weight (67kg) of subjects in 
study 611.  
7.2.3.2 ERY semi-PBPK model after single/repeat- PO doses (ERY base enteric-coated 
tablet formulation) 
7.2.3.2.1 Semi-PBPK model 
	
 A semi-PBPK model for PO ERY after enteric-coated tablet (EC) formulation (Figure 7.3) 
was built based on the reported in-vitro metabolic information, PK and physiological parameters 
(Table 7.1). A conventional two-compartmental body model with additional compartments for 
gut lumen, absorptive transit compartments, GW mucosa, GW serosa, portal vein, and liver was 
developed, by adding several absorptive compartments (gut lumen, absorptive transit 
compartments and GW mucosa) to the IV model.  
After PO administration of ERY EC base, ERY was dissolved in the intestinal lumen, and a 
fraction of drug (FabsERY) could permeate into GW mucosa. To determine the role of acid 
hydrolysis on GI absorption of ERY, Somogyi et al. (1995) conducted a clinical PK study, in 
which six healthy subjects received ERY as a 240 mg IV dose, a 250 mg PO solution 
administered via endoscope directly into the duodenum and bypassing the stomach, and an EC 
250 mg capsule. After calculating FGIERY and FabsERY•FGIERY by using the method in Chapter 3, 
Figure 3.2, assuming that FabsERY after duodenum injection was 100%, FabsERY after PO EC ERY 
was estimated to be 0.88. 
 Before ERY was absorbed into GW, a number of transit compartments were added to 
characterize an observed lag-time of ERY appearance in plasma after PO EC administration. 
Physiologically, transit compartments represented slow disintegration, dissolution or intestinal 
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transit of ERY before absorption into GW, and number of transit compartments was optimized 
based on observed lag-time of its plasma concentration-time profile (n = 7 was used in PO EC 
ERY model).  
Although ERY is identified a BCS class 3 (Heizmann et al., 1983) drug due to its high 
solubility within clinical relevant pH and low permeability as a potent P-gp substrate (Lin et al., 
2011; Nožini et al., 2010; Schuetz et al., 1998), P-gp is likely to be saturated at clinical relevant 
dose, potentially making it an apparent BCS class 1 drug, if gastric acid degradation is not 
considered. Hence it is reasonable to assume that permeating into the GW is the rate-limiting 
step of its oral absorption, and kGLERY ≈ kaERY (kaERY was the observed first-order oral absorption 
rate constant of ERY reported in literature (Josefsson et al., 1982)).  
Once it is permeated into GW through mucosa side, ERY can be metabolized by GW 
CYP3A enzymes located at the villous tips ( Yang et al., 2007; Watkins, 1997). Pre-systemic 
GW extraction is higher than systemic GW extraction, due to the negligible protein binding 
(fu,GW-MERY = 1.0) and potential higher concentrations at the mucosal side of intestinal 
epithelium. To calculate unbound pre-systemic GW intrinsic clearance (CLint,GW,uERY), vmax,GW-
3A
ERY was extrapolated from in-vitro metabolic study (Thummel et al., 1996) and Km,GW-3AERY 
was assumed to be the same as Km,hep-3AERY. fvilli was also added and used the same value as 
MDZ semi-PBPK model, which is an adjusting factor for GW CYP3A activity.  
Furthermore, a transit rate constant (kT) from mucosa to serosa was added to connect the two 
sides of GW, and set as Qvilli/VGW, to keep the outflow from mucosa to serosa of intestinal 
epithelium constant to be Qvilli.  
ERY is then carried into portal vein with blood flow of Qvilli, and reaches liver via portal 
vein. Before getting into the systemic blood compartment, it can be metabolized or excreted by 
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CYP3A and bile pre-systemically. Once it gets into the systemic blood, the disposition is the 
same as IV administration.  
With respect to renal clearance, Josefsson et al. (1982) conducted a SAD study (study 620) 
of PO EC ERY within the dose range of 250 mg to 1000 mg, and measured renal clearance in 
addition to systemic exposure. After corrected by average fuERY (fuERY at cmaxERY/2) at each dose, 
CLren,uERY was almost constant with dose, which cannot be predicted by the empirical hyperbolic 
model after IV ERY. This could probably due to lower systemic concentration after PO 
administration, given its low ForalERY, leading to less saturation of tubular reabsorption, or the 
narrower dose range (250 mg -1000 mg) after PO administration than IV administration (125 mg 
– 900 mg). As a result, a constant CLren,u-POERY (average of measured CLren,uERY at three dose 
levels) was used in PO EC ERY semi-PBPK model. Although this may cause inconsistency 
between ERY semi-PBPK models after difference routes of administration, the influence of renal 
clearance on ERY PK is limited, due to its minor contribution (2-15%) to total ERY clearance 
after IV administration. 
 
175	
	
 
 
 
Figure 7.3  Semi-PBPK model scheme for the disposition of ERY after PO administration.
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 Based on the model scheme, differential equations for mass transfer between compartments 
were expressed as equations (7.9) to (7.19): 
dA#$,&'() tdt = −c#$,&'() ∙ V#$ ∙ F123'() − c#$,&'() ∙ V#$ ∙ (1 − F123'()) 
when t = 0, AGL,uERY (0) = DosePOERY     (7.9) dA#789,&'() tdt = c#$,&'() ∙ V#$ ∙ F123'() − A#789,&'() ∙ k9'() 
when t = 0, AGIT1,uERY (0) = 0       (7.10) 
… 
dA#78;,&'() tdt = A#78(;<9),&'() ∙ k9'() − A#78;,&'() ∙ k9'() 
when t = 0, AGITn,uERY (0) = 0       (7.11) dA#=<>,&'() tdt = A#78;,&'() ∙ k#$'() − 	c#=<>,&'() ∙ V#= ∙ k8 − c#=<>,&'() ∙ (fABCCB ∙ vE1F,#=<GH>IJ ∙ E#=EL ) /(KE,#=<GH'() + c#=<>,&'() ) 
when t = 0, AGW-M,uERY (0) = 0      (7.12)
    
dA#=<P,&'() tdt = c#=<>,&'() ∙ V#= ∙ k8 + cQ,&'() ∙ QABCCB − (c#=<P,&'()KS,#=,&'() ) ∙ QABCCB 
when t = 0, AGW-S,uERY (0) = 0    (7.13) dATU,&'() tdt = c#=<P,&'() ∙ QABCCBKS,&,#='() + cQ,&'() ∙ fTU ∙ QTU − QABCCB − cTU,&'() ∙ QTU 
 when t = 0, APV,uERY (0) = 0           (7.14)
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dAVWS,&'() tdt = cQ,&'() ∙ QXH + cTU,&'() ∙ QTU − cVWS,&'() ∙ QVWSKS,&,VWS'() − cVWS,&'()
∙ vE1F,VWS<GH'() ∙ EVWSELKE,VWS<GH'() + cVWS,&'() + vE1F,2BCW'()KE,2BCW'() + cVWS,&'()  
                                                                         
when t = 0, Ahep,uERY (0) = 0           (7.15)
  dAQ,&'() tdt = cVWS,&'() ∙ QVWSKS,&,VWS'() + cT,&'() ∙ QY,&'() − cQ,&'() ∙ CL\W;,&<T]'() − cQ,&'() ∙ QABCCB − cQ,&'() ∙ fTU∙ QTU − QABCCB − cQ,&'() ∙ QXH − cQ,&'() ∙ QY,&'() 
when t = 0, ABERY (0) = 0        (7.16)
  
dAS,&'() tdt = cQ,&'() ∙ QY,&'() − cT,&'() ∙ QY,&'() 
when t = 0, AP,uERY (0) = 0           (7.17)
  
dE#=(t)dt = kB; − E#= ∙ k^W_ − E#= ∙ ( kB;1`a'() ∙ c#=<>,&'()K7,VWS'() + c#=<>,&'() ) 
when t = 0, EGW (0) = 1           (7.18)
 
dEVWS(t)dt = kB; − EVWS ∙ k^W_ − EVWS ∙ ( kB;1`a'() ∙ cVWS,&'()K7,VWS'() + cVWS,&'() ) 
when t = 0, Ehep (0) = 1           (7.19)
  
 where AGL,uERY, AGIT1,uERY,… AGITn,uERY and AGW-M,uERY are the amounts of unbound ERY in 
gut lumen, first GI transit compartment, … nth GI transit compartment and GW mucosa, 
respectively; cGL,uERY and cGW-M,uERY are unbound concentrations in gut lumen and GW mucosa, 
calculated by dividing amount (A) by the respective compartment volume: VGL and VGW. Initial 
amount for all the compartments are 0, except for gut lumen, which is DosePOERY.  
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7.2.3.2.2 Auto-inhibition model 
	
After multiple PO ERY, several studies (Birkett et al., 1990; McDonald et al., 1977; Miglioli 
et al., 1990) found that accumulation ratios at steady-state after PO ERY (EC and other 
formulations) were all higher than 2, when dosing interval was about 3-4 t1/2. This cannot be 
purely explained by PK nonlinearity, as discussed in section 7.3.3. Furthermore, Danan et al. 
(1981) and Larrey et al. (1983) demonstrated that ERY induced its own CYP3A – mediated 
transformation into metabolite, which formed an inactive 456-nm absorbing complex with the Fe 
(II) of CYP3A in rats and humans. All these evidence confirmed that ERY can inhibit its own 
CYP3A metabolism through MBI. In our semi-PBPK model, auto-inhibition was incorporated 
with respect to both GW and hepatic metabolism.  
In absence of ERY, hepatic or GW CYP3A level was determined by a zero-order synthesis 
rate (kin) and first-order degradation rate (kdeg), which can be expressed as equation (7.20). ^'(a)^a = kB; − E ∙ k^W_                                               (7.20) 
E represents hepatic or GW CYP3A level. At steady-state, dE(t)/dt = 0; thus, kB; = E ∙ k^W_                                                  (7.21) 
Assuming E at baseline (E0) is 100%, numerically, kin is equal to kdeg. 
In presence of ERY, the degradation rate of enzyme is increased by an apparent inactivation 
rate constant, kinact,appERY, which is a function of kinactERY, KIERY, and ERY unbound concentration 
in liver and GW mucosa, respectively (equation 7.22 and 7.23), assuming that kinactERY and KIERY 
are the same in hepatic and intestinal CYP3A inhibition. 
kB;1`a,1SS<VWS'() = bcdefghij ×`lmn,ohijpqhijr`lmn,ohij                                    (7.22) 
kB;1`a,1SS<#='() = bcdefghij ×`stuv,ohijpqhijr`stuv,ohij                                  (7.23) 
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 Equation (7.18) and (7.19) calculated relative GW (EGW) and hepatic (Ehep) levels change 
over time, and vmax,GW-3AERY and vmax,hep-3AERY were corrected by EGW/E0 and Ehep/E0, to reflect 
corresponding vmax change over time in presence of ERY. In terms of parameter values, kdeg was 
reported to be highly variable estimated by different in-vitro and in-vivo methods, between 8×10-
5 and 1.15×10-3 (CYP3A degradation t1/2 ranges from 10 hours to 144 hours) (Rowland Yeo et 
al., 2011; Wang, 2010; Yang et al., 2008). Therefore, kdeg was optimized between 8×10-5 and 
1.15×10-3 min-1, to find a value that could provide good predictions for all ERY PK studies that 
used for model validation. KIERY and kinactERY were also variably reported in several in-vitro 
inhibitory studies (Ito et al., 2003; McConn et al., 2004; Rowland Yeo et al., 2011; Xu et al., 
2009; Yamano et al., 2001; Yates et al., 2012; Zhang et al., 2009; Zhang et al., 2010; Ping Zhao 
et al., 2005), with KIERY ranged from 1.48 – 109 µM and kinactERY ranged from 0.017 – 0.066 min-
1. Finally, kinactERY was set at 0.0375 min-1 (Rowland Yeo et al., 2011) (value used in Simcyp® 
Erythromycin model) and KIERY was optimized in model validation, due to its large variability. 
 
7.2.3.3 ERY semi-PBPK model after single/repeat- PO doses (ERY stearate salt tablet 
formulation) 
Semi-PBPK model for PO ERY after ERY stearate salt (SS) formulation (Figure 7.3) was 
developed based on model for EC formulation, with several changes. 1) SS is reported to be less 
oral bioavailable than EC (Josefsson et al., 1982; McDonald et al., 1977; Mannisto et al., 1988), 
and in study 620 by Josefsson et al., both 500 mg ERY EC and SS formulations were 
administered to the same subjects, and mean reported AUC0-∞ERY after EC and SS formulations 
were 11.2 mg/L•hr and 7.5 mg/L•hr, respectively. Assuming difference in AUC was completely 
caused by FabsERY of the two formulations, FabsERY for EC (0.88) was corrected by the AUC ratio 
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of SS and EC, to come up with FabsERY for SS (0.59). 2) Number of transit compartments was 
optimized by plasma concentration – time profiles of ERY after SS formulation (n = 4 was used 
in PO SS ERY model). Number of transit compartment for SS model was less than that for EC 
model, indicating that ERY in EC formulation requires longer disintegration/dissolution time 
than in SS. 3) Absorption rate constant kGLERY  of SS was reported to be less than kGLERY of EC 
(Iliopoulou et al., 1982), either due to inter-study variability, or because ERY SS may be 
absorbed into GW as both ERY base and ERY SS format, leading to a lower permeability. 
Since only two ERY PO formulations (EC and SS) were administered in MDZ and ERY DDI 
studies, PBPK models for other ERY PO formulations were not developed. 
7.2.3.4 Model parameters and assumptions 
	
Initial model parameters used in semi-PBPK models of IV/PO ERY were summarized in 
Table 7.1. Physiological parameters were the same as MDZ semi-PBPK model. vmax,hep-3AERY, 
vmax,bileERY and FabsERY (EC) were further adjusted during model qualification for PO ERY model, 
discussed in section 7.3.5. 
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Table 7.1  Initial semi-PBPK ERY model parameters. 
 
Parameter Definition Value Source 
Physiological parameters 
VGL (ml/kg) Volume of gut lumen 3.57 Assumed to be 250ml (FDA, 2012) 
VGW (ml/kg) Volume of GW 33.6 
Calculated by equation (4.6), assumed 
to be the surface of gut lumen cylinder 
VPV (ml/kg) Volume of portal vein 0.97 Unknown methods (Ito et al., 2003) 
Vhep (ml/kg) Volume of liver 22.5 Calculated by equation (4.7) and (4.8) 
Qvilli (ml/min/kg) Villous blood flow 4.30 In-vivo experiment (Yang et al., 2007) 
Qhep (ml/min/kg) Hepatic blood flow 21.4 
In-vivo experiment (Tsunoda et al., 
1999) 
fHA 
Fraction of hepatic artery to total hepatic blood 
flow 0.25 
(Eipel et al., 2010) (QHA was 
calculated as fHA•Qhep; QPV was 
calculated as (1-fHA•Qhep) 
fPV 
Fraction of the components of portal vein that 
contain drug 1.00 
A correction factor that can be 
adjusted according to simulation 
results. 
fvilli IVIVE scaling factor and IIV adjusting factor 2.2 Optimized with data from study 21 
ERY PK Parameters (Systemic Disposition) 
VB,uERY (mL/kg) Unbound volume of central compartment 479 See Appendices G 
VP,uERY (mL/kg) Unbound volume of peripheral compartment 1853 See Appendices G 
Q2,uERY 
(ml/min/kg) Inter-compartmental clearance 34.1 See Appendices G 
CLren,u,minERY 
(ml/min/kg) Minimal unbound renal clearance after IV ERY 0.5 
Optimized by empiric hyperbolic 
model 
CLren,u,maxERY 
(ml/min/kg) Maximal unbound renal clearance after IV ERY 3.5 
Optimized by empiric hyperbolic 
model 
ED50ERY
 
(mg) Dose of IV ERY that requires to produce 50% tubular reabsorption 475 
Optimized by empiric hyperbolic 
model 
CLren,u-POERY 
(ml/min/kg) ERY unbound renal clearance after PO ERY  2.65 
Average of CLrenERY reported at 250, 
500, 1000mg dose
 
(Josefsson et al., 
1982) (corrected by average fuERY and 
B:PERY) 
1 vmax,hep-3AERY 
(µg/min/kg) Capacity of hepatic CYP3A to metabolize ERY 900 
Optimized by regimen 2 in study 
611(Austin et al., 1980) 
Km,hep-3AERY 
(µg/ml) Affinity of hepatic CYP3A to metabolize ERY 64.6 
In-vitro study (88 µM) (Riley & 
Howbrook, 1998) 
1 vmax,bileERY 
(µg/min/kg) Capacity of ERY biliary excretion 10 
Optimized by regimen 2 in study 
611(Austin et al., 1980) 
Km,bileERY (µg/ml) 
Affinity to drug transporter that is responsible for 
biliary excretion 0.1 
Optimized by regimen 2 in study 
611(Austin et al., 1980) 
Kp,hep,uERY 
liver-to-blood partition coefficient of unbound 
drug 2.71 (Ahmad, 2007) 
Kp,GW,uMDZ 
GW-to-blood partition coefficient of unbound 
drug 2.71 Assumed to be the same as Kp,hep,u
ERY 
B:PERY Blood-to-plasma partitioning ratio 0.85 (Ahmad, 2007) 
Bmax (mg/L) Binding capacity to AAG 8.15 See section 7.3.2 (11.1µM) 
Kb,50 (mg/L) Binding affinity to AAG 2.14 See section 7.3.2 (2.92µM) 
n Hill coefficient of AAG binding 1.32 See section 7.3.2 
m Slope of non-specific binding 0.265 See section 7.3.2 
ERY PK Parameters (Oral Absorption) 
2 FabsERY (EC) Fraction of ERY EC absorbed from gut lumen 0.88 
Estimated from study 624 (Somogyi et 
al., 1995) 
kGLERY (min-1) Absorption rate constant of EC from last transit 0.06 Assume to be kaERY in study 620 
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(EC) compartment to GW (Josefsson et al., 1982) 
FabsERY (SS) Fraction of ERY SS absorbed from gut lumen 0.59 
Relative bioavailability between EC 
and SS in study 620 (Josefsson et al., 
1982) 
kGLERY (min-1) 
(SS) 
Absorption rate constant of SS from last transit 
compartment to GW 0.018 
Assume to be kaERY in study 618 
(Iliopoulou et al., 1982) 
ERY PK Parameters (Auto-inhibition model on CYP3A) 
kdeg (min-1) CYP3A degradation rate constant 0.0008 
Optimized between t1/2 of 10 -144 
hours (Rowland Yeo et al., 2011; 
Wang, 2010; Yang et al., 2008) (t1/2 = 
14 hours) 
kinactERY (min-1) ERY maximum rate of inactivation on CYP3A  0.0375  
26
 
KIERY (mg/L) ERY inhibitory potency on CYP3A 30 
Optimized between 1 - 80 mg/L (1.48 
– 109 µM) (Ito et al., 2003; McConn et 
al., 2004; Rowland Yeo et al., 2011; 
Xu et al., 2009; Yamano et al., 2001; 
Yates et al., 2012; Zhang et al., 2009; 
Zhang et al., 2010; Ping Zhao et al., 
2005)  
 
1 Parameter values were adjusted in PO ERY model.  
 
2 Parameter value was adjusted in study 629. 
 
 
The assumptions made in semi-PBPK IV/PO ERY model included: 
1) ERY follows two-compartmental body model (except for GW, portal vein, liver) after IV 
administration. 
2) Perfusion (blood flow) is the rate-limiting step for ERY tissue distribution, rather than tissue 
uptake. 
3) Tubular reabsorption of ERY follows Michaelis-Menten kinetics with dose (saturated with 
increasing dose).  
4) Glomerular filtration and tubular secretion of ERY are constant across doses, and them in 
total is 3.5 ml/min/kg (CLren,u,maxERY). 
5) At very low dose, when tubular reabsorption is not saturated, unbound renal clearance of 
ERY is 0.5 ml/min/kg (CLren,uminERY). 
6) ERY is in equilibrium between hepatocytes and venous outflow (well-stirred model). 
7) Partition coefficient (Kp) for GW and liver are the same, and remain constant at simulated 
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concentration.  
8) Negligible GW metabolism occurs after IV ERY. 
9) Although ERY is a BCS Class 3 drug, it behaves like a BCS Class 1 drug after clinical 
relevant PO dose, and P-gp in enterocytes is saturated at clinical relevant concentration. 
Therefore, loss of ERY in gut lumen is due to gastric acid degradation, and FabsERY after 
duodenum ERY injection is 100%. 
10) Different systemic exposure between EC and SS after the same dose of ERY is mainly owing 
to gastric acid degradation difference, and FabsERY for SS can be calculated based on its 
relative bioavailability to EC formulation. 
11) ERY follows 1st-order diffusion across GW, and this process is the rate-limiting step of its 
oral absorption. (kGLERY ≈ kaERY)  
12) GW compartment is divided into mucosal side and serosal side; volumes of the two 
compartments are both VGW, and the transit rate (kT) from mucosa to serosa is Qvilli/VGW. 
13) With respect to ERY GW metabolism, Km,GW-3AERY was assumed to be the same as Km,hep-
3A
ERY. 
14) Baseline CYP3A level is determined by a zero-order synthesis rate (kin) and a first-order 
degradation rate (kdeg), and hepatic and GW CYP3A have the same synthesis and degradation 
rate constants. 
15) ERY can inhibit its own GW and hepatic metabolism by MBI, and maximal inactivation rate 
constant (kinactERY) and inhibitory potency (KIERY) are the same for hepatic and intestinal 
CYP3A inhibition. 
16) MDZ has no effect on ERY PK. 
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7.2.4 Model qualification and predictions 
	
As for IV ERY semi-PBPK model, uncertain model parameters (i.e., vmax,hep-3AERY, 
vmax,bileERY and Km,bileERY) were optimized by study 611, because this is the only SAD study after 
IV ERY, which can validate the model across doses, regardless of inter-study variability. In 
study 611, two IV dosage regimens were administered. Regimen 1 consisted of the 
administration of 250 mg (base equivalent) of ERY labtobionate infused over 3min. Regimen 2 
was to administer 125, 250, 500 and 900 mg (base equivalent) ERY lactobionate infused over 
15min. 24 healthy volunteers (12 males, 12 females, aged 17-23) participated in regimen 1, and 5 
healthy volunteers were included in regimen 2. Blood and urinary samples were collected over 
time, and a bioassay using Sarcina lutea organism was applied to measure total ERY 
concentrations in both plasma and urine. Since nonlinear PK was observed for ERY, observed 
PK profiles after regimen 2 were used to optimize vmax,hep-3AERY, vmax,bileERY and Km,bileERY, and 
regimen 1 in study 611, as well as studies 612  (Barre et al., 1987), 613 (Parsons & David, 1980), 
616 (Sun et al., 2010) and 624 (Somogyi et al., 1995) were used to externally validate the model 
by visual predictive check and exposure metrics comparison. 
As for PO EC ERY semi-PBPK model, number of transit compartments and uncertain 
parameters (vmax,hep-3AERY, vmax,bileERY, number of transit compartments) were further tweaked by 
study 620 (Josefsson et al., 1982), the only SAD study after PO EC ERY, given the potential 
large inter-study variability of vmax,hep-3AERY and vmax,bileERY. In study 620, ERY EC base was 
administered to 24 healthy males, with single oral dose of 250, 500, or 1000 mg. The subjects 
also received a film-coated ERY stearate tablet (equivalent to 500 mg base). Blood and urinary 
samples were collected over time, and a bioassay using Micrococcus lutea organism was applied 
to measure total ERY concentrations in both serum and urine. In addition, PO ERY EC model 
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was externally validated by several multiple doses ERY EC PK studies (studies 623 (Birkett et 
al., 1990), 626 (McDonald et al., 1977), 629 (Yakatan et al., 1985)), in which plasma 
concentration – time profiles after both single and multiple ERY EC doses were compared with 
predicted profiles by visual predictive check and exposure metrics comparison. To test the 
necessity of incorporating ERY auto-inhibition into its semi-PBPK model, predicted profiles in 
absence/presence of auto-inhibition in hepatic and GW metabolism were both compared with 
observed data. 
As for PO SS ERY semi-PBPK model, number of transit compartments was further adjusted 
by study 604 (Carls et al., 2014), the only SAD study after PO SS ERY. In study 604, ERY SS 
tablet was administered to 16 healthy volunteers (two dose groups, 250 mg and 1000 mg base 
equivalent dose, with n = 8), and a microdose of MDZ (3µg PO) was administered 1 hour after 
ERY dosing. Both ERY and MDZ plasma concentrations were measured by LC-MS. Since only 
PK profiles for ERY were provided (partial AUC of MDZ between 2 – 4 hours), study 604 was 
used to validate PO ERY SS model only, instead of MDZ and ERY DDI model. Besides study 
604, PO ERY SS model was externally validated by several multiple doses ERY SS PK studies 
(studies 615 (Triggs & Ashley, 1978), 626 (McDonald et al., 1977), 627 (Mather et al., 1981) 
and 625(Miglioli et al., 1990)), in which plasma concentration – time profiles after both single 
and multiple ERY SS doses were compared with predicted profiles by visual predictive check 
and exposure metrics comparison. To test the necessity of incorporating ERY auto-inhibition 
into the PBPK model, predicted profiles in absence/presence of auto-inhibition in hepatic and 
GW metabolism were both compared with observed data.  
The most commonly used criteria of prediction acceptance: predicted exposure metrics are 
within 0.5 to 2-fold of observed, were used to assess performance of ERY semi-PBPK model 
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after IV and two PO formulations. 
ERY concentrations in liver and GW mucosa were simulated and compared after different 
routes of administration at different dose levels, and additional simulations were conducted to 
interpret consequences of nonlinear PK and auto-inhibition. All M&S were implemented in 
Simbiology (MATLAB, 2015a), if not otherwise mentioned.  
To make more clinical relevant conclusions, sensitivity analysis and simulation of 
hepatic/GW CYP3A activity levels vs. time were performed under ERY dosing regimen in DDI 
studies, and will be discussed in Chapter 8. 
 
7.3 Results and Discussion 
7.3.1 Meta-analysis of ERY PK studies 
	
 A total of 7 IV studies with 95 healthy volunteers and 21 PO studies with 269 healthy 
volunteers were included in the final database. Each study was assigned a study ID number. In 
IV studies, 55 subjects were males, 34 subjects were females, and gender information was not 
provided in study 613 (Parsons & David, 1980).  In PO studies, 170 subjects were males, 75 
subjects were females, and gender information was not available in study 620 (Josefsson et al., 
1982) and study 632 (Benardi et al., 1988). Age ranged from 19 to 55 years in IV studies, and 
from 18 - 51 years in PO studies. As to dosing regimen, IV ERY were all administered after 
single dose, ranged from 125 mg to 1344 mg. PO ERY were administered as both single- and 
repeat- doses, with single PO dose ranged from 250 mg to 1000 mg, and repeat- PO doses 
(studies 615 (Triggs & Ashley, 1978), 623 (Birkett et al., 1990), 626 (McDonald et al., 1977), 
627 (Mather et al., 1981), 629 (Yakatan et al., 1985), 614 (Malmborg, 1979), 618 (Iliopoulou et 
al., 1982) and 625 (Miglioli et al., 1990)) ranged from 1000 mg to 2000 mg daily dose (different 
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dosing interval). Formulations used in IV studies were mostly ERY lactobionate salt, except for 
study 616 (Sun et al., 2010) and study 617 (Lappin et al., 2006) (formulation was not mentioned 
in the two studies). Formulations used in PO studies were ERY salts (stearate salt, piopionate 
salt), ERY base enteric-coated tablet, ERY base capsules containing enteric-coated pellets, and 
ERY ethylsuccinate ester.  
To investigate inter-study variability of different formulations, studies using the same dose 
and formulation were identified, and reported AUC0-∞ERY in these studies were compared and 
plotted in Figure 7.4. In studies 620, 623, 626 and 629, ERY were all administered as 250 mg 
single oral ERY base in an EC tablet, and their reported mean AUCs ranged by 3.8 fold, with SD 
overlapped with each other. In studies 604, 615, 626 and 627, ERY were all administered as 250 
mg single oral ERY SS in tablet, and their reported mean AUCs ranged by 2.2 fold. In studies 
604 and 625, ERY were both administered as 1000 mg single oral ERY SS in tablet, and their 
reported mean AUCs ranged by 1.9 fold. No demographic, study design or analytical assay 
difference could explain the exposure metrics variability among the studies. Overall, Figure 7.4 
indicates that inter-study variability exists for both EC ERY base formulation and ERY SS 
formulation after PO administration, and EC demonstrates higher variability than SS.  
Bioassay using microbiological activity to quantify ERY concentrations was applied in most 
studies, except for study 616, 617, 604 (Carls et al., 2014), and 623 (Birkett et al., 1990), in 
which HPLC was used. Bioassay measures total microbiologically active moieties, including 
both ERY and its active metabolite nd-ERY, while HPLC specifically measures ERY base. Due 
to less microbiological activity and negligible serum exposure of nd-ERY, measurements 
obtained by bioassay demonstrated similar exposures as HPLC measurements in studies using 
same IV or PO dose and formulations (e.g., study 611 vs. study 616; study 623 vs. study 620). 
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However, given the large inter-study variability of ERY PK, especially after PO EC formulation, 
it was still difficult to compare the two analytical methods, so that cautions were taken when 
comparing results from different analytical measurements. Detailed PK, demographic, study 
design and sample analysis information for all ERY IV and PO studies were summarized in 
Appendices H. 
 
Figure 7.4  Systemic exposure after the same oral single dose and formulation of ERY. 
a) AUC0-∞ERY after single 250 mg oral EC tablet containing ERY base or oral tablet containing 
ERY SS. b) AUC0-∞ERY after single 1000 mg oral tablet containing ERY SS. The symbols and 
bars are reported mean AUC and SD in each study (if available). The number inside each symbol 
is the study ID. 
 
7.3.2 Meta-analysis of ERY and MDZ DDI studies  
 
 MDZ and ERY were co-administered in 4 studies (study 28 (Olkkola et al., 1993), study 601 
(Zimmermann et al., 1996), study 603 (Okudaira et al., 2007) and study 604 (Carls et al., 2014)), 
with 38 healthy volunteers included in total. Subjects in all the studies experienced overnight fast 
before drug administration, thus food effect did’t need to be considered in future modeling 
process, and only ERY PK profiles measured in fasted subjects were used for ERY semi-PBPK 
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model validations. ERY was administered as repeat- oral doses in all the four DDI studies, and 
no IV ERY was co-administered with MDZ in any clinical DDI study. Study 601 was excluded 
from the final database, because it didn’t mention ERY formulation, which is an important factor 
influencing ERY’s PK profile. Study 604 was the only study providing both MDZ and ERY PK 
information: it provided ERY PK profiles after single SS 250 mg and 1000 mg doses, while only 
partial MDZ AUC (AUC measured between 2 – 4 hours after MDZ administration) was given. 
Therefore, study 604 was only used to validate PO ERY SS model, instead of MDZ and ERY 
DDI model. Eventually, MDZ and ERY DDI semi-PBPK model could only be validated by 
study 28 and study 603. Study 28 administered both IV and PO MDZ with placebo or 500mg PO 
EC ERY every 8 hours (q8h) for 7 days. Study 603 administered PO MDZ after various time 
course of PO SS ERY (2 days, 4 days, 7 days). Hence, PO ERY semi-PBPK model was only 
developed for ERY EC base formulation (short for “EC”) and ERY SS formulation (short for 
“SS”). Detailed PK, demographic, study design and sample analysis information for both ERY 
and MDZ were summarized in Appendices I. 
7.3.3 Saturable plasma protein binding model 
	
Parameter estimates and diagnostic plots of two models are demonstrated in Table 7.2 and 
Figure 7.5. From Table 7.2 and Figure 7.5, both the two models predict observed binding 
profiles well, with small CV% for all parameters. fuERY is then plotted against total (unbound + 
bound) ERY concentrations (Figure 7.6), to facilitate conversion between total and unbound 
concentrations. From Figure 7.6, model 1 (hyperbolic/linear model) underestimates fuERY at low 
concentrations, while model 2 (sigmoidal/linear model) perfectly characterizes entire observed 
binding profile. fuERY is around 0.5 originally, and gradually decreases to 0.28 (lowest value) at 
the total plasma concentration range of 1.5 – 6.5mg/L, and then increases back to 0.55 at around 
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27 mg/L. This is in agreement with reported fuERY of 0.27 - 0.31 in most studies (Barre et al., 
1987; Sun et al., 2010). The higher fuERY at very low concentration may because ERY can bind to 
other unknown high affinity (higher than AAG) low capacity plasma protein (globulin, 
fibrinogen, etc.) at very low concentration. As a conclusion, sigmoidal/linear model was further 
used in ERY semi-PBPK model, to transform between unbound and total ERY concentrations. 
fuERY can be estimated by equation (7.24). f&'() = 1 ( Qwexryz,odu{pz,|}d ryz,od + m + 1)                                 (7.24) 
where cb,u is unbound blood concentration of ERY (predicted value of concentration in 
systemic blood compartment in ERY semi-PBPK model). 
 
Table 7.2  Parameter estimates of two saturable plasma protein binding models. 
 
Model Parameter Estimate RSE (CV%) 
1 
  
Bmax (µM) 12.9 2.61 
Km (µM) 4.18 6.26 
M1 0.265 9.43 
2 
  
Bmax (µM) 11.1 1.84 
Km (µM) 2.92 4.06 
n 1.32 3.67 
M1  0.265 9.43 
 
1 m was fixed when estimating Bmax, Kb,50 and n. Relative standard error (RSE) of m was estimated in linear 
regression. 
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a)                                                                          b) 
  
 
Figure 7.5  Diagnostic plots of two saturable plasma protein binding models. 
a) Hyperbolic/linear model. b) Sigmoidal/linear model. Cbo-total is ERY total bound concentration, 
AAG Cbo is ERY AAG bound concentration, Cbo-ns is ERY non-specific bound concentration 
	
a)                                                                            b) 
  
 
Figure 7.6  Relationship between fuERY and total plasma ERY concentration. 
a) Hyperbolic/linear model. b) Sigmoidal/linear model. Symbols reflect observed data, and lines 
reflect predicted profiles. 
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7.3.4 Dose proportionality assessment 
	
 Due to large inter-study variability of ERY PK, dose proportionality assessment was 
performed only in SAD studies: study 611 after IV ERY and study 620 after PO EC ERY. PO SS 
ERY was administered only as 250 mg and 1000 mg single dose in study 604; thus, dose 
proportionality was not assessed in SS. Mean plasma AUC0-∞ of total (unbound + bound) ERY is 
plotted against ERY dose after 15-min IV infusion (regimen 2 in study 611) and PO EC 
administration (study 620). A power model (y = axb) was used to fit the data; an exponent value 
of 1 indicates dose-proportional PK. 95% CIs of the exponent, b, was generated by JMP Pro 9.0 
(SAS, Cary, NC) to assess if there was significant deviation from 1 (p < 0.05). Figure 7.7 
illustrates the dose-proportionality of IV and PO EC ERY. Parameter estimates for the power 
model and their 95% CIs are summarized in Table 7.3.  
 
Figure 7.7  Dose proportionality assessment after single dose IV ERY and PO EC ERY 
(total AUC versus dose). 
The dashed lines represent fits by power model, and symbols and bars represent the observed 
mean ± SD.  
	
y = 0.0253x1.0819
R² = 0.9953
y = 0.0035x1.2978
R² = 0.99994
0
10
20
30
40
50
60
70
0 200 400 600 800 1000 1200
A
U
C
0-
∞
E
R
Y
(m
g/
L
*h
r)
Dose (mg)
IV
PO
Power  (IV)
Power  (PO)
193	
	
 
Table 7.3  Summary of power model fit for total ERY plasma AUC vs dose plots. 
	
ERY Route Dose (mg) AUC0-∞
ERY 
(mg/L*hr) 
SD of  AUC0-∞ERY 
(mg/L*hr) 
Power 
coefficient 
95% CI of 
power r
2 
IV 
(Study 611) 
125 4.6 0.9 
1.08 (0.98, 1.18) 0.995 250 10.6 3 500 19.4 3.3 
900 41 23.1 
PO EC 
(Study 620) 
250 4.5 1.7 
1.30 (1.28, 1.32) 0.999 500 11.2 4.3 
1000 27.2 10.6 
  
From Figure 7.7 and Table 7.3, AUC after PO EC ERY is consistently lower than AUC 
after IV ERY at the same dose, indicating its relative low ForalERY after PO EC formulation. 
Power models fit both IV and PO EC dose-proportionality well, with r2 > 0.99 in both cases. 
Power coefficient and 95% CIs of power indicate that total (unbound + bound) ERY follows 
dose-proportional PK after IV administration and supra-proportional PK after PO EC ERY. 
However, since saturable plasma protein binding was observed within the dose range of study 
611, which could lead to infra-proportional PK of ERY, unbound ERY AUC was calculated, to 
further investigate ERY PK nonlinearities without the influence of plasma protein binding. Total 
ERY AUC was corrected by average fuERY (referred as fuERY at cmaxERY/2) at each dose, to 
generate unbound ERY AUC (AUCu), and dose proportionality was assessed again using AUCu 
and dose, demonstrated in Figure 7.8 and Table 7.4. After fuERY correction, ERY exhibites 
supra-proportional PK after both IV and PO administration, and the exponents of IV and PO 
power models are similar, with overlapped 95% CIs. 
194	
	
 
 
Figure 7.8. Figure 7.8  Dose proportionality assessment after single dose IV ERY and PO 
EC ERY (unbound AUC versus dose). 
The dashed lines represent fits by power models, and symbols represent the observed values. 
	
	
	
Table 7.4  Parameter estimates of power model fit using unbound ERY concentrations. 
	
ERY 
Route  Dose (mg) 
Total plasma 
AUC0-∞ERY 
(mg/L*hr) 
Average 
fuERY 
Unbound plasma 
AUC0-∞,uERY 
(mg/L*hr) 
Power 
coefficient 
95% CI of 
power r
2 
IV 
(Study 
611) 
125 4.6 0.29 1.3 
1.30 (1.13, 1.48) 0.992 250 10.6 0.29 3.1 500 19.4 0.35 6.8 
900 41 0.45 18.4 
PO 
(Study 
611) 
250 4.5 0.32 1.4 
1.23 (1.19, 1.26) 0.999 500 11.2 0.3 3.4 
1000 27.2 0.29 7.9 
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 In study 611, central compartment volume of distribution (Vdcc), steady-state volume of 
distribution (Vdss), total clearance (CLtot,pERY) and renal clearance (CLrenERY) were also provided, 
and non-renal clearance (CLnonren,pERY) could be calculated by subtracting CLrenERY from 
CLtot,pERY. All the volumes and clearances were corrected by average fuERY (referred as fuERY at 
cmaxERY/2), as shown in Table 7.5. Before fuERY correction, Vdcc and Vdss tend to increase with 
dose, while after converted to unbound volumes (Vdcc,u and Vdss,u), no obvious trend is found 
regarding the two volumes, confirming the existence of saturable plasma protein binding in study 
611. After fuERY correction on the three clearances, unbound renal clearance (CLren,uERY) 
increases with dose, indicating potential saturable tubular reabsorption. Meanwhile, both 
unbound total plasma clearance (CLtot,uERY) and unbound non-renal clearance (CLnonren,uERY) 
decrease with dose, suggesting the existence of saturable N-demethylation by CYP3A and/or 
saturable biliary excretion. Due to the high Km,hep-3AERY (64.6mg/L) reported by Riley et al. 
(Riley & Howbrook, 1998), CYP3A metabolism of ERY is not likely to be saturable within the 
concentrations in study 611, and saturable biliary excretion is the only plausible explanation of 
supra-proportional PK after IV ERY. There are no publications reported the contribution of 
CYP3A metabolism and biliary excretion to the total hepatic clearance of ERY. However, biliary 
excretion of ERY had been studied following parenteral administration in 23 patients, including 
9 patients underwent duodenoscopy, who were administered 300 mg IV ERY, 4 patients with 
partial or complete obstruction of bile ducts, who were given 300 mg IV ERY, and 10 patients 
underwent cholangiopancreatography, who were administered 100mg intramuscular (IM) ERY 
(Chelvan et al., 1979). It was found that mean bile levels of ERY were approximately ten times 
higher than corresponding serum concentration 1 hour after IV and IM injection, implying 
potential high accumulation of ERY in bile after IV administration. In addition, Rivory et al. 
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(Rivory et al., 2001) integrated 14CO2 flux as a function of time to infinity in an erythromycin 
breath test (EBT), in which 3-4 µCi of [14C] ERY was administered after IV injection. The 
authors mentioned that the integration of 14CO2 flux actually produces an estimate of the fraction 
of ERY that is metabolized by CYP3A, and was only 6-33%, according to their result, implying 
that only up to 1/3 of ERY is metabolized by CYP3A. This proves that biliary excretion may 
play a key role in hepatic clearance of ERY after IV administration, and it is highly likely that 
biliary excretion was saturated across the dose ranges in study 611 and study 620. As a P-gp and 
OATP1A4 (in rat) substrate, saturation of either of them could result in decreased CLnonren,uERY 
with dose. In rat hepatocytes, Km of OATP1A4 is 53mg/L (no human study available), higher 
than clinical relevant levels, so OATP1A4 is not likely to cause saturation of biliary excretion in 
human, and P-gp-mediated biliary excretion is the most likely source of supra-proportional PK of 
unbound ERY after IV administration. 
Table 7.5  Unbound PK parameters of IV ERY in study 611. 
	
Dose Average fuERY 
Vdcc,uERY Vdss,uERY CLtot,p,uERY CLren,uERY CLnonren,uERY 
mg ml/kg ml/kg ml/min/kg ml/min/kg ml/min/kg 
125 0.29 506 1620 23.0 1.2 21.8 
250 0.29 907 1970 23.5 1.1 22.4 
500 0.35 787 2870 17.2 1.8 15.4 
900 0.45 994 2434 13.9 2.3 11.6 
 
 For nonlinear PK drug, Foral cannot be easily estimated as dose-corrected AUC ratio. Instead, 
ERY Foral was roughly estimated by ratio of the corresponding IV and PO doses that produce the 
same unbound AUC, assuming that same drug exposure results in the same extent of 
nonlinearity. The method was illustrated in Figure 7.9. Since AUCu after 125 mg IV ERY (in 
study 611) and AUCu after 250 mg PO EC ERY (in study 620) were almost the same, ForalERY at 
250 mg PO EC ERY can be estimated as 125mg/250mg = 50%. Likewise, AUCu after 250 mg 
IV ERY (in study 611) and AUCu after 500 mg PO EC ERY (in study 620) were almost the 
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same, thus ForalERY at 500 mg PO EC ERY can be estimated as 250mg/500mg = 50%. AUCu after 
492 mg IV ERY (in study 611) and AUCu after 1000 mg PO EC ERY (in study 620) were almost 
the same, thus ForalERY at 1000 mg PO EC ERY can be estimated as 492mg/1000mg = 49%. As a 
result, ForalERY at different doses were almost constant in study 620, indicating that supra-
proportional PK after PO administration is more likely owing to systemic saturable 
metabolism/biliary excretion. 
 
Figure 7.9  Estimation of ForalERY at different ERY dose. 
ForalERY was calculated by ratio of the corresponding IV and PO doses, that produce the same 
unbound AUC (dose indicated by the same colors). A power model fit was performed on IV 
AUC0-∞,uERY versus dose data, and IV dose that could produce the same AUCu as 1000mg PO 
ERY was calculated based on power model (AUCu = 0.0023•DoseIV1.3048), which was estimated 
to be 492 mg. 
 
 Overall, after IV ERY, there are four partially offsetting sources of nonlinearities involved in 
the systemic disposition of ERY across clinical dose range: saturable plasma protein binding and 
saturable renal tubular reabsorption result in infra-proportional PK; saturable biliary excretion 
and potential saturable CYP3A metabolism (higher than clinical dose) result in supra-
proportional PK. The apparent dose-proportionality of total AUC and slight supra-
proportionality of unbound AUC reflect the overall net effects of the four sources. After PO 
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administration, ForalERY is almost constant with dose, indicating that supra-proportional PK after 
PO administration is more likely owing to systemic saturable metabolism/biliary excretion. 
7.3.5 ERY semi-PBPK model after single IV administration 
	
7.3.5.1 Predictive performance check 
	
 After optimization of vmax,hep-3AERY, vmax,bileERY and Km,bileERY, the observed and model-
predicted ERY PK profiles after IV administration are demonstrated in Figure 7.10 and the 
comparison of observed and model simulated exposure metrics are summarized in Table 7.6. 
From Figure 7.10a-b, the current parameters predict IV ERY PK profiles across doses (regimen 
2 of study 611) well, with all predicted profiles superimposable with observed data, except at the 
low dose (125 mg and 250 mg), terminal slopes of predicted profiles appear to be shallower than 
observed. However, after repeated “try and error” processes to tweak vmax,hep-3AERY, vmax,bileERY 
and Km,bileERY, a perfect description across doses cannot be obtained. Also, external validation by 
study 616 (125 mg IV ERY, Figure 7.10e-f) and study 624 (240 mg IV ERY, Figure 7.10g-h) 
demonstrated perfect match between observed and predicted data, confirming the validity of IV 
ERY PBPK model at low doses. In studies 612 and 613, although some discrepancies were 
demonstrated between predicted and observed profiles (Figure 7.10i-l), simulation results can be 
easily improved by adjusting systemic distribution parameters (i.e., VB,uERY and/or VP,uERY) in 
study 612 and hepatic clearance parameters (i.e., vmax,hep-3AERYand/or vmax,bileERY) in study 613, 
explained as inter-study variability. Deviations (%) of AUC0-∞ERY and various clearances are 
mostly less than 50%, except for feERY at 250 mg IV ERY and AUC of study 612. There is a 
huge discrepancy between reported feERY and CLren,pERY of 250mg ERY over 15min IV infusion 
(regimen 2) and over 3min IV infusion (regimen 1), indicating large inter-individual variability 
on feERY and CLren,pERY. The current model balances predictive deviations of CLren,pERY for the 
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two regimens in study 611, with predicted CLren,pERY overestimates observed value in regimen 2 
by 48%, and underestimates observed in regimen 1 by 50%. Even at the highest dose (900 – 1344 
mg ERY), only a slight plateau could be observed before terminal decline on semi-log plots 
(Figure 7.10b, l), probably because at high doses, CYP3A N-demethylation pathway becomes 
the predominant elimination pathway, which is not easy to saturate at clinical relevant 
concentrations. This occurs quite often clinically, when a drug has parallel elimination pathways.  
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c)         d) 
  
e)                                                                         f) 
  
g)                                                                         h) 
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i)  j) 
  
k)  l) 
  
Figure 7.10  Observed and model-predicted ERY PK profiles after IV administration. 
a-b) PK profiles after 125 mg, 250 mg, 500 mg or 900 mg IV ERY over 15 min infusion 
(regimen 2) in study 611 (Cartesian and semi-log plots) c-d) PK profiles after 250 mg IV ERY 
over 3 min infusion (regimen 1) in study 611 (Cartesian and semi-log plots) e-f) PK profiles after 
125 mg IV ERY over 30 min infusion in study 616 (Cartesian and semi-log plots) g-h) PK 
profiles after 240 mg IV ERY over 30 min infusion in study 624 (Cartesian and semi-log plots) i-
j) PK profiles after 500 mg IV ERY over 30 min infusion in study 612 (Cartesian and semi-log 
plots). Both unbound and total ERY plasma concentrations were reported.  k-l) PK profiles after 
2g ERY lactobionate (equivalent to 1344 mg IV ERY base) over 1-hour infusion in study 613 
(Cartesian and semi-log plots). The solid lines are predicted PK profiles. The symbols and bars 
are observed means and SD values (if available).  
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Table 7.6  Comparison of reported and PBPK model-predicted ERY plasma exposure 
metrics and clearances. 
Deviations greater than 50% were marked as bold. 
 
Study 
ID Dose (mg) 
Time of 
infusion 
(min) 
Deviation (%) 
AUC0-∞ERY CLtot,pERY(ml/min/kg) feERY CLren,pERY(ml/min/kg) 
CLnonren,pERY 
(ml/min/kg) 
611 125 (R2) 15 15% -13% 3% -10% -13% 
611 250 (R2) 15 15% -13% 70% 48% -16% 
611 500 (R2) 15 21% -17% 11% -9% -18% 
611 900 (R2) 15 -4% 4% -13% -9% 7% 
611 250 (R1) 3 38% -27% -31% -50% -24% 
616 125 30 38%     
624 240 30 -4%     
612 500 30 59%     
613 1344 60 -14%     
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Observed and model predicted total (unbound + bound) ERY clearances in study 611 
(regimen 2) are plotted against IV ERY dose (Figure 7.11). Although some discrepancies are 
demonstrated between predicted and observed clearances, the overall trends in all the three 
clearances are characterized well by the model, and residuals across doses are balanced around 0.  
 
Figure 7.11  Model-predicted and observed total (unbound + bound) ERY clearances 
versus dose. 
	
 Overall, predictive performance checks using exposure metrics in several clinical studies and 
using clearances in study 611 suggest that the semi-PBPK model for IV ERY predicts the 
observed data well, confirming the validity of this model and model parameters.  
  
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
0 200 400 600 800 1000
C
L
 (m
l/m
in
/k
g)
Dose (mg)
Observed CLtot,pERY
Observed CLren,pERY
Observed CLnonren,pERY
Predicted CLtot,pERY
Predicted CLren,pERY
Predicted CLnonren,pERY
205	
	
 
7.3.5.2 Model Predictions 
	
 Model predicted ERY unbound hepatic concentrations after various IV single dose relative to 
Km,bileERY, Km,hep-3AERY and KIERY are plotted in Figure 7.12a-b. It is clearly demonstrated in 
Figure 7.12b that biliary excretion of ERY is saturated even under the lowest dose, with chep,uERY 
above Km,bileERY for 1 hour, and at the highest dose (900 mg), it is saturated up to 7 hours. 
However, CYP3A metabolism is not saturated across doses, with chep,uERY less than Km,hep-3AERY 
throughout the entire profiles (Km,hep-3AERY was not marked in Figure 7.12a). MBI of CYP3A is 
also minor, as even cmax,hep,uERY at 900 mg dose is still less than half of KIERY (KIERY was not 
marked in Figure 7.12a). To compare hepatic concentration – time profiles across doses, low 
doses (125 mg and 250 mg) demonstrate apparently linear terminal phase, while high doses (500 
mg and 900 mg) show a plateau before linear decline, confirming the existence of saturation in 
hepatic clearance. IV ERY GW (serosa) concentrations were not plotted, because it is assumed 
that only ERY in GW mucosa can inhibit GW CYP3A metabolism of MDZ (details discussed in 
Chapter 8). 
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a)    
 
 
b) 
 
 
Figure 7.12  Model-predicted unbound hepatic ERY concentrations after various IV dose 
over 15-min infusion relative to Km,bileERY, Km,hep-3AERY and KIERY on Cartesian and semi-
log scales. 
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 Furthermore, model-predicted contribution of different elimination pathways (fraction 
relative to total clearance for unbound ERY) are plotted against IV ERY dose in Figure 7.13. 
After IV ERY, hepatic clearance is the predominant elimination pathway across doses, although 
its contribution decreases a bit, from 0.94 to 0.85, with increasing ERY dose from 125 mg to 900 
mg. Predicted feERY agrees well with observed feERY, showing an increasing trend with dose. 
Hepatic clearance consists of CYP3A metabolism and biliary excretion, the contribution of 
which relative to total clearance represent as fhep-3AERY and fhep-bileERY. Since ERY biliary 
excretion is a high affinity (Km,bileERY = 0.1 µg/ml) and low capacity (vmax,bileERY = 10 µg/min/kg) 
pathway, its contribution significantly reduces with dose (fhep-bileERY at 125 mg and 900 mg ERY 
dose are 0.68 and 0.33, respectively), due to its saturation at higher ERY doses. However, 
CYP3A metabolism is a low affinity (Km,hep-3AERY = 64.6 µg/ml) but high capacity pathway 
(vmax,hep-3AERY = 900 µg/min/kg), which is not saturated even at the highest dose, so that more 
drugs shift to CYP3A pathway to get eliminated, and its contribution almost doubles (from 0.27 
to 0.52) with increasing dose. From Figure 7.13., an obvious elimination shift is observed from 
biliary excretion to CYP3A metabolism, and when ERY IV dose is about 500 mg, the two 
parallel hepatic elimination pathways contribute almost the same to ERY’s total clearance after 
IV administration (~0.43 for each pathway). Although biliary excretion is saturated to a large 
extent at the highest dose, total fhepERY only decreases slightly, due to the increase contribution of 
CYP3A metabolism. 
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Figure 7.13  Model predicted contribution of different elimination pathways after various 
IV ERY dose in study 611. 
	
	
 Intrinsic clearance of biliary excretion and hepatic CYP3A metabolism vs. time were 
simulated by the model, as showed in Figure 7.14a-b. Without any saturation or inactivation, 
CLint,bileERY is ~7-fold of CLint,hep-3AERY, in consistent with the predominant contribution of biliary 
excretion to overall clearance at the lowest dose (Figure 7.13). Since Km,bileERY is as low as 0.1 
µg/ml, CLint,bileERY drastically decreases to around 0 - 10ml/min/kg, due to saturation, yet quickly 
recovers back to baseline within 10 hours, given the short pseudo steady-state t1/2 of ERY. With 
respect to CLint,hep-3AERY, it drops slightly at the beginning, followed by an extended decrease 
lasting for more than 10 hours. The initial drop is primarily due to marginal saturation of CYP3A 
enzyme, while the prolonged suppression of CLint,hep-3AERY is actually attibuted to auto-inhibition 
by ERY. Since only single ERY dose is administered, the effect of auto-inhibition is not 
substantial, but the 900 mg dose still produced ~ 40% sustained inhibition on CYP3A level. The 
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impact of CYP3A auto-inhibition will be discussed in detail in sections 7.3.5 and 7.3.6. 
Additionally, unbound ERY hepatic extraction ratio (ERhep,uERY) vs. time was calculated by its 
physiological definition: (inflow concentration – outflow concentration) / inflow concentration, 
shown in equation 7.25. 
ERVWS,&'() = [ÅÇÉ∙`Ñ,ohijr(9<ÅÇÉ)∙`ÖÜ,ohij ]<`lmn,ohij /pn,lmn,ohijÅÇÉ∙`Ñ,ohijr(9<ÅÇÉ)∙`ÖÜ,ohij                             (7.25) 
 As presented in Figure 7.14c, even in presence of saturation and auto-inhibition, ERhep,uERY 
is still relatively high across doses (mostly > 0.7), which is in consistent with literature that 
CLhep,uERY is similar to hepatic blood flow (98.6 L/hr) (Barre et al., 1987), indicating its high 
hepatic extraction ratio as unbound drug. For all the four doses, ERhep,uERY – time profiles 
demonstrate similar patterns, with ERhep,uERY rapidly decreases to different levels due to various 
extent of saturation, and then quickly recovers. However, ERhep,uERY cannot get back to baseline 
level (ERhep,uERY =1) within 10 hours, because of the maintained CYP3A auto-inhibition. 
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a)                                                                         b) 
  
 
c) 
 
 
Figure 7.14  Time course of intrinsic hepatic clearances and hepatic extraction ratio at 
different doses in study 611. 
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7.3.6 ERY semi-PBPK model after single/repeat- PO doses (ERY base enteric-coated 
tablet formulation) 
7.3.6.1 Predictive performance check 
	
 In PO ERY semi-PBPK model, all the parameters were originally assumed to be the same as 
IV model. However, the predicted ERY concentrations were consistently lower than observed 
levels from study 20 (Figure 7.15), and the observed terminal slopes were apparently over-
estimated, especially at 1000 mg dose. Since ERY was only administered orally in study 620, 
and no IV ERY information available in this study, vmax,hep-3AERY and vmax,bileERY were re-
optimized based on visual inspection of predictive performance after both single and repeat- PO 
EC doses across studies, and vmax,hep-3AERY and vmax,bileERY were finally adjusted to be 800 
µg/min/kg and 0.5 µg/min/kg, respectively. vmax,hep-3AERY is very close to vmax,hep-3AERY after IV 
ERY, while vmax,bileERY after PO EC ERY is 1/20 of the value used in IV ERY model. Schuetz et 
al. (1995) have determined the variation of P-gp protein in 41 human livers (only 10 of them 
were from normal adults) by Western blot. They didn’t specify the overall P-gp protein variation 
in normal human livers, but stated that variation of P-gp was 4.5-fold in 6 normal males, and 7.8-
fold in 4 normal females. Given the large variations of P-gp expression in very limited number of 
subjects, it is possible to presume a 20-fold difference in P-gp expression in two different studies, 
with varied subject demographics (i.e., age and gender).   
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a) 
 
 
b) 
 
 
Figure 7.15  Observed and model-predicted ERY PK profiles after PO EC administration 
in study 620 (Cartesian and semi-log scales). 
The solid lines are predicted PK profiles. The symbols and bars are observed means and SD 
values (if available). All parameters in PO EC ERY model were used the same values as IV ERY 
model. 
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 After changing vmax,hep-3AERY and vmax,bileERY, the adjusted PBPK model was used to predict 
PO EC ERY PK profiles after both single and multiple doses in studies 620, 623, 626 and 629. 
To demonstrate the importance of incorporating auto-inhibition of GW and hepatic CYP3A by 
ERY, predicted PK profiles in absence/presence of ERY auto-inhibition are both showed in 
Figure 16a-d, and exposure metrics are summarized in Table 7.7 and Table 7.8. From Figure 
16 and Table 7.8, PBPK model without auto-inhibition (“No MBI” model) slightly under-
estimates ERY concentrations after single dose in study 620, and significantly underestimates 
ERY concentrations after repeat- doses, with predicted accumulation ratio at the last 
administered dose (Rlast) for all three repeat- doses studies less than half of observed. After 
including auto- inhibition (“MBI” model), the PBPK model predictes ERY PK profiles 
reasonably well after both single- and repeat- doses, with deviations of AUCERY and cmaxERY, as 
well as accumulation ratio of AUCERY and cmaxERY, all less than 2-fold (ranged from -50% to 
100%) of observed, except for study 629 (shown in Table 7.7).  
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c) 
 
 
d) 
 
Figure 7.16  Observed and model-predicted ERY PK profiles after PO EC administration. 
a-b) PK profiles after 250 mg, 500 mg or 1000 mg single PO EC ERY in study 620 (Cartesian 
and semi-log plots) c-d) PK profiles after PO EC ERY 250 mg q6h for 17 doses (study 623), or 5 
doses (study 626), or 10 doses (study 629) (Cartesian and semi-log plots).  The solid lines are 
predicted PK profiles using PBPK model with auto-inhibition. The dash lines are predicted PK 
profiles using PBPK model without auto-inhibition (No MBI). The symbols and bars are 
observed means and SD values (if available).  
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 For study 629, “MBI” model significantly over-estimates ERY PK profiles after both single 
and repeat- doses. Due to the large variation of systemic exposure for EC formulation (see 
section 7.3.1), FabsERY (EC) was changed from 0.88 to 0.50 in study 629, which is within the 3.8-
fold inter-study variability of PO ERY EC systemic exposure. After adjusting FabsERY (EC) 
(Figure 7.17), the adjusted PBPK (“MBI”) model adequately captures PK profile of ERY in 
study 629 after the first two doses and the last dose, although some discrepancy in tmax is found, 
which can be easily improved by tweaking kGLERY further. The current model under-estimates 
ERY concentrations after the 9th dose, and observed data actually showed higher ERY levels 
after the 9th dose than the 10th dose, which cannot be reasonably explained. Since no discussion 
regarding this was provided in the literature, this phenomenon is considered as an artefact due to 
study error, and is ignored in visual predictive check. Deviations of AUCERY and cmaxERY, as well 
as accumulation ratio of AUCERY and cmaxERY, are also less than 2-fold of observed in study 629 
after adjustment. All adjusted parameter values are presented in Table 7.9.  
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a) 
 
b) 
 
 
Figure 7.17  Observed and model-predicted ERY PK profiles after PO EC administration 
in study 629 (Cartesian and semi-log plots). 
The black solid line represents predicted PK profile using original FabsERY (EC) (FabsERY = 0.88). 
The yellow solid line represents predicted PK profile using adjusted FabsERY (EC) (FabsERY = 0.50). 
The yellow dash line represents predicted PK profile using adjusted FabsERY (EC) (FabsERY = 0.50) 
by “No MBI” model. The symbols and bars are observed means and SD values (if available).  
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Table 7.7  Comparison of reported and semi-PBPK (“MBI”) model-predicted PO EC ERY plasma exposure metrics and accumulation 
ratios using PO ERY model (study 620, 623, 626) and adjusted model (study 629) parameters. 
Deviations greater than 2-fold were marked as bold. (vmax,hep-3AERY = 800 µg/min/kg; vmax,bileERY = 0.5 µg/min/kg) 
 
Study 
ID Formulation 
Dosing 
Regimen 
Observed 
1AUCERY 
(mg/L•hr) 
Observed 
cmaxERY 
(mg/L) 
Observed 
Rlast 
(AUC0-τ) 
Observed 
Rlast 
(cmax) 
Predicted 
1AUCERY 
(mg/L•hr) 
Predicted 
cmaxERY 
(mg/L) 
Predicted 
Rlast 
(AUC0-τ) 
Predicted 
Rlast 
(cmax) 
Deviation 
AUCERY 
(%) 
Deviation 
cmaxERY 
(%) 
Deviation 
Rlast 
(AUC0-τ, %) 
Deviation 
Rlast 
(cmax, %) 
620 Capsules of EC pellets 250mg SD 4.43 1.72   3.79 1.20   -14% -30%   
620 Capsules of EC pellets 500mg SD 11.24 3.47   9.88 2.86   -12% -18%   
620 Capsules of EC pellets 1000mg SD 26.88 6.31   29.19 6.55   9% 4%   
623 Capsules of EC pellets 250mg SD 3.80 1.74 2.84 1.65 3.16 1.20 3.54 2.62 -17% -31% 25% 59% 
623 Capsules of EC pellets 
250mg q6h for 
17 doses 10.80 2.87   11.19 3.15   4% 10%   
626 Capsules of EC pellets 250mg SD 3.02 0.98 2.62 3.09 3.16 1.20 2.38 1.94 5% 23% -9% -37% 
626 Capsules of EC pellets 
250mg q6h for 
5 doses 7.92 3.03   7.51 2.33   -5% -23%   
629 EC pellets 250mg SD 1.23 0.40 2.52 2.30 3.16 1.20 3.26 2.47 157% 200% 29% 7% 
629 EC pellets 250mg q6h for 10 doses 3.45 0.92   10.30 2.97   199% 222%   
629 EC pellets 250mg SD (Adjust FabsERY) 
1.23 0.40 2.52 2.30 1.53 0.59 2.02 1.72 24% 48% -20% -25% 
629 EC pellets 
250mg q6h for 
10 doses 
(Adjust FabsERY) 
3.45 0.92   3.09 1.02   -10% 11%   
 
1 For Study 620, AUC0-∞ERY was summarized; for other studies, AUC0-τERY was summarized. 
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Table 7.8  Comparison of reported and semi-PBPK (“MBI” or “No MBI”) model-predicted 
accumulation ratio of AUC0-τ after PO ERY EC or SS formulation. 
	
Study 
ID Formulation Dosing Regimen 
Observed 
Rlast  
Predicted 
Rlast (MBI) 
Predicted Rlast 
(No MBI) 
Deviation 
Rlast (MBI) 
Deviation Rlast 
(No MBI) 
(AUC0-τ) (AUC0-τ) (AUC0-τ) (AUC0-τ, %) (AUC0-τ, %) 
623 Capsules of EC pellets 250mg q6h for 17 doses 2.84 3.54 1.26 25% -56% 
626 Capsules of EC pellets 250mg q6h for 5 doses 2.62 2.38 1.26 -9% -52% 
629 EC pellets 250mg q6h for 10 doses 2.52 3.26 1.26 29% -50% 
629 EC pellets 250mg q6h for 10 doses (Adjust FabsERY) 
2.52 2.02 1.26 -20% -50% 
615 SS capsules 250mg q6h for 5 doses 2.76 1.93 1.3 -30% -53% 
626 SS capsules 250mg q6h for 5 doses 3.75 1.93 1.3 -48% -65% 
627 SS film-coated tablet 250mg q6h for 9 doses 2.86 2.28 1.3 -20% -55% 
625 SS  1000mg q12h for 7 doses 0.96 3.15 1.03 230% 8% 
 
Table 7.9  Adjusted semi-PBPK ERY model parameters. 
 
Parameter Definition Value Source 
vmax,hep-3AERY 
(µg/min/kg) Capacity of hepatic CYP3A to metabolize ERY 800 
Value used in PO ERY PBPK model 
optimized by PO EC and SS clinical studies 
vmax,bileERY 
(µg/min/kg) Capacity of ERY biliary excretion 0.50 
Value used in PO ERY PBPK model 
optimized by PO EC and SS clinical studies 
FabsERY (EC) Fraction of ERY EC absorbed from gut lumen 0.50 
Value used in study 629, based on visual 
predictive check. 
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7.3.6.2 Model Predictions 
	
 Model predicted ForalERY, FabsERY, FhepERY and FGIERY are plotted against PO EC ERY dose in 
Figure 7.18. FabsERY (EC) was set as 0.88, and unchanged with dose. To calculate ForalERY, 
unbound blood AUC after 125 mg, 250 mg, 500 mg and 1000 mg IV ERY and PO EC ERY 
were simulated using IV and PO EC ERY semi-PBPK model, respectively. vmax,hep-3AERY and 
vmax,bileERY in IV ERY model were also set at 800 and 0.5 µg/min/kg, to avoid the influence of 
different hepatic clearance on systemic exposure. ForalERY was roughly estimated by the method 
introduced in section 7.3.3, in which the corresponding IV dose that produces the same AUC0-
∞,u
ERY as 125 mg/250 mg/500 mg/1000 mg PO EC ERY (DoseIVERY) was predicted using a 
power model that could capture dose proportionality of IV ERY AUC0-∞,uERY vs. DoseIVERY 
(AUC0-∞,uERY = 0.0108•(DoseIVERY)1.0919). DoseIVERY was then divided by the corresponding PO 
EC ERY dose (125mg, 250 mg, 500 mg or 1000 mg) to come up with ForalERY estimation. 
Afterwards, ERGIERY was estimated by calculating the ratio of dose of ERY metabolized by GW 
metabolism (predicted by semi-PBPK model) and dose of ERY absorbed into GW (calculated by 
FabsERY•DosePOERY). FGIERY and FhepERY at each ERY dose were then derived by methods used in 
Chapter 3, section 3.2.3.1. From Figure 7.18, ForalERY, FGIERY and FhepERY are all increased with 
PO EC ERY dose. Since ERGIERY is very low, FGIERY only slightly increases with ERY dose (93% 
at 125 mg and 97% at 1000mg), primarily caused by MBI on GW CYP3A. EC ERY has low-to-
intermediate ERhepERY across doses, and its value at 1000 mg (27%) almost drops to half of that 
at 125 mg (49%), resulting in a 50% increase in FhepERY at the highest simulated dose compared 
to the lowest dose (51% at 125 mg vs. 73% at 1000 mg). This is due to saturable biliary 
excretion and MBI on hepatic CYP3A at the highest simulated dose. ForalERY is the multiplication 
of FabsERY, FGIERY and FhepERY, and as only a slight change with dose for FGIERY and constant with 
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dose for FabsERY are observed, ForalERY dose-dependency almost mimics FhepERY dose-dependency, 
with a 50% increase at 1000 mg (62%) from 125 mg dose (41%). Our estimated ForalERY across 
doses are higher than literature reported values (18%-45% (Somogyi et al., 1995)), probably 
because ForalERY reported in literature was calculated by the traditional method, which is to take 
the ratio of total ERY (unbound + bound) AUC0-∞ERY after PO and IV administration, corrected 
by corresponding dose, assuming ERY follows linear PK. Given several nonlinear sources of 
ERY PK after both IV and PO administration, it is not feasible to use traditional method to 
estimate ForalERY, and the ForalERY we estimated (assuming same unbound AUC value produces 
the same extent of nonlinearity) is specifically for unbound ERY. Due to higher unbound plasma 
concentration after IV than the same dose of PO ERY, a larger fraction unbound is expected after 
IV ERY, therefore, ForalERY for total ERY is expected to be smaller than unbound ForalERY. 
 
Figure 7.18  Model - predicted ForalERY and different contribution of ForalERY (FabsERY, 
FhepERY and FGIERY) versus PO EC ERY dose (125 mg, 250 mg, 500 mg, 1000 mg). 
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 Model predicted ERY unbound hepatic and GW mucosa concentrations after various PO EC 
single dose relative to Km,bileERY, Km,hep-3AERY (Km,GW-3AERY) and KIERY are plotted in Figure 
7.19a-d. It is clearly demonstrated in Figure 7.19a-b that biliary excretion of ERY is saturated 
even at the lowest dose, with chep,uERY above Km,bileERY for ~2 hours, and at the highest dose 
(1000 mg), it is saturated more than 10 hours. However, CYP3A metabolism is not saturated 
across doses, with chep,uERY less than Km,hep-3AERY throughout the entire profiles. MBI of CYP3A 
is also minor, as even cmax,hep,uERY at 1000 mg dose is only 1/3 of KIERY. To compare hepatic 
concentration – time profiles across doses, terminal phases after all single doses appear to be 
linear and parallel with each other, probably because saturation of biliary excretion mostly 
occurs before pseudo steady-state, which is difficult to tell from absorption/distribution phases. 
With respect to GW mucosa concentrations, cmax,GW-M,uERY at 1000 mg dose exceeds KIERY for 
~0.5 hour, while GW CYP3A metabolism is also not saturated across doses, with cGW-M,uERY less 
than Km,GW-3AERY (assumed to be the same as Km,GW-3AERY) throughout the entire profiles. To 
compare GW mucosa concentration – time profiles across doses, terminal phase after all single 
doses appear to be linear and parallel with each other, and decline much faster than hepatic 
unbound concentrations. This is because in our semi-PBPK model, PO ERY can only be 
unidirectional carried from GW mucosa to GW serosa, so that drug cannot enter GW mucosa via 
vascular blood stream (systemically). Therefore, no pseudo steady-state is reached between 
plasma and GW mucosa, and the terminal phase of GW mucosa concentration is determined by 
kGLERY (0.06 min-1), which is much larger than the derived ke (0.006 min-1) from ~2 hours-
plasma t1/2. GW mucosa concentrations peak higher and earlier than hepatic concentrations, 
owing to different inflow and outflow rate of drug transfer in the two tissues. Full simulations of 
dose-dependent MBI on hepatic and GW CYP3A levels by PO EC ERY will be presented and 
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discussed in Chapter 8. 
a)                                                                          b) 
  
c)                                                                        d) 
  
Figure 7.19  Model-predicted unbound ERY concentrations in liver and GW mucosa after 
125mg, 250mg, 500mg, 1000mg single PO EC ERY dose relative to Km,bileERY, Km,hep-3AERY 
(Km,GW-3AERY) and KIERY. 
a-b) Unbound ERY hepatic concentration – time profiles (Cartesian and semi-log plots) relative 
to Km,bileERY, Km,hep-3AERY and KIERY. c-d) Unbound ERY GW mucosa concentration – time 
profiles (Cartesian and semi-log plots) relative to Km,GW-3AERY and KIERY. 
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7.3.7 ERY semi-PBPK model after single/repeat- PO doses (ERY stearate salt tablet 
formulation) 
7.3.7.1 Predictive performance check 
 The same vmax,hep-3AERY (800 µg/min/kg) and vmax,bileERY (0.5 µg/min/kg) as PO EC ERY 
model were used in semi-PBPK model for PO SS ERY, to predict its PK profiles after both 
single- and repeat- doses in studies 604, 615, 626, 627 and 625. PO SS ERY was administered as 
250 mg q6h in study 615, 626 and 627, and in study 625, 1000 mg PO SS ERY was given q12h. 
To demonstrate the importance of incorporating auto-inhibition of GW and hepatic CYP3A by 
ERY, predicted PK profiles in absence/presence ERY auto-inhibition are both showed in Figure 
7.20a-f, and exposure metrics are summarized in Table 7.8 and Table 7.10. From Figure 7.20 
and Table 7.8, PBPK model without auto-inhibition (“No MBI” model) slightly under-estimates 
ERY concentrations after single dose in study 604, and significantly underestimates ERY 
concentrations after multiple doses, with predicted accumulation ratio at the last administration 
dose (Rlast) for all four multiple doses studies less than half of observed, except for study 625. 
After including CYP3A auto-inhibition (“MBI” model), the PBPK model predictes ERY PK 
profiles reasonably well after both single and repeat- doses, with deviations of AUCERY and 
cmaxERY, as well as accumulation ratio of AUCERY and cmaxERY, all less than 2-fold (ranged from -
50% to 100%) of observed, except for deviation (%) of repeated dose cmaxERY in study 627 and 
Rlast in study 629 (shown in Table 7.10). In study 604, predicted PK profiles after single 250 mg 
and 1000 mg SS ERY didn’t match with observed perfectly, but given large SD of observed data 
(not a crossover study), the predicted profiles well-capture the terminal phase and balance the 
absorption delay of the two doses (observed profile after 250 mg demonstrated a delay in rising 
phase, while profiles after 1000 mg didn’t), with deviation of exposure metrics and accumulation 
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within predefined requirement. For study 627, cmaxERY after multiple is largely under-estimated, 
however, since cmaxERY after single dose is also under-estimated (to a less extent) and there were 
large SDs of observed data, the model predictions are still considered acceptable. Regarding 
study 625, no accumulation was demonstrated from observed profiles, while MBI model 
predictes a 2-fold accumulation ratio in AUC. For this study, “No MBI” model actually provides 
better estimation of observed accumulation ratios. This could be explained as ERY in this study 
has higher KIERY or lower kinactERY (KIERY ranged from 1-80 mg/L in-vitro, but used as 30 mg/L 
in the model; kinactERY ranged from 0.017 – 0.066 min-1 in-vitro, but used as 0.0375 min-1 in the 
model) and/or shorter kdeg (kdeg ranged from 8×10-5 and 1.15×10-3 min-1 in-vitro, but used as 
8×10-3 min-1 in the model) than other studies.  
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c) 
 
 
d) 
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e) 
 
f) 
 
Figure 7.20  Observed and model-predicted ERY PK profiles after PO SS administration. 
a-b) PK profiles after 250 mg or 1000 mg single PO SS ERY in study 604 (Cartesian and semi-
log plots) c-d) PK profiles after PO SS ERY 250 mg q6h for 5 doses (study 615 and 626), or 9 
doses (study 627) (Cartesian and semi-log plots). e-f) PK profiles after PO SS ERY 1000 mg 
q12h for 7 doses (study 625) (Cartesian and semi-log plots). The solid lines are predicted PK 
profiles using PBPK model with auto-inhibition. The dash lines are predicted PK profiles using 
PBPK model without auto-inhibition (No MBI). The symbols and bars are observed means and 
SD values (if available).  
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Table 7.10  Comparison of reported and semi-PBPK (“MBI”) model-predicted PO SS ERY plasma exposure metrics and 
accumulation ratios using PO ERY model parameters. 
Deviations greater than 2-fold were marked as bold. (vmax,hep-3AERY = 800 µg/min/kg; vmax,bileERY = 0.5 µg/min/kg) 
 
Study 
ID Formulation 
Dosing 
Regimen 
Observed 
*AUCERY 
(mg/L•hr) 
Observed 
cmaxERY 
(mg/L) 
Observed 
Rlast 
(AUC0-τ) 
Observed 
Rlast  
(cmax) 
Predicted 
*AUCERY 
(mg/L•hr) 
Predicted 
cmaxERY 
(mg/L) 
Predicted 
Rlast 
(AUC0-τ) 
Predicted 
Rlast (cmax) 
Deviation 
AUCERY 
(%) 
Deviation 
cmaxERY 
(%) 
Deviation  
Rlast 
(AUC0-τ, %) 
Deviation 
Rlast 
(cmax, %) 
604 SS film-coated tablet 250mg SD 1.36 0.27   2.17 0.54   59% 98%   
604 SS film-coated tablet 1000mg SD 16.15 2.49   14.94 3.09   -7% 24%   
615 SS capsules 250mg SD 1.61 0.51 2.76 3.12 1.78 0.54 1.93 1.75 10% 5% -30% -44% 
615 SS capsules 250mg q6h for 5 doses 4.44 1.59   3.44 0.94   -23% -41%   
626 SS capsules 250mg SD 0.92 0.37 3.75 2.70 1.78 0.54 1.93 1.75 93% 45% -48% -35% 
626 SS capsules 250mg q6h for 5 doses 3.45 1.00   3.44 0.94   0% -6%   
627 SS film-coated tablet 250mg SD 2.19 0.80 2.86 2.84 1.78 0.54 2.28 2.02 -19% -33% -20% -29% 
627 SS film-coated tablet 
250mg q6h 
for 9 doses 6.26 2.27   4.06 1.08   -35% -52%   
625 SS  1000mg SD 30.27 7.99 0.96 0.86 14.47 3.09 3.15 2.20 -52% -61% 230% 155% 
625 SS  
1000mg 
q12h for 7 
doses 
28.93 6.90   45.58 6.79   58% -2%   
 
 
1 For Study 604, AUC0-∞ERY was summarized; for other studies, AUC0-τERY was summarized. 
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7.3.7.2 Model Predictions 
	
 Model predicted ForalERY, FabsERY, FhepERY and FGIERY are plotted against PO SS ERY dose in 
Figure 7.21. FabsERY (SS) was set as 0.59, and unchanged with dose. To calculate ForalERY, 
unbound blood AUC after 125 mg, 250 mg, 500 mg and 1000 mg IV ERY and PO EC ERY 
were simulated using IV and PO SS ERY semi-PBPK model, respectively. vmax,hep-3AERY and 
vmax,bileERY in IV ERY model were also set at 800 and 0.5 µg/min/kg, to avoid the influence of 
different hepatic clearance on systemic exposure. ForalERY was roughly estimated by the method 
introduced in section 7.3.3, in which the corresponding IV dose that produces the same AUC0-
∞,u
ERY as 125 mg/250 mg/500 mg/1000 mg PO SS ERY (DoseIVERY) was predicted using a power 
model that could capture dose proportionality of IV ERY AUC0-∞,uERY vs. DoseIVERY (AUC0-
∞,u
ERY = 0.0108•(DoseIVERY)1.0919). DoseIVERY was then divided by the corresponding PO SS ERY 
dose (125mg, 250 mg, 500 mg or 1000 mg) to come up with ForalERY estimation. Afterwards, 
ERGIERY was estimated by calculating the ratio of dose of ERY metabolized by GW metabolism 
(predicted by PBPK model) and dose of ERY absorbed into GW (calculated by 
FabsERY•DosePOERY). FGIERY and FhepERY at each ERY dose were then derived by methods used in 
Chapter 3, section 3.2.3.1. From Figure 7.21, ForalERY, FGIERY and FhepERY are all increased with 
PO EC ERY dose. Since ERGIERY is very low, and MBI on GW CYP3A is less than EC 
formulation -due to lower FabsERY for SS-, FGIERY is almost constant with dose (91%-92%). SS 
ERY has intermediate ERhepERY across doses (50% at 125 mg and 40% at 1000 mg), resulting in 
slightly higher FhepERY at 1000 mg (60%) than at 125 mg (50%). Compared with EC formulation, 
SS ERY has similar FhepERY after 125 mg, but lower FhepERY after 1000 mg, because less 
saturation in biliary excretion and less auto-inhibition on hepatic CYP3A occurs after SS 
formulation, due to lower hepatic ERY concentration (see Figure 7.22). Primarily because of 
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lower FabsERY (SS), ForalERY (SS) is less than ForalERY (EC) across doses, but ForalERY (SS) has less 
dose-dependency, ranging from 27% at the lowest to 33% at the highest simulated dose. 
  
Figure 7.21  Model - predicted ForalERY and different contribution of ForalERY (FabsERY, 
FhepERY and FGIERY) versus PO SS ERY dose (125 mg, 250 mg, 500 mg, 1000 mg). 
	
	
 Model predicted ERY unbound hepatic and GW mucosa concentrations after various PO SS 
single dose relative to Km,bileERY, Km,hep-3AERY (Km,GW-3AERY) and KIERY are plotted in Figure 
7.22a-d. It is clearly demonstrated in Figure 7.22a-b that biliary excretion of ERY is saturated 
even at the lowest dose, with chep,uERY above Km,bileERY for ~3 hours, and at the highest dose 
(1000 mg), it is saturated up to 10 hours. CYP3A metabolism and MBI are almost linear, due to 
much lower chep,uERY than Km,hep-3AERY and KIERY throughout the entire profiles. To compare 
hepatic concentration – time profiles across doses, terminal phase after all single doses appear to 
be linear and parallel with each other. With respect to GW mucosa concentrations, cGW-M,uERY is 
less than Km,GW-3AERY and KIERY throughout the entire profiles, reflecting negligible GW CYP3A 
saturation and MBI. To compare GW mucosa concentration – time profiles across doses, 
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terminal phase after all single doses appear to be linear and parallel with each other, and decline 
much faster than hepatic unbound concretions. This is because in our semi-PBPK model, PO 
ERY can only be unidirectional carried from GW mucosa to GW serosa, and drug cannot enter 
GW mucosa via vascular blood stream (systemically). Therefore, no pseudo steady-state is 
reached in GW mucosa concentrations, and the terminal phase of GW mucosa concentration is 
determined by kGLERY (0.018 min-1), which is larger than the derived ke (0.006 min-1) from ~2 
hours-plasma t1/2. GW mucosa concentrations peak higher and earlier than hepatic concentrations, 
owing to different inflow and outflow rate of drug transfer in the two organs.  
To compare hepatic and GW mucosa concentration after different ERY PO formulations, SS 
consistently has lower concentrations than EC at the same ERY dose (base equivalent), due to 
lower FabsERY after SS. Terminal decline of GW mucosa concentrations after SS is shallower than 
that after EC, because rate constant that determined permeating into GW mucosa (kGLERY) for SS 
is slower than EC in their respective semi-PBPK models. Full simulations of dose-dependent 
MBI on hepatic and GW CYP3A levels by PO SS ERY will be presented and discussed in 
Chapter 8. 
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a)                                                                         b) 
  
 
c)                                                                           d) 
 
 
Figure 7.22  Model-predicted unbound ERY concentrations in liver and GW mucosa after 
125mg, 250mg, 500mg, 1000mg single PO EC ERY dose relative to Km,bileERY, Km,hep-3AERY 
(Km,GW-3AERY) and KIERY. 
a-b) Unbound ERY hepatic concentration – time profiles (Cartesian and semi-log plots) relative 
to Km,bileERY, Km,hep-3AERY and KIERY.c-d) Unbound ERY GW mucosa concentration – time 
profiles (Cartesian and semi-log plots) relative to Km,GW-3AERY and KIERY. 
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7.4 Conclusions 
 ERY semi-PBPK models were developed to describe its clinical PK after IV and PO 
administration, with several nonlinear PK processes incorporated. In IV ERY model, saturable 
plasma protein binding was described by a sigmoidal/linear model; hepatic CYP3A metabolism 
and biliary excretion were characterized by two Michaelis-Menten equations; saturable tubular 
reabsorption was captured by an empirical hyperbolic model. ERY PO semi-PBPK model was 
specifically developed in EC and SS formulations. All nonlinear PK processes in IV model also 
exist in PO ERY semi-PBPK model, except for saturable tubular reabsorption. GW metabolism 
was described by a Michaelis-Menten equation after PO ERY. In both IV and PO ERY models, 
auto-inhibition on its own hepatic/GW CYP3A activity was considered to better predict ERY 
plasma PK profiles, especially after repeat-doses. IV semi-PBPK model was validated by several 
clinical PK studies of ERY after single dose, and PO semi-PBPK models for EC and SS were 
validated by both SAD studies and repeat- doses studies. After parameter optimization, plasma 
concentration – time profiles, exposure metrics, available clearances (CLren,pERY, CLnonren,pERY, 
CLtotal,pERY) and accumulation ratios at the last dose can be mostly predicted well by the models, 
with auto-inhibition incorporated. However, if auto-inhibition was not considered, observed 
accumulation ratios of exposure metrics were consistently underestimated. Additional 
simulations using IV ERY model show that biliary excretion is easily saturated across clinical 
relevant doses, while CYP3A metabolism is almost not saturated. Auto-inhibition on hepatic 
CYP3A after single dose is limited, but keeps for a long time. At the lowest simulated ERY dose 
(125 mg), biliary excretion is the predominant elimination pathway, while with increasing dose, 
more drugs shift to CYP3A metabolism pathway to get cleared, and at the highest simulated IV 
dose (900 mg), CYP3A metabolism becomes the major elimination route. CLint,bileERY, CLint,hep-
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3A
ERY and ERhepERY vs. time profiles are affected by both saturation in biliary excretion and auto-
inhibition on hepatic CYP3A. Additional simulations using PO ERY model show that EC 
formulation has moderate dose-dependent absorption due to saturable hepatobiliary (but not GW) 
extraction and auto-MBI on CYP3A. SS formulation exhibits less dose-dependent absorption 
than EC, due to relatively low hepatic/GW concentrations. ForalERY (EC) is higher than ForalERY 
(SS), primarily because of difference in fraction absorbed into GW. For both formulations, GW 
mucosa concentrations peak higher and earlier, but decline faster than hepatic concentrations - 
suggesting that the magnitude and time course of metabolic CYP3A inhibition by ERY in GW 
and liver are different and formulation-dependent. MDZ and ERY DDI model will be developed 
in the future based on this model. 
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CHAPTER 8 
 
 
8 SEMI-PBPK MODELING OF METABOLIC INHIBITION BETWEEN IV/PO ERY 
AND IV/PO MDZ 
	
	
	
	
8.1 Background and Objectives 
8.1.1 Available DDI studies 
	
 As mentioned in Chapter 7, two studies (study 28 and 603) were finally chosen to validate 
for MDZ and ERY DDI semi-PBPK model: in study 28, interaction between ERY and MDZ was 
investigated in two double-blind, randomized, crossover studies. In the first study, 12 healthy (3 
males, 9 females) volunteers were given 500 mg ERY TID as EC formulation or placebo for 1 
week, and PO MDZ (15 mg) was administered on the 6th day (2 hours) after the 2nd dose of ERY 
or placebo. In the second study, IV MDZ (0.05 mg/kg) was given to 6 of the same subjects after 
similar ERY/placebo pretreatment. Plasma concentrations of MDZ in absence/presence of ERY 
were measured in both studies, and a single ERY plasma concentration at the time point when 
MDZ was administered was provided. Thus, study 28 was used to validate the DDI model for 
IV/PO MDZ and PO EC ERY.  
In study 603, 12 healthy male volunteers participated in the randomized, 4 × 4 Latin square 
design study. The PK of PO MDZ was assessed under four conditions: (1) EM0: PO MDZ (5 mg) 
single dose without ERY (2) EM2: ERY SS 200 mg QID for 2 days + PO MDZ (2.5 mg) single 
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dose on day 2 (3) EM4: ERY SS 200 mg QID for 4 days + PO MDZ (2.5 mg) single dose on day 
4 (4) EM7: ERY SS 200 mg QID for 7 days + PO MDZ (2.5 mg) single dose on day 7. MDZ 
was administered one hour after the 1st dose of ERY for EM2, EM4, EM7 on day 2, 4, or 7, 
respectively. This study was used to validate the time course of DDI between PO MDZ and PO 
SS ERY after different ERY treatment periods, which specifically helps confirming the MBI 
inhibitory parameters of ERY.  
After comprehensive literature search, no IV ERY and MDZ DDI studies could be found; 
thus, MDZ and IV ERY DDI PBPK model could not be validated.  
The reported MDZ PK profiles and exposure metrics in absence/presence of repeat- PO ERY 
doses were compared with model-predicted profiles/exposure metrics, in order to qualify the 
model.  
8.1.2 ERY MBI information and simulation strategies 
	
 ERY is a mechanism-based (MBI) CYP3AI with low ForalERY (18% - 45%) (Somogyi et al., 
1995), primarily hepatically metabolized and excreted into bile with a short t1/2 (1.5-2 hours) 
(Austin et al., 1980). After IV administration, hepatic CYP3A metabolism is assumed to be the 
only elimination pathway for MDZ, thus the magnitude and time course of DDI are expected to 
be determined by ERY unbound hepatic concentration over time, relative to KIERY, as well as the 
endogenous synthesis and degradation rates of hepatic CYP3A. After PO administration, MDZ is 
subject to both GW and hepatic metabolism pre-systemically, as well as systemic hepatic 
metabolism. Hence, the unbound ERY concentration – time profiles in both GW mucosa and 
liver, relative to KIERY, as well as endogenous synthesis and degradation rates of hepatic and GW 
CYP3A activity, govern the magnitude and time course of ERY inhibition. Owing to the low-
intermediate ForalERY after different PO formulations (~60% after 1,000 mg EC ERY and ~30% 
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after 1,000 mg SS ERY), the hepatic ERY concentration after IV administration are expected to 
be greater than after PO formulations, leading to more inhibition on MDZ hepatic metabolism 
after IV ERY. After PO MDZ, both hepatic and GW metabolism (as ERY reaches the 
enterocytes from the gut lumen) can be inhibited, and GW mucosa concentrations after PO ERY 
are consistently higher than that after IV ERY (= 0), leading to greater GW CYP3A inhibition 
after PO ERY. Albeit the short plasma t1/2 of ERY, the duration of the DDI is expected to be 
prolonged, because as a MBI, the duration of metabolic inhibition is determined by turn-over 
kinetics of CYP3A rather than the PK of ERY. Meanwhile, maximal magnitude of DDI should 
occur when hepatic or GW CYP3A activity achieves its nadir, rather than the time when tissue 
concentration peak.  
 In addition, the impact of route of administration for either MDZ or ERY is also affected by 
dose/dosing interval of ERY (dose-dependent) and administration time interval between MDZ 
and ERY (time-dependent). Simulations were performed to assess dose- and time-dependency of 
route difference in DDI by varying IV/PO ERY doses and dosing intervals after different 
administration time prior to simulated doses of IV/PO MDZ. Sensitivity analysis was also 
performed on PK/MBI parameters in the DDI semi-PBPK model, to identify pivotal parameters 
that determine MDZ or ERY exposure metrics. 
 Finally, hypothetical CYP3AI and CYP3A substrates were created, based on ERY and MDZ 
semi-PBPK models, to assess the impact of Foral for a CYP3A MBI, and GW and hepatic 
metabolism for a CYP3A substrate on the magnitude and time course of route-dependent DDI. 
8.1.3 Objectives 
		
The major objectives of the chapter were to: 
a. Develop a semi-PBPK DDI model between MDZ and ERY, to describe IV/PO MDZ PK 
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profiles in presence of IV/PO (single-/repeat- doses) ERY. 
b. Validate the model using MDZ plasma concentration-time profiles and plasma exposures 
in presence of PO repeat- doses of ERY in clinical DDI studies. 
c. Identify pivotal PK/MBI parameters that determine MDZ plasma exposure metrics in 
presence of ERY, and ERY hepatic/GW mucosa exposure metrics after singl-e and 
repeat- doses by sensitivity analysis. 
d. Assess the impact of route of administration for MDZ and ERY on the magnitude and 
time course of their metabolic DDI after various administration time intervals between 
the two drugs. 
e. Assess the impact of route of administration for MDZ and ERY on the magnitude and 
time course of their metabolic DDI after various single- and repeat- dosing regimens of 
ERY. 
f. Explore route-dependent DDI between MDZ and a hypothetical CYP3A MBI with higher 
Foral (than ERY) and between two hypothetical CYP3A substrates with GW or hepatic 
metabolism removed or reduced and ERY.  
g. Predict profiles of ERY concentrations and relative CYP3A activity in GW and liver for 
all simulations for a better mechanistic understanding. 
8.2 Methods 
8.2.1 Development of MDZ-ERY DDI PBPK model 
	
8.2.1.1 DDI PBPK model/model parameters 
	
 A semi-PBPK model for IV/PO MDZ in presence of IV/PO ERY was built based on the 
reported in-vitro metabolic inhibitory information and the previously developed MDZ semi-
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PBPK and ERY semi-PBPK models (Figure 8.1). Metabolic inhibition parameters, along with 
previously discussed MDZ (as initial parameters) and ERY semi-PBPK model parameters are 
summarized in Table 8.1.  
 
Table 8.1  MDZ and ERY initial semi-PBPK DDI model parameters. 
	
	
Parameter Definition Value Source 
Physiological parameters 
VGL (ml/kg) Volume of gut lumen 3.57 Assumed to be 250ml (FDA, 2012) 
VGW (ml/kg) Volume of GW 33.6 
Calculated by equation (4.6), assumed to be the 
surface of gut lumen cylinder 
VPV (ml/kg) Volume of portal vein 0.97 Unknown methods (Ito et al., 2003) 
Vhep (ml/kg) Volume of liver 22.5 Calculated by equation (4.7) and (4.8) 
Qvilli 
(ml/min/kg) Villous blood flow 4.30 In-vivo experiment (Yang et al., 2007) 
Qhep 
(ml/min/kg) Hepatic blood flow 21.4 In-vivo experiment (Tsunoda et al., 1999) 
fHA 
Fraction of hepatic artery to total 
hepatic blood flow 0.25 
(Eipel et al., 2010) (QHA was calculated as fHA•Qhep; 
QPV was calculated as (1-fHA•Qhep) 
fPV 
Fraction of the components of portal 
vein that contain drug 1.00 
A correction factor that can be adjusted according to 
simulation results. 
fvilli 
IVIVE scaling factor and IIV 
adjusting factor 2.2 Optimized with data from study 21 
ERY PK Parameters (Systemic disposition) 
VB,uERY 
(mL/kg) 
Unbound volume of central 
compartment 479 See Appendices G 
VP,uERY 
(mL/kg) 
Unbound volume of peripheral 
compartment 1853 See Appendices G 
Q2,uERY 
(ml/min/kg) Inter-compartmental clearance 34.1 See Appendices G 
CLren,u,minERY 
(ml/min/kg) 
Minimal unbound renal clearance after 
IV ERY 0.5 Optimized by empiric hyperbolic model 
CLren,u,maxERY 
(ml/min/kg) 
Maximal unbound renal clearance 
after IV ERY 3.5 Optimized by empiric hyperbolic model 
ED50ERY
 
(mg) Dose of IV ERY that requires to produce 50% tubular reabsorption 475 Optimized by empiric hyperbolic model 
CLren,u-POERY 
(ml/min/kg) 
ERY unbound renal clearance after 
PO ERY  2.65 
Average of CLrenERY reported at 250, 500, 1000mg 
dose
 
(Josefsson et al., 1982) (corrected by average 
fuERY and B:PERY) 
1 vmax,hep-3AERY 
(µg/min/kg) 
Capacity of hepatic CYP3A to 
metabolize ERY 800 
Value used in PO ERY PBPK model optimized by 
PO EC and SS clinical studies 
Km,hep-3AERY 
(µg/ml) 
Affinity of hepatic CYP3A to 
metabolize ERY 64.6 In-vitro study (88 µM) (Riley & Howbrook, 1998) 
1 vmax,bileERY 
(µg/min/kg) Capacity of ERY biliary excretion 0.5 
Value used in PO ERY PBPK model optimized by 
PO EC and SS clinical studies 
Km,bileERY 
(µg/ml) 
Affinity to drug transporter that is 
responsible for biliary excretion 0.1 
Optimized by regimen 2 in study 611(Austin et al., 
1980) 
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Kp,hep,uERY 
liver-to-blood partition coefficient of 
unbound drug 2.71 (Ahmad, 2007) 
Kp,GW,uMDZ 
GW-to-blood partition coefficient of 
unbound drug 2.71 Assumed to be the same as Kp,hep,u
ERY 
B:PERY Blood-to-plasma partitioning ratio 0.85 (Ahmad, 2007) 
Bmax (mg/L) Binding capacity to AAG 8.15 See section 7.3.2 (11.1µM) 
Kb,50 (mg/L) Binding affinity to AAG 2.14 See section 7.3.2 (2.92µM) 
n Hill coefficient of AAG binding 1.32 See section 7.3.2 
m Slope of non-specific binding 0.265 See section 7.3.2 
ERY PK Parameters (Oral Absorption) 
2 FabsERY (EC) 
Fraction of ERY EC absorbed from 
gut lumen 0.88 Estimated from study 624 (Somogyi et al., 1995) 
kGLERY (min-1) 
(EC) 
Absorption rate constant of EC from 
last transit compartment to GW 0.06 
Assume to be kaERY in study 620 (Josefsson et al., 
1982) 
FabsERY (SS) 
Fraction of ERY SS absorbed from 
gut lumen 0.59 
Relative bioavailability between EC and SS in study 
620 (Josefsson et al., 1982) 
kGLERY (min-1) 
(SS) 
Absorption rate constant of SS from 
last transit compartment to GW 0.018 
Assume to be kaERY in study 618 (Iliopoulou et al., 
1982) 
ERY PK Parameters (Auto-inhibition model on CYP3A) 
kdeg (min-1) CYP3A degradation rate constant 0.0008 
Optimized between t1/2 of 10 -144 hours (Rowland 
Yeo et al., 2011; Wang, 2010; Yang et al., 2008) (t1/2 
= 14 hours) 
kinactERY (min-1) 
ERY maximum rate of inactivation on 
CYP3A  0.0375  
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KIERY (mg/L) ERY inhibitory potency on CYP3A 30 
Optimized between 1 - 80 mg/L (1.48 – 109 µM) 
(Ito et al., 2003a; McConn et al., 2004; Rowland Yeo 
et al., 2011; Xu et al., 2009; Yamano et al., 2001; 
Yates et al., 2012; Zhang et al., 2009; Zhang et al., 
2010; Zhao et al., 2005)  
MDZ PK Parameters 
VBMDZ (ml/kg) 
Volume of systemic blood 
compartment 140.4 See Appendices C 
VP1MDZ (ml/kg) 
Volume of shallow peripheral 
compartment 313.7 See Appendices C 
VP2MDZ (ml/kg) 
Volume of deep  
peripheral compartment 531.4 See Appendices C 
Q2MDZ(min-1) 
Inter-compartmental clearance 
between central and peripheral cpt-1 55.27 See Appendices C 
Q3MDZ(min-1) 
Inter-compartmental clearance 
between central and peripheral cpt-2 7.25 See Appendices C 
fuMDZ Fraction unbound of MDZ 0.03 
Assume to be the same in plasma and hepatocytes 
(Gandhi et al., 2012) 
fu,GW-MMDZ 
Fraction unbound at mucosal side of 
intestinal epithelium 1.0 Assumed to be negligible bound 
vmax,GWMDZ 
(ng/min/kg) 
GW CYP3A capacity to metabolize 
MDZ 3357.6 In-vitro experiment (Thummel et al., 1996) 
Km,GWMDZ 
(ng/ml) 
GW CYP3A affinity of metabolizing 
MDZ 1173 In-vitro experiment (Thummel et al., 1996) (3.6µM) 
vmax,hepMDZ 
(ng/min/kg) 
Hepatic CYP3A capacity to 
metabolize MDZ 305067 
In-vivo experiment, calculated from equation (5.7-
5.8), using data from study 21 
Km,hep (ng/ml) 
Hepatic CYP3A affinity of 
metabolizing MDZ 880 In-vitro experiment (Thummel et al., 1996) (2.7µM) 
Kp,GWMDZ  GW-to-blood partition coefficient 1.12 Scaled from rat Kp (Björkman et al., 2001) 
Kp,hepMDZ  Liver-to-blood partition coefficient 1.09 Scaled from rat Kp (Björkman et al., 2001) 
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B:PMDZ Blood-to-plasma partitioning ratio 0.86 (Ervine & Houston, 1994) 
kGLMDZ (min-1) 
Absorption rate constant from gut 
lumen to GW 0.05 
In-vivo experiment (Johnson et al., 2002; Kato et al., 
2008), assumed to be kaMDZ 
kT (min-1) 
Transit rate from mucosal to serosal 
side of intestinal epithelium 0.13 Assumed, calculated from Qvilli/VGW 
FabsMDZ 
Fraction of MDZ absorbed from gut 
lumen 100% BCS Class 1 drug (Wu & Benet, 2005) 
DDI Parameters (MBI) 
kdeg (min-1) CYP3A degradation rate constant 0.0008 Same as ERY auto-inhibition model, see above 
kinactERY (min-1) 
ERY maximum rate of inactivation on 
CYP3A  0.0375 Same as ERY auto-inhibition model, see above 
KIERY (mg/L) ERY inhibitory potency on CYP3A 30 Same as ERY auto-inhibition model, see above 
 
1  Different values were used in IV ERY semi-PBPK model (vmax,hep-3AERY = 900 µg/min/kg, vmax,bileERY = 10 
µg/min/kg) 
 
2  Parameter value was adjusted in study 629. 
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Figure 8.1  Semi-PBPK model scheme of MDZ in presence of ERY. 
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8.2.1.2 MBI Model 
 
 In presence of IV/PO ERY, unbound ERY in liver and GW mucosa irreversibly binds to 
CYP3A and results in MBI on hepatic/GW CYP3A metabolism. As a result, both CYP3A 
activity, i.e., vmax,hepMDZ and vmax,GWMDZ, are decreased relative to their baseline (EGW(t)/E0 and 
Ehep(t)/E0), respectively, and EGW(t) and Ehep(t) changed over time can be described by equation 
(8.1) and (8.2): dE#$(t)dt = k*+ − E#$ ∙ k./0 − E#$ ∙ ( k*+123456 ∙ c#$89,;456K=,>/?456 + c#$89,;456 ) 
when t = 0, EGW (0) = 1           (8.1) dE>/?(t)dt = k*+ − E>/? ∙ k./0 − E>/? ∙ ( k*+123456 ∙ c>/?,;456K=,>/?456 + c>/?,;456 ) 
when t = 0, Ehep (0) = 1           (8.2) 
8.2.1.3  Inhibition of GW metabolism: FLZ vs. ERY 
	
It is assumed that ERY enters GW mucosa from gut lumen only; therefore, only PO (but not 
IV) ERY causes inhibition of GW metabolism on MDZ and itself. This is different from the 
assumption made in FLZ semi-PBPK model, where both IV and PO FLZ can cause GW 
metabolic inhibition. This major difference between FLZ and ERY is mainly due to their 
different PK and physicochemical properties: 
FLZ is a BCS class 1 drug (Charoo et al., 2014), with a high apical-to-basolateral apparent 
permeability measured in Caco-2 cells (Papp A-BFLZ = 29.8 × 10-6cm/s (Yee, 1997)), albeit a low-
moderate log P value (log P = 0.5 (Salerno et al., 2010)). It has not been shown to be a potent 
substrate for any GI uptake transporters, thus, the high GI permeability is mainly due to passive 
diffusion. FLZ also has low plasma protein binding, with fuFLZ value of 0.88 (Humphrey et al., 
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1985), allowing more free drug available to cross intestinal epithelial membrane from the 
vascular serosal space. More importantly, study 103 (Ahonen et al., 1997), a clinical DDI study 
between PO MDZ and IV/PO FLZ demonstrated a 47% decrease in ERGIMDZ in presence of IV 
FLZ, based on quantitative meta-analysis in Chapter 3, confirming its inhibitory effect on GW 
metabolism of MDZ after IV administration of FLZ.  
On the other hand, ERY is a BCS class 3 drug, and a potent P-gp substrate. It was reported 
by Nožinić et al. (Nožini et al., 2010) that Papp A-BERY and Papp B-AERY in Caco-2 cells were 0.9 ± 
0.2 nm/s and 63.8 ± 3.3 nm/s, respectively, demonstrating its poor GI permeability due to P-gp 
efflux. After adding 10µM P-gp inhibitor (CY-P, full name not mentioned) (Yee, 1997), Papp A-
B
ERY was measured to be 3.73 nm/s, suggesting its low-moderate permeability even in absence of 
P-gp (predicted cLog P value = 0.8 (Erythromycin Scifinder Report)). It is also reasonable to 
assume that even if some ERY could reach the enterocyte from the basolateral side, P-gp at the 
apical side would efficiently remove intracellular ERY out of the GW. Moreover, ERY has 
relatively low fuERY(~0.3 at most clinical relevant concentrations), so that less free drug is 
available in blood to leave the vascular space and penetrate into the enterocyte from the serosal 
side. No IV ERY and MDZ DDI studies are available to clinically confirm this conclusion. As a 
consequence, we assume that ERY can only enter GW mucosa from gut lumen, but not via the 
GI vascular space, and only PO ERY can inhibit GW metabolism of PO MDZ.  
The corresponding differential equations for hepatic and GW mucosa mass transfer of MDZ 
were expressed as equations (8.3) and (8.4): dA>/?9BC tdt = cD9BC ∙ QFG + cHI9BC ∙ QHI − C>/?9BCK?,>/?9BC ∙ Q>/? − c>/?9BC ∙ f;9BC ∙ vM1N,>/?9BC
∙ E>/?EO /KM,>/?9BC  
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 when t = 0, AhepMDZ (0) =0              (8.3)
              
dA#$899BC tdt = c#Q9BC ∙ V#Q ∙ F1TU9BC ∙ k#Q9BC − 	c#$899BC ∙ V#$ ∙ kW − f;,#$899BC ∙ c#$899BC ∙ fX*YY* ∙ vM1N,#$9BC∙ E#$EO /(KM,#$9BC + f;,#$899BC ∙ c#$899BC ) 
when t = 0, AGW-MMDZ (0) =0             (8.4)
              
 Besides the assumptions mentioned in Chapter 5 and Chapter 7, two additional 
assumptions were made during the DDI modeling processes, which were: 
1) ERY can only enter GW mucosa from the gut lumen, therefore, only PO (but not IV) ERY 
causes inhibition of GW metabolism on MDZ and itself. 
2) The MBI by ERY on MDZ and its own metabolism (auto-inhibition) share the same KIERY 
and kinactERY in the liver and GW mucosa. 
 
8.2.2 Model qualification and predictions 
	
 Model-simulated MDZ plasma concentration-time profiles in absence/presence of ERY were 
compared with reported profiles from study 28 and 603 to assess model validity by predictive 
visual check and exposure metrics comparison. Since some parameters (i.e., vmax,hepMDZ, FabsERY 
(EC), kGLMDZ and fvilli) were optimized in different MDZ and ERY DDI, a more stringent 
acceptance criterion: predicted exposure metrics are ± 30% of observed, was used to assess 
performance of MDZ and ERY DDI semi-PBPK model. Plasma ERY GW mucosa and liver 
concentrations, as well as relative GW and hepatic CYP3A activity levels were also simulated, to 
better interpret observed metabolic DDI between the two drugs. All M&S were implemented in 
Simbiology (MATLAB, 2015a). 
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8.2.3 Sensitivity Analyses 
	
 Sensitivity analyses were performed to provide information about specific parameters that 
the model predictions are most sensitive to. Parameters (i.e., kdeg, KIERY, kinactERY, vmax,hep-3AERY, 
vmax,bileERY and Km,bileERY) that were highly variable /uncertain were selected for perspective 
sensitivity analyses. Considering high reported variability of these parameters, their values were 
increased and decreased by 5-fold relative to their original values (overall-fold change in values 
= 25 - fold), as showed in Table 8.2.  
As the purpose of a sensitivity analysis is to identify pivotal parameters in determining DDI 
magnitude, and facilitate parameter optimization for the MDZ and ERY DDI model, the ERY 
unbound concentration – and relative CYP3A activity – time profiles in the liver and GW 
mucosa were simulated under the dosing regimens of ERY in the two DDI studies (study 28 and 
603): 500 mg TID for 7 days (EC), and 200 mg (base equivalent) QID for 2, 4, and 7 days (SS). 
MDZ plasma concentration – time profiles were also simulated according to the dosing regimen 
in two DDI studies: 0.05 mg/kg IV bolus (as 2 min injection) or 15 mg PO MDZ was 
administered 2 hours after 2nd dose of EC ERY on the 6th day (study 28); 2.5 mg PO MDZ was 
administered 1 hour after 1st dose of SS ERY on day 2, 4, and 7 (study 603). AUC for all 
simulated profiles were estimated, and the sensitivity to each parameter was assessed by dividing 
the respective exposure metrics simulated at the upper limit by that simulated at the lower limit (-
fold change). As to MDZ, plasma AUC0-∞ was calculated; as to ERY, hepatic/GW mucosa 
AUC0-τ after single and repeat- ERY (EC/SS) doses were both calculated; as to relative 
hepatic/GW CYP3A activity, difference between AUC0-τ in absence and presence of MBI after 
single- and repeat-doses of ERY (EC/SS) (inhibited AUC0-τ) were both calculated. For vmax,hep-
3A
ERY and vmax,bileERY, sensitivity analyses were conducted by varying their values used in PO 
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ERY semi-PBPK model. 
Table 8.2  Values of parameters used in sensitivity analysis. 
	
Parameter Name Base Value Lower/Upper Sensitivity Limits -fold change = 25 
kdeg (min-1) 0.0008 0.00016; 0.004 
KIERY (mg/L) 30 6; 150 
kinactERY (min-1) 0.0375 0.0075; 0.1875 
vmax,hep-3AERY (µg/min/kg) 800 160; 4000 
vmax,bileERY(µg/min/kg) 0.5 0.1; 2.5 
Km,bileERY (µg/ml) 0.1 0.02; 0.5 
 
8.2.4 Simulations of route-dependent DDI with various administration time intervals  
	
 To investigate the impact of route difference for ERY and MDZ at different administration 
time intervals between the two drugs, as well as to explore the magnitude and duration of ERY 
inhibition, the final validated semi-PBPK DDI model between MDZ and ERY (using PO ERY 
model parameters) was employed to simulate MDZ PK profiles in presence of 1,000 mg IV (as 
15min infusion, and PO (EC/SS) ERY, and MDZ administered after 0, 0.5, 1, 2, 5, 10, 20, 50, 
100 hours as 1 mg IV MDZ or 3 mg PO MDZ dose. The simulated DDI dosing scheme is 
illustrated in Figure 8.2. The (inhibited/uninhibited) AUC0-∞MDZ ratio, ForalMDZ, ERhepMDZ and 
ERGIMDZ in presence of ERY for each scenario were calculated to assess the extent of inhibition. 
The 1,000 mg ERY dose was selected because it is the most commonly used daily (base-
equivalent) total dose of ERY (Arbor Pharmaceuticals, 2013). ERY unbound GW mucosa and 
hepatic concentrations, as well as relative GW and hepatic CYP3A levels were also simulated, to 
better interpret observed metabolic DDI between the two drugs. 
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Figure 8.2  Simulated DDI dosing scheme between ERY and MDZ. 
	
8.2.5 Assessment of linearity of MBI by ERY 
	
 According to Chapter 7, the apparent inactivation rate constant (kinact,app) of ERY on 
hepatic/GW CYP3A is a function of kinactERY, KIERY, and unbound ERY concentration in liver 
and GW mucosa, respectively (equation 7.22 and 7.23). If cGW-M,uERY or chep,uERY are much 
smaller than KIERY, kinact,appERY is almost proportional to the unbound ERY concentration, 
indicating as “linear” MBI. If cGW-M,uERY or chep,uERY is much greater than KIERY, kinact,appERY is 
maxed out, and remains as kinactERY, suggesting “nonlinear” (saturable) MBI. The assessment of 
linearity of MBI is a way to compare ERY tissue concentrations relative to their inhibitory 
potency, and evaluate how efficiently does ERY inhibit CYP3A. 
k*+123,1??8>/?456 = Z[\]^_`ab ×2def,g`abhi` abj2def,g`ab                                    (7.22) 
k*+123,1??8#$456 = Z[\]^_`ab ×2klmn,g`abhi` abj2klmn,g`ab                                  (7.23) 
 kinact,appERY simulated at 1,000 mg IV 15min-infusion ERY or PO (EC/SS) ERY were plotted 
against ERY unbound tissue concentration, to assess MBI linearity. 
8.2.6 Simulations of route-dependent DDI with various single doses of ERY 
	
 To investigate the impact of single dose of ERY on the route-dependent DDI between the 
two drugs, MDZ AUC0-∞ after 1 mg IV or 3 mg PO administration concurrent with (i.e., 
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administration time interval = 0) a series of SAD of ERY (namely, 100 mg, 200 mg, 500 mg, 
1,000 mg, 2,000 mg, 4,000 mg, 10,000 mg) administered either as 15-min IV infusion or PO EC 
were simulated. PO SS was not simulated because the major PK difference between the two 
formulations were FabsERY, and by increasing administered dose of SS, SS is expected to produce 
similar results with EC.  
AUCR of MDZ for each scenario was calculated, and ERY route difference was assessed to 
be the ratio of MDZ AUCR by PO (EC) ERY and that by IV ERY.	Unbound ERY 
concentration- and relative CYP3A activity-time profiles in the liver and GW mucosa were also 
simulated to better interpret the observed dose-dependent route-differences.   
8.2.7 Simulations of route-dependent DDI with different dosing intervals of ERY 
	
 To investigate impact of PO ERY dosing interval (same daily dose = 1,000 mg) on the route-
dependent DDI between the two drugs, as well as to compare ERY inhibition after single- and 
repeat- doses of PO ERY, MDZ AUC0-∞ were predicted after 1 mg IV or 3 mg PO administration 
in presence of 250 mg/500 mg/1,000 mg PO (EC/SS) SD ERY, or 250 mg PO (EC/SS) ERY 
QID, 500 mg PO (EC/SS) ERY BID, and 1,000 mg PO (EC/SS) ERY QD for 5 days (steady-
state was achieved for all three multiple dosing regimens). IV/PO MDZ was administered 2-
hours after SD ERY, or 2-hours after the 1st dose of EC/SS ERY on the 5th day (steady-state was 
achieved).  
The (inhibited/uninhibited) AUC0-∞ ratio of MDZ for each scenario was calculated, and ERY 
unbound concentration - and relative CYP3A activity-time profiles in the liver and GW mucosa 
were simulated, to better interpret observed dosing interval – dependent route difference. 
Accumulation ratio of ERY concentrations and inhibition ratio of CYP3A after single and 
repeat- PO (EC/SS) doses for ERY were also predicted.  
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8.2.8 Simulation of route-dependent DDI between CYP3A substrates and CYP3AIs 
 ERY is a relatively low-Foral and short t1/2 MBI, which are two important PK properties (and 
are different from FLZ). Thus, a relatively higher – Foral MBI (3AIX4) was created based on the 
ERY semi-PBPK model, by increasing FabsERY (EC) from 0.88 to 1.0. To avoid changing other 
PK properties of ERY, hepatic and GW metabolism of ERY were not modified. As a MBI, the 
duration of inhibition is affected by the turn-over kinetics of CYP3A rather than the PK of 
inhibitor, as a consequence, influence of changing t1/2ERY was not investigated further.		
As discussed in Chapter 6, route difference of IV/PO MDZ is primarily due to existence of 
pre-systemic hepatic/GW metabolism after PO (but not IV) MDZ, and IV/PO FLZ demonstrated 
DDI difference when simultaneously administered with PO MDZ, mainly because of different 
FLZ GW concentrations. Hence, a CYP3A substrate without GW metabolism (3ASX1) was 
derived from MDZ PBPK model, by setting fvilli, the parameter to adjust GW CYP3A activity, to 
0. Actually, based on the quantitative meta-analysis in Chapter 3, ERGIMDZ has very large inter-
study variability, and the derived ERGIMDZ in study 11 (Krishna et al., 2009) was 0, proving the 
clinical relevance of making this hypothetical CYP3A substrate.  
Furthermore, a second CYP3A substrate (3ASX2) was generated by setting fvilli to 0 (no GW 
metabolism), along with decreasing vmax,hepMDZ by 5-fold (limited hepatic metabolism), to create 
a high Foral (Foral = 89%) CYP3A substrate with limited first pass effect.  
All other PBPK parameters, including metabolic inhibitory potency and IV/PO doses, for the 
three hypothetical drugs remained unchanged from their original drugs, and changes were 
summarized in Table 8.3. 
  
252	
	
 
Table 8.3  Parameter modifications for hypothetical drugs, based on ERY and MDZ 
individual semi-PBPK models. 
(MDZ and ERY initial model parameters were used.) 
CYP3AI Foral t1/2 
Mechanism 
of DDI Change 
ERY ~60% (EC); ~30% (SS) ~2 hrs MBI - 
3AIX4 71% ~2 hrs MBI Change FabsERY from 0.88 to 1.0 
CYP3A 
Substrate Foral ERhep ERGI Change 
MDZ 0.28 0.40 (t1/2: ~2.5 hrs) 0.52 - 
3ASX1 0.60 0.40 (t1/2: ~2.5 hrs) 0 Change fvilli from 2.2 to 0.0. 
3ASX2 0.89 0.11 (t1/2: ~9 hrs) 0 
Change vmax,hepMDZ from 305067 µg/min/kg to 
61013.4 µg/min/kg and change fvilli from 2.2 to 0.0. 
 
 The route impact on metabolic DDI between MDZ (IV: 1 mg, PO: 3 mg) and 3AIX4 (1,000 
mg IV-15min-infusion and PO) and between 3ASX1/2 (same dose as MDZ) and ERY (1,000 mg 
IV-15min-infusion and PO EC) were investigated by simulating the -fold AUC0-∞substrate increase 
by CYP3AI at varying time intervals between single-dose substrate and CYP3AI administration 
(same strategy as Figure 8.2). 3AIX4 GW mucosa and liver concentrations, as well as relative 
GW and hepatic CYP3A activity were also simulated, to better interpret observed metabolic DDI 
between MDZ and 3AIX4. 
8.3 Results and Discussion 
8.3.1 Model evaluation 
	
8.3.1.1 Predictive performance check 
	
8.3.1.1.1 Study 28 
	
 The observed and model-predicted IV MDZ PK profiles in absence of ERY in study 28 are 
shown in Figure 8.3 (using parameter values from Table 8.1), and exposure metrics are 
summarized in Table 8.4. From Figure 8.3, the predicted terminal slope appears steeper than the 
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observed slope, resulting in under-estimation of MDZ AUC0-∞ by 35%. Thus, vmax,hepMDZ was 
optimized based on visual inspection of the terminal slope, and a value of  170,000 ng/min/kg 
was finally chosen to simulate MDZ PK profiles in study 28. This adjustment is within the 4.2-
fold inter-study variability of CLint,hepMDZ, as characterized in Chapter 3, section 3.3.3.1. After 
changing vmax,hepMDZ, the adjusted PBPK model predictes IV MDZ PK profile in absence of ERY 
reasonably well (shown in Figure 8.4), and the prediction of AUC0-∞MDZ is more accurate (see 
Table 8.4). 
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a)                                                                          b) 
  
Figure 8.3  Observed and model-predicted MDZ PK profiles after 0.05 mg/kg IV injection 
over 2 min (Cartesian and semi-log scales) (vmax,hepMDZ = 305067 µg/min/kg). 
The solid lines are the predicted PK profiles. The symbols and bars are observed means and SD 
values (if available). Time is relative to initial ERY/placebo dose. 
 
a)                                                                           b) 
  
Figure 8.4  Observed and model-predicted MDZ PK profiles after 0.05 mg/kg IV injection 
over 2 min (Cartesian and semi-log scales) (vmax,hepMDZ = 170,000vµg/min/kg). 
The solid lines are the predicted PK profiles. The symbols and bars are observed means and SD 
values (if available). Time is relative to initial ERY/placebo dose. 
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Table 8.4  Comparison of reported and semi-PBPK model-predicted MDZ plasma exposure metrics and Foral in the absence 
and presence of PO (EC/SS) ERY, as well as (inhibited/uninhibited) AUC0-∞MDZ ratio using PO ERY semi-PBPK model 
parameters (vmax,hep-3AERY = 800 µg/min/kg, vmax,bileERY = 0.5 µg/min/kg) with adjustments in study 28 and 603 (see Table 8.5) 
	
Study 
ID MDZ ERY 
Observed Predicted Deviation (%) 
AUC0-∞ 
(ng/ml•hr) 
Cmax 
(ng/ml) 
tmax after 
MDZ (hr) Foral AUCR 
AUC0-∞ 
(ng/ml•hr) 
Cmax 
(ng/ml) 
tmax after 
MDZ (hr) Foral AUCR 
AUC0-∞ 
(ng/ml•hr) 
Cmax 
(ng/ml) 
tmax after 
MDZ (hr) Foral AUCR 
28 IV: 0.05mg/kg  148 65 0.32 0.33  97 193 0.03 0.37  -35%   14%  
28 
IV: 0.05mg/kg 
(Adjust vmax,hep-
3A
MDZ)  
148 65 0.32   147 194 0.03   -1%     
28 PO: 15mg  232 48 1.52   280 82 0.73   21% 70% -52%   
28 
PO: 15mg (Adjust 
vmax,hep-
3A
MDZ,kGLMDZ) 
 232 48 1.52   261 64 0.86   12% 34% -43%   
28 
IV: 0.05mg/kg 
(Adjust vmax,hep-
3A
MDZ) 
500mg EC 
TID for 7 
days 
290 78 0.34 0.91 1.96 676 194 0.03 0.73 2.26 133%   -20% 16% 
28 
IV: 0.05mg/kg 
(Adjust vmax,hep-
3A
MDZ, FabsERY) 
500mg EC  
TID for 7 
days 
290 78 0.34  5.44 332 194 0.03  4.45 14%    -18% 
28 
PO: 15mg  
(Adjust vmax,hep-
3A
MDZ,kGLMDZ, 
FabsERY) 
500mg EC  
TID for 7 
days 
1264 163 1.06   1161 147 1.10   -8% -10% 4%   
603 PO: 5mg  42 9 1.38   43 17 0.66   3% 97% -52%   
603 
PO: 5mg  
(Adjust vmax,hep-
3A
MDZ,kGLMDZ, fvilli) 
 42 9 1.38   43 10 0.85   1% 17% -39%   
603 
PO: 5mg  
(Adjust vmax,hep-
3A
MDZ,kGLMDZ, fvilli) 
200mg SS 
QID for 2 
days 
99 17 1.93  2.36 110 20 1.97  2.58 10% 18% 2%  9% 
603 
PO: 5mg  
(Adjust vmax,hep-
3A
MDZ,kGLMDZ, fvilli) 
200mg SS  
QID for 4 
days 
146 23 2.05  3.45 128 22 1.98  3.02 -12% -4% -3%  -12% 
603 
PO: 5mg  
(Adjust vmax,hep-
3A
MDZ,kGLMDZ, fvilli) 
200mg SS  
QID for 7 
days 
141 21 2.11  3.35 130 22 1.98  3.06 -8% 2% -6%  -9% 
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 After adjusting vmax,hepMDZ, the observed and model-predicted PO MDZ PK profiles in 
absence of ERY in study 28 are shown in Figure 8.5 with exposure metrics summarized in 
Table 8.4. From Figure 8.5 and Table 8.4, the predicted cmax is significantly overestimated, with 
tmax underestimated, indicating that a slower than current absorption rate constant (kGLMDZ) 
should be used. The current kGLMDZ (0.05 min-1) was estimated for a PO dose of 3 mg MDZ, 
whereas in study 28, 15 mg PO MDZ was administered, possibly resulting in slower absorption 
rate due to solubility/dissolution limited-absorption. Thus, kGLMDZ was optimized based on visual 
inspection of cmax and tmax of PO MDZ profiles in study 28, and a value of 0.03 min-1 was finally 
chosen. After adjusting vmax,hepMDZ and kGLMDZ, the adjusted PBPK model improves the 
predictions of PO MDZ PK profile and exposure metrics in absence of ERY (shown in Figure 
8.6 and Table 8.4). Although greater than 30% deviations are still observed in cmax and tmax, 
AUC0-∞ is well predicted, and semi-PBPK DDI model using the adjusted kGLMDZ (0.03 min-1) 
also captures MDZ profiles in presence of ERY well (discussed later), confirming the necessity 
of parameter adjustment. 
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a)                                                                           b) 
  
 
Figure 8.5  Observed and model-predicted MDZ PK profiles after 15 mg PO MDZ 
(Cartesian and semi-log scales) (vmax,hepMDZ = 170,000 µg/min/kg, kGLMDZ = 0.05 min-1). 
The solid lines are the predicted PK profiles. The symbols and bars are observed means and SD 
values (if available). Time is relative to initial ERY/placebo dose. 
 
a)                                                                           b) 
  
 
Figure 8.6  Observed and model-predicted MDZ PK profiles after 15 mg PO MDZ 
(Cartesian and semi-log scales) (vmax,hepMDZ = 170,000 µg/min/kg, kGLMDZ = 0.03 min-1). 
The solid lines are the predicted PK profiles. The symbols and bars are observed means and SD 
values (if available). Time is relative to initial ERY/placebo dose. 
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 After adjusting vmax,hepMDZ, the observed and model-predicted IV MDZ PK profiles in 
presence of ERY in study 28 are shown in Figure 8.7 with exposure metrics summarized in 
Table 8.4. From Figure 8.7 and Table 8.4, the predicted terminal slope is apparently shallower 
than the observed slope, resulting in over-estimation of MDZ AUC0-∞ (in presence of ERY) by 
133%. Since MDZ AUC0-∞ in absence of ERY is well captured by the model parameters, this 
significant over-estimation is due to over-prediction of ERY’s inhibition. Although no ERY PK 
profiles were provided in study 28, it was reported that when MDZ was administered, ERY 
plasma concentration was measured to be 3.0 ± 0.7 mg/L. ERY plasma concentration – time 
profile was then simulated and presented in Figure 8.8a, and when MDZ is given, the predicted 
ERY plasma level is 8.7 mg/L, much higher than the reported value. Due to the large variation of 
systemic exposure for EC formulation (see section 7.3.1), FabsERY (EC) was changed from 0.88 to 
0.50 for study 28, which is within the 3.8-fold inter-study variability of PO ERY EC systemic 
exposure. After adjusting FabsERY (EC) (Figure 8.8b), the ERY plasma level is predicted to be 
3.2 mg/L, very close to the observed value, and observed IV MDZ PK profile in presence of EC 
ERY is characterized well by the adjusted PBPK model (shown in Figure 8.9 and Table 8.4), 
with exposure metrics (AUC0-∞, cmax, tmax), Foral and AUCR all within 30%. 
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a)                                                                          b) 
  
 
Figure 8.7  Observed and model-predicted IV MDZ (0.05mg/kg) PK profiles in presence of 
EC ERY (500 mg TID for 7 days, IV MDZ was administered 2 hours after the 2nd ERY 
dose on the 6th day) on Cartesian and semi-log scales. 
(vmax,hepMDZ = 170,000 µg/min/kg, FabsERY (EC) = 0.88). The solid lines are the predicted PK 
profiles. The symbols and bars are observed means and SD values (if available). Time is relative 
to initial ERY/placebo dose. 
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a) 
 
 
b) 
 
 
Figure 8.8  Semi-PBPK model-predicted ERY plasma concentration – time profile. 
Red dash line represents the time when IV MDZ was administered. a) FabsERY (EC) = 0.88. b) 
FabsERY (EC) = 0.50. Reported ERY plasma level at the time MDZ was given was 3.0 ± 0.7 mg/L 
(indicated as black dot).  
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a)                                                                           b) 
  
 
Figure 8.9  Observed and model-predicted IV MDZ (0.05mg/kg) PK profiles in presence of 
EC ERY (500mg TID for 7 days, IV MDZ was administered 2 hours after the 2nd ERY dose 
on the 6th day) on Cartesian and semi-log scales. 
(vmax,hepMDZ = 170,000µg/min/kg, FabsERY (EC) = 0.50). The solid lines are the predicted PK 
profiles. The symbols and bars are observed means and SD values (if available). Time is relative 
to initial ERY/placebo dose.  
 
 
 Since only hepatic metabolic inhibition occurs after IV MDZ, unbound blood/hepatic 
concentration of ERY as well as relative hepatic CYP3A activity in presence of hepatic CYP3A 
inhibition by ERY were simulated by semi-PBPK DDI model using adjusted parameters (Figure 
8.10). ERY unbound hepatic concentration reaches steady-state after 9 doses, and accumulation 
ratio at steady-state is ~4.5-fold. Throughout the entire profile, chep,uERY is above Km,bileERY, but 
much lower than KIERY and Km,hep-3AERY, suggesting its apparently linear PK (biliary excretion is 
a minor elimination pathway in PO ERY PBPK model) at the current dosing regimen, and 
“linear” MBI. Concentrations in the liver are much higher than blood, due to high liver-to-blood 
partition coefficient (Kp,hep,uERY = 2.71). When MDZ is administered (indicated as the red dashed 
line), relative hepatic CYP3A activity reaches the nadir of steady state, and fluctuates between 
33% - 46% afterwards. 
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Figure 8.10  Semi-PBPK model - predicted unbound hepatic and blood concentration – 
time profiles for ERY and relative hepatic CYP3A activity for study 28. 
ERY was administered as 500 mg EC TID for 7 days, and MDZ was administered 2 hours after 
the 2nd EC dose on day 6 (2nd EC dose on day 6 was given 2-hours before scheduled). Red 
dashed line represents the time when IV MDZ was administered. Time is relative to initial 
ERY/placebo dose. 
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 After adjusting vmax,hepMDZ, kGLMDZ and FabsERY (EC), the reported PO MDZ PK profile in 
presence of ERY (Figure 8.11) is well captured by the adjusted PBPK model, with exposure 
metrics (AUC0-∞, cmax, tmax), Foral and AUCR all within 30% of observed (Table 8.4), confirming 
the validity of model and final model parameters. 
a) b) 
  
Figure 8.11  Observed and model-predicted PK profiles after 15 mg PO MDZ in presence 
of EC ERY (500 mg TID for 7 days; PO MDZ was administered 2 hours after the 2nd ERY 
dose on the 6th day) on Cartesian and semi-log scales. 
(vmax,hepMDZ = 170,000 µg/min/kg, kGLMDZ  = 0.03 min-1, FabsERY (EC) = 0.50). The solid lines are 
the predicted PK profiles. The symbols and bars are observed means and SD values (if available). 
Time is relative to initial ERY/placebo dose. 
 
 
 After PO MDZ, both GW and hepatic CYP3A are inhibited by ERY. Unbound hepatic ERY 
concentration and relative hepatic CYP3A activity are the same as Figure 8.10. With respect to 
ERY GW mucosa concentrations (Figure 8.12), no accumulation is observed due to its rapid loss 
(quick transfer to GW serosa compartment) and minor contribution to ERY’s pre-systemic 
metabolism (<10%). The peak ERY GW mucosa concentration (~10 mg/L) is much higher than 
its hepatic concentration, resulting in faster inactivation of CYP3A in GW, and greater maximal 
GW CYP3A inhibition (inhibited by 72%). However, due to the rapid drop of cGW-M,uERY, 
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fluctuation of GW CYP3A (25% - 48%) is larger than hepatic CYP3A, and when MDZ is 
administered, GW CYP3A reaches its nadir (25% of original). 
 
Figure 8.12  Semi-PBPK model-predicted ERY unbound hepatic/GW mucosa/blood 
concentration – time profiles and relative hepatic/GW CYP3A activity for study 28. 
ERY was administered as 500 mg EC TID for 7 days, and MDZ was administered 2 hours after 
the 2nd EC dose on day 6 (2nd EC dose on day 6 was given 2-hours before scheduled). Red 
dashed line represents the time when PO MDZ was administered.  
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8.3.1.1.2  Study 603 
	
For study 603, all model parameters were originally assumed to be the values in Table 8.1. 
The reported and model-predicted PO MDZ PK profiles in absence of ERY are shown in Figure 
8.13 and exposure metrics are summarized in Table 8.4. After visual inspection of PK profiles 
and exposure metrics, the model over-estimates the terminal slope and cmax of MDZ PK profile; 
thus, vmax,hepMDZ and kGLMDZ were optimized to 170,000 µg/min/kg and 0.03 min-1, explained as 
inter-individual variability of hepatic CYP3A and possible solubility/dissolution-limited 
absorption in study 603 (5 mg MDZ dose was administered). fvilli was also adjusted (to 5.0) to 
better characterize the observed MDZ PK profile, attributed to inter-individual variability of GW 
CYP3A activity. After optimizing vmax,hepMDZ, kGLMDZ and fvilli, the adjusted PBPK model 
predicts PO MDZ PK profile and exposure metrics (AUC0-∞, cmax, tmax) well (shown in Figure 
8.14 and Table 8.4). All adjusted PBPK parameters for study 28 and 603 are summarized in 
Table 8.5. 
Table 8.5  Adjusted semi-PBPK DDI (MDZ+ERY) model parameters for study 28 and 603. 
	
Parameter Definition Value Source 
vmax,hepMDZ 
(ng/min/kg) 
Hepatic CYP3A capacity to 
metabolize MDZ 170,000 
Value used for study 28 and 603 based on terminal 
slope optimization 
kGLMDZ (min-1) 
Absorption rate constant from gut 
lumen to GW 0.03 
Value used for study 28 and 603 due to presumably 
solubility/dissolution limited absorption   
FabsERY (EC) 
Fraction of ERY EC absorbed from 
gut lumen 0.50 
Value used for study 28 based on reported ERY 
plasma level 
fvilli 
IVIVE scaling factor and IIV 
adjusting factor 5.0 
Value used for study 603 based on observed PO 
MDZ PK profile 
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a) b) 
 
 
Figure 8.13  Observed and model-predicted MDZ PK profiles after 5 mg PO 
administration (Cartesian and semi-log scales) (vmax,hepMDZ = 305,067 µg/min/kg, kGLMDZ = 
0.05 min-1, fvilli = 2.2). 
The solid lines are the predicted PK profiles. The symbols and bars are observed means and SD 
values (if available).  
 
a) b) 
  
 
Figure 8.14  Observed and model-predicted MDZ PK profiles after 5 mg PO 
administration (Cartesian and semi-log scales) (vmax,hepMDZ = 170,000 µg/min/kg, kGLMDZ = 
0.03 min-1, fvilli = 5.0). 
The solid lines are the predicted PK profiles. The symbols and bars are observed means and SD 
values (if available).  
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 After adjusting vmax,hepMDZ, kGLMDZ and fvilli, model-predicted PO MDZ PK profiles in 
presence of 2 days/4 days/7days ERY are all well captured by the adjusted PBPK model 
parameters (Figure 8.15), with exposure metrics (AUC0-∞, cmax, tmax), Foral and AUCR all within 
30% of observed (Table 8.4), confirming the validity of model and final model parameters, 
especially the MBI parameters. 
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a)     b) 
  
c) d) 
  
e) f) 
 
 
Figure 8.15  Observed and model-predicted 2.5 mg PO MDZ PK profiles (profiles scaled to 
5 mg MDZ dose) in presence of SS ERY (200mg QID for 2, 4 or 7 days). 
(vmax,hepMDZ = 170,000µg/min/kg, kGLMDZ  = 0.03 min-1, fvilli = 5.0). a-b) MDZ administered 1-
hour after the 1st ERY dose on 2nd day (Cartesian and semi-log scales). c-d) MDZ administered 
1-hour after the 1st ERY dose on 4th day (Cartesian and semi-log scales). e-f) MDZ administered 
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1-hour after the 1st ERY dose on 7th day (Cartesian and semi-log scales). The solid lines are the 
predicted PK profiles. The symbols and bars are observed means and SD values (if available). 
Time is relative to initial ERY/placebo dose.  
 
 
 
 Unbound ERY blood/hepatic/GW mucosa concentrations for ERY, as well as relative 
hepatic/GW CYP3A activity were simulated by the final semi-PBPK DDI model using adjusted 
parameters (Figure 8.16). ERY was administered as SS formulation 200 mg QID for 2 days 
(Figure 8.16a), 4 days (Figure 8.16b) and 7 days (Figure 8.16c), and 2.5 mg MDZ was 
administered 1 hour after the 1st dose of ERY on day 2, day 4 and day 7 (indicated as red dashed 
line). Throughout the entire profile, chep,uERY is above Km,bileERY, but much lower than KIERY and 
Km,hep-3AERY, confirming its apparently linear PK (biliary excretion is a minor elimination 
pathway) at the current dosing regimen, and “linear” MBI. With respect to ERY GW mucosa 
concentration, no accumulation is observed due to its rapid decline (quick transfer to GW serosa 
compartment) and minor contribution to ERY’s pre-systemic metabolism (<10%). Peak ERY 
GW mucosa concentration (~3.5 mg/L) is much higher than hepatic concentration, resulting in 
faster inactivation of CYP3A in GW, and greater maximal CYP3A inhibition (inhibited by 65%) 
than hepatic CYP3A inhibition (inhibited by 47%). Relative GW CYP3A level reaches steady-
state almost on day 2, so there is no difference regarding GW CYP3A inhibition among day 2, 4 
or 7. However, hepatic CYP3A level reaches steady-state on day 4, and when MDZ is 
administered on day 2, the nadir of hepatic CYP3A level within 6-hours of MDZ administration 
(first ERY dosing interval after MDZ administration) is 68%, compared with 58% when MDZ is 
administered on day 4 and 7. As a result, the different observed MDZ AUCR after various time 
course of ERY SS administration (EM2: AUCR = 2.4; EM4 and EM7: AUCR = 3.4) is primarily 
due to different hepatic metabolic inhibition between 2 days of SS and 4 or 7 days of SS. There 
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is no difference between metabolic inhibition by 4 days SS and 7 days SS. Concentrations in the 
liver and GW mucosa are much higher than blood, due to high liver-to-blood and GW-to-blood 
partition coefficients (Kp,hep,uERY = 2.71, KGW,uERY = 2.71).  
a) 
 
 
b) 
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c) 
 
 
Figure 8.16  Semi-PBPK model predicted ERY unbound hepatic/GW mucosa/blood 
concentration – time profiles and relative hepatic/GW CYP3A activity in study 603. 
a) ERY was administered as 200 mg SS QID for 2 days, and MDZ was administered 1-hour after 
the 1st SS dose on day 2. b) ERY was administered as 200 mg SS QID for 4 days, and MDZ was 
administered 1-hour after the 1st SS dose on day 4. c) ERY was administered as 200 mg SS QID 
for 7 days, and MDZ was administered 1-hour after the 1st SS dose on day 7. Red dashed line 
represents the time when PO MDZ was administered.  
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8.3.1.2 Sensitivity analysis 
	
 The -fold change in MDZ plasma AUC0-∞, GW/hepatic CYP3A inhibited AUC0-τ and 
GW/hepatic ERY AUC0-τ after single- and repeat- doses were calculated by dividing AUC 
simulated at the upper limit by that simulated at the lower limit. Table 8.6 summarizes the 
results of this sensitivity analysis under dosing regimen of study 28, and Table 8.7 summarizes 
sensitivity analysis under dosing regimen of study 603. A greater than 2-fold or less than 0.5-fold 
change was highlighted in bold, indicating the corresponding exposure is sensitive to that 
parameter. All sensitivity analysis plots are presented in Appendices K (for study 28) and L (for 
study 603).  
For study 28, AUC0-∞ for both IV and PO MDZ are substantially affected by kdeg, KIERY, 
kinactERY and vmax,hepERY, due to their impact on hepatic/GW CYP3A activity after multiple ERY 
EC doses. The AUCR of PO MDZ is changed more than AUCR of IV MDZ, because besides 
systemic hepatic metabolism, pre-systemic GW and hepatic metabolism are also inhibited by 
ERY. With respect to the -fold change in inhibited AUC0-τCYP3A, kdeg alters AUC0-τCYP3A to a 
greater extent after repeat- ERY doses than after single dose, because after repeat- doses, the 
natural recovery (without considering MBI) of CYP3A activity, dependent on kin (numerically 
equal to kdeg) and kdeg, is more essential to determine CYP3A activity than after single ERY dose. 
However, KIERY, kinactERY and vmax,hepERY influence AUC0-τCYP3A after single-dose more than 
repeat- doses, because all the three parameters affect MBI of ERY. After multiple ERY doses for 
7 days, CYP3A inhibition has reached steady-state, while after single dose, a lower KIERY, a 
higher kinactERY or a smaller vmax,hepERY  can all shorten the time required to reach steady-state 
(Figure K.10, Figure K.16, Figure K.22), resulting in larger inhibited AUC0-τCYP3A after single 
ERY dose. Hepatic CYP3A is affected more than GW CYP3A, due to the more rapid ERY GW 
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mucosa concentration decline than hepatic concentration decline. With respect to ERY hepatic 
and GW mucosa concentration, kdeg can only affect hepatic AUC0-τERY after multiple dosing (but 
not single dose). KIERY, kinactERY and vmax,hepERY influence hepatic AUC0-τERY after both single- and 
repeat- doses, and AUC0-τERY after repeat- EC doses is affected more than after single dose 
(Figure K.12, Figure K.18, Figure K.24). This is because for MBI, there is a delay between 
maximal inhibition (hepatic CYP3A nadir) and cmax of hepatic ERY concentration; when CYP3A 
achieves its nadir (within the first dosing interval), hepatic ERY concentration has already 
dropped to the terminal phase of its concentration profile, which won’t have much influence on 
its hepatic AUC. After multiple dosing, hepatic CYP3A level is consistently low, affecting the 
entire hepatic ERY PK profile, and a greater extent of AUC influence should be observed. No 
influence on GW mucosa concentration is found after either single or multiple doses, due to its 
rapid decline (quick transfer to GW serosa compartment) and minor contribution to ERY’s pre-
systemic metabolism (<10%). AUC0-τCYP3A is consistently more sensitive to kdeg, KIERY, kinactERY 
and vmax,hepERY than AUC0-τERY, due to the slow degradation t1/2 of CYP3A (~14 hours) and the 
fast plasma elimination t1/2 of ERY (~2 hours). Since biliary excretion in the PO ERY semi-
PBPK model is not a major route of elimination, neither vmax,bileERY nor Km,bileERY has significant 
influence on any exposure metrics. 
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Table 8.6  Sensitivity analysis heat-map results for semi-PBPK MDZ and ERY EC DDI 
model under dosing regimen in study 28. 
 (PO EC ERY 500 mg TID for 7 days; IV (0.05 mg/kg) or PO (15 mg) MDZ was administered 2 
hours after the 2nd EC dose on the 6th day) 
 (More solid green indicates smaller value; more solid red indicates larger value) 
 
ERY+MDZ Sensitivity Analysis -Fold change in inhibited  AUCτ
CYP3A 
after single ERY dose 
-Fold change in AUCτ,uERY 
after single ERY dose 
Parameter GW CYP3A Hepatic CYP3A CGW-M,uERY Chep,uERY 
kdeg 0.54 0.55 1.00 0.97 
KIERY 0.16 0.06 0.96 0.55 
kinactERY 7.98 20.34 1.06 2.21 
vmax,hep-3AERY 1.00 0.11 1.00 0.06 
vmax,bileERY 1.00 0.86 1.00 0.80 
Km,bileERY 1.00 1.02 1.00 1.04 
 
-Fold change in 
plasma AUC0-∞MDZ 
-Fold change in inhibited  AUCτCYP3A 
CYP3A after repeat- ERY dose 
-Fold change in  AUCτ,uERY 
after repeat- ERY dose 
Parameter IV MDZ PO MDZ GW CYP3A Hepatic CYP3A CGW-M,uERY Chep,uERY 
kdeg 0.09 0.05 0.29 0.14 0.95 0.11 
KIERY 0.12 0.07 0.37 0.15 0.96 0.13 
kinactERY 9.85 19.85 3.18 7.15 1.05 9.48 
vmax,hep-3AERY 0.21 0.17 1.00 0.18 1.00 0.02 
vmax,bileERY 0.75 0.73 1.00 0.79 1.00 0.57 
Km,bileERY 1.03 1.03 1.00 1.02 1.00 1.06 
 
 
  In study 603, repeat- SS ERY was administered for different time courses, and sensitivity 
analyses were conducted after different duration of pretreated SS. AUC0-∞ of PO MDZ is also 
substantially affected by kdeg, KIERY, kinactERY and vmax,hepERY, and with increasing duration of SS 
ERY treatment, the extent of influence becmes larger. There is no significant difference between 
AUC0-∞ after 4 days and 7 days SS, because inhibition of ERY on GW and hepatic CYP3A reach 
steady-state on day 4. Some influence (i.e. KIERY, kinactERY, vmax,bileERY) on AUC0-∞MDZ is slightly 
larger after 4 days SS than 7 days, because the sensitivity analysis for MDZ administered on day 
2, 4, and 7 was simulated simultaneously, and the slightly higher impact on day 4 is due to minor 
carry-over effect of MDZ administered on day 2. The carry-over effect is mostly negligible, 
given the 2-day washout period and the short MDZ t1/2 (6 hours without inhibition), and the 
sensitivity analysis results should be almost the same after 4 days SS and 7 days SS. Inhibited 
AUC0-τCYP3A and AUC0-τERY are also affected by kdeg, KIERY, kinactERY and vmax,hepERY. Neither 
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vmax,bileERY nor Km,bileERY has significant influence on any exposure metrics. 
Table 8.7  Sensitivity analysis heat-map results for semi-PBPK MDZ and ERY SS DDI 
model under dosing regimen in study 603. 
 (PO SS ERY 200 mg QID for 7 days; PO 5 mg MDZ was administered 1 hours after the 1st SS 
dose on the 2nd/4th/7th day) 
 (More solid green indicates smaller value; more solid red indicates larger value) 
ERY+MDZ Sensitivity Analysis -Fold change in inhibited  AUCτCYP3A after single ERY dose 
-Fold change in AUCτ,uERY 
after single ERY dose 
Parameter GW CYP3A Hepatic CYP3A CGW-M,uERY Chep,uERY 
kdeg 0.69 0.71 1.00 0.99 
KIERY 0.09 0.05 1.00 0.80 
kinactERY 12.63 23.16 1.00 1.27 
vmax,hep-3AERY 1.00 0.11 1.00 0.08 
vmax,bileERY 1.00 0.77 1.00 0.72 
Km,bileERY 1.00 1.04 1.00 1.05 
 
-Fold change in plasma AUC0-
∞
MDZ administered on day 2 
-Fold change in inhibited  
AUCτCYP3A CYP3A after repeat- 
ERY dose (2 days) 
-Fold change in  AUCτ,uERY 
after repeat- ERY dose (2 
days) 
Parameter PO MDZ GW CYP3A Hepatic CYP3A CGW-M,uERY Chep,uERY 
kdeg 0.30 0.26 0.15 1.00 0.63 
KIERY 0.13 0.22 0.07 1.00 0.24 
kinactERY 9.32 4.85 14.54 1.00 4.89 
vmax,hep-3AERY 0.43 1.00 0.10 1.00 0.04 
vmax,bileERY 0.89 1.00 0.70 1.00 0.62 
Km,bileERY 1.02 1.00 1.06 1.00 1.08 
 
-Fold change in plasma AUC0-
∞
MDZ administered on day 4 
-Fold change in inhibited  
AUCτCYP3A CYP3A after repeat- 
ERY dose (4 days) 
-Fold change in  AUCτ,uERY 
after repeat- ERY dose (4 
days) 
Parameter PO MDZ GW CYP3A Hepatic CYP3A CGW-M,uERY Chep,uERY 
kdeg 0.12 0.23 0.08 1.00 0.22 
KIERY 0.10 0.27 0.09 1.00 0.19 
kinactERY 12.62 4.05 11.23 1.00 6.44 
vmax,hep-3AERY 0.39 1.00 0.12 1.00 0.03 
vmax,bileERY 0.85 1.00 0.68 1.00 0.58 
Km,bileERY 1.03 1.00 1.06 1.00 1.09 
 
-Fold change in plasma AUC0-
∞
MDZ administered on day 7 
-Fold change in inhibited  
AUCτCYP3A CYP3A after repeat- 
ERY dose (7 days) 
-Fold change in  AUCτ,uERY 
after repeat- ERY dose (7 
days) 
Parameter PO MDZ GW CYP3A Hepatic CYP3A CGW-M,uERY Chep,uERY 
kdeg 0.09 0.23 0.08 1.00 0.15 
KIERY 0.11 0.27 0.10 1.00 0.18 
kinactERY 12.39 4.01 10.95 1.00 6.50 
vmax,hep-3AERY 0.39 1.00 0.12 1.00 0.03 
vmax,bileERY 0.84 1.00 0.68 1.00 0.57 
Km,bileERY 1.03 1.00 1.06 1.00 1.09 
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8.3.2 Model Predictions 
8.3.2.1 Simulation of route-dependent DDI between MDZ and ERY after various 
administration time intervals 
 AUCR for each scenario was calculated to assess the extent of inhibition, and is plotted 
against administration interval time shown in Figure 8.17 (same dose IV ERY vs. PO EC ERY) 
and Figure 8.18 (same dose IV ERY vs. PO SS ERY). ERY unbound hepatic/GW mucosa 
concentration – time profiles and relative hepatic/GW CYP3A activity were simulated to better 
interpret Figure 8.17 and Figure 8.18 (Figure 8.19: comparing IV ERY and PO EC ERY; 
Figure 8.20: comparing IV ERY and PO SS ERY). 
 For IV MDZ, ERY causes more inhibition after IV than after PO (EC and SS) administration, 
due to ERY’s relatively low Foral (EC: ~60%; SS: ~30%) and higher unbound (peak) hepatic 
concentrations after IV than after PO administration (Figure 8.19a, Figure 8.20a). Although 
tmax,hepERY after IV administration is different from that after PO administration, Figure 8.19b 
and Figure 8.20b clearly demonstrat that IV ERY produces more inhibition on hepatic CYP3A 
throughout the entire profile than PO ERY, and the difference between IV and PO SS ERY is 
larger than the difference between IV and PO EC ERY, due to the lower ForalERY after SS 
formulation. The peak DDI magnitude is achieved when MDZ is dosed ~5 hours after ERY 
(when hepatic CYP3A activity level achieves its nadir), which is much later than the time for 
ERY to reach its hepatic peak concentration (0.3 hour after IV, 1.7 hours after PO EC, and 1.4 
hours after PO SS ERY). This is because for MBI, ERY hepatic concentrations directly affects 
inactivation rate of CYP3A in the liver, but it still takes time for the existing CYP3A to be 
inactivated; thus, there is a lag time between peak of ERY hepatic concentration and nadir of 
hepatic CYP3A activity.  
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 For PO MDZ, when simultaneously administered with MDZ, ERY still shows more 
inhibition after IV than after PO (EC and SS) administration, while the inhibition by PO ERY 
gradually exceeds (for EC) or equals (SS) the one by IV ERY over time.  This is primarily 
because ERY is assumed to enter the GW mucosa from the gut lumen only; since its high plasma 
protein binding and low lipophilicity prevent serosal GW access (see section 8.2.1); therefore, 
only PO (but not IV) ERY causes inhibition of GW metabolism (Figure 8.19c-d, Figure 8.20c-
d). However, because there is a lag time for ERY to enter GW mucosa (represented by several 
transit compartments), when the two drugs are dosed simultaneously, their DDI still mainly 
reflects DDI in hepatic CYP3A, which is the reason why IV ERY still won over PO ERY at the 
beginning. Maximal DDI magnitude for EC exceeds IV ERY, whereas that for SS only matchs 
with IV ERY, because the hepatic CYP3A inhibition difference between SS and IV ERY is 
larger than that between EC and IV ERY, and only EC can easily surpass IV ERY with GW 
CYP3A inhibition. The peak DDI magnitude is achieved when MDZ is dosed ~2-5 hours later 
than ERY (when GW/hepatic CYP3A activity levels achieves their nadirs), which is much later 
than the time for ERY to reach its hepatic/GW peak concentration. Despite ERY’s short 
plasma/pseudo steady-state elimination t1/2 (~2 hours.), its metabolic DDI with MDZ lasts about 
4 days - regardless of route of administration, because the recovery of CYP3A activity mainly 
depends on the degradation t1/2 of CYP3A (~ 14 hours). 
 With respect to route difference for MDZ, due to its pre-systemic hepatic and GW 
metabolism, PO MDZ is consistently more sensitive to metabolic inhibition than IV MDZ, 
regardless of ERY route.  
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Figure 8.17  MDZ AUCR by 1,000 mg ERY IV (as 15-min infusion) or PO (EC) 
administration followed by MDZ (IV: 1 mg; PO 3 mg) at various time intervals. 
Red dash line indicates no inhibition on MDZ exposure. 
 
 
Figure 8.18  MDZ AUCR by 1,000 mg ERY IV (as 15-min infusion) or PO (SS) 
administration followed by MDZ (IV: 1 mg; PO 3 mg) at various time intervals. 
Red dash line indicates no inhibition on MDZ exposure. 
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a)                                                                          b) 
  
 
c)                                                                           d) 
  
 
Figure 8.19  Plots of unbound hepatic/GW concentrations for ERY and relative CYP3A 
activity profiles after a single dose of ERY (1,000 mg; IV: 15-min infusion, PO: EC). 
a) ERY unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of ERY. c) ERY unbound GW concentration – time profiles. d) Relative GW CYP3A 
activity in presence of ERY. Dash lines in a) and c) represent KIERY. Dash lines in b) and d) 
represent no change in hepatic and GW CYP3A activity. 
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a)                                                                        b) 
  
 
c)                                                                         d) 
  
 
Figure 8.20  Plots of unbound hepatic/GW concentrations for ERY and relative CYP3A 
activity profiles after a single dose of ERY (1,000 mg; IV: 15-min infusion, PO: SS). 
a) ERY unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of ERY. c) ERY unbound GW concentration – time profiles. d) Relative GW CYP3A 
activity in presence of ERY. Dash lines in a) and c) represent KIERY. Dash lines in b) and d) 
represent no change in hepatic and GW CYP3A activity. 
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 ForalMDZ (Figure 8.21), ERGIMDZ and ERhepMDZ in presence of different routes of ERY, as well 
as (inhibited/uninhibited) ratio of ERGIMDZ and ERhepMDZ (Figure 8.22) are plotted against 
administration time interval (ERY followed by MDZ) between the two drugs.  
ERGIMDZ in absence/presence of ERY was estimated by calculating the ratio of dose of MDZ 
metabolized by GW metabolism (predicted by PBPK model) and total dose of MDZ absorbed 
into GW mucosa (calculated by FabsMDZ•DosePOMDZ). ERhepMDZ in absence/presence of ERY was 
calculated by CLhepMDZ divided by Qhep, and CLhepMDZ was derived from DoseIVMDZ and 
AUCIVMDZ, assuming that hepatic clearance is the only elimination route of IV MDZ.  
ForalMDZ in absence of ERY is 28%, and both routes of ERY can increase ForalMDZ but to 
different extent. When concurrently administered with MDZ (administration time interval = 0), 
IV ERY increases ForalMDZ a little more than PO (EC/SS) ERY, because there is a lag time for 
ERY to enter the GW mucosa after PO administration, and at zero time interval, the increase in 
ForalMDZ is mainly due to pre-systemic/systemic hepatic metabolic inhibition after PO MDZ. With 
MDZ dosed further apart from ERY, PO (EC/SS) ERY inhibites GW metabolism of MDZ, thus 
a more profound increase in ForalMDZ is observed after PO ERY than IV ERY. PO ERY can raise 
ForalMDZ up to 63% and 54% for EC and SS formulations, respectively, and IV ERY only elevates 
ForalMDZ up to 36%. The maximal increase is achieved after ~2-5 hours, when hepatic/GW 
CYP3A levels achieve their nadir. The duration of ForalMDZ increase by both routes of ERY are 
up to 50 hours, reflecting the slow recovery of CYP3A activity levels.  
282	
	
 
 
Figure 8.21  ForalMDZ in presence of ERY (1,000 mg; IV: 15-min infusion, PO: EC/SS) 
administered at various time intervals before 1 mg IV/3 mg PO MDZ. 
Red dash line indicates ForalMDZ without ERY. 
 
 ERGIMDZ and ERhepMDZ, without ERY, are 52% and 40%, respectively, translating to 
intermediate hepatic/GW extraction ratios. Only PO ERY reduces ERGIMDZ, and due to the lag 
time of ERY GW mucosa absorption, very little inhibition on ERGIMDZ is observed when the two 
drugs are administered simultaneously. With MDZ dosed further apart from ERY, the inhibition 
on ERGIMDZ is more profound, and the lowest ERGI(i)MDZ is 0.2 (60% inhibition) after EC ERY, 
and 0.25 (50% inhibition) after SS ERY. Due to the fast transit of ERY from GW mucosa to 
serosa compartment, the inhibition on GW metabolism fades away more quickly than that on 
hepatic metabolism. Both IV and PO (EC/SS) ERY inhibit ERhepMDZ, and the order of DDI 
magnitude depends on the order of Foral (IV > PO EC > PO SS). For the two PO ERY 
formulations, when they are simultaenouly administered with MDZ, more inhibition on hepatic 
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formulations), because hepatic ERY concentration can inhibit both pre-systemic and systemic 
MDZ hepatic metabolism, while only pre-systemic GW ERY (in GW mucosa) inhibits MDZ 
GW meatbolism. Maximum DDI on ERhepMDZ occurs at ~5 hours, when hepatic CYP3A activity 
achievs its nadir, and lowest ERhepMDZ is 0.18 (inhibited by 55%), 0.21 (inhibited by 47%), 0.27 
(inhibited by 32%) after IV, PO EC and PO SS ERY, respectively. 
a)                                                                           b) 
  
c)                                                                           d) 
 
Figure 8.22  Hepatic/GW extraction ratio of MDZ in presence of ERY (1,000 mg; IV: 15-
min infusion, PO: EC/SS) administered at various time intervals before 1 mg IV/3 mg PO 
MDZ. 
a) ERGIMDZ in presence of ERY b). (Inhibited/uninhibited) ERGIMDZ ratio in presence of ERY. c) 
ERhepMDZ in presence of ERY d). (Inhibited/uninhibited) ERhepMDZ ratio in presence of ERY. Red 
dash lines in a) and c) indicate ERGIMDZ and ERGIMDZ without ERY. Red dash lines in b) and d) 
indicate no inhibition on ERGIMDZ and ERhepMDZ (ratio = 1).  
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8.3.2.2 Linearity of MBI by ERY 
	
 To assess MBI linearity, kinact,appERY profiles were simulated at 1,000 mg IV-15min-infusion 
ERY or PO (EC/SS) ERY and plotted against ERY unbound tissue concentration in Figure 8.23. 
Except for GW mucosa concentration after PO EC ERY, all other concentrations at the sites of 
DDI are below KIERY, leading to apparent linear MBI (kinact,appERY is proportional to cuERY). In 
addition, regardless of ERY routes and interaction sites (i.e., liver or GW), kinact,appERY is much 
below kinactERY, indicating that MBI is not maxed out in all scenarios. 
	
Figure 8.23  Relationship between apparent inactivation rate constant of ERY (kinact,appERY) 
and unbound ERY tissue (liver or GW) concentrations after 1,000 mg ERY (IV 15min-
infusion, PO: EC/SS). 
Red dashed line represents KIERY, and black dashed line represents kinactERY. 
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8.3.2.3 Simulations of route-dependent DDI with various single doses of ERY 
	
 To compare the impact of ERY route of administration on DDI after various ERY single 
doses, the ratios of MDZ AUCR in presence of PO EC ERY and IV ERY are plotted against 
ERY single dose (Figure 8.24). To contrast with the MDZ - FLZ dose-dependency results, 
simulations were conducted when MDZ and ERY are dosed simultaneously.  
Hepatic CYP3A activity levels vs. time after IV ERY, hepatic and GW CYP3A activity 
levels vs. time after PO EC ERY (Figure 8.25) were also plotted to better interpret dose-
dependency of ERY on route difference.  
Regardless of MDZ route of administration, the ERY dose-dependency on DDI route 
difference is similar. At the lowest ERY dose (100 mg), there is no IV/PO (EC) ERY route 
difference, while with increasing doses, PO EC ERY produces a lower MDZ AUC increase than 
IV ERY, and the largest ERY route difference is observed at a dose of 2,000 mg (AUCRMDZPO-EC 
ERY/AUCRMDZIV-ERY = 0.7). For doses above 2,000 mg, the route difference between IV and PO 
EC ERY gradually declines, and at the largest simulated dose (10,000 mg), AUCRMDZPO-EC 
ERY/AUCRMDZIV-ERY is 0.75. When the two drugs are simultaneously administered, due to the lag 
time for ERY to enter GW mucosa, their DDI mainly reflectes metabolic inhibition in hepatic 
CYP3A metabolism, which is the reason that the route difference for ERY is similar for both IV 
and PO MDZ. Figure 8.25b, d, f illustrates that IV ERY doesn’t have any delay in inhibition of 
hepatic CYP3A, whereas PO ERY has ~0.2 hour delay in GW metabolic inhibition, and ~0.5 
hour delay in hepatic metabolic inhibition. Hepatic inhibition lasts longer than GW inhibition. 
When MDZ is concurrently administered with ERY, CYP3AI inhibition at the early time (0-6 
hours) is very important to the overall AUCR of MDZ, since MDZ concentration peaks 
immediately after IV administration and within 1 hour after PO administration. At very low 
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doses, both IV and PO ERY lead to trivial inhibition on hepatic CYP3A, while at very high 
doses, both routes largely inhibit hepatic CYP3A, reducing their route difference. It is at the 
middle dose (~2,000 mg), above clinically relevant doses, unbound hepatic concentration of 
ERY is close to KIERY, and the hepatic concentration difference of ERY translates into largest 
hepatic CYP3A inhibition difference. Unbound hepatic/GW mucosa ERY concentrations and 
relative CYP3A activity in liver and GW were simulated for the 10,000 mg ERY dose (Figure 
8.26), in comparison with 1,000 mg ERY dose. From Figure 8.26a - b, unbound hepatic 
concentrations of ERY after both routes are greater than KIERY for more than 30 hours, 
translating into similar inhibition on hepatic CYP3A after IV and PO EC ERY (Figure 8.26e). 
Unbound GW mucosa ERY concentrations at 10,000 mg PO EC dose are above KIERY for ~5 
hours, driving a large GW CYP3A inhibition difference compared with IV ERY (Figure 8.26c-d 
and f). However, when MDZ is concurrently dosed with ERY, GW CYP3A inhibition is only 
marginal, due to its absorption delay. 
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Figure 8.24  Ratio of MDZ AUCR by ERY (IV: 15-min infusion, PO: EC) after various 
ERY single dose. 
(MDZ was simultaneously administered with ERY). 
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a)                                                                          b) 
  
c)                                                                         d) 
  
e)                                                                         f) 
  
Figure 8.25  Relative CYP3A activity after various single doses of IV 15min infusion or PO 
EC ERY. 
a) Relative hepatic CYP3A activity levels vs. time after IV ERY (0-150 hours). b) Relative 
hepatic CYP3A activity levels vs. time after IV ERY (0-6 hours) c) Relative hepatic CYP3A 
activity levels vs.  time after PO EC ERY (0-150 hours). d) Relative hepatic CYP3A activity 
levels vs. time after PO EC ERY (0-6 hours) e) Relative GW CYP3A activity levels vs. time 
after PO EC ERY (0-150 hours) f) Relative GW CYP3A activity levels vs. time after PO EC 
ERY (0-6 hours) 
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a)                                                                          b) 
  
c)                                                                          d) 
  
e)                                                                         f)  
  
Figure 8.26  Plots of ERY unbound concentrations and relative CYP3A activity after 
10,000 mg and 1,000 mg ERY (IV: 15min infusion, PO: EC). 
a) ERY unbound hepatic concentration – time profiles (Cartesian plot). b) ERY unbound hepatic 
concentration – time profiles (Semi-log plot). c) ERY unbound GW mucosa concentration – time 
profiles (Cartesian plot). d) ERY unbound GW mucosa concentration – time profiles (Semi-log 
plot). e) Relative hepatic CYP3A activity in presence of ERY. f) Relative GW CYP3A activity 
in presence of ERY.  
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8.3.2.4 Simulations of route-dependent DDI with different ERY dosing intervals  
	
 The (inhibited/uninhibited) MDZ AUCR in presence of PO EC ERY is plotted against 
different ERY dosing regimens: 250 mg/500 mg/1,000 mg single dose (SD) or 250mg 
QID/500mg BID/1,000 mg QD (same daily dose) multiple doses (MD) in Figure 8.27. ERY 
unbound hepatic/GW mucosa concentrations after the three multiple dosing regimens were also 
simulated and plotted in Figure 8.28 and relative hepatic/GW activity in presence of single-
/repeat- doses PO EC ERY are showed in Figure 8.29.  
After ERY PO EC single dose, 1,000 mg SD increases IV MDZ AUC 38% more than 250 
mg SD (AUCR = 1.8 after 1,000 mg SD; AUCR = 1.3 after 250 mg SD), due to higher ERY 
unbound hepatic concentrations and stronger inhibition of hepatic CYP3A metabolism after 
1,000 mg SD (shown in Figure 8.28a and Figure 8.29a (dashed lines)). After PO MDZ, 1,000 
mg SD PO EC produces 2.6-fold higher AUC increase than 250 mg SD EC (AUCR = 4.1 after 
1,000 mg SD; AUCR = 1.6 after 250 mg SD) due to higher unbound ERY concentration and 
lower CYP3A level in liver and GW at 1,000 mg SD (shown in Figure 8.28b and Figure 8.29b 
(dashed lines)). Repeat- doses of EC ERY gives rise to higher AUCR than single-dose EC ERY 
at all the three repeat- dosing regimens; because both hepatic and GW CYP3A levels are 
considerably lower after repeat- EC doses than single dose (Figure 8.29). However, given same 
daily dose of 1,000 mg, 1,000 mg QD of EC ERY only induces a 17% and 36% higher AUCR 
than 250 mg QID for IV and PO MDZ, respectively. As shown in Figure 8.29, CYP3A activity 
levels in presence of 1,000 mg QD ERY has the lowest nadir, but the largest fluctuation, 
compared to the other two regimens. After MDZ administration (indicated as black dashed line 
in Figure 8.29), 1,000 mg QD can inhibit MDZ hepatic/GW metabolism to the greatest extent at 
the beginning, but the inhibitory effect quickly fades away, whereas 250 mg QID regimen yields 
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less fluctuating hepatic/GW CYP3A levels, so that the inhibitory effect is sustained for a longer 
time; thus, eventually, no significant difference in AUCR is found among the three multiple 
dosing regimens.  
The accumulation ratio for ERY unbound hepatic/GW mucosa AUC0-τERY and inhibited 
hepatic/GW AUC0-τCYP3A are plotted for different multiple dosing regimens in Figure 8.30. From 
Figure 8.30, inhibited hepatic and GW AUC0-τCYP3A both have more accumulation than hepatic 
and GW mucosa AUC0-τERY for all the three regimens, because ERY hepatic/GW mucosa 
concentrations have much shorter elimination t1/2 than hepatic and GW CYP3A (~14 hours). 
ERY hepatic elimination t1/2 is the same as plasma/pseudo steady-state t1/2 (~2 hours), and ERY 
GW mucosa t1/2 is even shorter than hepatic concentrations, due to the rapid transit of ERY to the 
GW serosa, and there is no accumulation on ERY GW mucosa concentration for all the multiple 
dosing regimens.  
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a) 
		
	
b) 
 
 
Figure 8.27  AUCR of MDZ in presence of single dose PO EC ERY 250 mg/500 mg/1,000 
mg or multiple doses PO EC ERY 250 mg QID/500 mg BID/1,000 mg QD (same daily 
dose). 
a) 1 mg IV MDZ was adminsitered 2 hours after SD EC, or 2 hours after the 1st dose of EC on 
the 5th day. b) 3 mg PO MDZ was adminsitered 2 hours after SD EC, or 2 hours after the 1st dose 
of EC on the 5th day. Red dashes lines represent no increase in MDZ AUC. 
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a) 
 
 
b) 
 
 
Figure 8.28  Unbound ERY concentration after PO EC 250 mg QID, 500 mg BID and 1,000 
mg QD. 
a) Unbound ERY hepatic concentration over time b) Unbound ERY GW mucosa concentration 
over time. Red dashed lines represent KIERY. 
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a) 
 
 
b) 
 
 
Figure 8.29  Relative CYP3A activity after PO EC ERY single dose (250 mg / 500 mg/ 1,000 
mg) or multiple doses (250 mg QID/ 500 mg BID/ 1,000mg QD). 
a) Relative hepatic CYP3A activity. B) Relative GW CYP3A activity. Black dashed lines 
represent the time when MDZ was administered. 
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Figure 8.30  (Steady-state) accumulation ratio (Rss) of ERY unbound hepatic/GW mucosa 
concentration, and inhibited hepatic/GW CYP3A after 250 mg QID / 500 mg BID / 1,000 
mg QD PO EC ERY. 
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 The (inhibited/uninhibited) MDZ AUCR in presence of PO SS ERY is plotted against ERY 
dosing regimen: 250 mg/500 mg/1,000 mg single dose (SD) or 250mg QID/500mg BID/1,000 
mg QD (same daily dose) multiple doses (MD) in Figure 8.31. ERY unbound hepatic/GW 
mucosa concentrations after the three multiple dosing regimens were also simulated and plotted 
in Figure 8.32 and relative hepatic/GW activity in presence of single-/repeat- doses PO EC ERY 
are showed in Figure 8.33. Similar as EC formulation, 1,000 mg SD SS increase IV MDZ AUC 
31% more than 250 mg SD (AUCR = 1.4 after 1,000 mg SD; AUCR = 1.1 after 250 mg SD), 
due to higher ERY unbound hepatic concentration and stronger inhibition on hepatic CYP3A 
metabolism after 1,000 mg SD (shown in Figure 8.32a and Figure 8.33a (dashed lines)). After 
PO MDZ, 1,000 mg SD PO EC produces a 2-fold higher AUC increase than 250 mg SD EC 
(AUCR = 2.7 after 1,000 mg SD; AUCR = 1.4 after 250 mg SD) due to higher unbound ERY 
concentration and lower CYP3A level in liver and GW at 1,000 mg SD (shown in Figure 8.32b 
and Figure 8.33b (dashed lines)). Multiple doses SS ERY gives rise to higher AUCR than single 
dose SS ERY at all the three multiple dosing regimens, because hepatic and GW CYP3A levels 
are considerably lower after multiple SS doses than single dose (Figure 8.32). However, given 
same daily dose of 1,000 mg, 1,000 mg QD of SS ERY causes only 16% and 23% higher AUCR 
than 250 mg QID for IV and PO MDZ, respectively. Due to lower Foral than EC, SS ERY has 
lower hepatic and GW mucosa concentration (Figure 8.32) and less inhibition on CYP3A 
(Figure 8.33) compared with EC, but the accumulation ratio (Figure 8.34) calculated for ERY 
unbound hepatic/GW mucosa AUC0-τERY and inhibited hepatic/GW AUC0-τCYP3A exhibit the same 
trend for different dosing regimens as EC formulation. 
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Figure 8.31  AUCR of MDZ in presence of single dose PO SS ERY 250 mg/500 mg/1,000 
mg or multiple doses PO SS ERY 250 mg QID/500 mg BID/1,000 mg QD (same daily dose). 
a) 1 mg IV MDZ was adminsitered 2 hours after SD SS, or 2 hours after the 1st dose of SS on the 
5th day. b) 3 mg PO MDZ was adminsitered 2 hours after SD SS, or 2 hours after the 1st dose of 
SS on the 5th day. Red dashes lines represent no increase in MDZ AUC. 
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b) 
 
 
Figure 8.32  Unbound ERY concentration after PO SS 250 mg QID, 500 mg BID and 1,000 
mg QD. 
a) Unbound ERY hepatic concentration over time b) Unbound ERY GW mucosa concentration 
over time. Red dashed lines represent KIERY. 
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a) 
 
b) 
 
 
Figure 8.33  Relative CYP3A activity after PO SS ERY single dose (250 mg / 500 mg/ 1,000 
mg) or multiple doses (250 mg QID/ 500 mg BID/ 1,000mg QD). 
a) Relative hepatic CYP3A activity. B) Relative GW CYP3A activity. Black dashed lines 
represent the time when MDZ was administered. 
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Figure 8.34  (Steady-state) accumulation ratio (Rss) of ERY unbound hepatic/GW mucosa 
concentration, and inhibited hepatic/GW CYP3A after 250 mg QID / 500 mg BID / 1,000 
mg QD PO SS ERY. 
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8.3.2.5 Simulation of route-dependent DDI between MDZ and hypothetical CYP3AI and 
between hypothetical CYP3A substrates and ERY 
8.3.2.5.1 Route-dependent DDI between MDZ and 3AIX4 
	
 To change ERY to a higher Foral CYP3AI (3AIX4), FabsERY was increased from 0.88 to 1.0, 
while hepatic and GW pre-systemic metabolism of ERY were kept unchanged from ERY.  
MDZ AUC in presence of IV/PO 3AIX4 with different administration time intervals were 
simulated, and AUCR of MDZ for each scenario is plotted against administration interval time as 
shown in Figure 8.35. Plots of 3AIX4 concentrations and corresponding relative CYP3A levels 
in GW and liver were simulated (Figure 8.36), based on the dosing regimen of 1,000 mg IV (15-
min infusion) or PO 3AIX4. For 3AIX4, Foral is higher than ERY, but because of its hepatic first-
pass metabolism, it is still only 71%, leading to slightly less hepatic CYP3A inhibition after PO 
than IV administration (maximal DDI: 2.1- vs. 2.2-fold).  However, since GW inhibition only 
occurs when both MDZ and 3AIX4 are dosed PO, the DDI magnitude after PO 3AIX4 is much 
higher than IV 3AIX4 (maximal DDI: 4.7- vs. 2.9-fold), when PO MDZ is administered more 
than 1 hour after 3AIX4. Although 3AIX4 has a short plasma t1/2 (~ 2 hours), the DDI lasts for 
about 4 days, as the MBI duration depends strongly on synthesis and degradation rates of 
CYP3A activity. Maximal DDI magnitude happens when hepatic or GW CYP3A level achieves 
its nadir (~2-5 hours).   
302	
	
 
	
Figure 8.35  MDZ AUCR by 3AIX4 (1,000 mg; IV: 15-min infusion, or PO) administered at 
various time intervals before 1 mg IV/3 mg PO MDZ. 
Red dash line indicates no inhibition on MDZ exposure. 
  
0.0
1.0
2.0
3.0
4.0
5.0
6.0
0 0.5 1 2 5 10 20 50 100
A
U
C
0-
∞
(i)
M
D
Z
/A
U
C
0-
∞
M
D
Z
Administration Time Interval (hr)
IV MDZ + IV 3AIX4
IV MDZ + PO 3AIX4
PO MDZ + IV 3AIX4
PO MDZ + PO 3AIX4
303	
	
 
a) b) 
	 	
c) d) 
	 	
	
Figure 8.36  Plots of 3AIX4 unbound concentrations and relative CYP3A activity under 
1,000 mg IV 15-min infusion or PO 3AIX4. 
a) 3AIX4 unbound hepatic concentration – time profiles. b) Relative hepatic CYP3A activity in 
presence of 3AIX4. c) 3AIX4 unbound GW mucosa concentration – time profiles. d) Relative 
GW CYP3A activity in presence of 3AIX4. Dash lines in a) and c) represent KI3AIX4 value. Dash 
lines in b) and d) represent no change in hepatic and GW CYP3A activity. 
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8.3.2.5.2 Route-dependent DDI between 3ASX1/2 and ERY 
	
Subsequently, two CYP3A substrate (3ASX1: no GW metabolism; 3ASX2: no GW 
metabolism and decreased hepatic metabolism) were derived from MDZ PBPK model. 3ASX1/2 
AUC in presence of 1,000 mg IV 15min infusion or PO (EC) ERY with different administration 
time intervals were simulated, and AUCR of 3ASX1/2 for each scenario is plotted against 
administration interval time as shown in Figure 8.37 and Figure 8.38.  
From Figure 8.37, PO 3ASX1 is consistently more sensitive to metabolic inhibition than 
after IV administration, because 3ASX still has pre-systemic hepatic metabolism after PO 
administration.  However, the impact of the ERY administration route is the same regardless of 
3ASX1 route, as the metabolic DDI is limited to hepatic metabolism of 3ASX1 (but no GW 
metabolism). 
 
 
Figure 8.37  3ASX1 AUCR by 1,000 mg ERY (IV: 15-min infusion or PO) administered at 
various time intervals before (1 mg IV/3 mg PO) 3ASX1. 
Red dash line indicates no inhibition on 3ASX1 exposure.  
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From Figure 8.38, no clinical significant IV-PO route difference (<10%) of 3ASX2 is 
observed, due to limited pre-systemic hepatic extraction (ERhep3AIX2 = 0.11) and no GW. To 
compare Figure 8.37 and Figure 8.38, maximal DDI between PO 3ASX2 and ERY is smaller 
than maximal DDI between PO 3ASX1 and ERY, because 3ASX1 has lower Foral than 3ASX2, 
and more potential to increase Foral in presence of ERY. Furthermore, AUCR of 3ASX2 are fairly 
constant when 3ASX2 is dosed less or equal than 5 hours apart from ERY (difference < 10%), 
while AUCR of 3ASX1 when ERY is simultaneously dosed is ~50% less than AUCR when 
ERY is dosed 5 hours before 3ASX1 (maximal DDI). The smaller impact of administration time 
interval for 3ASX2 is because 3ASX2 has a longer plasma t1/2, and even if inhibitory effect of 
ERY has a delay due to its mechanism-based inhibitory characteristics, the terminal phase of 
3ASX2’s PK profile is still significantly inhibited, resulting in similar DDI magnitude as delayed 
administration of 3ASX2 from ERY. 
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Figure 8.38  3ASX2 AUCR by 1,000 mg ERY (IV: 15-min infusion or PO) administered at 
various time intervals before (1 mg IV/3 mg PO) 3ASX2. 
Red dash line indicates no inhibition on 3ASX2 exposure.  
 
8.4 Conclusions 
 A semi-PBPK DDI model was developed to describe IV/PO MDZ PK profiles in presence of 
IV/PO (single-/repeat- doses) ERY. The model was validated against available reported MDZ 
plasma concentration – time profiles and exposure metrics from two DDI studies, in which 
IV/PO MDZ was co-administered with repeat- doses of PO ERY as EC or SS tablets; no IV 
ERY-MDZ DDI information was publically available.  
After optimizing model parameters (vmax,hepMDZ, kGLMDZ and FabsERY for study 28; vmax,hepMDZ, 
kGLMDZ and fvilli for study 603) based on MDZ PK profiles without ERY, the DDI model captures 
MDZ PK profiles in presence of ERY well, with deviations (%) of exposure metrics, ForalMDZ and 
MDZ AUCR less than ± 30% in most scenarios, confirming the validity of model and final 
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model parameters. Formal parameter sensitivity analyses were conducted for 6 uncertain model 
parameters; kdeg, KIERY, kinactERY and vmax,hep-3AERY are identified as pivotal parameters, that affect 
both MDZ systemic exposure metrics, and hepatic/GW CYP3A inhibition profiles.  
Simulations with the validated semi-PBPK-DDI model was performed to predict the DDI 
magnitude and time course for ERY (IV vs. PO) followed by MDZ (IV vs. PO) at various time 
intervals: 1) For IV MDZ, ERY causes more inhibition after IV than after PO (EC/SS) 
administration, due to ERY’s relatively low Foral (EC: ~60%; SS: ~30%) and higher unbound 
hepatic concentrations after IV than after PO administration. 2) For PO MDZ, although ERY still 
shows more inhibition after IV than after PO (simultaneous!) co-administration with MDZ, the 
inhibition by PO ERY gradually exceeds (for EC) or equals (SS) the one by IV ERY over time.  
This is primarily because ERY is assumed to enter the GW mucosa from the gut lumen only, due 
to its high plasma protein binding and low lipophilicity preventing serosal GW access; therefore, 
only PO (but not IV) ERY is assumed to cause inhibition of GW metabolism. 3) Regardless of 
the ERY route, PO MDZ is more sensitive to metabolic inhibition than IV MDZ. 4) Overall, the 
maximal DDI occurred when hepatic/GW CYP3A activity achieve their nadir, and the DDI 
duration exceeds the plasma/tissue t1/2 of ERY - due to the slow recovery of CYP3A activity, 
which depends on endogenous CYP3A synthesis and degradation rates.  
 Regarding MBI linearity, ERY unbound hepatic and GW mucosa concentrations at 1,000 mg 
for both routes remain mostly below KIERY, suggesting “linear” MBI at this dose. To compare 
ERY route differences across doses, a series of single ERY doses were simulated simultaneously 
administered with IV/PO MDZ. Regardless of MDZ route of administration, the dose-
dependency of ERY on DDI route difference is similar. Only slight ERY route differences are 
observed at the lowest and the highest single ERY dose, and the largest ERY route difference 
308	
	
 
(DDI: PO EC ERY < IV ERY) is observed at an intermediate ERY dose of 2000 mg when ERY 
unbound hepatic/GW concentration is close to KIERY.  
The impact of PO (EC/SS) ERY dosing interval (same daily dose) after multiple doses (for 5 
days) on route difference is also assessed, and it is shown that dosing interval only has only 
marginal (<20%) impact on route difference when MDZ is administered intravenously; when 
MDZ is administered orally, 1000 mg QD can produce slightly (~20-30%) more MDZ AUC 
increase than 250 mg QID regimen. 
 A high Foral MBI CYP3AI (3AIX4) and two CYP3A substrates (3ASX1/2) were also 
simulated to generalize the conclusions above. For DDI between MDZ and 3AIX4, marginal IV/ 
PO route difference of 3AIX4 is observed after IV MDZ. However, since GW inhibition only 
occurred when both MDZ and 3AIX4 are dosed PO, the DDI magnitude after PO 3AIX4 is much 
higher than IV 3AIX4, when PO MDZ is administered more than 1 hour after 3AIX4. For DDI 
between 3ASX1 and ERY, PO 3ASX1 is still inhibited more than IV 3ASX1, but the route 
effects of ERY are the same no matter how 3ASX1 is given. For DDI between 3ASX2 and ERY, 
marginal route difference of 3ASX2 is observed, due to its limited hepatic first-pass metabolism 
(low ERhep3ASX2).  
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CHAPTER 9 
 
 
9 OVERALL CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS 
	
	
	
	
9.1 Overall Conclusions 
 The focus of the project was to to use PBPK modeling in order to predict metabolic DDI for 
different routes of administration (IV vs. PO) for a prototypical CYP3A substrate, MDZ, and two 
prototypical CYP3AIs (FLZ and ERY), along with other, derived hypothetical CYP3A substrates 
and inhibitors. The ultimate goal is to generalize the obtained results and to identify key in-vitro 
and in-vivo substrate and inhibitor properties (e.g., Foral, terminal t1/2, contribution of gut wall and 
hepatic metabolism to overall first-pass extraction and CLtot, inhibitory mechanism and potency) 
as well as physiological characteristics (e.g., hepatic and gut wall CYP3A expression and turn-over 
kinetics) that are likely to impact significantly the magnitude and time course of the DDI, depending 
on the respective route of administration of substrate and/or inhibitor. As a result, generalized 
decision trees were proposed -using pivotal information about clinical PK/ADME/in-vitro DDI 
substrate and inhibitor properties- to assess the likelihood (and particular circumstances, e.g., timing 
of inhibitor relative to substrate administration) of clinically significant route differences in DDI 
magnitude between IV and PO administered substrate and/or inhibitor. 
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9.1.1 Substrate properties 
	
 Figure 9.1 illustrates the impact of administration route (IV vs. PO) of the victim drug on its 
metabolic inhibitory DDI. First, the contribution of CYP3A metabolism to overall systemic/pre-
systemic clearance of victim drug needs to evaluated, in order to determine whether a CYP3A DDI 
is likely clinically significant or not. Once the victim drug is confirmed to be a CYP3A substrate, 
and CYP3A metabolism has been found to be a major (fmCYP3A > 20%) elimination pathway 
(typically assessed from information integrating in vitro/in vivo ADME and DDI studies with 
prototypical CYP3AI), the impact of its route of administration (IV vs. PO) on DDI depends on 
whether it is subject to significant pre-systemic GW/hepatic CYP3A first-pass metabolism: 
If the victim drug is a high Foral drug, or a low Foral drug due to poor GI solubility or poor GI 
permeability (rather than pre-systemic CYP3A-mediated first-pass effects), the metabolic inhibition 
will likely be similar for the IV or PO route. Previous M&S for 3ASX2 confirmed this proposed 
rule for a high Foral victim drug. However, even the victim drug has high Foral or low Foral not due to 
first-pass metabolism, its unbound hepatic and GW concentration – time profiles after the IV and 
PO routes of administration are not exactly the same, and in some circumstances, the concentration 
difference in hepatocytes and enterocytes may still lead to minor route differences in DDI, 
especially for competitive or non-competitive metabolic inhibition. 
If the victim drug has extensive CYP3A-mediated GW and/or hepatic pre-systemic metabolism, 
it is expected to be more sensitive to metabolic inhibition after PO than after IV administration, 
because besides the inhibition of systemic clearance (decreasing CLtot), the pre-systemic first-pass 
metabolism is also inhibited (increasing Foral) by CYP3AIs, resulting in a greater increase in 
systemic exposure after PO than after IV administration. The extent of route difference between IV 
and PO routes is dependent on the ERhep of the victim drug: the higher ERhep a victim drug has, the 
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larger DDI route difference is expected between IV and PO administration (PO > IV). Previous 
M&S for MDZ and 3ASX1 confirmed this proposed rule for a victim drug with low-intermediate 
Foral. 
 
Figure 9.1  Proposed decision tree to determine the impact of route of administration 
(IV/PO) on the metabolic inhibitory DDI for the victim drug. 
	
	
9.1.2 CYP3AI properties 
	
 With respect to the perpetrator drug, Foral and inhibitory mechanism are two important 
determinants of the magnitude and time course of its route difference. Therefore, two decision trees 
are proposed in Figure 9.2 and Figure 9.3, to predict the the likely route of administration 
difference in DDI under different Foral and inhibitory mechanism of perpetrator drugs: 
First, to follow the decision tree in Figure 9.2, the perpetrator drug has to be identified as a 
potential CYP3AI, in order to produce any clinical significant CYP3A-mediated DDI, typically by 
in-vitro studies that are extrapolated in vivo and/or in-vivo DDI studies with a protocypical CYP3A 
substrate. Subsequently, confirmed CYP3AI are divided into two categories based on their Foral  
(high/not-high), using 70% as a proposed cut-off. For a high Foral CYP3AI, if victim drug doesn’t 
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have substantial pre-systemic GW metabolism (IV victim, or PO victim with no GW CYP3A 
metabolism), only marginal IV/PO route differences are expected. This is because for high Foral 
CYP3AI, their hepatic concentration – time profiles after IV and PO administration are similar, 
while their GW concentration – time profiles could be quite different, as shown in previous 
simulations for FLZ, 3AIX2 and 3AIX4 (see Chapter 6). M&S for IV MDZ and FLZ, IV MDZ 
and 3AIX2, IV MDZ and 3AIX4, IV/PO 3ASX1 and FLZ, IV/PO 3ASX2 and FLZ, IV/PO 3ASX2 
and 3AIX2 confirmed this proposed rule. 
On the other hand, if victim drug has extensive pre-systemic GW metabolism (after PO 
administration), PO CYP3AI produces more inhibition than IV CYP3AI, but the duration of the 
route difference depends on the DDI mechanism and whether the IV inhibitor can inhibit GW 
metabolism, i.e., has access to the enterocyte from the vascular side. Although it is typically difficult 
to definitively deterrmine whether the IV inhibitor can inhibit GW metabolism or not (for a 
conclusive determination, a protoctypical victim drug subject to GW metabolism, such as MDZ, 
needs to be chosen, and a DDI study between both IV and PO substrate and the IV inhibitor needs 
to be conducted), extrapolations can be made based on available in vitro/in vivo PK, BCS 
classification and physicochemical properties of the inhibitor: 
For a BCS class 1 CYP3AI with little plasma protein binding, such as FLZ and 3AIX2, the 
CYP3AI can enter enterocytes through both apical/GI luminal and basolateral/vascular sides. 
Hence, any IV-PO route difference for the inhibitor can only occur when the perpetrator drug is 
simultaneously dosed with PO victim drug, as the resulting GW concentration of CYP3AI and its 
GW inhibition of CYP3A are higher after PO than after IV administration only during its oral 
absorption phase. With increasing separation of victim drug from perpetrator drug administration 
(administered when CYP3AI’s systemic distribution has achieved its pseudo steady-state), 
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no/marginal CYP3AI route difference is expected. Previous M&S for PO MDZ and FLZ, PO MDZ 
and 3AIX2 confirmed this proposed rule (see Chapter 6). However, the magnitude and time course 
of the route difference is also affected by dosing regimen (i.e., dose, infusion time) of the CYP3AI, 
as well as the t1/2 of the CYP3AI relative to t1/2 of the substrate. In the simulations for the MDZ- 
FLZ DDI, 400 mg of FLZ gave rise to the largest route difference (~62%), while the lowest (40 mg) 
or highest (4,000 mg) simulated FLZ dose could not bring about a clinically significant DDI route 
difference (change in AUCR< 20%), due to their much lower (40 mg) or much higher (4,000 mg) 
hepatic/GW FLZ concentrations than corresponding KiFLZ. In addition, previous simulations were 
performed when IV FLZ was administered as 1-hour infusion, and different infusion times affect 
the cmax and tmax of hepatic and GW concentration – time profiles of FLZ after IV administration, 
potentially leading to a route difference. Furthermore, DDI simulations between 3ASX2, a long t1/2 
CYP3A substrate, and 3AIX2, a short t1/2 FLZ-derived CYP3AI demonstrated a smaller DDI than 
FLZ’s inhibition on 3ASX2 (see Chapter 6), suggesting that altering t1/2 for CYP3AI may affect 
both the magnitude and duration of DDI. 
For a BCS class 3 CYP3AI with high plasma protein binding, such as 3AIX4 (a ERY-like 
drug), a sustained IV-PO route difference for CYP3AI is expected, even if the victim drug is dosed 
further apart from the perpetrator drug. As opposed to FLZ and its derivatives discussed above, 
ERY and 3AIX4 can access the enterocyte via GI luminal/apical side, i.e., after PO administration, 
only, and no pseudo steady-state can be achieved between (systemic) plasma and GW mucosa. 
Hence, a continuous IV-PO route difference for 3AIX4 can be expected regarding the metabolic 
inhibition on GW metabolism (see Chapter 8).  
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Moreover, the duration and peak time of any DDI route difference are also governed by 
mechanism of inhibition, which will be discussed in Figure 9.3. As a consequence, multiple 
circumstances of route difference may be observed clinically, for different modes of inhibition. 
 For a low Foral CYP3AI, if victim drug doesn’t have substantial pre-systemic GW metabolism 
(IV victim, or PO victim without GW CYP3A metabolism), greater inhibition is expected after IV 
than after PO CYP3AI – assuming that PO and IV doses are identical. This is due to lower 
hepatic concentrations and less hepatic CYP3A inhibition after PO administration, given its low 
Foral. It is assumed that the low Foral of the inhibitor is not due to GW/hepatic first pass 
metabolism. Previous M&S for IV MDZ and ERY, IV MDZ and 3AIX1, IV MDZ and 3AIX3, 
IV/PO 3ASX1 and ERY, IV/PO 3ASX2 and ERY validated this proposed rule.  
However, if a drug has a low Foral, its clinical PO dose is usually increased to match systemic 
exposures after IV administration. Therefore, it may not be appropriate to compare route difference 
at the same clinical IV and PO inhibitor dose, when it has a low Foral. 
On the other hand, if the victim drug has extensive GW metabolism (after PO administration), 
the impact of inhibitor route of administration is difficult to predict, as it depends on the 
concentration – time profiles of CYP3AI in GW and liver relative to their corresponding potency 
values (Ki). The route difference of MBI CYP3AI can also be influenced by kinact and enzyme 
kinetics (natural synthesis/degradation rate constants). In the previous M&S, IV administration of 
3AIX1 and IV 3AIX3 produce more inhibition of PO MDZ than after PO administration; IV ERY 
produces a similar maximal inhibition on PO MDZ as PO (SS) ERY, but less maximal inhibition 
than PO (EC) ERY. This inconsistency is due to different dosing regimen (i.e., dose, dosing 
interval, formulation, administration time interval between victim and perpetrator), 
PK/physicochemical properties (Foral, terminal t1/2, permeability, fraction unbound in plasma) and 
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inhibition mechanism (MBI or non/-competitive) and potency of the CYP3AI, and have to be 
considered on a case-by-case basis. 
Another interesting finding is the DDI time course between 3ASX2 and ERY:  Prolonging the 
plasma (elimination) t1/2 of the CYP3A substrate can reduce the impact of administration time 
interval between victim and perpetrator, if perpetrator drug is a MBI. This is because even if the 
inhibitory effect of MBI is delayed relative to its tissue concentration, there is still a significant 
alteration of the terminal phase of the PK profile for a victim drug with long elimination t1/2, 
resulting in similar DDI magnitude after delayed administration of victim drug relative to 
perpetrator drug administration. This prolongation of t1/2 for the victim drug also reduces the DDI 
route difference for ERY, especially after PO 3ASX2, because the inhibition/reduction of its 
CLtot contributes more to the DDI magnitude than the increase in its Foral; as a consequence, the 
magnitude of inhibitor route difference becomes similar after IV and PO 3ASX2.  
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Figure 9.2  Proposed decision tree to determine the impact of route of administration (IV/PO) on the DDI for perpetrator drug 
(based on Foral).  
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 Figure 9.3 outlines the the difference between reversible (non-/competitive) inhibitors and 
irreversible inhibitors (MBI): 
 If the perpetrator drug is a non-/competitive CYP3AI, the peak and duration of its DDI are 
determined by its oral absorption rate and, for a given inhibitory potency (Ki), by its hepatic 
and/or GW concentration-time profiles. The plasma t1/2 of either the victim or the perpetrator 
may also affect the time course of the DDI. 
 If the perpetrator drug is a MBI CYP3AI, besides its inhibitory hepatic and/or GW 
concentration-time profiles, the peak and duration of DDI are also determined by the endogenous 
turn-over kinetics of CYP3A. Maximum inhibition occurs when GW/hepatic CYP3A activities 
achieve their nadir (which is delayed from their respective peak concentrations), and the DDI 
duration depends on hepatic/GW t1/2CYP3A (kdeg); if the plasma/hepatic/GW concentration t1/2 of 
the perpetrator drug is shorter than t1/2CYP3A (most likely scenario, although it is possible that the 
CYP3AI t1/2 can be longer than t1/2CYP3A, e.g., after extended-release/long acting dosage forms, 
resulting in flip-flop PK). In addition, the t1/2 of victim drug may also affect the time course of 
DDI route difference as discussed above. 
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Figure 9.3  Proposed decision tree to determine the impact of route of administration 
(IV/PO) on the DDI for perpetrator drug (based on mechanism of inhibition) 
	
	
Overall, this research project allows the identification of key substrate and inhibitor properties, 
likely to contribute to route of administration (IV vs. PO) differences in DDI magnitude and time 
course: 
 For a CYP3A substrate, its Foral, ERhep and ERGW are the three main properties that determine 
DDI route differences after CYP3A inhibition. 
 For a CYP3AI, its Foral and whether IV CYP3AI inhibits GW metabolism are the two key 
determinants for DDI route differences for inhibition of CYP3A substrates. 
For example, for a low ERhep CYP3A substrate/investigational drug without GW metabolism, if 
a pharmaceutical company had conducted a DDI study between their investigational drug after PO 
administration and a prototypical CYP3AI, they could extrapolate these results to IV administration 
of their drug with CYP3AI, and potentially avoid a prospective DDI study with their drug after IV 
administration CYP3AI. On the other hand, for a high ERhep CYP3A substrate and/or a victim drug 
subject to both intermediate-to-high ERhep and/or ERGW metabolism, even if the pharmaceutical 
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company had conducted DDI study between PO substrate and CYP3AI and observed a clinically 
significant DDI, it would be still necessary to prospectively assess the DDI between IV substrate 
and CYP3AI as well, because IV substrate is expected to be much less sensitive to the metabolic 
inhibition than PO substrate.  However, if the original PO substrate DDI study had demonstrated no 
clinically significant DDI, it is unlikely that IV substrate administration would result in a clinically 
significant DDI. 
Overall, this M&S approach can be leveraged prospectively in clinical drug development and 
regulatory decision-making by allowing extrapolation of a DDI from an available to a different 
route of administration and by helping decide whether a designated clinical DDI study may be 
necessary for a new/different route in order to support adequate product labeling recommendations. 
 
9.2 Limitations and Future Directions 
 In this M&S research project, no random sources of variability (i.e., inter-study variability, 
inter-individual variability, residual error) on parameters were incorporated in the PBPK model; 
as a consequence, some parameters (i.e., vmax,hepMDZ, fvilli, kGLMDZ, vmax,hepERY, vmax,bileERY, FabsERY) 
had to be adjusted for the validation from specific studies, in order to better characterize the 
respective observed PK profiles.  These parameter adjustments were supported by findings from 
the model-independent analysis in Chapter 3 and Chapter 7, section 7.3.1 (meta-analysis of 
MDZ and ERY), consistent with mechanistic reasoning, supported by the results of the 
sensitivity analyses and kept to a minimum.  Full-fledged Monte Carlo simulations (MCS) could 
be performed to incorporate statistical distributions for each/some parameters. However, due to 
the large number of parameters (n = 63) used in the semi-PBPK models and the unknown 
underlying distributions for most parameters, MCS were not used in this research. 
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 There are no individual clinical DDI studies that reported MDZ profiles after both IV and PO 
MDZ in presence of both IV and PO CYP3AI. FLZ is the only CYP3AI with a DDI study 
available where both IV and PO CYP3AI had been concomitantly administered with PO MDZ, 
assessing the impact of route of administration of FLZ in the same study. As to ERY, only PO 
ERY was used in the reported ERY - MDZ clinical DDI studies. Therefore, no DDI study results 
could be used to validate the IV FLZ and IV MDZ DDI model, or the IV ERY and IV/PO MDZ 
DDI model. In the DDI modeling development for ERY, the key assumption that only PO ERY 
(but not IV ERY) can inhibit GW metabolism of PO MDZ was made based on the PK and 
physicochemical properties of ERY. 
 Regarding model validation/qualification, besides visual inspection of predicted plasma 
concentration –time profiles for the drugs of interest, exposure metrics (i.e., AUC, cmax and tmax) 
of plasma PK profiles were calculated to compare with observed. If the same original parameters 
were used across all validation studies (FLZ, ERY individual semi-PBPK models), an empiric 
acceptance criterion of 0.5 – 2 fold of observed was used for the exposure metrics. If parameters 
were adjusted from the initial/original model parameters to account for inter-study differences 
(based on preliminary meta-analysis of the variability of certain parameters (MDZ individual, 
MDZ-FLZ DDI, MDZ-ERY DDI semi-PBPK models)), a tighter acceptance criterion of within ± 
30% of observed was used instead. 
The clinical significance of the PBPK-model predicted DDIs (expressed as change in AUCR 
of substrate drug), however, depends not only on exposure changes in plasma parent drug, but 
also any metabolite exposure changes (if they contribute to safety and/or efficacy), other known 
patient covariates that may affect substrate and/or CYP3AI PK, e.g., renal function for FLZ, 
inter-individual (random) variability as well as therapeutic windows for parent substrate 
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drug/metabolites and overall risk benefit analysis. 
Prospectively, these semi-PBPK DDI models can be extended to CYP3A inducers in order to 
investigate the impact of administration routes for DME inducers on DDI magnitude and time 
course.  Also, important patient intrinsic/extrinsic factors (e.g., age, gender, pharmacogenetics, 
etc.) can be included by modifying model parameters (e.g., enzyme expression levels, renal 
clearance, etc.) accordingly. In addition, DDI route of administration differences for 
victim/perpetrator drugs with metabolic inhibition of other DME, such as CYP2D6, can be 
assessed using a similar strategy. Finally, PBPK models for other routes of administration (e.g., 
intramuscular injection, transdermal penetration, pulmonary inhalation) can also be developed to 
assess their impact on DDI. 
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A. MDZ META-ANALYSIS
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A.1 Summary of MDZ meta-analysis after IV administration in absence of CYP3AI 
 MDZ Dosing regimen MDZ exposure metrics MDZ secondary PK parameters 
Study 
ID 
MDZ 
Route 
Dose AUCIVMDZ 
SD of  
AUCIVMDZ 
CLtot,pMDZ CLtot,bMDZ ForalMDZ Qhep ERhep ERpresys ERGI CLint,hepMDZ 
[mg/kg] [µg/L*hrs] [µg/L*hrs] [ml/min/kg] [ml/min/kg] [%] [ml/min/kg] [%] [%] [%] [mg/min/kg] 
1 IV 0.025 73.8 31.7 5.6 6.6 26% 21.4 31% 74% 63% 9.5 
8 IV 0.050 216.3 58.5 3.9 4.5 32% 21.4 21% 68% 60% 5.7 
11 IV 0.005 11.6 3.5 7.7 8.9 59% 21.4 42% 41% -1% 15.3 
11 IV 0.005 12.1 3.5 7.3 8.5 53% 21.4 40% 47% 12% 14.2 
16 IV 0.050 119.0 43.0 7.0 8.1 42% 21.4 38% 58% 33% 13.1 
17 IV 0.029 63.4 18.7 7.5 8.7 31% 21.4 41% 69% 48% 14.8 
18 IV 0.050 109.2 52.5 6.6 6.61 34% 21.4 26% 66% 54% 8.8 
20 IV 0.013 36.2 10.4 5.9 5.91 31% 21.4 28% 69% 57% 8.2 
21 IV 0.014 29.2 7.2 8.2 9.5 26% 21.4 45% 76% 56% 17.2 
22 IV 0.014 28.4 4.0 7.9 7.91 25% 21.4 37% 75% 61% 12.6 
23 IV 0.007 23.4 13.0 4.7 4.71 29% 21.4 22% 71% 62% 6.1 
25 IV 0.050 151.0 40.0 5.5 6.4 32% 21.4 30% 68% 54% 9.2 
26 IV 0.050 95.8   8.7 10.1 38% 21.4 47% 62% 37% 19.2 
28 IV 0.050 106.8   7.8 9.1 28% 21.4 42% 72% 52% 15.7 
30 IV 0.071 199.0 16.0 6.0 7.0 24% 21.4 33% 76% 65% 10.3 
201 IV 0.100 219.9   7.6 8.8 24% 21.4 41% 76% 59% 12.2 
202 IV 0.013 45.6   4.9 4.9a 26% 21.4 23% 74% 66% 6.3 
203 IV 0.030 80.7 5.9 6.2 7.2 27% 21.4 34% 73% 59% 8.7 
204 IV 0.029 125.8 83.7-268.7 3.8 4.4 22% 21.4 21% 78% 73% 4.6 
1582 IV  0.013 52.1 11.4 4.2 4.9  21.4 23%    5.2 
  0.013 48.9 10.1         
    0.013 48.0 12.9              
 
1 AUC were estimated using blood concentrations, thus CLtot,b was calculated.  
2 AUC of IV MDZ in CYP3A*1*1, CYP3A5*1*X and CYP3A5*X*X populations were provided, and an average AUC among three populations was 
calculated to generate secondary PK parameters. 
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 1'-OH-MDZ 4-OH-MDZ 
Study 
ID 
cmaxmet 
SD of 
cmaxmet 
tmaxmet 
Range of 
tmaxmet 
AUCIVmet SD of AUCIVmet MRIV 
SD of 
MRIV 
CLtot,pmet/fmet Foralmet' AUC 
SD of 
AUC MRIV SD of MRIV 
[ng/ml] [ng/ml] [h] [h] [µg/L*hrs] [µg/L*hrs]   [ml/min/kg] [%] [ml/min/kg] [%]  [ml/min/kg] 
1               8               11               11               16 3.7 1.2 0.5 0.25-1.5 22.61 8.3 0.18 0.07 36.9 0.92     
17               18               20               21               22               23               25 3.8 0.9 0.8 0.25-1.5 16.1 3.2 0.10 0.04 51.8 0.81     
26               28               30 6.9 0.7 0.5 0.17 24.5 3.8 0.12 0.01 48.6 0.78     
201     27.8  0.12  59.9 0.65     202     5.8 1.8 0.12 0.04 38.3 0.77     203 2.8 0.4   9.4 1.8 0.11 0.02 52.7 1.00     204 3.5 1.7-6.5 2.2 1.8-4.2 14.7 8.9-21.6 0.11 0.05 32.4 1.03 1.90 1.5-2.5 0.015 0.003 
158    
CYP3A5 
*1*1 4.6 1.1 0.08 0.02 47.5  0.75 0.21 0.010 0.004 
    
CYP3A5
*1*X 8.7 1.6 0.17 0.06 25.1  1.03 0.27 0.020 0.005 
    
CYP3A5
*X*X 8.1 3.0 0.15 0.05 27.0  1.30 0.44 0.027 0.006 
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 Study Design Demographics 
Study 
ID 
Sample 
size Cross-over 
Infusion 
time Age 
Weight 
(M: Male; F: Female) Gender Race Contraceptive 
  (Yes=1, No=0) [h] [yrs] [kg] M/F  (Yes=1, No=0) 1 8 1 0.50   8/0   
8 3 1 0.50 20-40  2/1   
11 12 1 0.50 42.8 80.6 11/1 White 0 
11         16 12 1 0.03 25.5 69 6/6  1 
17 9 0  26 77.5 for M, 59.7 for F 6/3 White 0 
18 16 1 0.50 20-40 78 for M, 65 for F 8/8 M: 6 White+2 Hispanic; F: 6 White+1 Black+ 1 Asian 1 
20 16 1  33 78 5/11 14 White+1 Asian+1 African American 1 
21 12 1  24 70 6/6  0 
22 10 1  27 74 5/5  0 
23 24 1 0.03      
25 10 1 0.03 23-29 65-100 10/0   
26 12 1 0.03 19-25 57-85 7/5  1 
28 6 0 0.03 20-22 56-70 2/4  1 
30 8 1  25 70 8/0   
201 8 1 0.25 22 69 4/4   
202 20 1  31.5 83 for M; 70 for F 10/10   
203 20 1 0.5 21-34 67 10/10   
204 8 1  21-46 70 8/0   
158 19 1  24 76 6/13 African American  
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 Sample analysis  
Study ID Sample time points Assay method LLOQ Comments 
 [h]  ng/ml  1 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 GC-MS   8 0.5,0.75,1,1.5,2,4,8,12 LC-MS 0.25 Sample size is small. 
11 0,0.5,1,2,3,4,8,12,24 LC-MS 0.1 IV 16h below LLOQ, large AUC variability 
11     16 0,0.25,0.5,1,1.5,2,3,4,5,6,7,8,10,12,18 HPLC 2 IV 5h under LLOQ, 1’-OH-MDZ above LLOQ 
17 0,0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,8 HPLC   18 0.083, 0.25, 0.5,0.75,1,1.5,2,2.5,3,4,5,6,8,10,12,24 GC-MS 0.25  20 Many UPLC-MS 0.1  21 0,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8 LC-MS 0.1  22 0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,7,8,9 LC-MS 0.125 MDZ given together with Alfitanil 
23 0,0.167,0.24,0.33,0.5,0.75,1,2,4,6,8,10,12,24 LC-MS 0.1 No information of volunteer, MDZ given together with digoxin 
25 0,0.25,0.5,1,1.5,2,3,4,6,8,12,24 HPLC 2 1ng/ml for 1’-OH-MDZ, not known if under LLOQ 
26 0,0.25,0.5,1,1.5,2,3,4,5,6,7,17 GC 0.1  28 0,0.25,0.5,0.75,1,2,3,4,5,6,7,8,18 GC  CL is provided instead of AUC 30 0,0.083,0.167,0.333,0.667,1,1.5,2,2.5,3.5,5,7,9,24 HPLC 1 CL is provided instead of AUC 
201 0,0.085,0.167,0.25,0.583,0.75,1,1.5,2,2.5,3,4,5,6,8 GLC 1 All above LLOQ 
202 0,0.083, 0.25,0.5,1,2,3,4,5,6 GC-MS 0.3  
203 0.25,0.5,0.67,0.83,1,1.25,1.5,2,3,4,6,8 LC-MS 0.5 Contraceptive included. Given together with sugar cream, AUC0-8h 
204 0,0.083,0.167,0.33,0.5,0.67,1.5,2,4,6,8,10,12 LC-MS 0.05 Nonsmoker 
158 0,0.083,0.167,0.25,0.75,1,2,3,4,6,8,10,12 GC-MS 0.1            
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A.2 Summary of MDZ meta-analysis after PO administration in absence of inhibitors 
 
MDZ dosing 
regimen MDZ exposure metrics 
MDZ secondary PK 
parameters 1’-OH-MDZ 
Study 
ID 
MDZ 
Route Dose AUCPO
MDZ SD of AUCPOMDZ 
cmaxMDZ 
SD of 
cmaxMDZ 
CLtot,pMDZ/ 
ForalMDZ 
CLtot,bMDZ/ 
ForalMDZ 
cmaxmet 
SD of 
cmaxmet 
tmaxmet 
Range of 
tmaxmet 
AUCPOmet 
SD of 
AUCPOmet 
MRPO 
SD of 
MRPO 
  [mg/kg] [µg/L*hrs] [µg/L*hrs] [ng/ml] [ng/ml] [mg/min/kg] [mg/min/kg] [ng/ml] [ng/ml] [h] [h] [µg/L*hrs] [µg/L*hrs]   1 PO 0.075 57.1 22.3 20.8 5.8 21.9 25.5         
8 PO 0.050 69.0 15.7 15.8 2.8 12.1 14.0         
11 PO 0.025 31.9 12.4 7.0 2.2 13.1 15.2         
11 PO 0.025 30.1 11.7 6.6 1.7 13.8 16.1         
16 PO 0.109 108.0 59.3 26.9 8.6 16.8 19.5 8.7 1.9 1.5 1-3 45.4 15.1 0.4 0.1 
17 PO 0.086 58.2 31.1 19.1 8.1 24.5 28.5         
18 PO 0.056 41.3 18.1 8.8  19.4 19.4         20 PO 0.026 22.7 9.4   18.8 18.8         21 PO 0.043 21.3 10.3 8.8 4.5 33.5 39.0         
22 PO 0.041 20.9 4.2 9.1 2.4 32.3 32.3         
23 PO 0.027 27.4 8.0 7.7 2.1 16.2 16.2 3.1 1.6 10.2 4.6 10.2 4.6 0.4 0.2 
25 PO 0.094 91.0 30.0 24.1 7.2 17.2 20.0 8.2 2.7 1 0.5-2.0 24.4 5.7 0.3 0.1 
26 PO 0.107 78.0 24.0 28.0 9.0 22.9 26.6         
28 PO 0.244 200.0 16.7 70.0 9.0 20.3 23.6         
30 PO 0.214 143.0 26.0   25.0 29.0 29.6 5.2 0.6 0.2 57.2 9.6 0.4 0.0 201 PO 0.109 45.33  25.0 5.0 40.0 46.5 12.0 2.0 0.8 0.1 19.7  0.4 0.0 202 PO 0.027 23.93    18.6 18.6     8.9 3.1 0.4 0.1 203 PO 0.060 44.3 7.5 24.6 7.6 22.5 26.4 12.2 4.9   18.8 7.0 0.4 0.2 
204 PO 0.107 102.9 64-163.7 63.1 25.9-80.2 17.4  36.9 15-52.6 5.8 1.8-21.8 56.6 30.7-91.9 0.5  
103 PO 0.104 113.0 16.4 37.4 3.9 15.4 24.8 14.7 1.5   41.2 5.1 0.4 0.4 
 
3 AUCPOMDZ was calculated by apparent total clearance (CLtot,pMDZ/ForalMDZ). 
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 1’-OH-MDZ secondary PK parameters 4-OH-MDZ exposure metrics 
Study 
ID 
CLtotmet/fmet/
Foralmet' 
AUCsysmet AUCpresysmet AUChepmet AUCpresys-hepmet AUCpresys-GImet AUCPOmet 
SD of 
AUCPOmet 
MRPO 
SD of 
MRPO 
 [ml/min/kg] [µg/L*hrs] [µg/L*hrs] [µg/L*hrs] [µg/L*hrs] [µg/L*hrs] [µg/L*hrs] [µg/L*hrs]   
1           8           11           11           16 39.9 20.5 24.8 30.2 9.7 15.2     17           18           20           21           22           23 43.6          25 64.0 9.7 14.7 13.0 3.3 11.4     26           28           30 62.4 17.6 39.6 24.2 6.6 33.0     201 92.0 7.3 12.4 11.1 3.9 8.6     202 49.8 3.0 5.9 3.9 0.9 5.0     203 52.8 5.2 13.7 7.2 2.0 11.6     204 31.5 12.0 44.6 14.5 2.5 42.1 6.3 5.4-9.8 0.06 0.01 
103 42.1          
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 Study design 
Study ID Sample size Crossover Age Weight M: Male; F: Female 
Gender 
M: Male: F: Female Race Contraceptive 
  (Yes=1, No=0) [yrs] [kg] M/F  (Yes=1, No=0) 1 12 1      8 3 1 20-40  2/1   11 12 1 42.8 80.6 11/1 White 0 
11        16 12 1 25.5 69 6/6  1 17 9 0 26 77.5 for M, 59.7 for F 6/3 White 0 
18 16 1 20-40 78 for M, 65 for F 8/8 M: 6 White+2 Hispanic; F: 6 White+1 Black+ 1 Asian 1 
20       1 21 12 1 24 70 6/6  0 22 10 1 27 74 5/5  0 23 23 1      25 10 1 23-29 65-100 10/0   26 12 1 19-25 57-85 7/5  1 28 12 0 18-29 50-73 3/9  1 30 8 1 25 70 8/0   201 8 1 22 69 4/4   202        203 20 1 21-34 67 10/10   204 8 1 21-46 70 10/0   103 9 1 19-25 52-92 5/4   
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 Sample Analysis  Study 
ID Sample time points Assay method LLOQ Comments 
 [h]  [ng/ml]  1 before, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24    8 0.5,0.75,1,1.5,2,4,8,12,24 LC-MS 0.25 Sample size is small. 
11 before,0.5,1,2,3,4,8,12,24 LC-MS 0.1 IV 16h below LLOQ, large AUC variability 
11     16 before,0.5,1,1.5,2,3,4,5,6,7,8,10,12,18 HPLC 2 IV 5h under LLOQ, 1’-OH-MDZ above LLOQ 
17 0,0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,8,12,24 HPLC   18 0.083, 0.25, 0.5,0.75,1,1.5,2,2.5,3,4,5,6,8,10,12,24 GC-MS 0.25  20     21 0,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8 LC-MS 0.1  22 0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,7,8,9 LC-MS 0.125 MDZ given together with Alfitanil 
23 0,0.25,0.5,0.75,1,1.5,2,4,6,8,10,12,24 LC-MS 0.1 No information of volunteer, MDZ given together with digoxin 
25 0,0.5,1,1.5,2,3,4,6,8,12,24 HPLC 5 1ng/ml for 1’-OH-MDZ, not known if under LLOQ 
26 0,0.5,1,1.5,2,3,4,5,6,7,17 GC 0.1  28 0,0.25,0.5,0.75,1,2,3,4,5,6,18 GC  CL is provided instead of AUC 30 0,0.083,0.167,0.333,0.667,1,1.5,2,2.5,3.5,5,7,9,24 HPLC 1 CL is provided instead of AUC 
201 0,0.085,0.167,0.25,0.583,0.75,1,1.5,2,2.5,3,4,5,6,8  1 All above LLOQ 
202 0,0.25,0.5,1,2,3,4,5,6    203 0,0.16,0.33,0.5,0.75,1,1.5,2,3,4,5,6 LC-MS 1.61 Contraceptive included. Given together with sugar cream, AUC0-8h 
204 0,0.167,0.33,0.5,0.67,1.5,2,3,4,6,8,10,12 LC-MS 0.05 Nonsmoker 
103 before, 0.5,1,1.5,2,3,4,5,6,7,17 HPLC 1  
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A.3 Summary of MDZ meta-analysis after IV administration in presence of CYP3AI 
 MDZ dosing regimen Inhibitor MDZ exposure metrics Study ID MDZ Route Dose Name Category Route Dose AUCPOMDZ SD of AUCPOMDZ 
  [mg/kg]     [µg/L*hrs] [µg/L*hrs] 1 IV 0.025 Telithromycin ABX PO Day 2-7: 800mg QD 159.0 57.2 
8 IV 0.050 Diltiazem DTZ PO Day 1-6: 120mg BID 372.0 58.0 
11 IV 0.005 Posaconazole Azole PO Day 1-7: 200mg BID 51.3 22.1 
  0.005 Posaconazole Azole PO Day 1-7: 400mg BID 72.3 33.3 11 IV 0.005 Ketoconazole Azole PO Day 1-7: 400mg BID 95.2 25.7 
16 IV 0.050 Saquinavir PI PO Day 1-5: 1200mg TID 296.0 133.0 
17 IV 0.029 Ketoconazole Azole PO Day 1-2: 200mg BID 300.0 104.0 
18 IV 0.050 Clarithromycin ABX PO Day 2-8: 500mg BID 300.1 102.3 
20 IV 0.013 Ritonavir PI PO Day 3-17: 400mg BID 120.0 23.6 
 IV 0.013 Nelfinavir PI PO Day 3-17: 400mg BID 66.3 22.0 21 IV 0.014 Fluconazole Azole PO SD: 100mg 37.0 9.2 
  0.014 Fluconazole Azole PO SD: 200mg 42.5 10.1 
  0.014 Fluconazole Azole PO SD: 400mg 56.6 17.4 22 IV 0.014 Troleandomycin ABX PO SD: 500mg 132.0 46.0 
 IV 0.014 Grapefruit juice GFJ PO Day 1: 8oz; Day 2:3oz (double strength) 35.5 17.4 23 IV 0.007 Telaprevir PI PO Day 8-23: 750mg BID 115.0 38.4 
25 IV 0.050 Voriconazole Azole PO Day 1-2: 200mg BID 534.0 88.0 
26 IV 0.050 Itraconazole Azole PO Day 1-6: 200mg QD 308.6  
  0.050 Fluoconazole Azole PO Day 1: 400mg qd; Day 2-6: 200mg QD 193.8  28 IV 0.050 Erythromycin ABX PO Day 1-7: 500mg TID 231.5  30 IV 0.071 Grapefruit juice GFJ PO SD: 200ml 207.0 15.0 
158 IV 0.013 Fluconazole Azole PO SD: 400mg 74.0 195.5 
  0.013 Fluconazole Azole PO SD: 400mg 85.3 224.8 
  0.13 Fluconazole Azole PO SD: 400mg 100.4 186.3 
ABX: antibiotics; DTZ: diltiazem; PI: proteinase inhibitor; GFJ: grape fruit juice 
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 MDZ secondary PK paramters 
Study 
ID 
CLtot,pMDZ CLtot,bMDZ ForalMDZ Qhep ERhepMDZ ERpresysMDZ ERGIMDZ CLint,hepMDZ 
[mg/min/kg] [mg/min/kg] [%] [ml/min/kg] [%] [%] [%] [ml/min/kg] 
1 2.6 3.0 74% 21.4 14% 26% 13% 3.6 
8 2.2 2.6 74% 21.4 12% 26% 15% 3.0 
11 1.6 1.9 62% 21.4 9% 38% 32% 2.1 
 1.2 1.3 46% 21.4 6% 54% 50% 1.4 
11 0.9 1.0 48% 21.4 5% 52% 49% 1.1 
16 2.8 3.3 87% 21.4 15% 13% -3% 3.9 
17 1.6 1.8 80% 21.4 9% 20% 13% 2.0 
18 2.4 2.4 86% 21.4 9% 14% 5% 2.6 
20 1.8 1.8 78% 21.4 8% 22% 15% 1.9 
 3.2 3.2 58% 21.4 15% 42% 31% 3.8 
21 6.4 6.4 42% 21.4 30% 58% 41% 9.2 
 5.6 5.6 55% 21.4 26% 45% 25% 7.6 
 4.2 4.2 62% 21.4 20% 38% 23% 5.2 
22 1.7 1.7 85% 21.4 8% 15% 7% 1.9 
 6.3 6.3 37% 21.4 30% 63% 47% 9.0 
23 1.0 1.0 80% 21.4 5% 20% 16% 1.0 
25 1.6 1.8 85% 21.4 8% 15% 7% 2.0 
26 2.7 3.1 87% 21.4 15% 13% -2% 3.7 
 4.3 5.0 73% 21.4 23% 27% 4% 6.5 
28 3.6 4.2 78% 21.4 20% 22% 3% 5.2 
30 5.8 6.7 35% 21.4 31% 65% 49% 9.7 
158 3.0 3.4       
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 1'-OH-MDZ 4-OH-MDZ  
Study 
ID cmax
met SD of cmaxmet 
tmaxmet Range of tmax AUCIVmet 
SD of 
AUCIVmet 
MRIV SD of MRIV CLtot,pmet/fmet Foralmet’ AUCIVmet SD of AUCIVmet MRIV SD of MRIV 
 ng/ml [ng/ml] [h[ [h] [µg/L*hrs] [µg/L*hrs]   [ml/min/kg] [%] [µg/L*hrs] [µg/L*hrs]   1               8               11                              11               16 2.1 1.2 0.5 0.25-3 23.68 14.80 0.08 0.05 35.19 0.87     17               18               20                              21                                             22                              23               25 3.1 1.2 2 1.0-3.0 27.0 13.1 0.0 0.0 30.9 1.20     26                              28               30 8.2 1.4 0.48 0.13 26.1 3.9 0.1 0.0 45.6 0.95     158    CYP3A5 *1*1 5.7 0.8 0.1 0.0 38.7  1.64 0.48 0.02 0.006     CYP3A5*1*X 10.6 3.2 0.1 0.0 20.8  2.39 0.75 0.03 0.004     CYP3A5*X*X 10.5 3.1 0.1 0.0 20.8  3.62 0.82 0.04 0.005 
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 Study design Demographics 
Study 
ID Sample size Crossover Infusion time Age 
Weight 
M: Male; F: Female 
Gender 
M: Male: F: Female Race 
  (Yes=1, No=0) [h] [yrs] [kg] M/F  1  1 0.50   12/0  8 3 1 0.50 20-40  2/1  11 12 1 0.50 42.8 80.6 11/1 White 
        11        16 12 1 0.03 25.5 69 6/6  17 9 0  26 77.5 for M, 59.7 for F 6/3 White 
18 16 1 0.50 20-40 78 for M, 65 for F 8/8 M: 6 White+2 Hispanic; F: 6 White+1 Black+ 1 Asian 
20                21 12 1  24 70 6/6                  22 10 1  27 74 5/5          23 22  0.03     25 10 1 0.03 23-29 65-100 10/0  26 12 1 0.03 19-25 57-85 7/5          28 6 0 0.03 20-22 56-70   30 8 1  25 70 8/0  158 19 1  24 76 6/13 African American 
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 Sample Analysis 
Study ID Sample time points Assay 
method 
LLOQ Comments 
 [h] [ng/ml]  
1 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 48 GC-MS   
8 0,0.5,0.75,1,1.5,2,4,8,12 LC-MS 0.25 Sample size is small. 
11 0,0.5,1,2,3,4,8,12,24 LC-MS 0.1       11    Long duration of Midazolam, may cause auto-induction of CYP3A. 16 0,0.25,0.5,1,1.5,2,3,4,5,6,7,8,10,12,18 HPLC 2 IV 12h under LLOQ 
17 0,0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,8 HPLC   18 0.083, 0.25, 0.5,0.75,1,1.5,2,2.5,3,4,5,6,8,10,12,24 GC-MS 0.25  20          21 0,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8 LC-MS 0.1 Inhibitor single dose 
          22 0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,7,8,9,10,12 LC-MS 0.125 MDZ give together with Alfitanil 
     23 0,0.167,0.24,0.33,0.5,0.75,1,2,4,6,8,10,12,24 LC-MS 0.1 No information of volunteer, MDZ given together with digoxin 
25 0,0.25,0.5,1,1.5,2,3,4,6,8,12,24 HPLC 5  26 0,0.5,1,1.5,2,3,4,5,6,7,17 GC 0.1 contraceptive steroids were used; CL is provided, instead of AUC 
     28 0,0.25,0.5,0.75,1,2,3,4,5,6,7,8,18 GC  CL is provided, instead of AUC 30 0,0.083,0.167,0.333,0.667,1,1.5,2,2.5,3.5,5,7,9,24 HPLC 1 Single dose of inhibitor 
158 0,0.083,0.167,0.25,0.75,1,2,3,4,6,8,10,12 GC-MS 0.1            
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A.4 Summary of MDZ meta-analysis after PO administration in presence of CYP3AI 
 MDZ dose regimen Inhibitor MDZ exposure metrics 
Study 
ID 
MDZ 
Route Dose Name Category Route Dose AUCPO
MDZ SD of AUCPOMDZ 
cmaxMDZ 
SD of 
cmaxMDZ 
 [mg/kg]     [µg/L*hrs] [µg/L*hrs] [ng/ml] [ng/ml] 1 PO 0.075 Telithromycin ABX PO Day 2-7: 800mg QD 354.0 145.1 54.6 15.8 
8 PO 0.050 Diltiazem DTZ PO Day 1-6: 120mg BID 276.7 33.3 41.3 14.0 
11 PO 0.025 Posaconazole Azole PO Day 1-7: 200mg BID 159.0 54.1 15.4 3.1 
  0.025 Posaconazole Azole PO Day 1-7: 400mg BID 168.0 42.0 16.3 3.6 11 PO 0.025 Ketoconazole Azole PO Day 1-7: 400mg BID 230.0 34.5 18.1 2.0 
16 PO 0.109 Saquinavir PI PO Day 1-5: 1200mg TID 559.0 258.0 63.2 16.3 
17 PO 0.086 Ketoconazole Azole PO Day 1-2: 200mg TID 719.0 181.0 81.0 28.9 
18 PO 0.056 Clarithromycin ABX PO Day 2-8: 500mg BID 289.0 120.4 34.4  20 PO 0.026 Ritonavir PI PO Day 3-17: 400mg BID 188.0 33.0   
  0.026 Nelfinavir PI PO Day 3-17: 400mg BID 77.4 51.5   21 PO 0.043 Fluconazole Azole PO SD: 100mg 46.1 13.0 15.6 6.1 
  0.043 Fluconazole Azole PO SD: 200mg 70.7 20.2 19.0 7.9 
  0.043 Fluconazole Azole PO SD: 400mg 105.0 30.0 24.9 8.1 22 PO 0.041 Troleandomycin ABX PO SD: 500mg 338.0 95.0 35.5 14.9 
 PO 0.041 Grapefruit juice GFJ PO 
Day 1: 8oz; Day 2:3oz 
(double strength) 39.5 6.4 15.6 4.2 
23 PO 0.027 Telaprevir PI PO Day 8-23: 750mg BID 369.0 116.0 22.3 6.5 
25 PO 0.094 Voriconazole Azole PO Day 1-2: 200mg BID 855.0 104.0 86.6 26.2 
26 PO (Day 6) 0.107 Itraconazole Azole PO Day 1-6: 200mg QD 578.0 142.0 88.0 15.0 
 PO (Day-6) 0.110 Fluoconazole Azole PO 
Day 1: 400mg QD; Day 2-6: 
200mg QD 313.0 117.0 61.0 16.0 
28 PO 0.244 Erythromycin ABX PO Day 1-7: 500mg TID 883.3 116.7 189.0 16.0 
30 PO 0.214 Grapefruit juice GFJ PO SD: 200ml 217.0 31.0 189.0 16.0 
103 PO 0.104 Fluconazole Azole IV SD: 400mg 389.0 37.2 66.8 8.0 
 PO 0.104 Fluconazole Azole PO SD: 400mg 421.0 42.1 85.9 9.8 
 1’-OH-MDZ exposure metrics 1’-OH-MDZ secondary PK parameters 
Study ID cmax
met SD of cmaxmet 
tmaxmet 
Range of 
tmax 
AUCPOmet 
SD of 
AUCPOmet 
MRPO 
SD of 
MRPO 
CLtot,pmet/fmet/Foralmet' AUCsysmet AUCpresysmet 
[ng/ml] [ng/ml] [h] [h] [µg/L*hrs] [µg/L*hrs]   [ml/min/kg] [µg/L*hrs] [µg/L*hrs] 1            8            11                        
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11            16 5.4 1.8 2 1-4 44.72 22.36 0.08 0.04 40.51 44.7 0.0 
17            18            20                        21                                    22                        23 0.42 0.18   6.2 4.5 0.0 0.0 71.5   25 7.7 3.8 1 0.5-6.0 60.8 22.1 0.1 0.0 25.7 43.2 17.6 
26                        28            30 29.6 5.3 1.27 0.26 74.6 14.6 0.3 0.0 47.9 27.4 47.2 
103 11.9 1.7   61.8 8.0 0.2 0.2 28.1    13.3 1.9   64.3 9.7 0.2 0.2 27.0   
 
 
 
 
 
 
 1’-OH-MDZ Study design Demographics 
Study ID AUChepmet AUCpresys-hepmet AUCpresys-GImet Sample size Crossover Age 
Weight 
M: Male; F: Female 
Gender 
M: Male; F: Female Race 
 [µg/L*hrs] [µg/L*hrs] [µg/L*hrs]  (Yes=1, No=0) [yrs] [kg] M/F  1    3 1     8    3 1 20-40  2/1  
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11    12 1 42.8 80.6 11/1 White           11          16 51.3 6.6 -6.6 12 1 25.5 69 6/6  17    9 0 26 77.5 for M, 59.7 for F 6/3 White 
18    16 1 20-40 78 for M, 65 for F 8/8 
M: 6 White+2 Hispanic; 
F: 6 White+1 Black+ 1 Asian 
20                    21    12 1 24 70 6/6                      22    10 1 27 74 5/5            23    21      25 46.6 3.3 14.2 10 1 23-29 65-100 10/0  26    12 1 29 72 7/5            28    12 0 18-29 50-73 3/9  30 37.1 9.8 37.5 8 1 25 70 8/0  103    9 1 19-25 52-92 5/4            
 
 
 
 
 
 Sample Analysis     Study 
ID 
Sample time points Assay method LLOQ Comments 
[h]  [ng/ml]  
1 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 (day1,6) GC-MS   
8 0,0.5,0.75,1,1.5,2,4,8,12,24 LC-MS 0.25 Sample size is small. 
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11 0,0.5,1,2,3,4,8,12,24 LC-MS 0.1  
     
11     16 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,18 HPLC 2  17 0,0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,8 HPLC   18 0.083, 0.25, 0.5,0.75,1,1.5,2,2.5,3,4,5,6,8,10,12,24 GC-MS 0.25  20          21 0,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8 LC-MS 0.1 Inhibitor single dose 
          22 0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,7,8,9,10,12 LC-MS 0.125 MDZ give together with Alfitanil 
     
23 0,0.25,0.5,0.75,1,1.5,2,4,6,8,10,12,24 LC-MS 0.1 No information of volunteer, MDZ given together with digoxin 
25 0,0.5,1,1.5,2,3,4,6,8,12,24 HPLC 5  26 0,0.5,0.75,1,1.5,2,2.5,3,4,6,8 LC-MS 0.25 Cocktail administration 
     28 0,0.25,0.5,0.75,1,2,3,4,5,6,18 GC  CL is provided, instead of AUC 30 0,0.083,0.167,0.333,0.667,1,1.5,2,2.5,3.5,5,7,9,24 HPLC 1 Single dose of inhibitor 
103 before, 0.5,1,1.5,2,3,4,5,6,7,17 HPLC 1 1 woman uses oral contraceptive 
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B. SENSITIVITY ANALYSIS OF FLZ 
 
a)                                                                           b) 
 
 
c) 
 
 
Figure B.1 Sensitivity analysis of FLZ concentrations after IV administration to the change 
in fpv. a) FLZ unbound blood concentration – time profile (top line: fpv = 0.0; middle line: fpv = 
0.5; bottom line: fpv = 1.0) b) FLZ unbound hepatic concentration – time profile (top line: fpv = 
1.0; middle line: fpv = 0.5; bottom line: fpv = 0.0) c) FLZ unbound GW concentration – time 
profile (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.2 Sensitivity analysis of FLZ concentrations after IV administration to the change 
in Kp,hepFLZ. a) FLZ unbound blood concentration – time profile (top line: Kp,hepFLZ = 0.5; middle 
line: Kp,hepFLZ = 1.0; bottom line: Kp,hepFLZ = 2.0) b) FLZ unbound hepatic concentration – time 
profile (top line: Kp,hepFLZ = 2.0; middle line: Kp,hepFLZ = 1.0; bottom line: Kp,hepFLZ = 0.5) c) FLZ 
unbound GW concentration – time profile (top line: Kp,hepFLZ = 0.5; middle line: Kp,hepFLZ = 1.0; 
bottom line: Kp,hepFLZ = 2.0) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.3 Sensitivity analysis of FLZ concentrations after IV administration to the change in 
Kp,GWFLZ. a) FLZ unbound blood concentration – time profile (Kp,GWFLZ = 0.5; middle line: 
Kp,GWFLZ = 1.0; bottom line: Kp,GWFLZ = 2.0) b) FLZ unbound hepatic concentration – time 
profile (top line: Kp,GWFLZ = 0.5; middle line: Kp,GWFLZ = 1.0; bottom line: Kp,GWFLZ = 2.0) c) FLZ 
unbound GW concentration – time profile (top line: Kp,GWFLZ = 2.0; middle line: Kp,GWFLZ = 1.0; 
bottom line: Kp,GWFLZ = 0.5) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.4 Sensitivity analysis of FLZ concentrations after IV administration to the change 
in CLint,hepFLZ. a) FLZ unbound blood concentration – time profile (top line: CLint,hepFLZ = 0.05; 
middle line: CLint,hepFLZ = 0.1; bottom line: CLint,hepFLZ = 0.2) b) FLZ unbound hepatic 
concentration – time profile (top line: CLint,hepFLZ = 0.05; middle line: CLint,hepFLZ = 0.1; bottom 
line: CLint,hepFLZ = 0.2) c) FLZ unbound GW concentration – time profile (top line: CLint,hepFLZ = 
0.05; middle line: CLint,hepFLZ = 0.1; bottom line: CLint,hepFLZ = 0.2) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.5  Sensitivity analysis of FLZ concentrations after IV administration to the 
change in CLrenFLZ. a) FLZ unbound blood concentration – time profile (top line: CLrenFLZ = 0.1; 
middle line: CLrenFLZ = 0.2; bottom line: CLrenFLZ = 0.4) b) FLZ unbound hepatic concentration – 
time profile (top line: CLrenFLZ = 0.1; middle line: CLrenFLZ = 0.2; bottom line: CLrenFLZ = 0.4) c) 
FLZ unbound GW concentration – time profile (top line: CLrenFLZ = 0.1; middle line: CLrenFLZ = 
0.2; bottom line: CLrenFLZ = 0.4) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.6  Sensitivity analysis of FLZ concentrations after PO administration to the 
change in fpv. a) FLZ unbound blood concentration – time profile (top line: fpv = 0.0; middle line: 
fpv = 0.5; bottom line: fpv = 1.0) b) FLZ unbound hepatic concentration – time profile (top line: 
fpv = 1.0; middle line: fpv = 0.5; bottom line: fpv = 0.0) c) FLZ unbound GW concentration – time 
profile (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.7  Sensitivity analysis of FLZ concentrations after PO administration to the 
change in Kp,hepFLZ. a) FLZ unbound blood concentration – time profile (top line: Kp,hepFLZ = 0.5; 
middle line: Kp,hepFLZ = 1.0; bottom line: Kp,hepFLZ = 2.0) b) FLZ unbound hepatic concentration – 
time profile (top line: Kp,hepFLZ = 2.0; middle line: Kp,hepFLZ = 1.0; bottom line: Kp,hepFLZ = 0.5) c) 
FLZ unbound GW concentration – time profile (top line: Kp,hepFLZ = 0.5; middle line: Kp,hepFLZ = 
1.0; bottom line: Kp,hepFLZ = 2.0) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.8  Sensitivity analysis of FLZ concentrations after PO administration to the 
change in Kp,GWFLZ. a) FLZ unbound blood concentration – time profile (top line: Kp,GWFLZ = 
0.5; middle line: Kp,GWFLZ = 1.0; bottom line: Kp,GWFLZ = 2.0) b) FLZ unbound hepatic 
concentration – time profile (top line: Kp,GWFLZ = 0.5; middle line: Kp,GWFLZ = 1.0; bottom line: 
Kp,GWFLZ = 2.0) c) FLZ unbound GW concentration – time profile (top line: Kp,GWFLZ = 2.0; 
middle line: Kp,GWFLZ = 1.0; bottom line: Kp,GWFLZ = 0.5) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.9  Sensitivity analysis of FLZ concentrations after PO administration to the 
change in CLint,hepFLZ. a) FLZ unbound blood concentration – time profile (top line: CLint,hepFLZ 
= 0.05; middle line: CLint,hepFLZ = 0.1; bottom line: CLint,hepFLZ = 0.2) b) FLZ unbound hepatic 
concentration – time profile (top line: CLint,hepFLZ = 0.05; middle line: CLint,hepFLZ = 0.1; bottom 
line: CLint,hepFLZ = 0.2) c) FLZ unbound GW concentration – time profile (top line: CLint,hepFLZ = 
0.05; middle line: CLint,hepFLZ = 0.1; bottom line: CLint,hepFLZ = 0.2) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.10  Sensitivity analysis of FLZ concentrations after PO administration to the 
change in CLrenFLZ. a) FLZ unbound blood concentration – time profile (top line: CLrenFLZ = 0.1; 
middle line: CLrenFLZ = 0.2; bottom line: CLrenFLZ = 0.4) b) FLZ unbound hepatic concentration – 
time profile (top line: CLrenFLZ = 0.1; middle line: CLrenFLZ = 0.2; bottom line: CLrenFLZ = 0.4) c) 
FLZ unbound GW concentration – time profile (top line: CLrenFLZ = 0.1; middle line: CLrenFLZ = 
0.2; bottom line: CLrenFLZ = 0.4) 
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a)                                                                           b) 
 
 
c) 
 
 
Figure B.11  Sensitivity analysis of FLZ concentrations after PO administration to the 
change in kGLFLZ. a) FLZ unbound blood concentration – time profile (line with lowest cmaxFLZ: 
kGLFLZ = 0.0106; line with middle cmaxFLZ: kGLFLZ = 0.0213; line with highest cmaxFLZ: kGLFLZ = 
0.0426) b) FLZ unbound hepatic concentration – time profile (line with lowest cmaxFLZ: kGLFLZ = 
0.0106; line with middle cmaxFLZ: kGLFLZ = 0.0213; line with highest cmaxFLZ: kGLFLZ = 0.0426) c) 
FLZ unbound GW concentration – time profile (line with lowest cmaxFLZ: kGLFLZ = 0.0106; line 
with middle cmaxFLZ: kGLFLZ = 0.0213; line with highest cmaxFLZ: kGLFLZ = 0.0426) 
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C. ESTIMATION OF VBMDZ, VP1MDZ, VP2MDZ, Q2MDZ AND Q3MDZ 
 In study 21 (Kharasch et al., 2005b), a three-exponents PK profile was clearly demonstrated 
after IV MDZ (in absence of FLZ), thus three - compartmental body model was applied to fit 
observed plasma concentrations extracted from this study. To link the parameters estimated from 
study 21 and our PBPK model, plasma concentrations were converted into blood concentrations, 
corrected by 0.86 (B:PMDZ) (Chien et al., 2006). The observed blood concentrations were listed 
in Table C.1. 
Table C.1  Observed and predicted MDZ blood concentrations after 1mg IV MDZ (data 
were digitized from study 21). 
 
Time Observed Mean Blood Concentration 
Predicted Mean 
Blood Concentration 
hour ng/ml ng/ml 
0.02 62.21 62.21 
0.08 25.12 25.11 
0.20 17.57 17.60 
0.48 12.45 12.37 
0.95 7.87 7.80 
1.05 6.94 7.20 
1.14 6.59 6.74 
1.24 6.46 6.29 
1.49 5.41 5.41 
1.75 4.87 4.74 
1.99 4.30 4.25 
2.48 3.46 3.54 
2.98 3.02 2.99 
3.99 2.12 2.19 
4.99 1.58 1.62 
5.99 1.29 1.21 
6.98 0.90 0.90 
8.00 0.66 0.70 
8.99 0.52 0.50 
 
 The model estimation was performed by Scientist v2.0 (Micromath®, MO) with Stiff 
episode. Model control file, statistics reports and diagnostic plots were presented below.  
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Model control file 
//MDZ PK model-IV 
//Version 2 (using study 21 data) 
// 
//Aug, 04, 2014 
// 
//Mengyao Li 
// 
//Units 
//All units for CL and Q are ml/hr/kg 
//All units for V is ml/kg 
//All units for T is hr 
//All units for amount (A) is ng/kg 
//All units for blood concentration (C) is ng/ml. 
//All units for rate constant is h-1 
// 
IndVars: T 
DepVars: C1 
Params: V1, V2, V3, Q2, Q3, CL 
//Equations 
K12=Q2/V1 
K21=Q2/V2 
K10=CL/V1 
K13=Q3/V1 
K31=Q3/V3 
C1=A1/V1 
C2=A2/V2 
C3=A3/V3 
// 
//PK MODEL 
// 
//CENTRAL CPT 
A1'=-C1*V1*K10+C2*V2*K21-C1*V1*K12+C3*V3*K31-C1*V1*K13 
// 
//PERIPHERAL CPT 1 
// 
A2'=C1*V1*k12-C2*V2*k21 
// 
//PERIPHERAL CPT 2 
// 
A3'=C1*V1*k13-C3*V3*k31 
// 
//IC 
t=0 
A1=14286 
A2=0 
A3=0 
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Statistical Reports 
 
Weighted Unweighted 
 Sum of squared observations: 5262.59 5262.59 
  Sum of squared deviations: 0.17 0.17 
  Standard deviation of data: 0.11 0.11 
  R-squared: 1.00 1.00 
  Coefficient of determination: 1.00 1.00 
  Correlation: 1.00 1.00 
  Model Selection Criterion: 9.37 9.37 
 
 
Confidence Intervals: 
 
 Parameter Name :  V1 
  Estimate Value =  140.369988 
  Standard Deviation =  1.42923189 
  95% Range (Univar) =  137.282320    143.457656 
  95% Range (S-Plane) =  134.392515    146.347461 
 
 Parameter Name :  V2 
  Estimate Value =  337.160239 
  Standard Deviation =  6.54249323 
  95% Range (Univar) =  323.026042    351.294436 
  95% Range (S-Plane) =  309.797584    364.522894 
 
 Parameter Name :  V3 
  Estimate Value =  564.986465 
  Standard Deviation =  23.7537865 
  95% Range (Univar) =  513.669529    616.303401 
  95% Range (S-Plane) =  465.641054    664.331876 
 
 Parameter Name :  Q2  
  Estimate Value =  3315.89346 
  Standard Deviation =  44.5358636 
  95% Range (Univar) =  3219.67958    3412.10734 
  95% Range (S-Plane) =  3129.63121    3502.15571 
 
 Parameter Name :  Q3 
  Estimate Value =  434.875188 
  Standard Deviation =  19.4748834 
  95% Range (Univar) =  392.802260    476.948116 
  95% Range (S-Plane) =  353.425425    516.324951 
 
 Parameter Name :  CL 
  Estimate Value =  418.475366 
  Standard Deviation =  5.81287833 
  95% Range (Univar) =  405.917406    431.033326 
  95% Range (S-Plane) =  394.164177    442.786555 
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Diagnostic Plots 
 
a)                                                                     b) 
  
 
c) 
 
 
Figure C.1  Diagnostic plots of MDZ 3-compartmental model fit. 
 a) Observed and predicted MDZ blood concentration – time profiles on Cartesian scale. b) 
Observed and predicted MDZ blood concentration – time profiles on semi-log scale. c) 
Relationship between residual and time. Solid lines in a) and b) are predicted profiles. Symbols 
in a), b) and c) are observed blood concentrations. 
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As the results showed above, the model can perfectly depict observed data from study 21, 
and model parameters were precisely predicted. Residuals were evenly spread throughout the x-
axle, indicating no systemic bias exists. CL estimated by this compartmental model 
(418.5ml/hr/kg) matched perfectly with non-compartmental analysis (412.3ml/hr/kg) (Kharasch 
et al., 2005b). In the semi-PBPK model, physiological volumes of GW, portal vein and liver 
should be excluded from the estimated V1, V2 or V3. Since estimated V1 was almost identical to 
total blood volume in normal human body (6-8 L), the three physiological volumes should be 
subtracted from V2 or V3. Blood flow to liver (QHA) and portal vein (QPV) were more rapid than 
Q3 (Q3MDZ, inter-compartmental clearance between central and peripheral cpt-2), suggesting that 
liver and portal vein were in shallow peripheral compartment, and GW was considered to be in 
deep peripheral compartment. The final parameters used in our semi-PBPK model were 
demonstrated in Table C.2. Q2MDZ and Q3MDZ were not affected by the partition to physiological 
compartments.  
Table C.2  Final systemic distribution parameters used in MDZ semi-PBPK model. 
Parameters Values Source 
VBMDZ (ml/kg) 140.4 Model estimated V1 
VP1MDZ (ml/kg) 313.7 Model estimated V2-Kp,hepMDZ•Vhep-VPV 
VP2MDZ (ml/kg) 531.4 Model estimated V3-Kp,GWMDZ•VGW 
Q2MDZ (ml/min/kg) 55.27 Model estimated (after unit conversion) 
Q3MDZ (ml/min/kg) 7.25 Model estimated (after unit conversion) 
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D. SENSITIVITY ANALYSIS OF MDZ 
 
 
Figure D.1 Sensitivity analysis of MDZ plasma concentrations after IV administration to 
the change in fpv. (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0)  
 
 
 
Figure D.2 Sensitivity analysis of MDZ plasma concentrations after IV administration to 
the change in vmax,hepMDZ. (top line: vmax,hepMDZ = 152534 ng/min/kg; middle line: vmax,hepMDZ = 
305067 ng/min/kg; bottom line: vmax,hepMDZ = 610134 ng/min/kg)  
371	
	
 
 
 
 
Figure D.3 Sensitivity analysis of MDZ plasma concentrations after IV administration to 
the change in Kp,hepMDZ. (top line: Kp,hepMDZ = 0.55; middle line: Kp,hepMDZ = 1.09; bottom line: 
Kp,hepMDZ = 2.18)  
 
 
 
Figure D.4 Sensitivity analysis of MDZ plasma concentrations after IV administration to 
the change in Kp,GWMDZ. (Kp,GWMDZ = 0.56/1.12/2.24 are superimposable). 
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Figure D.5 Sensitivity analysis of MDZ plasma concentrations after IV administration to 
the change in Q2MDZ. (Q2MDZ = 27.7/55.3/110.6 ml/min/kg are superimposable)  
 
 
 
Figure D.6 Sensitivity analysis of MDZ plasma concentrations after IV administration to 
the change in Q3MDZ. (line with highest terminal levels: Q3MDZ = 3.63; line with middle terminal 
levels: Q3MDZ = 7.25; line with lowest terminal levels: Q3MDZ = 14.5)  
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Figure D.7 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in fpv. (Top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0)  
 
 
 
Figure D.8 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in vmax,hepMDZ. (top line: vmax,hepMDZ = 152534 ng/min/kg; middle line: vmax,hepMDZ = 
305067 ng/min/kg; bottom line: vmax,hepMDZ = 610134 ng/min/kg)  
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Figure D.9 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in Kp,hepMDZ. (top line: Kp,hepMDZ = 0.55; middle line: Kp,hepMDZ = 1.09; bottom line: 
Kp,hepMDZ = 2.18)  
 
 
 
Figure D.10 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in Kp,GWMDZ. (line with highest cmaxMDZ: Kp,GWMDZ = 0.56; line with middle cmaxMDZ: 
Kp,GWMDZ = 1.12; line with lowest cmaxMDZ: Kp,GWMDZ = 2.24) 
375	
	
 
 
 
Figure D.11 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in Q2MDZ. (Q2MDZ = 27.7/55.3/110.6 ml/min/kg are superimposable)  
 
 
 
Figure D.12 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in Q3MDZ. (line with highest terminal levels: Q3MDZ = 3.63; line with middle terminal 
levels: Q3MDZ = 7.25; line with lowest terminal levels: Q3MDZ = 14.5)  
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Figure D.13 Sensitivity analysis of MDZ plasma concentrations after PO administration to the 
change in fvilli. (top line: fvilli = 1.1; middle line: fvilli = 2.2; bottom line: fvilli = 4.4)  
 
 
 
Figure D.14 Sensitivity analysis of MDZ plasma concentrations after PO administration to 
the change in kGLMDZ. (line with highest cmaxMDZ: kGLMDZ = 0.1; line with middle cmaxMDZ: 
kGLMDZ = 0.05; line with lowest cmaxMDZ: kGLMDZ = 0.025) 
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E. SENSITIVITY ANALYSIS OF MDZ IN PRESENCE OF FLZ 
 
 
Figure E.1 Sensitivity analysis of IV MDZ plasma concentrations in presence of IV FLZ to 
the change in fpv. (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0)  
 
 
 
Figure E.2 Sensitivity analysis of IV MDZ plasma concentrations in presence of IV FLZ to 
the change in vmax,hepMDZ. (top line: vmax,hepMDZ = 152534 ng/min/kg; middle line: vmax,hepMDZ = 
305067 ng/min/kg; bottom line: vmax,hepMDZ = 610134 ng/min/kg)  
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Figure E.3 Sensitivity analysis of IV MDZ plasma concentrations in presence of IV FLZ to 
the change in Kp,hepMDZ. (top line: Kp,hepMDZ = 0.55; middle line: Kp,hepMDZ = 1.09; bottom line: 
Kp,hepMDZ = 2.18)  
 
 
 
Figure E.4 Sensitivity analysis of IV MDZ plasma concentrations in presence of IV FLZ to 
the change in Kp,GWMDZ. (Kp,GWMDZ = 0.56/1.12/2.24 are superimposable). 
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Figure E.5  Sensitivity analysis of IV MDZ plasma concentrations in presence of IV FLZ to 
the change in Kp,hepFLZ. (top line: Kp,hepMDZ = 2.0; middle line: Kp,hepMDZ = 1.0; bottom line: 
Kp,hepMDZ = 0.5)  
 
 
 
Figure E.6  Sensitivity analysis of IV MDZ plasma concentrations in presence of IV FLZ to 
the change in Ki,hepFLZ. (top line: Ki,hepMDZ = 1915 ng/ml; middle line: Ki,hepMDZ = 3829 ng/ml; 
bottom line: Ki,hepMDZ = 7658 ng/ml)  
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Figure E.7 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO FLZ to 
the change in fpv. (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0)  
 
 
 
Figure E.8 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO FLZ to 
the change in vmax,hepMDZ. (top line: vmax,hepMDZ = 152534 ng/min/kg; middle line: vmax,hepMDZ = 
305067 ng/min/kg; bottom line: vmax,hepMDZ = 610134 ng/min/kg)  
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Figure E.9 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO FLZ to 
the change in Kp,hepMDZ. (top line: Kp,hepMDZ = 0.55; middle line: Kp,hepMDZ = 1.09; bottom line: 
Kp,hepMDZ = 2.18)  
 
 
 
Figure E.10 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO FLZ 
to the change in Kp,GWMDZ. (Kp,GWMDZ = 0.56/1.12/2.24 are superimposable). 
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Figure E.11 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO FLZ 
to the change in Kp,hepFLZ. (Top line: Kp,hepMDZ = 2.0; middle line: Kp,hepMDZ = 1.0; bottom line: 
Kp,hepMDZ = 0.5)  
 
 
 
Figure E.12 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO FLZ 
to the change in Ki,hepFLZ. (top line: Ki,hepMDZ = 1915 ng/ml; middle line: Ki,hepMDZ = 3829 ng/ml; 
bottom line: Ki,hepMDZ = 7658 ng/ml)  
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Figure E.13 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in fpv. (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0)  
 
 
 
Figure E.14 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in vmax,hepMDZ. (top line: vmax,hepMDZ = 152534 ng/min/kg; middle line: vmax,hepMDZ 
= 305067 ng/min/kg; bottom line: vmax,hepMDZ = 610134 ng/min/kg)  
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Figure E.15 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in Kp,hepMDZ. (top line: Kp,hepMDZ = 0.55; middle line: Kp,hepMDZ = 1.09; bottom line: 
Kp,hepMDZ = 2.18)  
 
 
 
Figure E.16 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in Kp,GWMDZ. (line with highest cmaxMDZ: Kp,GWMDZ = 0.56; line with middle 
cmaxMDZ: Kp,GWMDZ = 1.12; line with lowest cmaxMDZ: Kp,GWMDZ = 2.24) 
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Figure E.17 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in Kp,hepFLZ. (Top line: Kp,hepMDZ = 2.0; middle line: Kp,hepMDZ = 1.0; bottom line: 
Kp,hepMDZ = 0.5)  
 
 
 
Figure E.18 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in Kp,GWFLZ. (top line: Kp,GWFLZ = 2.0; middle line: Kp,GWFLZ = 1.0; bottom line: 
Kp,GWFLZ = 0.5)  
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Figure E.19 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in Ki,hepFLZ. (top line: Ki,hepMDZ = 1915 ng/ml; middle line: Ki,hepMDZ = 3829 ng/ml; 
bottom line: Ki,hepMDZ = 7658 ng/ml)  
 
 
 
Figure E.20 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in Ki,GWFLZ. (top line: Ki,GWMDZ = 1591 ng/ml; middle line: Ki,GWMDZ = 3182 
ng/ml; bottom line: Ki,GWMDZ = 6364 ng/ml)  
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Figure E.21 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in fvilli. (top line: fvilli = 1.1; middle line: fvilli = 2.2; bottom line: fvilli = 4.4)  
 
 
 
Figure E.22 Sensitivity analysis of PO MDZ plasma concentrations in presence of IV FLZ 
to the change in kGLMDZ. (line with highest cmaxMDZ: kGLMDZ = 0.1; line with middle cmaxMDZ: 
kGLMDZ = 0.05; line with lowest cmaxMDZ: kGLMDZ = 0.025) 
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Figure E.23 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in fpv. (top line: fpv = 0.0; middle line: fpv = 0.5; bottom line: fpv = 1.0)  
 
 
 
Figure E.24 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in vmax,hepMDZ. (top line: vmax,hepMDZ = 152534 ng/min/kg; middle line: vmax,hepMDZ 
= 305067 ng/min/kg; bottom line: vmax,hepMDZ = 610134 ng/min/kg)  
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Figure E.25 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in Kp,hepMDZ. (top line: Kp,hepMDZ = 0.55; middle line: Kp,hepMDZ = 1.09; bottom line: 
Kp,hepMDZ = 2.18)  
 
 
 
Figure E.26 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in Kp,GWMDZ. (line with highest cmaxMDZ: Kp,GWMDZ = 0.56; line with middle 
cmaxMDZ: Kp,GWMDZ = 1.12; line with lowest cmaxMDZ: Kp,GWMDZ = 2.24) 
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Figure E.27 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in Kp,hepFLZ. (top line: Kp,hepMDZ = 2.0; middle line: Kp,hepMDZ = 1.0; bottom line: 
Kp,hepMDZ = 0.5)  
 
 
 
Figure E.28 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in Kp,GWFLZ. (top line: Kp,GWFLZ = 2.0; middle line: Kp,GWFLZ = 1.0; bottom line: 
Kp,GWFLZ = 0.5)  
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Figure E.29 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in Ki,hepFLZ. (top line: Ki,hepMDZ = 1915 ng/ml; middle line: Ki,hepMDZ = 3829 ng/ml; 
bottom line: Ki,hepMDZ = 7658 ng/ml)  
 
 
 
Figure E.30 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in Ki,GWFLZ. (top line: Ki,GWMDZ = 1591 ng/ml; middle line: Ki,GWMDZ = 3182 
ng/ml; bottom line: Ki,GWMDZ = 6364 ng/ml)  
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Figure E.31 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in fvilli. (top line: fvilli = 1.1; middle line: fvilli = 2.2; bottom line: fvilli = 4.4)  
 
 
 
Figure E.32 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO FLZ 
to the change in kGLMDZ. (line with highest cmaxMDZ: kGLMDZ = 0.1; line with middle cmaxMDZ: 
kGLMDZ = 0.05; line with lowest cmaxMDZ: kGLMDZ = 0.025) 
  
393	
	
 
F. ESTIMATION OF SATURABLE (SPECIFIC) PLASMA PROTEIN BINDING 
PARAMETERS OF ERY 
F.1. Control profile of hyperbolic binding model (using ADAPT) 
CC 
C----------------------------------------------------------------------C 
C   Enter as Indicated                                                 C 
C----c-----------------------------------------------------------------C 
 
      NDEqs   =  0   ! Enter # of Diff. Eqs. 
      NSParam =  2   ! Enter # of System Parameters. 
      NVparam =  0   ! Enter # of Variance Parameters. 
      NSecPar =  0   ! Enter # of Secondary Parameters. 
      NSecOut =  0  ! Enter # of Secondary Outputs (not used). 
      Ieqsol  =  3  ! Model type: 1 - DIFFEQ, 2 - AMAT, 3 - OUTPUT only. 
      Descr   = ' ERY Binding Model - Cb-Cu  ' 
CC 
C----------------------------------------------------------------------C 
C   Enter Symbol for Each System Parameter (eg. Psym(1)='Kel')         C 
C----c-----------------------------------------------------------------C 
        PSym(1) = 'Bmax' 
        PSym(2) = 'BC50' 
CC 
C----------------------------------------------------------------------C 
C   Enter Output Equations Below   {e.g.  Y(1) = X(1)/P(2) }           C 
C----c-----------------------------------------------------------------C 
 
        Y(1) = P(1)*t/(P(2)+t) 
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F.2. Control profile of Sigmoidal binding model (using ADAPT) 
CC 
C----------------------------------------------------------------------C 
C   Enter as Indicated                                                 C 
C----c-----------------------------------------------------------------C 
 
      NDEqs   =  0   ! Enter # of Diff. Eqs. 
      NSParam =  3   ! Enter # of System Parameters. 
      NVparam =  2   ! Enter # of Variance Parameters. 
      NSecPar =  0   ! Enter # of Secondary Parameters. 
      NSecOut =  0  ! Enter # of Secondary Outputs (not used). 
      Ieqsol  =  3  ! Model type: 1 - DIFFEQ, 2 - AMAT, 3 - OUTPUT only. 
      Descr   = ' ERY Binding Model - Cb-Cu--add n  ' 
 
CC 
C----------------------------------------------------------------------C 
C   Enter Symbol for Each System Parameter (eg. Psym(1)='Kel')         C 
C----c-----------------------------------------------------------------C 
        PSym(1) = 'Bmax' 
        PSym(2) = 'BC50' 
        PSym(3) = 'n' 
CC 
C----------------------------------------------------------------------C 
C   Enter Output Equations Below   {e.g.  Y(1) = X(1)/P(2) }           C 
C----c-----------------------------------------------------------------C 
 
        Y(1) = P(1)*(t**P(3))/(P(2)**P(3)+t**P(3)) 
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F.3. In-vitro total binding data digitized from Detta et al. (Dette et al., 1982) 
Cu(µM) Cbo-total (µM) 
0.37 0.79 
0.50 1.20 
0.68 1.81 
0.68 1.67 
0.93 2.43 
1.18 2.67 
1.24 3.04 
1.43 3.38 
1.62 3.72 
1.68 4.07 
1.80 4.41 
2.24 5.09 
2.30 5.30 
3.12 6.42 
3.68 7.55 
4.25 8.30 
4.44 7.93 
9.95 11.87 
10.20 12.42 
16.76 14.39 
17.01 14.59 
17.33 14.63 
 
F.4. In-vitro non-specific binding data digitized from Detta et al. (Dette et al., 1982) 
Cu(µM) Cbo-ns (µM) 
0.38 0.10 
1.97 0.48 
4.33 1.35 
10.18 3.28 
16.82 4.29 
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G. ESTIMATION OF VB,UERY, VP,UERY AND Q2,UERY 
In order to estimate PK parameters of unbound ERY in the blood, all measurements from 
study 611 were digitized and corrected by fuERY at corresponding total ERY concentration (using 
equation (7.24)), and blood-to-plasma partition ratio (B:PERY = 0.85), as shown in equation (G.1) C",$%&' = C),*%&' ∙ f$%&' ∙ B: P%&'                                         (G.1) 
Cb,uERY is ERY unbound blood concentration and Cp,tERY is ERY total plasma concentration 
reported in study 611(Austin et al., 1980b). Observed total plasma concentrations and calculated 
fraction unbound, unbound plasma, unbound blood, and SD of total plasma concentrations at 
different dose levels were presented in Table G.1. 
Table G.1 Observed total plasma concentrations and calculated fraction unbound, 
unbound plasma, unbound blood, and SD of total plasma concentrations at different dose 
levels. 
 
125mg 15min IV infusion (Regimen 2) 
 
Time (hr) Cp,t (mg/L) fu Cp,u (mg/L) Cb,u (mg/L) SD(mg/L) 
0.28 7.26 0.36 2.59 2.20 0.00 
0.52 2.38 0.29 0.70 0.59 0.00 
0.76 1.47 0.30 0.45 0.38 0.00 
1.02 0.99 0.32 0.31 0.27 0.19 
1.28 0.87 0.32 0.28 0.24 0.00 
1.52 0.67 0.33 0.22 0.19 0.17 
1.78 0.61 0.34 0.21 0.17 0.07 
2.03 0.64 0.33 0.21 0.18 0.07 
2.53 0.50 0.35 0.17 0.15 0.12 
3.03 0.36 0.36 0.13 0.11 0.00 
3.53 0.29 0.37 0.11 0.09 0.14 
4.02 0.21 0.39 0.08 0.07 0.00 
4.52 0.14 0.42 0.06 0.05 0.07 
5.02 0.11 0.43 0.05 0.04 0.00 
6.02 0.05 0.46 0.02 0.02 0.04 
7.02 0.02 0.50 0.01 0.01 0.00 
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250mg 15min IV infusion (Regimen 2) 
 
Time (hr) Cp,t (mg/L) fu Cp,u (mg/L) Cb,u (mg/L) SD(mg/L) 
0.28 10.11 0.36 3.67 3.12 3.61 
0.52 5.24 0.30 1.57 1.34 1.72 
0.75 3.31 0.29 0.96 0.82 0.00 
1.00 2.55 0.29 0.74 0.63 0.00 
1.29 2.49 0.29 0.73 0.62 1.06 
1.52 2.49 0.29 0.73 0.62 0.62 
1.78 1.96 0.30 0.58 0.49 0.00 
2.03 1.75 0.30 0.52 0.44 0.52 
2.53 1.01 0.31 0.32 0.27 0.11 
3.02 1.06 0.31 0.33 0.28 0.66 
3.54 0.95 0.32 0.30 0.26 0.00 
4.02 0.78 0.32 0.25 0.22 0.27 
4.53 0.55 0.34 0.19 0.16 0.03 
5.02 0.30 0.37 0.11 0.09 0.05 
6.00 0.16 0.40 0.07 0.06 0.01 
7.07 0.09 0.43 0.04 0.03 0.06 
 
 
500mg 15min IV infusion (Regimen 2) 
 
Time (hr) Cp,t (mg/L) fu Cp,u (mg/L) Cb,u (mg/L) SD(mg/L) 
0.26 17.89 0.48 8.60 7.31 0.00 
0.54 7.46 0.32 2.42 2.06 0.00 
0.75 5.26 0.30 1.58 1.34 0.00 
1.02 3.32 0.29 0.96 0.82 1.03 
1.30 3.33 0.29 0.97 0.82 0.00 
1.51 2.92 0.29 0.85 0.72 1.25 
1.78 3.72 0.29 1.08 0.92 0.00 
2.04 2.40 0.29 0.70 0.60 1.21 
2.52 2.40 0.29 0.70 0.60 0.82 
3.04 2.11 0.29 0.62 0.53 0.00 
3.56 2.26 0.29 0.66 0.56 0.61 
4.04 2.16 0.29 0.64 0.54 0.78 
4.52 1.74 0.30 0.52 0.44 0.63 
5.04 1.15 0.31 0.36 0.30 0.32 
6.01 0.70 0.33 0.23 0.20 0.36 
7.04 0.40 0.36 0.14 0.12 0.00 
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900mg 15min IV infusion (Regimen 2) 
 
Time (hr) Cp,t (mg/L) fu Cp,u (mg/L) Cb,u (mg/L) SD(mg/L) 
0.12 20.85 0.51 10.73 9.12 0.00 
0.28 29.61 0.59 17.35 14.75 0.00 
0.54 13.77 0.42 5.81 4.94 4.01 
0.75 8.15 0.33 2.72 2.31 0.00 
1.06 8.90 0.34 3.07 2.61 0.00 
1.26 8.91 0.34 3.07 2.61 4.43 
1.54 7.16 0.32 2.30 1.95 0.00 
1.78 7.17 0.32 2.30 1.95 0.00 
2.04 9.33 0.35 3.27 2.78 6.89 
2.56 6.03 0.31 1.85 1.58 0.00 
3.02 5.78 0.30 1.76 1.50 3.98 
3.56 4.35 0.29 1.28 1.09 0.00 
4.04 3.50 0.29 1.02 0.87 2.24 
4.56 3.43 0.29 1.00 0.85 0.00 
5.04 2.42 0.29 0.71 0.60 1.70 
6.02 1.91 0.30 0.57 0.48 0.00 
7.02 1.50 0.30 0.45 0.39 1.02 
 
250mg 3min IV infusion (Regimen 1) 
Time (hr) Cp,t (mg/L) fu Cp,u (mg/L) Cb,u (mg/L) SD(mg/L) 
0.11 9.39 0.35 3.31 2.81 3.52 
0.25 5.15 0.30 1.54 1.31 1.61 
0.50 3.42 0.29 0.99 0.85 0.90 
0.76 2.89 0.29 0.84 0.71 0.79 
1.02 2.33 0.29 0.68 0.58 0.56 
1.26 2.01 0.30 0.59 0.50 0.69 
1.50 1.93 0.30 0.57 0.48 0.63 
1.75 1.73 0.30 0.52 0.44 0.67 
2.01 1.49 0.30 0.45 0.38 0.60 
2.49 1.21 0.31 0.37 0.32 0.41 
2.99 1.18 0.31 0.37 0.31 0.31 
3.50 0.68 0.33 0.23 0.19 0.27 
4.02 0.57 0.34 0.19 0.17 0.28 
4.51 0.42 0.36 0.15 0.13 0.19 
5.01 0.30 0.37 0.11 0.09 0.17 
6.00 0.17 0.40 0.07 0.06 0.10 
7.01 0.10 0.43 0.04 0.04 0.08 
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Model estimation was performed by ADAPT 5 (BMSR Biomedical Simulations Resource, 
available at https://bmsr.usc.edu/software/adapt/). Model control file was presented below. 
Model Control Profile: 
 
CC 
C----------------------------------------------------------------------C 
C   Enter as Indicated                                                 C 
C----c-----------------------------------------------------------------C 
 
      NDEqs   =  2   ! Enter # of Diff. Eqs. 
      NSParam =  4   ! Enter # of System Parameters. 
      NVparam =  2   ! Enter # of Variance Parameters. 
      NSecPar =  3   ! Enter # of Secondary Parameters. 
      NSecOut =  0  ! Enter # of Secondary Outputs (not used). 
      Ieqsol  =  1  ! Model type: 1 - DIFFEQ, 2 - AMAT, 3 - OUTPUT only. 
      Descr   = ' ERY IV PK Modeling  ' 
CC 
C----------------------------------------------------------------------C 
C   Enter Symbol for Each System Parameter (eg. Psym(1)='Kel')         C 
C----c-----------------------------------------------------------------C 
      Psym(1)='V1' 
      Psym(2)='V2' 
      Psym(3)='CL' 
      Psym(4)='Q' 
CC 
C----------------------------------------------------------------------C 
C   Enter Symbol for Each Variance Parameter {eg: PVsym(1)='Sigma'}    C 
C----c-----------------------------------------------------------------C 
      PVsym(1)='SDinter' 
      PVsym(2)='SDslope' 
CC 
C----------------------------------------------------------------------C 
C   Enter Symbol for Each Secondary Parameter {eg: PSsym(1)='CLt'}     C 
C----c-----------------------------------------------------------------C 
      PSsym(1)='k10' 
      PSsym(2)='k12' 
      PSsym(3)='k21' 
 
C----------------------------------------------------------------------C 
C----------------------------------------------------------------------C 
C 
        Return 
        End 
CC 
C----------------------------------------------------------------------C 
C   Enter Differential Equations Below  {e.g.  XP(1) = -P(1)*X(1) }    C 
C----c-----------------------------------------------------------------C 
      XP(1)=-(P(3)/P(1)+P(4)/P(1))*X(1)+P(4)/P(2)*X(2)+R(1) 
      XP(2)=P(4)/P(1)*X(1)-P(4)/P(2)*X(2) 
C---------------------------)-------------------------------------------C 
C----------------------------------------------------------------------C 
C 
        Return 
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        End 
CC 
C----------------------------------------------------------------------C 
C   Enter Output Equations Below   {e.g.  Y(1) = X(1)/P(2) }           C 
C----c-----------------------------------------------------------------C 
 
        Y(1) =X(1)/P(1) 
CC 
C----------------------------------------------------------------------C 
C   Enter Variance Model Equations Below                               C 
C         {e.g. V(1) = (PV(1) + PV(2)*Y(1))**2 }                       C 
C----c-----------------------------------------------------------------C 
      V(1)=(PV(1)+PV(2)*Y(1))**2 
 
C----------------------------------------------------------------------C 
C----------------------------------------------------------------------C 
C 
        Return 
        End 
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The final estimates of central, peripheral compartment volume of distribution and inter-
compartmental clearance from the two compartmental model fit (V1,u, V2,u and Q2,u) were 
averaged across the four doses in regimen 2, to come up with distribution parameters across 
doses (shown in Table G.2). Parameter estimates from regimen 1 data (250mg ERY 3min IV 
infusion) were also demonstrated in Table G.2, but not included in calculating final VB,uERY, 
VP,uERY and Q2,uERY values in semi-PBPK model, because PK profiles with different infusion 
time may lead to different parameter estimates. 
Table G.2 PK parameters estimated from two-compartmental model fit of unbound blood 
concentrations in study 611. 
 
Parameters 
(CV%) 
125mg 
(Regimen 2) 
250mg 
(Regimen 2) 
500mg 
(Regimen 2) 
900mg 
(Regimen 2) 
250mg 
(Regimen 1) 
Average of 
regimen 2 
V1,u (ml/kg) 408 (2.5%) 715 (4.0%) 523 (4.2%) 517 (6.3%) 715 (3.7%) 541 
V2,u (ml/kg) 1385 (6.2%) 1589 (7.8%) 2812 (13%) 1990 (18%) 2103 (3.6%) 1944 
CLu 
(ml/min/kg) 22.2 (2.3%) 20.9 (3.7%) 19.5 (7.1%) 15.4 (11%) 25.4 (2.2%) 
 Q2,u 
(ml/min/kg) 26.9 (3.3%) 38.1 (6.9%) 36.9 (5.2%) 34.6 (10%) 75 (2.8%) 34.1 
 
 In the semi-PBPK model, physiological volumes of GW, portal vein and liver should be 
excluded from the estimated V1,u or V2,u. Portal vein and liver were presumably included in 
central compartment, and GW volume was presumably incorporated into peripheral 
compartment. The final parameters used in ERY semi-PBPK model were demonstrated in Table 
G.3. Q2,uMDZ was not affected by the perfusion to physiological compartments.  
Table G.3 Final systemic distribution parameters used in ERY semi-PBPK model. 
Parameters Values Source 
VB,uERY (ml/kg)   479 Model estimated V1,u-VPV-Kp,hep,uERY•Vhep 
VP,uERY (ml/kg) 1853 Model estimated V2,u-Kp,GW,uERY•VGW 
Q2,uERY (ml/min/kg) 34.1 Model estimated Q2,u  
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H. ERY META-ANALYSIS 
H.1. Meta-analysis of IV ERY studies 
 ERY Dosing Regimen ERY Exposure Metrics Non-compartmental Analysis Parameters 
Study 
ID 
ERY 
Route Dose Formulation AUCIV
ERY SD of AUCIVERY 
fuERY CLrenERY CLtot,pERY CLtot,bERY CLint,hep VssERY t1/2ERY MRTERY 
  [mg]  [mg/L*hrs] [mg/L*hrs] % ml/min/kg ml/min/kg ml/min/kg ml/min/kg mL/kg hr hr 
611 IV 250 ERY Lactobionate (Abbott Lab) 9.3   0.8 7±2.5 7.3 11.1 693±190 1.5±0.3  
611 IV 125 ERY Lactobionate (Abbott Lab) 4.6 0.9  0.4 7±1.5 7.8 12.2 493±67 1.3±0.1  
611 IV 250 ERY Lactobionate (Abbott Lab) 10.5 3  0.3 7.2±3.6 8.1 13.1 603±375 1.3±0.2  
611 IV 500 ERY Lactobionate (Abbott Lab) 19.4 3.3  0.6 6.2±1.1 6.6 9.5 1031±167 2.4±0.4  
611 IV 900 ERY Lactobionate (Abbott Lab) 41 23.1  1.1 6.2±2.8 6.0 8.3 1088±377 2.4±0.4  
612 IV 500 ERY Lactobionate (Abbott Lab)   30.5±2.8 1.2 8.9±3.2 9.1 15.7 900±231 1.4±0.4  
613 IV 1000 ERY Lactobionate 41.63 1.79   5.7 6.1 8.4    
616 IV 125  3.58 1.02 27±5 0.5±0.17 8.8±2.2 9.8 18.0 740±190 2.3±1.03 1.41±0.3 
617 IV 0.1 ERY powder 0.004 0.003   5.21 (76.4%) 5.5 7.4 1140 (68%) 2.52 (34.6%)  
619 IV 500 ERY lactobionate (Abbott)     9.10 9.6 17.5 770 1.6  
624 IV 240 ERY lactobionate (Abbott) 12.2 4.4   6.42±2.33 6.8 10.0 450±150 1.54 1.19 
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 Compartmental Analysis Parameters Study Design Demographics 
Study 
ID 
No. of 
Comp V1
ERY V2ERY k10ERY k12ERY k21ERY Fast 
Sample 
size Crossover 
Infusion 
time Age Weight Gender Race 
  ml/kg ml/kg hr
-1 hr-1 hr-1 (Yes=1, No=0)  
(Yes=1, 
No=0) [min] [yrs] [kg] 
(M: Male; F: Female) 
M/F 
(AA: African American; 
C: Caucasian; AP: Asian 
Pacific) 
611 2 260±140 434    1 24 0 3 19.2±1.4 64±9.4 12/12  611 2 154±28 339    1 5 1 15 19-20 66.98 3/2  611 2 278±263 325    1 5 1 15 19-20 66.98 3/2  611 2 263±70 768    1 4 1 15 19-20 68.175 3/1  611 2 444±414 644    1 3 1 15 19 70.5 2/1  612 2         6 0 30 24.5±1.6 64±7.2 5/1  613 2 or 3   0.78 0.49 0.84  6 0 60 21.8±0.31 63.7±2.4   
616         1 12  30 44.8±8.5 75±19.4 6/6 7/2/3 (AA/C/AP) 617         1 30 0 30 18-80  24/6  619 2 450 320    1 6  60 23-31  2/4  624 2        0 6 1 30 20-21 60.7 3/3  
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 Sample Analysis  Study 
ID Sample time points Assay method LLOQ Comments 
 [h]  [ng/ml]  
611 0.125,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4.5,5,6,7 Bioassay using Sarcina 
lutea 
 V1ERY and CLtot,pERY were significantly different between 
males and females; t1/2α and t1/2β were provided. 
611 0.125,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4.5,5,6,7 Bioassay using Sarcina 
lutea 
   
611 0.125,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4.5,5,6,7 Bioassay using Sarcina 
lutea 
   
611 0.125,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4.5,5,6,7 Bioassay using Sarcina 
lutea 
   
611 0.125,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4.5,5,6,7 Bioassay using Sarcina 
lutea 
   
612 0.1,0.2,0.3,0.4,0.5 during infusion and 0.083, 
0.167,0.25,0.5,0.75,1,1.5,2,3,4,6,9,12 after infusion 
Bioassay using Sarcina 
lutea 
70 Mean serum AAG levels = 10.3 ± 2.1µmol/L in normal 
subjects 
613 0.25,0.5,0.75,1,1.5,2,3,4,6,8,12,16,20,24 Bioassay using Sarcina 
lutea 
 Not sure if dose of ERY base was 1000 mg or dose of 
lactobionate was 1000 mg; Didn’t mention reported 
AUC values were AUC0-∞ or AUC0-t; Macro-rate 
constants (A and B) after 2 –compartmental model fit 
were  provided. 
616 0.5,1,1.5,2,4,6,8,10,12,14,24 LC-MS 1.5   
617   HPLC-AMS (Accelerator 
Mass Spectrometry) 
0.01   
619 0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,7,8,8,10,11,12 Bioassay using Sarcina 
lutea 
100 α and β were provided. 
624 0.167,0.33,0.5,0.58,0.67,0.83,1,1.25,1.5,2,2.5,3.5,4.5,5.5,6.5 Bioassay using 
Micrococcus luteaus 
100   
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H.2. Meta-analysis of PO ERY studies 
 ERY Dosing Regimen ERY Exposure Metrics 
Study 
ID 
ERY 
Route Dose Formulation AUCIV
ERY SD of AUCIVERY 
CmaxERY SD of CmaxERY tmaxERY tmaxERY range 
  [mg]  [mg/L*hrs] [mg/L*hrs] µg/ml µg/ml hr hr 
604 PO 250 SS 1.3  0.371 0.1-0.64 2 1.5-5 
604 PO 1000 SS 16.2  3 2.0-3.9 1.38 0.5-4 
614 PO 500 SS (Abbott) 5.6 0.4 1.3 0.1 2  
614 PO 500 SS (Abbott) 7.2 0.8 2.8 0.3 1  
614 PO 500mg q8h for 7 days SS (Abbott) 12.4 1.7 2.9 0.5 1.5  
614 PO 500 ERY base (Lilly) 4.6 0.7 1.2 0.2 4  
614 PO 500 ERY base (Lilly)     Vareid  
614 PO 500mg q8h for 7 days ERY base (Abbott) Varied      
615 PO 250mg q6h for 5 doses SS       
616 PO 250  1.0 0.7 0.45 0.30 0.92 ±0.56 
617 PO 250 ERY-SS 250 granulate suspension (Abbott) 1.6 0.6 0.72 0.27 0.45 22.30% 
618 PO 500mg q8h for 5 days SS (Erythromcin, Abbott Lab) 7.2 3.6 1.45 0.87   
619 PO 500 EC       
620 PO 250 EC 4.5 1.7 1.9 0.8 1.5-2.5  
620 PO 500 EC 11.2 4.3 3.8 1.4 1.5-2.5  
620 PO 1000 EC 27.2 10.6 6.5 2.9 1.5-2.5  
620 PO 500 SS 7.5 3.4 2.9 1.7 1.5-2.5  
621 PO 500 EC 9.0 5.9 1.5 0.91 6.3 6-8 
622 PO 500 SS 8.3 0.8 2 0.3 2  
622 PO 500 SS 7.5 1.2 2.2 0.4 1.5  
622 PO 500 EC 10.6 1.1 1.5 0.5 4 1.5-10 
622 PO 500 EC 8.8 1.2 1.5 0.2 5  
623 PO 250 EC 4.7 2.0 1.74 0.9 2.85 0.54 
623 PO 250mg q6h for 5 days EC 10.8 3.4 2.87 0.83 3.11 1 
624 PO 271 duodenal solution 5.0 1.3 2.3 0.55 0.25 0.08 
624 PO 250 EC 4.1 2.2 1.66 0.79 2.92 0.53 
625 PO 1000 SS 29.1 4.7 8 1.3 1.5 0.2 
625 PO 1000mg q12h for 4 days  25.1 4.8 6.8 0.7 2 0.2 
626 PO 250 SS 1.0 0.3 0.41 0.34 2.1 0.6 
626 PO 250 EC 2.9 1.8 1.18 0.73 2.7 1.3 
626 PO 250mg q6h for 5 doses SS 4.1 2.6 1.38 0.87 2.1 0.6 
626 PO 250mg, q6h for 5 doses EC 7.9 2.2 2.59 0.76 2.1 0.3 
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627 PO 250 SS 2.2 0-5.9 1.1 0-3.3 2.1 1-6 
627 PO 250 EC 0.5 0-5.5 0.4 0-2.2 3 1.2-6 
627 PO 250mg q6h for 9 doses SS 5.7 1.6-16.6 2.7 0.6-7.3 2 1.3-3.5 
627 PO 250mg q6h for 9 doses EC 3.5 0.5-11.1 1.4 0.2-4.9 3 0.75-6 
628 PO 500 SS 4.7 1.6 1.23 0.37 2.92 0.49 
629 PO 250mg q6h for 10 doses EC       
629 PO 400mg q6h for 10 doses ERY ethylsuccinate       
630 PO 7.5mg/kg ERY piopionate capsules 27.7 5.1 4.07 0.29   
630 PO 7.5mg/kg SS 2.1? 0.43? 2.15? 0.14?   
631 PO 250 ERY acistrate (EA) 1.9 0.4 0.46 0.07 1.3 0.3 
631 PO 250 ERY stearate (ES) 4.5 1.0 0.93 0.23 2.6 0.4 
631 PO 250 EC 5.8 0.5 1.6 0.1 3.3 0.4 
632 PO 500 SS 6.4 2.2 0.66 0.18 2.79 0.56 
633 PO 500 SS (Resibion ®) 12.2 3.0 3.35 0.85 2.5 0.3 
633 PO 500 SS (Erythrocin®) 17.9 4.9 3.86 0.67 2.3 0.4 
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 Non-compartmental Analysis Parameters Compartmental Analysis Parameters 
Study 
ID fu
ERY CLrenERY 
CLtot,pERY/
ForalERY 
t1/2ERY MRTERY ForalERY ERhepERY FhepERY FabsERY•FGIERY 
No. of 
Comp ka
ERY V1ERY V2ERY k21ERY 
 % ml/min/kg ml/min/kg hr hr % % % %  h
-1 ml/kg hr-1  
604   92.6 
2.25 
(1.78-2.72)           
604   17.7 
2.79 
(2.42-3.16)           
614    1.8           614    1.2           614    2.1           614    2.5        308.2   614            471.7   614               
615               
616 27±5   2.86±1.27 1.52±0.56 15±6 46% 
50%±10
% 33%±30%      
617    2.50 (17.6%)  14% 26% 74% 19%      
618 28±4   2.8 0.6      1.07    
619    2  34.90% 45% 55% 63%      
620  0.65±0.26  2±2      2 3.2±1.3    620  0.76±0.35  2.5±1.0      2 4.3±2.2    620  0.63±0.30  3.0±1.7      2 3.2±1.8    620  0.59±0.24  2.7±2.3      2 2.3±0.7    
621    3.4      2 1   0.163±0.058 
622    2.5           622    1.9           622    1.9           622    1.6           
623    1.53±0.42           623               
624     2.17±0.46 43%±14% 32% 68% 63%      624     3.28±0.28 32%±7% 32% 68% 47%      
625   10.7±2.3 2.6±0.3           625   11.5±1.8 2.3±0.2           
626  0.59±0.51        1 3    626  0.41±0.11        1 2.2    626  0.36±0.14        1 1.9    626  0.40±0.13        1 1.7    
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627               627               627               627               
628    1.18±0.19           
629               629               
630    5.22±0.86           630    6.61±0.95           
631    2.5±0.6           631    1.5±0.1           631    1.5±0.1           
632    1.57±0.33           
633  0.41±0.06  1.43±0.08           633  0.37±0.05  1.78±0.16           
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 Study Design Demographics Sample Analysis  
Study 
ID Fast 
Sample 
size 
Cross-
over Age Weight Gender Race 
Oral 
contraceptives Sample time points Assay method LLOQ Comments 
 Yes=1,No=0  
Yes=1, 
No=0 [yrs] [kg] M/F  
Yes = 1, 
No = 0 [h]  ng/ml  
604  8 0 28±7  9/7  1 0.25,0.5,1,1.5,2,2.5,3,4,6,8 LC-MS 1 Auto-
inhibition of 
ERY 
clearance 
604  8 0 28±7  9/7  1 0.25,0.5,1,1.5,2,2.5,3,4,6,8 LC-MS 1 
614 1 15 1 22-30 66.7 (52-88) 9/6  3 out of 5 0.5,1,1.52,2.5,3,4,6,7.5 Bioassay using Sarcina lutea 200 
Food delays 
the release of 
drug from the 
enteric coated 
tablets, but the 
absorption is 
not prevented 
614 0 15 1 22-30 66.7 (52-88) 9/6  3 out of 5 0.5,1,1.52,2.5,3,4,6,7.5 Bioassay using Sarcina lutea 200 
614 0 15 1 22-30 66.7 (52-88) 9/6  3 out of 5 0.5,1,1.52,2.5,3,4,6,7.5 Bioassay using Sarcina lutea 200 
614 1 15 1 22-30 66.7 (52-88) 9/6  3 out of 5 0.5,1,1.52,2.5,3,4,6,7.5 Bioassay using Sarcina lutea 200 
614 0 15 1 22-30 66.7 (52-88) 9/6  3 out of 5 0.5,1,1.52,2.5,3,4,6,7.5 Bioassay using Sarcina lutea 200 
614 0 15 1 22-30 66.7 (52-88) 9/6  3 out of 5 0.5,1,1.52,2.5,3,4,6,7.5 Bioassay using Sarcina lutea 200 
615 0 12    12/0   0.5,1,1.5,2,3,4,6 Bioassay using Sarcina lutea  
Both single 
and multiple 
doses profiles 
were available 
616 1 12  44.8±8.5 75±19.4 6/6 
7/2/3 
(AA/C/
AP) 
 0.5,1,1.5,2,4,6,8,10,12,14,24 LC-MS 1.47  
617 1 30 0 18-80  24/6    LC-MS 0.01  
618  6  20-32 52-75 2/4   0.167,0.33,0.5,0.75,1,1.5,2,2.5,3,4,6,8,12,24 
Bioassay using 
Sarcina lutea  
CmaxERY is 
Css,maxERY 
619 1 6  23-31  2/4   0.25,0.5,0.75,1,1.5,2,2.5,3,4,5,6,7,8,8,10,11,12 
Bioassay using 
Sarcina lutea 100  
620 1 24 0 26.4 (22-36) 76.7 (63-92)    0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,9,11 
Bioassay using 
Micrococcus 
luteaus 
60 keERY was 
provided 
 620 1 24 0 26.4 (22-36) 76.7 (63-92)    0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,9,11 
Bioassay using 
Micrococcus 
luteaus 
60 
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620 1 24 0 26.4 (22-36) 76.7 (63-92)    0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,9,11 
Bioassay using 
Micrococcus 
luteaus 
60 
620 1 24 0 26.4 (22-36) 76.7 (63-92)    0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,9,11 
Bioassay using 
Micrococcus 
luteaus 
60 
621 1 6  30±1.8 83±11.4    0,1,2,3,4,6,8,10,12,14,16,24 
Bioassay using 
Micrococcus 
luteaus 
25 
AUC0-t was 
provided, 
instead of 
AUC0-∞; keERY 
was provided; 
α and β were 
provided. 
622 0 16  25.6 (24-29)  8/8   
0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,8,9,
10 
Bioassay using 
Micrococcus 
luteaus 
100 
SS & EC 
cmaxERY were 
significantly 
different. 
622 0 10  25.6 (24-29)  5/5   
0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,8,9,
10 100 
622 0 16  25.6 (24-29)  8/8   
0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,8,9,
10 100 
622 0 10  25.6 (24-29)  5/5   
0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,8,9,
10 100 
623 0 12  20.8±2.5 (18-28) 70.3±5.3 12/0   0.25,0.5,0.75,1,1.5,2,2.5,3,4,56 HPLC-electrochemical 
detection 
100  
623 0 12  20.8±2.5 (18-28) 70.3±5.3 12/0   0.25,0.5,0.75,1,1.5,2,2.5,3,4,56 100  
624 0 6 1 20-21 60.7±9.1 3/3   
0.1,0.167,0.33,0.5,0.67,0.83,1,1.
67,1.33,1.5,1.67,1.83,2,2.25,2.5,
2.75,3,4,5,6 
Bioassay using 
Micrococcus 
luteaus 
100 
ForalERY 
calculation 
was not 
corrected. 
624 0 6 1 20-21 60.7±9.1 3/3   0.5,1,1.5,2,2.5,3,4,5,6 100  
625 1 8  26-34 56-77 4/4   1,1.5,2,3,4,6,8,10,12 Bioassay using 
Sarcina lutea 
  
625 1 8  26-34 56-77 4/4   1,1.5,2,3,4,6,8,10,12   
626 1 10  18-24  13/3   0.5,1,1.5,2,3,4,6 
Bioassay using 
Sarcina lutea 
500  
626 1 10  18-24  13/3   0.5,1,1.5,2,3,4,6 500  
626 1 10  18-24  13/3   0.5,1,1.5,2,3,4,6 500  
626 1 10  18-24  13/3   0.5,1,1.5,2,3,4,6 500  
627 
60min 
before 
meal 
32 1  64±9.4 12/12   
0.25,0.5,0.75,1,1.25,1.5,1.75,2,2
.15,2.5,3,3.5,4,4.5,5,5.5,6 (1st & 
9th dose) 
Bioassay 
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627 
30min 
after 
meal 
32 1  64±9.4 12/12   
0.25,0.5,0.75,1,1.25,1.5,1.75,2,2
.15,2.5,3,3.5,4,4.5,5,5.5,6 (1st & 
9th dose) 
  
627 
60min 
before 
meal 
32 1  64±9.4 12/12   
0.25,0.5,0.75,1,1.25,1.5,1.75,2,2
.15,2.5,3,3.5,4,4.5,5,5.5,6 (1st & 
9th dose) 
  
627 
30min 
after 
meal 
32 1  64±9.4 12/12   
0.25,0.5,0.75,1,1.25,1.5,1.75,2,2
.15,2.5,3,3.5,4,4.5,5,5.5,6 (1st & 
9th dose) 
  
628 1 6 1 20-30  3/3   0.33,0.67,1,1.5,2,4,6,8,12,24 Bacillus subtilis 40  
629 1 24 1 26 76 (61-92) 24/0   
1,2,3,4,5,6,7,8,9,10,11,12,48,49,
50,51,52,53,54,55,56,67,58,59,6
0,62,64,66 
   
629 1 24 1 26 76 (61-92) 24/0   
1,2,3,4,5,6,7,8,9,10,11,12,48,49,
50,51,52,53,54,55,56,67,58,59,6
0,62,64,66 
   
630 1 8 1 28-40 70.5 (62-87) 4/4   1,2,4,8,10,12 Fluorimetric 
method 
 Individual 
data available 630 1 8 1 28-40 70.5 (62-87) 4/4   1,2,4,8,10,12  
631 1 12 1 22±2 64±15 12/0   0.25,0.5,1,1.5,2,3,4,6,8,10 
Bacillus subtilis 
500 3 phases of 
studies; check 
literature for 
details 
631 1 12 1 22±2 64±15 12/0   0.25,0.5,1,1.5,2,3,4,6,8,10 500 
631 1 12 1 22±2 64±15 12/0   0.25,0.5,1,1.5,2,3,4,6,8,10 500 
632 1 12 1 25-51 48-86    0.5,1,2,3,4,6,8,12,24 Microbiological assay   
633 1 6 1 30.7±8.2 60.8±4.1 6/0    Microbiologica
l assay 
(Sarcinalutea) 
40 Multiple dose 
study was also 
conducted. 633 1 6 1 30.7±8.2 60.8±4.1 6/0    40 
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I. META-ANALYSIS OF MDZ AND ERY DDI STUDIES 
 
Without ERY, IV 
 MDZ Dosing Regimen MDZ Exposure Metrics Study Design 
Study 
ID 
MDZ 
Route Dose AUC0-∞
MDZ SD of AUC0-∞MDZ 
CmaxMDZ 
SD of 
CmaxMDZ 
tmaxMDZ 
tmaxMDZ 
range 
Sample 
size Crossover Fast 
  [mg/kg] [ug/L*hrs] [ug/L*hrs] ng/ml ng/ml hr hr  
(Yes=1, 
No=0) (Yes=1, No=0 
28 IV 0.050 106.8      6 0 1 Without ERY, PO 
Study 
ID 
MDZ 
Route Dose AUC0-∞
MDZ SD of AUC0-∞MDZ 
CmaxMDZ 
SD of 
CmaxMDZ 
tmaxMDZ 
tmaxMDZ 
range 
Sample 
size Crossover Fast 
  [mg/kg] [ug/L*hrs] [ug/L*hrs] ng/ml ng/ml hr hr  
(Yes=1, 
No=0) Yes=1, No=0) 
28 PO 0.244 200.0 16.7 70.0 9.0   12 0 1 601 PO 0.205 173.8 24.7 67.2 11.4 0.5  12 1 1 
603 PO 0.078 35.8 7.8 11.0 2.6 15 0.67-2 12 1 Took light breakfast at 7:20am, took ERY at 8am 
604 PO 0.00004       16 1  
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Without ERY, IV 
 Demographics Sample Analysis  
Study 
ID Age Weight Gender Race 
Oral 
contraceptives 
Infusion 
time Sample time points 
Assay 
method LLOQ Comments 
 [yrs] [kg] M/F  (Yes = 1, No = 0) [h] [h]  ng/ml  28 20-22 56-70 2/4  2 out of 4 0.03 0,0.25,0.5,0.75,1,2,3,4,5,6,7,8,18 GC   Without ERY, PO 
Study 
ID Age Weight Gender Race 
Oral 
contraceptives 
Infusion 
time Sample time points 
Assay 
method LLOQ Comments 
 [yrs] [kg] M/F   [h] [h]  ng/ml  28 18-29 50-73 3/9  2 out of 9  0,0.25,0.5,0.75,1,2,3,4,5,6,18 GC   601 24-53 49-97 12/0    0.5,1,2,3,4,5,6,8,12,24 GC 2  
603 21-28 54.3-73.4 4/8  4 out of 9  0.33, 0.66, 1, 1.5, 2, 3, 5, 8, 14, 22 HPLC 1 
No smoking, no GFJ, 
SJW, alcohol, caffeine 
604 28±7  9/7  1  0.25,0.5,1,1.5,2,2.5,3,4,6,8 UPLC-MS 0.0001 
AUC2-4 was provided; 
CLmet was estimated 
using partial AUC 
regression method.  
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With ERY, IV 
 ERY Dosing Regimen MDZ Dosing Regimen MDZ Exposure Metrics 
Study 
ID 
ERY 
Route ERY Formulation ERY Dose 
MDZ 
Route 
MDZ 
Dose AUC0-∞
MDZ SD of  AUC0-∞MDZ 
CmaxMDZ 
SD of 
CmaxMDZ 
tmaxMDZ 
tmaxMDZ 
range 
     [mg/kg] [ug/L*hrs] [ug/L*hrs] ng/ml ng/ml hr hr 
28 PO EC Day 1-7: EC 500mg q8h; Day 6 (2h after ERY): MDZ IV 0.05mg/kg IV 0.050 231.5      
With ERY, PO 
Study 
ID 
ERY 
Route ERY Formulation ERY Dose 
MDZ 
Route 
MDZ 
Dose AUC0-∞
MDZ SD of  AUC0-∞MDZ 
CmaxMDZ 
SD of 
CmaxMDZ 
tmaxMDZ 
tmaxMDZ 
range 
     [mg/kg] [ug/L*hrs] [ug/L*hrs] ng/ml ng/ml hr hr 
28 PO EC Day 1-7: EC 500mg q8h; Day 6 (2h after ERY): MDZ IV 15 mg PO 0.244 883.3 116.7 189.0 16.0   
601 PO  Day 1-5: EC ERY 500mg q8h; Day 5 (1.5h after ERY): MDZ PO 15 mg PO 0.205 662.7 76.5 182.3 22.9 0.5  
603 PO SS (Dainippon Pharmaceutical Co) 
Day 1-2: SS 200mg q6h; Day 2 (1h 
after ERY): MDZ PO 2.5mg PO 0.039 83.1 37.7 20.0 5.9 1.0 0.33-2 
603 PO SS (Dainippon Pharmaceutical Co) 
Day 1-4: SS 200mg q6h; Day 4 (1h 
after ERY): MDZ PO 2.5mg PO 0.039 118.7 57.0 26.4 8.7 1.0 0.67-2 
603 PO SS (Dainippon Pharmaceutical Co) 
Day 1-7: SS 200mg q6h; Day 7 (1h 
after ERY): MDZ PO 2.5mg PO 0.039 119.2 50.8 25.8 9.9 1.0 0.33-2 
604 PO SS 
Day 1: 3µg MDZ was administered; 
Day 3 250mg SS was administered 
1h before 3µg MDZ 
PO 0.00004       
604 PO SS 
Day 1: 3µg MDZ was administered; 
Day 3 250mg SS was administered 
1h before 3µg MDZ 
PO 0.00004       
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With ERY, IV 
 Study Design Sample Analysis  
Study 
ID Fast 
Sample 
size 
Cross-
over Age Weight Gender 
Oral 
contraceptives 
Infusion 
time Sample time points 
Assay 
method LLOQ Comments 
 Yes=1,No=0  
(Yes=1, 
No=0) [yrs] [kg] M/F  [h] [h]  ng/ml  
28 1 6 0 20-22 56-70  2 out of 4 0.03 
0,0.25,0.5,0.75,1,2,3,4,5,6,7,
8,18 GC  
ERY concentration 
available 
With ERY, PO 
Study 
ID  
Sample 
size 
Cross-
over Age Weight Gender 
Oral 
contraceptives 
Infusion 
time Sample time points 
Assay 
method LLOQ Comments 
   
(Yes=1, 
No=0) [yrs] [kg] M/F Yes = 1, No = 0 [h] [h]  ng/ml  
28 1 12 0 18-29 50-73 3/9 2 out of 9  0,0.25,0.5,0.75,1,2,3,4,5,6,18 GC  
ERY concentration 
available 
601 1 12 1 24-53 49-97 4/8 4 out of 9  0.5,1,2,3,4,5,6,8,12,24 GC 2  
603 Took light 
breakfast at 
7:20am, took 
ERY at 8am 
 
12 1 21-28 54.3-73.4 12/0   
0.33, 0.66, 1, 1.5, 2, 3, 5, 8, 
14, 22 HPLC 1 No smoking, no 
GFJ, SJW, alcohol, 
caffeine; Dose-
corrected AUC,cmax 
603 12 1 21-28 54.3-73.4 12/0   
0.33, 0.66, 1, 1.5, 2, 3, 5, 8, 
14, 22 HPLC 1 
603 12 1 21-28 54.3-73.4 12/0   
0.33, 0.66, 1, 1.5, 2, 3, 5, 8, 
14, 22 HPLC 1 
604  8 0 28±7  9/7 1  0.25,0.5,1,1.5,2,2.5,3,4,6,8 
UPLC-
MS 0.0001 
AUC2-4 was 
provided; CLmet 
was estimated 
using partial AUC 
regression method. 
604  8 0 28±7  9/7 1  0.25,0.5,1,1.5,2,2.5,3,4,6,8 
UPLC-
MS 0.0001 
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J. ESTIMATION OF UNBOUND ERY RENAL CLEARANCE AFTER IV 
ADMINISTRATION 
J.1. Assumptions 
Assumptions made in CLren,u-IVERY estimation were: 
1) Both glomerular filtration and tubular secretion processes are constant with dose. 
2) Tubular reabsorption follows Michaelis-Menten kinetics with dose (saturated with 
increasing dose).  
3) Maximal CLren,u-IVERY is 3.5 ml/min/kg, which is achieved at very high ERY dose, when 
tubular reabsorption is fully saturated. Therefore, CL#$,&'() + CL+,,&'() = 3.5ml/min/kg	(CL:;<,&,=>?'() ) 
 CLgf,uERY is unbound glomerular filtration clearance of ERY, CLts,uERY is unbound tubular 
secretion clearance of ERY. 
4) Minimal CLren,u-IVERY is 0.5 ml/min/kg, which is achieved at very low ERY dose, when 
tubular reabsorption is not saturated and remains a constant. Therefore, CL#$,&'() + CL+,,&'() − CL:>,&'() = 0.5ml/min/kg	(CL:;<,&,=C<'() ) 
 CLra,uERY is unbound tubular reabsorption clearance of ERY. 
J.2. Predictability assessment of empirical hyperbolic renal clearance model 
 In order to assess predictability of empirical hyperbolic renal clearance model, predicted 
CLren,uERY after IV administration were plotted against observed CLren,uERY (Figure J.1), and 
deviation (%) at each dose was calculated and presented in Table J.1. Observed CLren,uERY was 
transformed from study reported total ERY plasma renal clearance (CLren,pERY) by dividing 
average fuERY (fuERY at cmaxERY/2) at each dose and B:PERY. 
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Figure J.1. Predictability assessment of empirical hyperbolic renal clearance model after 
IV ERY. The symbols represent observed unbound blood renal clearance after various dose of 
IV ERY in study 611. The line represents predicted unbound blood renal clearance after various 
dose of IV ERY.  
 
Table J.1 Predictability assessment of empirical hyperbolic renal clearance model after IV 
ERY. 
 
Dose (mg) Observed CLren,u
ERY 
(ml/min/kg) 
Predicted CLren,uERY 
(ml/min/kg) Deviation (%) 
125 1.51 1.13 -25% 
250 1.27 1.53 21% 
500 2.26 2.04 -10% 
900 2.93 2.46 -16% 
 
From Figure J.1 and Table J.1, the empirical model successfully balances deviation (%) of 
predicted values around 0 from observed data, and adequately characterizes the increasing trend 
of CLren,uERY with dose, given the limited available data. 
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K. SENSITIVITY ANALYSIS OF DDI BETWEEN MDZ AND EC ERY FOR STUDY 28 
 
 
Figure K.1 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in kdeg. (top line: kdeg = 0.00016 min-1; middle line: kdeg = 0.0008 min-1; 
bottom line: kdeg = 0.004 min-1). Time is relative to initial ERY/placebo dose. 
 
 
 
Figure K.2 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO EC 
ERY to the change in kdeg. (top line: kdeg = 0.00016 min-1; middle line: kdeg = 0.0008 min-1; 
bottom line: kdeg = 0.004 min-1). Time is relative to initial ERY/placebo dose. 
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Figure K.3. Sensitivity analysis of relative GW CYP3A activity to the change in kdeg. (top 
line: kdeg = 0.004 min-1; middle line: kdeg = 0.0008 min-1; bottom line: kdeg = 0.00016 min-1)  
 
 
 
Figure K.4 Sensitivity analysis of relative hepatic CYP3A activity to the change in kdeg. (top 
line: kdeg = 0.004 min-1; middle line: kdeg = 0.0008 min-1; bottom line: kdeg = 0.00016 min-1)  
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Figure K.5 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in kdeg. (kdeg = 0.00016/0.0008/0.004 min-1 are superimposable.)  
 
 
 
Figure K.6 Sensitivity analysis of ERY unbound hepatic concentration to the change in kdeg. 
(top line: kdeg = 0.00016 min-1; middle line: kdeg = 0.0008 min-1; bottom line:kdeg = 0.004 min-1)  
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Figure K.7 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in KIERY. (top line: KIERY = 6 mg/L; middle line: KIERY = 30 mg/L; bottom 
line: KIERY = 150 mg/L). Time is relative to initial ERY/placebo dose. 
 
 
 
Figure K.8 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO EC 
ERY to the change in KIERY. (top line: KIERY = 6 mg/L; middle line: KIERY = 30 mg/L; bottom 
line: KIERY = 150 mg/L). Time is relative to initial ERY/placebo dose. 
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Figure K.9 Sensitivity analysis of relative GW CYP3A activity to the change in KIERY. (top 
line: KIERY = 150 mg/L; middle line: KIERY = 30 mg/L; bottom line: KIERY = 6 mg/L)  
 
 
 
Figure K.10 Sensitivity analysis of relative hepatic CYP3A activity to the change in KIERY. 
(top line: KIERY = 150 mg/L; middle line: KIERY = 30 mg/L; bottom line: KIERY = 6 mg/L)  
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Figure K.11 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in KIERY. (KIERY = 6/30/150 mg/L are superimposable)  
 
 
 
Figure K.12 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
KIERY. (top line: KIERY = 6 mg/L; middle line: KIERY = 30 mg/L; bottom line: KIERY = 150 mg/L)  
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Figure K.13 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in kinactERY. (top line: kinactERY = 0.1875 min-1; middle line: kinactERY = 0.0375 
min-1; kinactERY = bottom line: 0.0075 min-1). Time is relative to initial ERY/placebo dose. 
 
 
 
Figure K.14 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO EC 
ERY to the change in kinactERY. (top line: kinactERY = 0.1875 min-1; middle line: kinactERY = 0.0375 
min-1; bottom line: kinactERY = 0.0075 min-1). Time is relative to initial ERY/placebo dose. 
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Figure K.15 Sensitivity analysis of relative GW CYP3A activity to the change in kinactERY. 
(top line: kinactERY = 0.0075 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: kinactERY = 
0.1875 min-1)  
 
 
 
Figure K.16 Sensitivity analysis of relative hepatic CYP3A activity to the change in kinactERY. 
(top line: kinactERY = 0.0075 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: kinactERY = 
0.1875 min-1)  
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Figure K.17 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in kinactERY. (kinactERY = 0.0075/0.0375/0.1875 min-1 are superimposable)  
 
 
 
Figure K.18 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
kinactERY. (top line: kinactERY = 0.1875 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: 
kinactERY = 0.0075 min-1)  
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Figure K.19 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in vmax,hep-3AERY. (top line: vmax,hep-3AERY = 160 µg/min/kg; middle line: 
vmax,hep-3AERY = 800 µg/min/kg, bottom line: vmax,hep-3AERY = 4000 µg/min/kg). Time is relative to 
initial ERY/placebo dose. 
 
 
Figure K.20 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO EC 
ERY to the change in vmax,hep-3AERY. (top line: vmax,hep-3AERY = 160 µg/min/kg; middle line: 
vmax,hep-3AERY = 800 µg/min/kg, bottom line: vmax,hep-3AERY = 4000 µg/min/kg). Time is relative to 
initial ERY/placebo dose. 
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Figure K.21 Sensitivity analysis of relative GW CYP3A activity to the change in vmax,hep-
3A
ERY. (vmax,hep-3AERY = 160/800/4000 µg/min/kg are superimposable)  
 
 
 
Figure K.22 Sensitivity analysis of relative hepatic CYP3A activity to the change in vmax,hep-
3A
ERY. (top line: vmax,hep-3AERY = 4000 µg/min/kg; middle line: vmax,hep-3AERY = 800 µg/min/kg; 
bottom line: vmax,hep-3AERY = 160 µg/min/kg)  
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Figure K.23 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in vmax,hep-3AERY. (vmax,hep-3AERY = 160/800/4000 µg/min/kg are superimposable)  
 
 
 
Figure K.24 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
vmax,hep-3AERY. (top line: vmax,hep-3AERY = 160 µg/min/kg; middle line: vmax,hep-3A-3AERY = 800 
µg/min/kg; bottom line: vmax,hep-3AERY = 4000 µg/min/kg)  
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Figure K.25 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in vmax,bileERY. (top line: vmax,bileERY = 0.1 µg/min/kg; middle line: vmax,bileERY 
= 0.5 µg/min/kg, bottom line: vmax,bileERY = 2.5 µg/min/kg). Time is relative to initial 
ERY/placebo dose. 
 
 
Figure K.26 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO EC 
ERY to the change in vmax,bileERY. (top line: vmax,bileERY = 0.1 µg/min/kg; middle line: vmax,bileERY 
= 0.5 µg/min/kg, bottom line: vmax,bileERY = 2.5 µg/min/kg). Time is relative to initial 
ERY/placebo dose. 
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Figure K.27 Sensitivity analysis of relative GW CYP3A activity to the change in vmax,bileERY. 
(vmax,bileERY = 0.1/0.5/2.5 µg/min/kg are superimposable)  
 
 
 
Figure K.28 Sensitivity analysis of relative hepatic CYP3A activity to the change in 
vmax,bileERY. (top line: vmax,bileERY = 2.5 µg/min/kg; middle line: vmax,bileERY = 0.5 µg/min/kg; 
bottom line: vmax,bileERY = 0.1 µg/min/kg)  
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Figure K.29 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in vmax,bileERY. (vmax,bileERY = 0.1/0.5/2.5 µg/min/kg are superimposable)  
 
 
 
Figure K.30 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
vmax,bileERY. (top line: vmax,bileERY = 0.1 µg/min/kg; middle line: vmax,bileERY = 0.5 µg/min/kg; 
bottom line: vmax,bileERY = 2.5 µg/min/kg)  
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Figure K.31 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in Km,bileERY. (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable). Time is 
relative to initial ERY/placebo dose. 
 
 
 
Figure K.32 Sensitivity analysis of PO MDZ plasma concentrations in presence of PO EC 
ERY to the change in Km,bileERY. (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable). Time is 
relative to initial ERY/placebo dose. 
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Figure K.33 Sensitivity analysis of relative GW CYP3A activity to the change in Km,bileERY. 
(Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable)  
 
 
 
Figure K.34 Sensitivity analysis of relative hepatic CYP3A activity to the change in 
Km,bileERY. (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable) 
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Figure K.35 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in Km,bileERY (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable). 
 
 
 
Figure K.36 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
Km,bileERY (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable). 
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L. SENSITIVITY ANALYSIS OF DDI BETWEEN MDZ AND SS ERY FOR STUDY 603 
 
 
Figure L.1 Sensitivity analysis of PO MDZ (administered on day 2, 4 and 7) plasma 
concentrations in presence of PO SS ERY to the change in kdeg. (top line: kdeg = 0.00016 min-
1; middle line: kdeg = 0.0008 min-1; bottom line: kdeg = 0.004 min-1). Time is relative to initial 
ERY/placebo dose. 
 
 
Figure L.2 Sensitivity analysis of relative GW CYP3A activity to the change in kdeg. (top 
line: kdeg = 0.004 min-1; middle line: kdeg = 0.0008 min-1; bottom line: kdeg = 0.00016 min-1)  
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Figure L.3 Sensitivity analysis of relative hepatic CYP3A activity to the change in kdeg. (top 
line: kdeg = 0.004 min-1; middle line: kdeg = 0.0008 min-1; bottom line: kdeg = 0.00016 min-1)  
 
 
 
Figure L.4 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in kdeg. (kdeg = 0.00016/0.0008/0.004 min-1 are superimposable.)  
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Figure L.5 Sensitivity analysis of ERY unbound hepatic concentration to the change in kdeg. 
(top line: kdeg = 0.00016 min-1; middle line: kdeg = 0.0008 min-1; bottom line: kdeg = 0.004 min-1)  
 
 
 
Figure L.6 Sensitivity analysis of PO MDZ (administered on day 2, 4 and 7) plasma 
concentrations in presence of PO EC ERY to the change in KIERY. (top line: KIERY = 6 mg/L; 
middle line: KIERY = 30 mg/L; bottom line: KIERY = 150 mg/L). Time is relative to initial 
ERY/placebo dose. 
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Figure L.7 Sensitivity analysis of relative GW CYP3A activity to the change in KIERY. (top 
line: KIERY = 150 mg/L; middle line: KIERY = 30 mg/L; bottom line: KIERY = 6 mg/L)  
 
 
 
Figure L.8 Sensitivity analysis of relative hepatic CYP3A activity to the change in KIERY. 
(top line: KIERY = 150 mg/L; middle line: KIERY = 30 mg/L; bottom line: KIERY = 6 mg/L)  
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Figure L.9 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in KIERY. (KIERY = 6/30/150 mg/L are superimposable)  
 
 
 
Figure L.10 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
KIERY. (top line: KIERY = 6 mg/L; middle line: KIERY = 30 mg/L; bottom line: KIERY = 150 mg/L)  
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Figure L.11 Sensitivity analysis of PO MDZ (administered on day 2, 4 and 7) plasma 
concentrations in presence of PO EC ERY to the change in kinactERY. (top line: kinactERY = 
0.1875 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: kinactERY = 0.0075 min-1). Time is 
relative to initial ERY/placebo dose. 
 
 
 
Figure L.12 Sensitivity analysis of relative GW CYP3A activity to the change in kinactERY. 
(top line: kinactERY = 0.0075 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: kinactERY = 
0.1875 min-1)  
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Figure L.13 Sensitivity analysis of relative hepatic CYP3A activity to the change in kinactERY. 
(top line: kinactERY = 0.0075 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: kinactERY = 
0.1875 min-1)  
 
 
 
Figure L.14 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in kinactERY. (kinactERY = 0.0075/0.0375/0.1875 min-1 are superimposable)  
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Figure L.15 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
kinactERY. (top line: kinactERY = 0.1875 min-1; middle line: kinactERY = 0.0375 min-1; bottom line: 
kinactERY = 0.0075 min-1)  
 
 
 
Figure L.16 Sensitivity analysis of PO MDZ (administered on day 2, 4, or 7) plasma 
concentrations in presence of PO EC ERY to the change in vmax,hep-3AERY. (top line: vmax,hep-
3A
ERY = 160 µg/min/kg; middle line: vmax,hep-3AERY = 800 µg/min/kg, bottom line: vmax,hep-3AERY = 
4000 µg/min/kg). Time is relative to initial ERY/placebo dose. 
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Figure L.17 Sensitivity analysis of relative GW CYP3A activity to the change in vmax,hep-
3A
ERY. (vmax,hep-3AERY = 160/800/4000 µg/min/kg are superimposable.)  
 
 
 
Figure L.18 Sensitivity analysis of relative hepatic CYP3A activity to the change in vmax,hep-
3A
ERY. (top line: vmax,hep-3AERY = 4000 µg/min/kg; middle line: vmax,hep-3AERY = 800 µg/min/kg; 
bottom line: vmax,hep-3AERY = 160 µg/min/kg)  
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Figure L.19 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in vmax,hep-3AERY. (vmax,hep-3AERY = 160/800/4000 µg/min/kg are superimposable)  
 
 
 
Figure L.20 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
vmax,hep-3AERY. (top line: vmax,hep-3AERY = 160 µg/min/kg; middle line: vmax,hep-3A-3AERY = 800 
µg/min/kg; bottom line: vmax,hep-3AERY = 4000 µg/min/kg)  
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Figure L.21 Sensitivity analysis of IV MDZ plasma concentrations in presence of PO EC 
ERY to the change in vmax,bileERY. (top line: vmax,bileERY = 0.1 µg/min/kg; middle line: vmax,bileERY 
= 0.5 µg/min/kg, bottom line: vmax,bileERY = 2.5 µg/min/kg). Time is relative to initial 
ERY/placebo dose. 
 
 
 
Figure L.12 Sensitivity analysis of relative GW CYP3A activity to the change in vmax,bileERY. 
(vmax,bileERY = 0.1/0.5/2.5 µg/min/kg are superimposable)  
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Figure L.23 Sensitivity analysis of relative hepatic CYP3A activity to the change in 
vmax,bileERY. (Top line: vmax,bileERY = 2.5 µg/min/kg; middle line: vmax,bileERY = 0.5 µg/min/kg; 
bottom line: vmax,bileERY = 0.1 µg/min/kg)  
 
 
 
Figure L.24 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in vmax,bileERY. (vmax,bileERY = 0.1/0.5/2.5 µg/min/kg are superimposable)  
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Figure L.25 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
vmax,bileERY. (top line: vmax,bileERY = 0.1 µg/min/kg; middle line: vmax,bileERY = 0.5 µg/min/kg; 
bottom line: vmax,bileERY = 2.5 µg/min/kg)  
 
 
 
Figure L.26 Sensitivity analysis of PO MDZ (administered on day 2, 4, and 7) plasma 
concentrations in presence of PO EC ERY to the change in Km,bileERY. (Km,bileERY = 
0.02/0.1/0.5 mg/L are superimposable). Time is relative to initial ERY/placebo dose. 
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Figure L.27 Sensitivity analysis of relative GW CYP3A activity to the change in Km,bileERY. 
(Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable)  
 
 
 
Figure L.28 Sensitivity analysis of relative hepatic CYP3A activity to the change in 
Km,bileERY. (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable) 
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Figure L.29 Sensitivity analysis of ERY unbound GW mucosa concentration to the change 
in Km,bileERY (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable). 
 
 
 
Figure L.30 Sensitivity analysis of ERY unbound hepatic concentration to the change in 
Km,bileERY (Km,bileERY = 0.02/0.1/0.5 mg/L are superimposable). 
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